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A Toxicological Profile for Americium, Draft for Public Comment, was released in May 2001.  This 
edition supersedes any previously released draft or final profile.   
Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at: 
Agency for Toxic Substances and Disease Registry
 
Division of Toxicology/Toxicology Information Branch 














The toxicological profiles are developed by ATSDR pursuant to Section 104(i) (3) and (5) of the 
Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or 
Superfund) for hazardous substances found at Department of Energy (DOE) waste sites. 
CERCLA directs ATSDR to prepare toxicological profiles for hazardous substances most 
commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the 
most significant potential threat to human health, as determined by ATSDR and the EPA. 
ATSDR and DOE entered into a Memorandum of Understanding on November 4, 1992 which 
provided that ATSDR would prepare toxicological profiles for hazardous substances based upon 
ATSDR’s or DOE’s identification of need. The current ATSDR priority list of hazardous 






























        




QUICK REFERENCE FOR HEALTH CARE PROVIDERS 
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous 
substance. Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation 
of available toxicologic and epidemiologic information on a substance.  Health care providers treating 
patients potentially exposed to hazardous substances will find the following information helpful for fast 
answers to often-asked questions. 
Primary Chapters/Sections of Interest 
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating 
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant 
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of 
the general health effects observed following exposure. 
Chapter 2: Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets, 
and assesses the significance of toxicity data to human health. 
Chapter 3: Health Effects: Specific health effects of a given hazardous compound are reported by type 
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are 
reported in this section. 
NOTE: Not all health effects reported in this section are necessarily observed in the clinical 
setting. Please refer to the Public Health Statement to identify general health effects 
observed following exposure. 
Pediatrics: Four new sections have been added to each Toxicological Profile to address child health 
issues: 
Section 1.6 How Can (Chemical X) Affect Children? 

Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)? 

Section 3.7 Children’s Susceptibility 

Section 6.6 Exposures of Children 

Other Sections of Interest: 
Section 3.8 Biomarkers of Exposure and Effect 
Section 3.11 Methods for Reducing Toxic Effects 
ATSDR Information Center  
Phone:  1-888-42-ATSDR or (404) 498-0110 Fax: (770) 488-4178 
E-mail:  atsdric@cdc.gov Internet: http://www.atsdr.cdc.gov 
The following additional material can be ordered through the ATSDR Information Center: 
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure 





























Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide 
Toxicity; and numerous chemical-specific case studies. 
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident. Volumes I and II are planning guides to assist first responders and hospital emergency 
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials. 
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances. 
Other Agencies and Organizations 
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the 
workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-
3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational 
diseases and injuries, responds to requests for assistance by investigating problems of health and 
safety in the workplace, recommends standards to the Occupational Safety and Health 
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains 
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH. 
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on 
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212. 
Radiation Emergency Assistance Center/Training Site (REAC/TS) provides support to the U.S. 
Department of Energy, the World Health Organization, and the International Atomic Energy
Agency in the medical management of radiation accidents.  A 24-hour emergency response 
program at the Oak Ridge Institute for Science and Education (ORISE), REAC/TS trains, 
consults, or assists in the response to all kinds of radiation accidents.  Contact: Oak Ridge 
Institute for Science and Education, REAC/TS, PO Box 117, MS 39, Oak Ridge, TN 37831-0117 
• Phone 865-576-3131 • FAX 865-576-9522 • 24-Hour Emergency Phone 865-576-1005 (ask for 
REAC/TS) • e-mail: cooleyp@orau.gov • website (including emergency medical guidance): 
http://www.orau.gov/reacts/default.htm 
Referrals 
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact: 
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 •
FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/. 














The American College of Occupational and Environmental Medicine (ACOEM) is an association of 
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact: ACOEM, 55 West Seegers Road, Arlington Heights, IL 
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A peer review panel was assembled for americium.  The panel consisted of the following members:  
1. 	 Ronald Kathren, C.H.P., D.E.E., Emeritus Professor of Pharmaceutical Science, Washington 
State University; President, The Kathren Group, Inc., Richland, WA, 
2.	 Richard Leggett, Ph.D., Life Sciences Division, Oak Ridge National Laboratory, Knoxville, TN, 
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5.	 Raymond Guilmette, Ph.D., Los Alamos National Laboratory, Los Alamos, NM, and  
6. 	 Melvin Sikov, Ph.D., Scientist Emeritus, Pacific Northwest National Laboratory, Richland, WA. 
These experts collectively have knowledge of amercium's physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer 
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended. 
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer 
reviewers' comments and determined which comments will be included in the profile.  A listing of the 
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.  A list of databases reviewed and 
a list of unpublished documents cited are also included in the administrative record. 
The citation of the peer review panel should not be understood to imply its approval of the profile's final 
content. The responsibility for the content of this profile lies with the ATSDR. 
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1. PUBLIC HEALTH STATEMENT 
This public health statement tells you about americium and the effects of exposure.   
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in 
the nation. These sites make up the National Priorities List (NPL) and are the sites targeted for 
long-term federal cleanup activities.  Americium has been found in at least 8 of the 1,636 current 
or former NPL sites.  However, the total number of NPL sites evaluated for americium is not 
known. As more sites are evaluated, the sites at which americium is found may increase.  This 
information is important because exposure to americium may harm you and because these sites 
may be sources of exposure.  
When a substance is released from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  This release does not always lead to 
exposure. You are normally exposed to a substance only when you come in contact with it.  You 
may be exposed by breathing, eating, or drinking the substance, or by skin contact.  However, 
since americium is radioactive, you can also be exposed to its radiation if you are near it. 
External or internal exposure to radiation may occur from natural or man-made sources.  
Naturally occurring sources of radiation are cosmic radiation from space or naturally occurring 
radioactive materials in our body or in soil, air, water, or building materials.  Man-made sources 
of radiation are found in consumer products, industrial equipment, atom bomb fallout, and to a 
smaller extent, from hospital waste and nuclear reactors. 
If you are exposed to americium, many factors determine whether you’ll be harmed.  These 
factors include the dose (how much), the duration (how long), and how you come in contact with 
it. You must also consider the other chemicals or radioactive materials you’re exposed to and 


















1. PUBLIC HEALTH STATEMENT 
1.1 WHAT IS AMERICIUM? 
Americium (pronounced, 1am-c-0ris(h)-‘-cm) is a human-made, radioactive element.  There are 
no naturally occurring or stable isotopes of americium.   Pure americium is a silvery metal.  
There are two important isotopes of americium, americium 241 and americium 243, also written 
as 241Am and 243Am, and read as americium two-forty-one and americium two-forty-three.  Both
isotopes have the same chemical behavior in the environment.  
Quantities of americium, as well as other radioactive elements, can be measured in units of mass 
(grams), but are usually measured in terms of their radioactivity (curies or becquerels).  Both the 
curie (Ci) and the becquerel (Bq) tell us how much a radioactive material decays every second.  
The becquerel is a new international unit and the curie is a traditional unit; both units are 
currently used in the United States.  A becquerel is the amount of radioactive material in which 
1 atom transforms every second, and a curie is the amount of radioactive material in which 
37 billion atoms transform every second.  
Each radioactive isotope of an element, including americium, constantly gives off radiation, 
which changes it into an isotope of a different element or a different isotope of the same element.  
This newly formed nuclide may be stable or radioactive.  This process is called radioactive 
decay. 241Am and 243Am give off alpha particles (sometimes referred to as alpha radiation) and 
change into neptunium 237 (237Np) and neptunium 239 (239Np), respectively. Neptunium is also 
radioactive, so isotopes of this element also give off radiation and change into isotopes of other 
elements.  This process continues and eventually ends when stable isotopes of bismuth and lead 
are formed.   
Half-life is the term that is used to describe the rate of the decay process.  Specifically, the half-
life is the time it takes for half of the atoms of a radionuclide to undergo radioactive decay and 

















1. PUBLIC HEALTH STATEMENT 
Specific activity is a term that describes the relative rates of decay of the same mass of different 
radioactive materials.  If you have 1 gram of each isotope of americium side by side, the specific 
activities would be 3.4 curies per gram for 241Am and 0.2 curies per gram for 243Am.  Thus, for 
the same mass, 241Am is about 17 times more radioactive (i.e., its specific activity would be 
17 times higher) than that of 243Am.  The higher the specific activity of a radioisotope, the faster 
it is decaying.  
The predominant commercial use of 241Am is in ionization-type smoke detectors.  This 
application relies on the alpha particles that are produced when the isotope decays as an 
ionization source. A typical household smoke detector contains 0.9 microcuries (µCi; a µCi is 
one millionth of a curie) or 33,000 Bq of 241Am, and 1 g of americium dioxide is sufficient to 
make 5,000 smoke detectors.  241Am is also used for industrial gauging applications and in 
medical diagnostic devices.  There are research applications, but no commercial applications for 
243Am.  This will change if the United States and Russia turn nuclear warheads into power 
reactor fuel by making a mixed oxide fuel of uranium and plutonium.  This fuel, called MOX, 
will contain both 241Am and 243Am, and the plan is to use it to make electricity.  Once used, the 
spent nuclear fuel is to be sent for disposal. 
For more information about the properties and uses of americium, see Chapters 4, 5, and 6. 
1.2 WHAT HAPPENS TO AMERICIUM WHEN IT ENTERS THE ENVIRONMENT?  
241Am can be released to the environment from nuclear reactors, nuclear explosions, and 
accidents, as well as from manufacturing products containing americium (such as smoke 
detectors). Americium is a byproduct of plutonium production.  241Am is formed from the 
radioactive decay of plutonium 241 (241 Pu), which itself is produced from uranium 238 (238U) 
while it is inside an operating nuclear reactor.  In the absence of clean-up procedures, radioactive 
decay is the only way for decreasing the amount of americium in the environment.  Because 
241Am has a long half-life, it will be present in the environment for a long time.  Since 241Pu can 
be released along with 241Am in the decay process, the amount of 241Am will slowly increase for 




















1. PUBLIC HEALTH STATEMENT 
241Am released to the atmosphere will be associated with particles and will settle to earth or be 
washed from the air in precipitation (e.g., rain, snow).  241Am from atmospheric nuclear weapons 
tests may remain in the atmosphere for decades before settling to earth.  For example, 241Am
released in nuclear accidents, like the accident at Chernobyl, will stay in the lower atmosphere 
and begin to settle to earth near the site from which it was released.  Larger particles will settle 
out more quickly and over a smaller area; smaller particles may remain in the atmosphere for 
several months and travel far from where they were released.  Precipitation removes particles 
from the air more rapidly.  
241Am released into water from nuclear facilities will tend to stick to particles in the water or the 
sediment.  241Am deposited on soil is so strongly attached to soil particles that it does not travel 
very far into the ground.  Ultimately, most americium ends up in soil or sediment.  
While plants may take up 241Am from the soil, the amount taken up is small, especially in the 
parts of the plant that are most often eaten (i.e., the fruit, grain, and seeds).  While fish may take 
up 241Am, the amount that builds up in the flesh is very small.  Most of the 241Am found in 
shellfish like shrimp or mussels is contained in the shell, rather than in the edible parts of the 
animal.  For more information about what happens to americium in the environment, see 
Chapter 6. 
1.3 HOW MIGHT I BE EXPOSED TO AMERICIUM?  
You may be exposed to 241Am  by breathing air, drinking water, or eating food containing 241Am; 
however, the levels of 241Am in air, water, soil, and food are generally very low, and of little 
health consequence. 
People working at sites where nuclear waste is stored, in nuclear power plants, or in other 
nuclear facilities that handle 241Am may be exposed to higher levels of americium than the 
general population. People living near these sites also may be exposed to elevated levels of 


















1. PUBLIC HEALTH STATEMENT 
exposed to higher levels.  In the case of a nuclear accident, exposure could occur by breathing or 
eating dust containing 241Am.  Even at sites that contain measurable levels of radioactive 
contamination, the amount of 241Am that is taken up into plant and animal tissue is so small that 
it is of little concern. You can find more information on how you may be exposed to americium 
in Chapter 6.
1.4 HOW CAN AMERICIUM ENTER AND LEAVE MY BODY?  
Americium can enter your body from the air you breathe, the food you eat, or the water you 
drink, or from contact with your skin.  If you breathe in air that contains americium, some forms 
of americium that dissolve easily in lung fluid stay in your lungs for hours or days.  Other forms 
that do not dissolve easily in lung fluid might stay in your lungs for months or years.  Some
americium that enters your lungs may get into your blood.  If you swallow americium, a very 
small amount of what enters your digestive tract may also enter your blood.  Most of the 
americium entering your blood leaves your body in your urine and feces.  Of the small amount 
that stays in your body, most goes to your bones, where it can remain for many decades; a 
smaller amount goes into your liver and other organs, where it may remain for a few years as the 
body clears it. 
1.5 HOW CAN AMERICIUM AFFECT MY HEALTH?  
To protect the public from the harmful effects of toxic chemicals and to find ways to treat people 
who have been harmed, scientists use many tests.   
One way to see if a chemical will hurt people is to learn how the chemical is absorbed, used, and 
released by the body. In the case of a radioactive chemical, it is also important to gather 
information concerning the radiation dose and dose rate to the body.  For some chemicals, 
animal testing may be necessary.  Animal testing may also be used to identify health effects such 
as cancer or birth defects. Without laboratory animals, scientists would lose a basic method to 
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responsibility to treat research animals with care and compassion.  Laws today protect the 
welfare of research animals, and scientists must comply with strict animal care guidelines. 
In the process of radioactive decay, americium releases alpha particles and gamma rays.  Alpha 
particles are relatively high energy particles, but travel only extremely short distances and do not 
penetrate the skin. However, if americium is taken into the body and enters body tissues, alpha 
particles may produce damage to nearby cells.  Gamma rays can travel much greater distances 
and can penetrate the entire body. Since alpha particles do not penetrate the skin and the gamma 
rays released from americium sources are relatively low in energy, external exposure to 
americium is not usually considered to be a danger to your health. 
The radiation from americium is the primary cause of adverse health effects from absorbed 
americium.  Upon entering the body by any route of exposure, americium moves relatively 
rapidly through the body and is deposited on the surfaces of the bones where it remains for a 
long time.  As americium undergoes radioactive decay in the bone, alpha particles collide with 
nearby cell matter and give all of their energy to this cell matter.  The gamma rays released by 
decaying americium can travel much farther before hitting cellular material, and many of these 
gamma rays leave the body without hitting or damaging any cell matter.  The dose from this 
alpha and gamma radiation can cause changes in the genetic material of these cells that could 
result in health effects such as bone cancers. Exposure to extremely high levels of americium, as 
has been reported in some animal studies, has resulted in damage to organs such as the lungs, 
liver, kidneys, and thyroid. It is rare, however, that a person would be exposed to amounts of 
americium large enough to cause harmful effects in these organs. 
1.6 HOW CAN AMERICIUM AFFECT CHILDREN?  
This section discusses potential health effects from exposures during the period from conception 
to maturity at 18 years of age in humans.  
Americium accumulates in human bones and remains there for a long time.  Americium emits 


















1. PUBLIC HEALTH STATEMENT 
body normally repairs all of the damage, but if it fails, bone cancer could result after many years.  
If americium exposure to children occurs, the exposure to the radiation from americium may be 
for a longer period of time, causing a larger radiation dose over their lifetime and increasing the 
likelihood of producing cancer. However, there are no published data showing that children are 
more susceptible than adults to radiation-induced americium toxicity.  A developing baby is 
expected to have some americium in its body.  It could be affected by this americium while in 
the womb if the pregnant mother has high enough levels of americium in her blood. 
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO AMERICIUM?  
If your doctor finds that you have been exposed to significant amounts of americium, ask 
whether your children might also be exposed.  Your doctor might need to ask your state health 
department to investigate. 
While discharges from nuclear waste sites, nuclear reactors, or plants that manufacture ionization 
smoke detectors or gauges containing americium are regulated, it is possible that higher-than­
normal levels of americium may be in soil near a nuclear waste site, nuclear reactor, or plant that 
manufactures ionization smoke detectors or gauges containing americium.  If you live near any 
of these types of nuclear or manufacturing sites, discourage your children from putting their 
hands in their mouths and engaging in other hand-to-mouth activities. 
Discharge water and air emissions from facilities that make americium smoke detectors or 
gauges or produce plutonium for nuclear weapons may contain some americium.  These 
operations are strictly regulated, but you can check local health advisories before consuming fish 
or other food from these waters.  Nuclear reactors are not expected to discharge measurable 
amounts of americium.
Ionization smoke detectors that contain americium are safe when installed; however, you should 
not allow your children to play with these detectors.  If the detectors are damaged or are no 
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1.8 	 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN
EXPOSED TO AMERICIUM? 
Physicians do not test for americium in their offices, but they can collect samples and send them
to special laboratories or request that you be sent to such a laboratory.  If you are exposed to a 
large dose of radiation from americium, your blood can be tested for signs of damage to the cell 
chromosomes.  If americium were to enter your body from contaminated air, food, or water, the 
amount of americium (in Ci or Bq) can be estimated by measuring the radiation given off by the 
americium present in samples of blood, urine, teeth, or tissue.  If in the lungs, the amount of 
americium can be estimated by measuring the americium gamma radiation that exits the body.  
Radiation detector systems used for these purposes are at a limited number of locations.  The 
amount in your lungs and excretions fall sharply after exposure, so tests should be done as soon 
as possible. 
1.9 	 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO 
PROTECT HUMAN HEALTH?  
The federal government develops regulations and recommendations to protect public health.  
Regulations can be enforced by law. Federal agencies that develop regulations for toxic 
substances include the Environmental Protection Agency (EPA), the Occupational Safety and 
Health Administration (OSHA), the Food and Drug Administration (FDA), and the U.S. Nuclear 
Regulatory Commission (USNRC).   
Recommendations provide valuable guidelines to protect public health but cannot be enforced by 
law. Federal organizations that develop recommendations for toxic substances include the 
Agency for Toxic Substances and Disease Registry (ATSDR), the National Institute for 
Occupational Safety and Health (NIOSH), and FDA. 
Regulations and recommendations can be expressed in not-to-exceed levels in air, water, soil, or
food that are usually based on levels that affect animals; then they are adjusted to help protect 
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different exposure times (an 8-hour workday or a 24-hour day), the use of different animal 
studies, or other factors. 
Recommendations and regulations are also periodically updated as more information becomes 
available. For the most current information, check with the federal agency or organization that 
provides it. Some regulations and recommendations for americium include the following: 
The USNRC established radiation dose limits to the public and to workers.  To ensure that these 
limits are met, USNRC also set concentration limits for 241Am in air, water, and sewer discharge 
that can be released from licensed facilities.  This ensures that the annual radiation dose will not 
exceed 0.1 rem (0.001 sievert) to the public, or 5 rem (0.05 sievert) to the worker or 50 rem
(0.5 sievert) to their bones. The concentration limits are 0.00000000000002 microcurie per 
milliliter (2x10-14 µCi/mL) for air, 0.00000002 microcurie per milliliter (2x10-8 µCi/mL) for 
water, and 0.0000002 microcurie per milliliter (2x10-7 µCi/mL) for releases to sewers. The 
USNRC requires that intake of americium not exceed the specified annual limits on intake (ALI) 
for inhalation or oral routes of exposure.  The occupational exposure limits are 6x10-3 µCi (ALI) 
for workers inhaling 241Am and 8x10-1 µCi (ALI) for ingestion of 241Am.  The level of 241Am in 
workplace air, specified as the derived air concentration (DAC), is not to exceed 3x10-12 µCi/mL 
(which can be adjusted to account for work weeks shorter or longer than 40 hours).  The FDA 
has set a food contamination guideline of 2 Bq/kg per kilogram (5.4x10-5 µCi/kg) for 241Am to 
protect 3-month-old children.  This is the population group that would receive the highest 
radiation dose from eating food that contains americium.  The EPA has established a public 
drinking water limit of 15 picocurie per liter (pCi/L).  This is for the sum of all radioactive 
materials that give off alpha radiation.  241Am and 243Am are examples, but drinking water 
normally contains other alpha emitters, such as uranium, thorium, and radium. 




























1. PUBLIC HEALTH STATEMENT 
1.10 WHERE CAN I GET MORE INFORMATION?  
If you have any more questions or concerns, please contact your community or state health or 
environmental quality department, your regional Nuclear Regulatory Commission office, or 
contact ATSDR at the address and phone number below. 
ATSDR can also tell you the location of occupational and environmental health clinics.  These 
clinics specialize in recognizing, evaluating, and treating illnesses resulting from exposure to 
hazardous substances. 
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM. You 
may request a copy of the ATSDR ToxProfiles CD-ROM by calling the information and 
technical assistance toll-free number at 1-888-42ATSDR (1-888-422-8737), by email at 
atsdric@cdc.gov, or by writing to: 
Agency for Toxic Substances and Disease Registry 

Division of Toxicology 

1600 Clifton Road NE 

 Mailstop F-32 

Atlanta, GA 30333 

 Fax: 1-770-488-4178 

For-profit organizations may request a copy of final profiles from the following: 
National Technical Information Service (NTIS) 

5285 Port Royal Road 

Springfield, VA 22161 

Phone: 1-800-553-6847 or 1-703-605-6000 




























2. RELEVANCE TO PUBLIC HEALTH 

2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO AMERICIUM IN THE 
UNITED STATES 
Americium is a human-made, radioactive, actinide element; it has no stable isotopes.  The only isotope 
used commercially is 241Am, several kilograms of which are produced annually.  The only other 
americium isotope produced in macroscopic quantity (10–100 g annually) is 243Am.  Both 241Am and 
243Am can be formed when either 238U (the major uranium isotope used in nuclear power reactor fuel) or 
238,239Pu (primarily used in nuclear weapons) are exposed to neutrons, as occurs in a nuclear reactor or 
nuclear explosion. Neutron activation of 238U to 239U followed by combinations of decay to 239Np and 
239Pu and neutron activation to higher masses of each produces a range of isotopes of these elements.  
Similarly, neutron activation of 238,239Pu yields higher mass isotopes.  Any 241Pu or 243Pu formed by these 
processes will decay to 241Am and 243Am, respectively.  The most common application of americium is in 
ionization smoke detectors; a typical home smoke detector contains about 0.9 µCi (33.3 kBq) of 
radioactivity.  One gram of 241AmO2 provides enough active material for more than 5,000 smoke 
detectors. Americium is also used in a wide range of industrial gauging applications. 
Very low levels of 241Am may be found in environmental media worldwide, a legacy of atmospheric 
nuclear weapons testing that predominantly took place between 1945 and 1963. In nuclear reactors, 
241Am has been detected in primary coolant water, stack aerosols, and waste water (Rosner et al. 1978).  
Because 241Am is produced from the decay of 241Pu (half-life=14.4 years), releases of 241Pu result in 
increased environmental levels of 241Am. The maximum concentration of 241Am following an accidental 
release of 241Pu occurs 70–80 years post release (EPA 1976).  Consequently, the impact of 241Am from
atmospheric nuclear weapons testing will reach its peak in about the year 2035, when its rate of 
production from 241Pu decay equals its rate of decay.  Environmental levels of 241Am will subsequently 
decline. Exposure of the general population to 241Am via air, water, soil, and food is generally very low; 
these ‘background’ levels are a result of fallout from past atmospheric nuclear weapons tests.  Since 1973, 
241Am air concentrations have been <1 aCi/m3 (1 attocurie [aCi]=1x10-18 Ci) (0.037 µBq/m3) and are 
expected to continue to decline, assuming no significant additional atmospheric nuclear testing after 1976 
(Bennett 1979).  Levels around nuclear power plants are indistinguishable from fallout background levels 





















2. RELEVANCE TO PUBLIC HEALTH 
10 Bq/m3 (270 pCi/m3) between 1976 and 1988 (Pattenden and McKay 1994), but may be considerably 
higher near discharges from nuclear facilities.  In the Food and Drug Administration (FDA) Total Diet 
Studies in 1983–1986 and 1987–1992, the concentrations of radionuclides were sufficiently low as to 
require no specific action or simple monitoring. 
2.2 SUMMARY OF HEALTH EFFECTS  
Americium exists only in the form of radioactive isotopes; there are no stable forms.  Reports of adverse 
health effects in animals that were administered massive doses of americium are most certainly the result 
of the ionizing radiation, not the chemical toxicity of americium.  The specific activity of 241Am is
approximately 17 times greater than that of 243Am.  Its higher specific activity and greater abundance 
make 241Am of greater health concern than 243Am.  Both 241Am and 243Am release alpha particles and 
gamma rays during decay.  Alpha radiation is primarily an internal hazard, and the low energy, low 
intensity gamma radiation is typically not the main health concern.  The charged alpha particles generally
travel a straight path, interacting with or colliding into other atomic particles.  A collision between an 
atom and an alpha particle can result in a transfer of energy sufficient to “knock out” an electron from the 
atom, producing an ionized or excited atomic state.  Alpha particles have short ranges, and those from
americium isotopes are not able to penetrate the outer layers of skin; thus, they are not considered an 
external hazard.  Once americium enters the body via ingestion, inhalation, dermal transport, or a dermal 
wound, however, the alpha particles that it emits present an internal hazard.  The alpha energy induces 
rapid physical changes to localized cell matter in its path and via chemical interactions with the water in 
human cells.  Radiation hydrolysis of water produces a cascade of rapid chemical reactions, forming 
ionized and excited chemical species referred to as radiolysis products.  These reactive species can 
interact with biological molecules in ways that can damage cells.  Cellular damage can result both directly 
from radiation interactions and indirectly from the chemical reactions involving reactive species of 
radiolysis products.  The gamma rays emitted during the decay of 241Am are the only components of 
external radiation exposure, but they represent a small component of the decay scheme and are 
sufficiently low in energy and intensity so as to pose little hazard from external exposure.  Internalized 
gamma rays can travel greater distances than the heavier alpha particles, but deposit a lower amount of 
energy with each interaction.  Although the gamma rays emitted from the decaying americium atom are 


























2. RELEVANCE TO PUBLIC HEALTH 
Information regarding health effects in humans following exposure to americium is mainly limited to a 
case report of an individual accidentally exposed to high levels of americium resulting in a significant 
internal dose from americium that was absorbed via external wounds.  Lymphopenia, thrombocytopenia, 
and histological signs of bone marrow peritrabecular fibrosis, bone cell depletion, and bone marrow 
atrophy were noted (Filipy et al. 1995; Priest et al. 1995).  These data are supported by findings in 
laboratory animals exposed to high doses of americium.  Elevated hematopoietic activity, leukopenia, 
decreased hematocrit and platelet levels, and increased cellularity in bone marrow were observed in 
animals exposed to americium via inhalation (Buldakov et al. 1972; Thomas et al. 1972) or parenteral 
injection (Dougherty 1970); these effects are likely due to the inability to support hematopoiesis and the 
reduced colony-forming capacity.  Degenerative changes in bone, liver, kidneys, and thyroid have also 
been observed following inhalation (Moushatova et al. 1996; Thomas et al. 1972) or parenteral (Lloyd et 
al. 1970; Taylor et al. 1991, 1993a) exposure to 241Am. Comparisons between single exposure and 
repeated exposure studies suggest that the severity of the tissue damage increases with duration of 
exposure. Although many of the animal studies employed parenteral injection as the route of exposure, 
available inhalation data indicate similarity in targets of toxicity.  The radiation dose resulting from
inhaling large quantities of 241Am can also produce respiratory insufficiency and pneumonia (Buldakov et 
al. 1972; DOE 1978; Thomas et al. 1972).  Experimental studies in animals demonstrate that internal 
exposure to the radioactive isotope, 241Am, results in the development of cancer in the tissues that 
sequester this element.  Animal studies indicate increased risk of bone cancer in areas of bone containing 
relatively high levels of americium.  Increases in bone cancer have occurred in dogs receiving a single 
inhalation exposure to 241AmO2 (Gillett et al. 1985) and in dogs (Jee et al. 1985; Lloyd et al. 1994a, 
1994b), rats (Carter et al. 1951), and mice (Schoeters et al. 1991; Taylor et al. 1983; Van Den Heuvel et 
al. 1995) receiving a single intraperitoneal or intravenous injection of 241Am.  Studies of cancer risk 
specifically associated with exposure of humans to radioactive americium isotopes were not located.  
However, the EPA has determined that ionizing radiation is a Group A known carcinogen, and by
extension, all radionuclides, including americium, are considered to be known carcinogens. 
Based on the outcome of accidental human exposures and experimental animal study data, as well as the 
application of physiological model simulations, the toxic effects following exposure to americium
compounds can be predicted from the associated radiation dose.  The potential for adverse health effects 
occurs when americium enters the body via ingestion, inhalation, dermal absorption, or dermal 
penetration where radiation from the americium compounds and their radioactive decay products inside 
the body can cause localized cell damage.  Because americium accumulates in the bone and remains there 
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hematopoietic system if the americium is deposited at a sufficient depth in the bone that its alpha particles 
can reach the marrow.  Although human studies have not correlated americium exposure with an increase 
in cancer rate, one can calculate a theoretical risk based on dose and values from cancer risk tables.  Risk 
may be significant at high doses, but such high-level exposures are not likely among the general 
population. 
2.3 MINIMAL RISK LEVELS (MRLs)  
Inhalation MRLs 
No acute-, intermediate-, or chronic-duration inhalation MRLs were derived for americium due to the lack 
of suitable human or animal data regarding health effects following inhalation exposure to americium.
Oral MRLs 
No acute-, intermediate-, or chronic-duration oral MRLs were derived for americium due to the lack of 



















   







3. HEALTH EFFECTS 
3.1 INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of americium.  It 
contains descriptions and evaluations of toxicological studies and epidemiological investigations and 
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health. 
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile. 
The potential for adverse health effects to humans exposed to americium is dependent on the amount of 
americium isotopes (241Am and 243Am) present in the body as well as the radiation dose and dose rate that 
each produce. Both 241Am and 243Am can be formed when either 238U (the major uranium isotope used in 
nuclear power reactor fuel) or 238,239Pu (primarily used in nuclear weapons) are exposed to neutrons, as 
occurs in a nuclear reactor or nuclear explosion.  Neutron activation of 238U to 239U, followed by
combinations of decay to 239Np and 239Pu and neutron activation to higher masses of each, produces a 
range of isotopes of these elements.  Similarly, neutron activation of 238,239Pu yields higher mass isotopes.  
Any 241Pu or 243Pu formed by these processes will decay to 241Am and 243Am, respectively.  These can 
also be neutron activated, producing other americium isotopes (e.g., 242,244,245Am).  The isotopes, 242Am
and 243Am, are produced in lower abundance than 241Am (see Chapter 4 for decay schemes and other 
more detailed information).  These americium radionuclides may be released into the atmosphere in sites 
that surround nuclear production facilities, store nuclear waste, or leak americium into the soil or 
groundwater. The radiation dose from these radionuclides can be classified as either external (if the 
source is outside the body) or internal (if the source is inside the body). 
The external dose from americium radionuclides may be attributed to the gamma radiation.  Alpha 
particle decay emits alpha radiation, which cannot penetrate the outer layers of the skin, and a variety of 
low energy gamma rays, which do penetrate the skin, although rarely in sufficient quantity to exceed a 
regulatory limit.  At very high doses of americium, there is increased risk for gamma radiation to cause 


























3. HEALTH EFFECTS 
Once radioactive americium is internalized, it is distributed and excreted at a rate of transfer that is 
dependent on age.  The internal radiation dose from americium is actually a measure of the amount of 
energy that the alpha and gamma emissions deposit in tissue.  The short-range alpha radiation produces a 
localized dose, while the low energy gamma radiation contributes to a larger distribution of dose.  
Molecular damage results from the direct ionization of atoms that are encountered by alpha and gamma 
radiation and by interactions of resulting free radicals with nearby atoms.  Tissue damage results when the 
molecular damage is extensive and not sufficiently repaired in a timely manner.
In radiation biology, the term absorbed dose refers to the amount of energy deposited by radiation per 
unit mass of tissue, expressed in units of rad or gray (Gy) (see Appendix D for a detailed description of 
principles of ionizing radiation).  The term dose equivalent (H) refers to the biologically significant dose, 
which is determined by multiplying the absorbed dose (D) by a quality factor (Q) for the type and energy 
of the radiations involved. Dose equivalent (H) is expressed as H=DxQ in units of rem or sievert (Sv).  
The quality factor (Q) for alpha radiation emitted from 241Am is rated 20 because of the high stopping 
power for charged particles. The dose equivalent (H) from internalized americium radionuclides is 
estimated using the quantity of material entering the body (via ingestion or inhalation), the biokinetic 
parameters for americium (retention, distribution, and excretion), the energies and intensities of the alpha 
and gamma radiation emitted, and the parameters describing the profile of absorbed radiation energy
within the body.  If, for example, a person ingests a given activity of 241Am (measured in curies [Ci] or 
becquerels [Bq]), the tissues of the body will absorb some of the energy of the emitted alpha and gamma 
radiation in a pattern reflecting the kinetics of distribution and elimination of the ingested 241Am, the rate
at which the radioactive isotope decays to a stable form, and the age of the person at the time of ingestion 
(which affects both the biokinetics of the americium as well as the potential length of time over which the 
tissues can be exposed to the radiation).  Each tissue, therefore, can receive a different dose equivalent.  
The total effective dose equivalent for the body will reflect the integration of the dose equivalents for the 
various tissues using a weighting scheme for the relative sensitivities of tissues and organs. 
The EPA has published a set of internal dose conversion factors for reference persons of various ages 
(newborn; 1, 5, 10, or 15 years of age; and adult) in its Federal Guidance Report No. 13 supplemental CD
(EPA 2000). For example, the EPA has estimated that the dose equivalent following ingestion of 1 Bq of 
241Am is 2.1x10-7 Sv (assuming an integration time of 50 years for an adult following the initial 
exposure). Age-specific dose coefficients for inhalation and ingestion of any of the radioactive isotopes 
of americium by the general public can be found in ICRP publications 67 (ICRP 1993), 71 (ICRP 1995), 
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radionuclides can be found in U.S. EPA Federal Guidance Report No. 11 (EPA 1988). Dose coefficients 
for external exposure to radioisotopes of americium in air, surface water, or soil contaminated to various 
depths can be found in U.S. EPA Federal Guidance Report No. 12 (EPA 1993). 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE  
To help public health professionals and others address the needs of persons living or working near 
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects).  These data are discussed in terms of three exposure 
periods: acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more). 
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures. The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest­
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies. 
LOAELs have been classified into "less serious" or "serious" effects.  "Serious" effects are those that 
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death). "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be 
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR 
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects.  The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which 
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not 
the effects vary with dose and/or duration, and place into perspective the possible significance of these 
effects to human health. 
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 





























3. HEALTH EFFECTS 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no 
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs. 
Americium is a human-made element that has no stable form; all isotopes of americium are radioactive 
(see Section 4.1). Americium isotopes vary with respect to decay rates, decay chain isotopes produced, 
and specific activity (see Section 4.2). Of particular interest is 241Am, a decay product of 241Pu. 
Americium is produced in small quantities (see Section 5.1), and information regarding human exposure 
is limited.  Although this Toxicological Profile is not limited to health and pharmacokinetics data for any
particular radioisotope of americium, available studies primarily involve the isotope 241Am and, to a much 
lesser extent, 243Am.  Accidental occupational or environmental exposures to 241Am in humans are usually
associated with co-exposures to 241Pu (typically in a mixture with a range of plutonium isotopes of mass 
from 238 up to 244) and other radioactive isotopes comprising the major sources of radiation associated 
with nuclear fallout from nuclear explosions and releases from processing and fuel reprocessing plants 
(see Chapter 6).  Isolated accidental exposures to household products containing 241Am (e.g., ingestion of 
241Am-containing parts of smoke detectors) have been reported, but did not result in observed adverse 
health effects. Available information on the health effects of americium is based entirely on effects 
observed in humans and animals from radioactivity attributable, at least in part, to americium exposures.  
The animal studies discussed below involve exposures to high doses of ionizing radiation from uptake of 
241Am.  As with other substances, uptake and disposition of americium in the body (and, hence, the 
potential for specific health effects from internalized americium) depend upon the chemical properties of 
the particular americium compound to which one may be exposed, as well as the route of exposure (see 
Section 3.4 for more information regarding uptake and disposition of americium).  Based on available 
toxicokinetic information and the emissions of americium, the major health concern is radiation damage
from internalized americium.  Health effects may be deterministic in nature or stochastic with a lengthy
latency period, similar to those reported for other radionuclides with comparable half-lives and 
distribution schemes.  Inhalation, ingestion, or dermal absorption of americium compounds (or 
compounds that generate americium via radioactive decay) in amounts large enough to pose a chemical 




























3. HEALTH EFFECTS 
3.2.1 Inhalation Exposure 
Available information from human exposures indicates that airborne americium-containing particles are 
deposited in the respiratory tract, cleared to some extent via mucociliary action, and swallowed or 
expelled (Edvardsson and Lindgren 1976; Fry 1976; Newton et al. 1983; Sanders 1974; Toohey and
Essling 1980). Descriptions of human respiratory tract models that can be used for radiation protection 
also include relevant information regarding biokinetics of inhaled particles (ICRP 1994b, 1995; NCRP 
1997).  Quantitative data for uptake fractions of americium compounds resulting in fast, medium, and 
slow systemic absorption are summarized by ICRP (1996).  Supporting animal studies include inhalation 
exposure to aerosols of americium (Buldakov et al. 1972; DOE 1978; Gillett et al. 1985; Sanders and 
Mahaffey 1983; Talbot et al. 1989; Thomas et al. 1972) or intratracheal instillation of americium
compounds (Moushatova et al. 1996). Estimates of tissue or organ body burden of americium are 
provided in some study reports to demonstrate the target areas of internal deposition of americium.
3.2.1.1 Death 
No reports were located regarding death in humans resulting from acute-, intermediate-, or chronic-
duration inhalation exposure to americium. 
Death was noted within 6 months in an unspecified number of dogs following acute exposure to 241Am
aerosols (as americium nitrate) resulting in inhaled activity of 1.5 µCi/kg (55.5 kBq/kg) (Buldakov et al. 
1972).  Significant early mortality, attributed to radiation pneumonitis, was noted in rats following acute 
inhalation of 241AmO2 particles (activity median aerodynamic diameter [AMAD] 0.75–1.39 µm) resulting 
in an approximate initial lung burden of 1.3 µCi (48 kBq) and radiation dose to the lungs of 1,500 rad 
(1.5 Gy) (Sanders and Mahaffey 1983). 
3.2.1.2 Systemic Effects  
No data were located regarding gastrointestinal, dermal, or ocular effects in humans or animals following 

























3. HEALTH EFFECTS 
Respiratory Effects. No reports were located regarding respiratory effects in humans following 
acute-, intermediate-, or chronic-duration inhalation exposure to americium.  External measurements of 
internally deposited 241Am in the lungs of a man exposed to americium in an occupational accident 
determined an initial lung burden of 960 kBq (26 µCi) measured 3 days after the exposure that decreased 
to 55 kBq (1.5 µCi) after 2 years (Breitenstein and Palmer 1989; Robinson et al. 1983).  However, no 
pathological changes to the lung attributed to radiation exposure were identified in the autopsy of this 
man 11 years later (Filipy et al. 1995).  Exposure was predominantly dermal via facial lacerations, but 
included inhalation.  Toohey and Kathren (1995) estimated that the man received a total lung dose of 
1.7 Gy (170 rem) based on the Breitenstein and Palmer (1989) estimate of 1.3 Gy (130 rem) for the first 
5.7 years plus a dose of 0.4 Gy (40 rem) for the remaining 5.7 years, based on estimated lung burden at 
autopsy.  See Section 3.2.3.2 for additional information regarding this case of accidental mixed exposure 
to americium.
No reports were located regarding respiratory effects in animals following intermediate- or chronic-
duration inhalation exposure to americium.  Respiratory insufficiency and pulmonary pneumonia were 
reported in a group of five dogs following acute exposure to 241Am aerosols (as americium nitrate) 
resulting in an inhaled activity of 1.5 µCi/kg (55.5 kBq/kg) (Buldakov et al. 1972).  In another study, 
gross and microscopic lung lesions, including pleural thickening, fibrosis, mineralization, and cell 
proliferation, were noted in dogs sacrificed from 127 to 1,022 days following a 10-minute inhalation 
exposure to aerosols of 241Am dioxide (relatively insoluble) that was generated by heating 241Am oxide to 
600 ºC).  Exposures resulted in estimated initial 241Am body burdens between 38 and 51 µCi (1.4 and 
1.9 MBq).  Increased respiratory frequency and decreased tidal volume were observed in two of the early
sacrifices (Thomas et al. 1972).  Radiation pneumonitis was observed in rats exposed once (nose-only) to 
241AmO2 aerosols resulting in a lung tissue activity level of approximately 650 nCi (24 kBq), but not at 
lung tissue activity level of 31 nCi (1.15 kBq) (DOE 1978).   
Cardiovascular Effects. No reports were located regarding cardiovascular effects in humans 
following acute-, intermediate-, or chronic-duration inhalation exposure to americium. 
No reports were located regarding cardiovascular effects in animals following intermediate- or chronic-
duration inhalation exposure to americium.  Various effects on the cardiovascular system, including shifts 
in hemodynamics (blood pressure and flow), electrocardiographic changes, and myocardial ischemia were 
reported in a group of five dogs following acute exposure to 241Am aerosols (as americium nitrate) 


























3. HEALTH EFFECTS 
Hematological Effects. Persistent clinical lymphopenia and thrombocytopenia were observed in a 
64-year-old man exposed to 241Am when an ion-exchange column containing about 100 g of 241Am
exploded in his face (Filipy et al. 1995).  The explosion resulted in contact exposure predominantly via 
lacerated skin and chemical burns on the face and neck areas as well as presumed inhalation exposure 
introducing 241Am into the surrounding tissues and blood circulatory system (Ragan et al. 1983; Robinson
et al. 1983). The administration of chelating agents would have affected the blood concentration and 
deposition, and may have reduced the potential duration and severity of symptoms. 
No reports were located regarding hematological effects in animals following intermediate- or chronic-
duration inhalation exposure to americium.  Leukopenia and elevated hematopoietic activity were 
reported in a group of five dogs following acute exposure to 241Am aerosols (as americium nitrate) 
resulting in inhaled activity of 1.5 µCi/kg (55.5 kBq/kg) (Buldakov et al. 1972). Hematocrit, total white 
blood cell counts, neutrophils, lymphocytes, and platelets were decreased from pre-exposure values in 
dogs following a 10-minute inhalation exposure to aerosols of 241Am (presumed to be relatively insoluble, 
having been generated by heating 241Am oxide to 600 ºC), resulting in estimated initial 241Am lung 
burdens between 38 and 51 µCi (1.4 and 1.9 MBq) (Thomas et al. 1972).  These values remained lower 
than pre-exposure values in the dogs individually sacrificed 127, 256, and 512 days postexposure; the 
only apparent recovery occurred in the platelet count of the dog sacrificed 1,022 days postexposure, 
reaching near pre-exposure values approximately 900 days postexposure. 
Musculoskeletal Effects. Information regarding musculoskeletal effects in humans is limited to the 
findings of bone marrow peritrabecular fibrosis and decreased cellularity in bone samples taken from the 
corpse of a 64-year-old man who had been exposed to 241Am when an ion-exchange column containing 
about 100 g of 241Am exploded in his face (Priest et al. 1995).  See Section 3.2.3.2 for additional 
information regarding this accident. 
No reports were located regarding musculoskeletal effects in animals following intermediate- or chronic-
duration inhalation exposure to americium.  Pathologic findings in the bone, including fibrosis with focal 
osteoid thickening, focal resorption, and cartilage degeneration, were observed in dogs (initial body
weights between 8.4 and 10.6 kg) sacrificed between 127 and 1,022 days following a 10-minute 
inhalation exposure to aerosols of 241Am dioxide (presumed to be relatively insoluble, having been 
generated by heating 241Am oxide to 600 ºC).  Exposures resulted in estimated initial 241Am body burdens 
























3. HEALTH EFFECTS 
Hepatic Effects. No reports were located regarding hepatic effects in humans following acute-, 
intermediate-, or chronic-duration inhalation exposure to americium. 
No reports were located regarding hepatic effects in animals following intermediate- or chronic-duration 
inhalation exposure to americium.  Changes were observed in the livers of male rats 30 days after a single 
intratracheal instillation (0.2 mL) of 241Am (as americium nitrate), resulting in an internal activity of 
0.05 µCi (1.8 kBq); the effects were predominantly hepatic parenchyma degeneration and focal necrosis 
with the effect observed in areas where blood entered the organ (Moushatova et al. 1996).  Liver lesions 
(fatty changes in the centri-lobular region) were also observed in two beagle dogs 512 or 1,022 days
following a 10-minute inhalation exposure to aerosols of 241Am dioxide (presumed to be relatively
insoluble, having been generated by heating 241Am oxide to 600 ºC).  Exposures resulted in estimated 
initial 241Am body burdens between 38 and 51 µCi (1.4 and 1.9 MBq) (Thomas et al. 1972).   
Renal Effects. No reports were located regarding renal effects in humans following acute-, 
intermediate-, or chronic-duration inhalation exposure to americium. 
No reports were located regarding renal effects in animals following intermediate- or chronic-duration 
inhalation exposure to americium.  Kidney lesions (generalized glomerular mesangial thickening with 
obliteration) were observed in two beagle dogs 512 or 1,022 days following a 10-minute inhalation 
exposure to aerosols of 241Am dioxide (presumed to be relatively insoluble, having been generated by 
heating 241Am oxide to 600 ºC).  Exposures resulted in estimated initial 241Am body burdens between 
38 and 51 µCi (1.4 and 1.9 MBq) (Thomas et al. 1972). 
Endocrine Effects. No reports were located regarding endocrine effects in humans following acute-, 
intermediate-, or chronic-duration inhalation exposure to americium. 
No reports were located regarding endocrine effects in animals following intermediate- or chronic-
duration inhalation exposure to americium.  Thyroid gland lesions (gross atrophy, with fibrosis) were 
observed in two beagle dogs 512 or 1,022 days following a 10-minute inhalation exposure to aerosols of 
241Am dioxide (presumed to be relatively insoluble, having been generated by heating 241Am oxide to 
600 EC). Exposures resulted in estimated initial 241Am body burdens between 38 and 51 µCi (1.4 and 


























3. HEALTH EFFECTS 
measured from day 127 through 1,022 days after exposure to 241Am dioxide aerosols (Thomas et al. 
1972). 
Body Weight Effects.    No reports were located regarding body weight effects in humans following 
acute-, intermediate-, or chronic-duration inhalation exposure to americium.
No reports were located regarding body weight effects in animals following intermediate- or chronic-
duration inhalation exposure to americium.  One of four dogs lost approximately 15% of its body weight 
during the time period of 365 days to sacrifice at 512 days following a 10-minute inhalation exposure to 
aerosols of 241Am dioxide (presumed to be relatively insoluble, having been generated by heating 241Am
oxide to 600 EC). Exposure resulted in an estimated initial body burden of 38 µCi (1.4 MBq) (Thomas et 
al. 1972). 
Metabolic Effects. No reports were located regarding metabolic effects in humans following acute-, 
intermediate-, or chronic-duration inhalation exposure to americium. 
No reports were located regarding metabolic effects in animals following intermediate- or chronic-
duration inhalation exposure to americium.  Increased B-glucuronidase activity was reported in mice 
receiving a single 30-minute nose-only exposure to aerosols of 241Am (as americium nitrate) that resulted 
in a lung-averaged cumulative radiation dose of 2,000 rad (20 Gy) (Talbot et al. 1989). 
3.2.1.3 Immunological and Lymphoreticular Effects  
Lymphopenia was noted in a 64-year-old man exposed to 241Am when an ion-exchange column 
containing about 100 g of 241Am exploded in his face (Filipy et al. 1995), but information regarding the 
immunological consequences of this finding was not available (see Section 3.2.3.2 for additional 
information regarding this accident). 
Leukopenia was reported in a group of five dogs following acute exposure to 241Am aerosols (as 
americium nitrate) resulting in inhaled activity of 1.5 µCi/kg (55.5 kBq/kg) (Buldakov et al. 1972).  Total 
white blood cell counts, neutrophils, and lymphocytes were decreased from pre-exposure values in dogs 
following a 10-minute inhalation exposure to aerosols of 241Am dioxide (presumed to be relatively


























3. HEALTH EFFECTS 
initial 241Am body burdens between 38 and 51 µCi (1.4 and 1.9 MBq) (Thomas et al. 1972).  These values 
decreased in the dogs individually sacrificed 127, 256, and 512 days postexposure.  However, no reports 
were located regarding immunological consequences of reduced leukocyte counts in animals exposed to 
americium.
No reports were located regarding the following health effects in humans or animals following acute-, 
intermediate-, or chronic-duration inhalation exposure to americium: 
3.2.1.4 Neurological Effects 
3.2.1.5 Reproductive Effects  
3.2.1.6 Developmental Effects 
3.2.1.7 Cancer 
No reports were located regarding cancer in humans following acute-, intermediate-, or chronic-duration 
inhalation exposure to americium, and no signs of cancer were found during the autopsy of a heavily 
exposed worker who died 11 years later of unrelated causes (see Section 3.2.3.2).  However, EPA 
considers all radionuclides to be known human carcinogens and has calculated cancer risk factors for 
inhaled 241Am and 243Am (see Table 8-1 in Chapter 8 for additional information). 
No reports were located regarding cancer in animals following intermediate- or chronic-duration 
inhalation exposure to americium.  Osteosarcomas developed in 4 of 15 dogs surviving more than 
1,000 days following a single inhalation exposure to aerosols of 241AmO2 that resulted in initial lung 
burdens of approximately 2–6 µCi (74–222 kBq) (Gillett et al. 1985).  Among the four dogs that
developed osteosarcomas, the radiation doses to the skeleton, calculated to 1,000 days postexposure, were 
96–410 rad (0.96–4.1 Gy).
3.2.2 Oral Exposure  
No reports were located regarding the following health effects in humans or animals following acute-, 





























3. HEALTH EFFECTS 
3.2.2.1 Death 
3.2.2.2 Systemic Effects  
3.2.2.3 Immunological and Lymphoreticular Effects  
3.2.2.4 Neurological Effects 
3.2.2.5 Reproductive Effects  
3.2.2.6 Developmental Effects 
3.2.2.7 Cancer 
No reports were located regarding cancer in humans following acute-, intermediate-, or chronic-duration 
oral exposure to americium, and no signs of cancer were found during the autopsy of a heavily exposed 
worker who died 11 years later of unrelated causes (see Section 3.2.3.2).  EPA considers all radionuclides 
to be known human carcinogens and has calculated cancer risk factors for ingested 241Am and 243Am (see
Table 8-1 in Chapter 8 for additional information). 
3.2.3 Dermal Exposure  
3.2.3.1 Death 
No reports were located regarding death in humans or animals following acute-, intermediate-, or chronic-
duration dermal exposure to americium. 
3.2.3.2 Systemic Effects  
No data were located regarding respiratory effects, cardiovascular effects, gastrointestinal effects, hepatic 
effects, renal effects, endocrine effects, dermal effects, ocular effects, body weight effects, or metabolic  





























3. HEALTH EFFECTS 
Information regarding systemic effects in humans following dermal exposure to americium derives 
mainly from a single case in which a 64-year-old male (USTUR Case 0246) was exposed when an ion-
exchange column containing about 100 g of 241Am exploded in his face.  Numerous studies relate various 
aspects of this accident as well as subsequent treatment and follow-up (Breitenstein and Palmer 1989; 
Filipy et al. 1995; Jech et al. 1983; McMurray 1983; Palmer et al. 1983; Robinson et al. 1983; Thompson 
1983; Toohey and Kathren 1995).  The explosion resulted in contact exposure through the intact and 
lacerated skin and in presumed inhalation exposure, evident from external chest measurements of 
radioactivity.  The amount of activity initially deposited on the man and his clothing was estimated to be 
1–5 Ci (37–185 GBq).  Immediate treatment reduced contamination to approximately 6 mCi (222 MBq).
By the end of the first day after the accident, the activity had been reduced to 1 mCi (37 MBq).  Intense, 
long-term chelation therapy was employed to reduce body burden. Levels of 241Am in the victim’s blood 
collected the day of the exposure was estimated initially at 6.4 µCi and decreased 10-fold 6 days later to 
0.64 µCi following chelation therapy (Robinson et al. 1983). 
Hematological Effects. Significant, but transient effects on erythropoiesis were indicated by a 
decrease in erythrocyte concentration, hemoglobin concentration, and packed red cell volumes.  Clinical 
lymphopenia and thrombocytopenia persisted for 5 years post-exposure.  The lymphopenia had rapid 
onset and a slow recovery, although pre-exposure values were not attained by 11 years postexposure, at 
which time, the man died of unrelated causes (Filipy et al. 1995).  Histopathologic examination of bone at 
autopsy revealed pathologic changes including peritrabecular fibrosis, bone cell depletion, and bone 
marrow atrophy (Priest et al. 1995), but these changes could not be directly related to estimated radiation 
dose or bone turnover rates as a result of dermal exposure. 
3.2.3.3 Immunological and Lymphoreticular Effects  
Leukopenia was observed in a 64-year-old man following 241Am exposure (Filipy et al. 1995), but 
information regarding the immunological consequences of this finding was not available. 
No reports were located regarding the following health effects in humans or animals following acute-, 



























3. HEALTH EFFECTS 
3.2.3.4 Neurological Effects 
3.2.3.5 Reproductive Effects  
3.2.3.6 Developmental Effects 
3.2.3.7 Cancer 
No reports were located regarding cancer in humans following acute-, intermediate-, or chronic-duration 
dermal exposure to americium, however, no signs of cancer were found during the autopsy of a heavily
exposed worker who died 11 years later of unrelated causes (see Section 3.2.3.2).  EPA considers all 
radionuclides to be known human carcinogens and has calculated cancer risk factors for external exposure 
to 241Am and 243Am (see Table 8-1 in Chapter 8 for additional information). 
3.2.4 Other Routes of Exposure 
3.2.4.1 Death 
No reports were located regarding death in humans resulting from acute-, intermediate-, or chronic-
duration exposure to americium by routes other than inhalation, oral, dermal, or external exposure. 
Dose-related decreased long-term survival was observed in beagle dogs following single intravenous 
injections of 241Am at average activity levels of 1.9–2,900 nCi/kg (0.07–107 kBq/kg) (Taylor et al. 1991, 
1993a). 
3.2.4.2 Systemic Effects  
No data were located regarding systemic effects in humans following acute-, intermediate-, or chronic-
duration exposure to americium by routes other than inhalation, oral, dermal, or external exposure.  No 
data were located regarding respiratory effects, cardiovascular effects, gastrointestinal effects, renal 
effects, dermal effects, ocular effects, or metabolic effects animals following exposure to americium by

























3. HEALTH EFFECTS 
Hematological Effects. A limited study reported dose-related depressions in white blood cell counts 
in dogs that were administered single intravenous injections of 241Am at activity levels of 0.1–2.8 µCi/kg 
(3.7–103.6 kBq/kg) (Dougherty 1970).  Maximum depression in granular leukocytes and monocytes was 
reached approximately 1 month post injection.  Depression of lymphocytes occurred more slowly;
minimal values were reached 1 year or more post injection, with little indication for recovery in the dogs 
receiving the two highest doses of 0.9 or 2.8 µCi/kg (33.3 or 103.6 kBq/kg).  Depression of red blood 
cells was observed only in groups of dogs injected with 241Am at activity levels of ≥0.9 µCi/kg
(33.3 kBq/kg). 
Hepatic Effects. Degenerative liver changes, severe reduction in liver weight, and early death 
(typically attributed to bone cancer) were observed in dogs following single intravenous injections of 
241Am citrate at activity levels of approximately 2.9 µCi/kg (107 kBq/kg) (Taylor et al. 1991).  The 
average radiation dose to the liver in these dogs was 590 rad (5.9 Gy).  Degenerative liver changes and 
early death were also reported in dogs administered single intravenous injections of 241Am at a similar 
activity level (2.8 µCi/kg or 104 kBq/kg) (Lloyd et al. 1970; Taylor et al. 1993a).
Endocrine Effects. Thyroid weights were significantly lower in adult beagle dogs administered 
single intravenous injections of 241Am citrate at activity levels ranging from approximately 0.3 to 
2.75 µCi/kg (11–102 kBq/kg) than those of controls (Taylor et al. 1993a), resulting in thyroid doses of 8– 
2,976 rad (0.08–29.76 Gy).  Histologic examination revealed follicular hyperplasia and degenerative 
cellular changes.  Lower serum thyroxine levels were noted in the peripheral blood of dogs in the two 
highest exposure groups. 
3.2.4.3 Immunological and Lymphoreticular Effects  
A limited study reported dose-related depressions in white blood cell counts in dogs that were 
administered single intravenous injections of 241Am citrate at activity levels of 0.1–2.8 µCi/kg (3.7– 
103.6 kBq/kg) (Dougherty 1970).  Maximum depression in granular leukocytes and monocytes was 
reached approximately 1 month post injection.  Depression of lymphocytes occurred more slowly;





























3. HEALTH EFFECTS 
3.2.4.4 Neurological Effects 
No reports were located regarding neurological effects in humans or animals following acute-, 
intermediate-, or chronic-duration exposure to americium by routes other than inhalation, oral, dermal, or 
external exposure. 
3.2.4.5 Reproductive Effects  
No reports were located regarding reproductive effects in humans following acute-, intermediate-, or 
chronic-duration exposure to americium by routes other than inhalation, oral, dermal, or external 
exposure. 
Dose-related increased incidences of death were reported among 14- and 17-day-old fetuses of rats that 
had been administered single intravenous injections of 241Am between 1 and 10 days prior to mating 
(Moskalev et al. 1969).  In this study, 241Am was administered at activity levels of 0.2–96 µCi/kg (7.4– 
3,552 kBq/kg) that produced antenatal fetal tissue doses up to 200 rad (2 Gy).  During gestation, 
concentrations of 241Am were 9–15 times higher in placental tissues than in fetuses.  The investigators 
indicated that death may have been the result of placental changes. 
3.2.4.6 Developmental Effects 
No reports were located regarding developmental effects in humans following acute-, intermediate-, or 
chronic-duration exposure to americium by routes other than inhalation, oral, dermal, or external 
exposure. 
Decreased fetal weight and increased fetal death were reported following single intravenous injection of 
pregnant rats with 241Am (activity level 90 µCi/kg or 3,330 kBq/kg) on gestation day 9 (Rommereim and 
Sikov 1986; Rommereim et al. 1985).  The investigators indicated a tendency toward increased incidences 






















3. HEALTH EFFECTS 
3.2.4.7 Cancer 
No reports were located regarding carcinogenic effects in humans following acute-, intermediate-, or 
chronic-duration exposure to americium by routes other than inhalation, oral, dermal, or external 
exposure. 
Increases in bone cancers occurred in animals administered a single intraperitoneal or intravenous 
injection of 241Am and observed over their life span.  Schoeters et al. (1991) reported bone tumor 
induction in mice receiving injections of 22,000 or 58,000 Bq 241Am/kg (0.59 µCi or 1.57 µCi/kg) and 
early mortality from non-neoplastic diseases in mice receiving larger activities of 190, 373, or 1,197 kBq 
241Am/kg (5.14, 10.1, or 32.4 µCi/kg). Mice administered 45,000, 90,000, or 213,000 Bq 241Am/kg (1.22,
2.43, or 5.76 µCi) (Van Den Heuvel et al. 1995) via intravenous injection, which produced respective 
radiation doses to the femur of 2.3, 3.6, and 8.4 Gy (230, 360, and 840 rad), showed increased incidence 
for osteosarcomas at 45,000 Bq/kg (0.8 kBq/mouse).  Rats administered 0.03 µCi 241Am/g via injection 
into the tail developed osteosarcomas (Carter et al. 1951).  Young adult beagle dogs were administered a 
single injection of graded activities of 0.016-3.0 µCi/kg 241Am (592–111,000 Bq/kg) that resulted in bone 
sarcomas at low doses not expected to cause adverse effects.  A 100% incidence of sarcomas was 
observed in the dogs receiving higher activities (Jee et al. 1985).  Companion experiments using bone-
seeking radionuclides in beagle dogs were conducted over 35 years (1952–1987) by Lloyd et al. (1994a, 
1994b, 1995); several biological effects were observed during the lifespan of the animals.  The initial 
report, a comparative toxicity study for 241Am to 226Ra, both bone-seeking internal emitters, showed 
similar ratios for relative effectiveness for bone cancer induction in dogs (Lloyd et al. 1994a) and mice 
(Taylor et al. 1983) administered 241Am via intravenous injection.  Lloyd et al. (1994b) reported skeletal 
malignancies among beagles receiving graded activities of 0.07–104 kBq 241Am/kg (0.002–2.8 µCi/kg) 
via a single intravenous injection as the first of the companion experiments.  In the second part of the 
experiment, Lloyd et al. (1995) conducted an analysis of all soft tissue tumors in the dogs treated by
intravenous injection.  The authors reported both positive and negative associations between exposure and 
tumor incidence, apparent in a variety of soft tissues, but the development of these tumors appeared to be 
influenced by the competing risk of death from bone cancer or other severe radiation effects (Lloyd et al. 
1995).  Incidence of tumors in mice administered activities of 6, 17, or 29 kBq 241Am/kg (0.2, 0.5, or 
0.8 µCi/kg) were higher for liver (adenomas and carcinomas) than for bone sarcomas (Ellender et al. 
2000), supporting similar findings in earlier investigations.  In a study of dogs administered single 
intravenous injections of 241Am that ranged from 0.07 to 107 kBq Am/kg (from 0.002 to 2.9 µCi/kg), the 






















3. HEALTH EFFECTS 
However, the incidence of liver tumors was higher than that of bone tumors in dogs exposed to lower 
levels of 241Am.  Moskalev et al. (1989) reported that injecting pregnant Wistar rats with 92.5 kBq  
241Am/kg (3.4 µCi/kg) as nitrate on gestation day 16 produced 4 osteosarcomas in 78 female and 52 male 
offspring, compared with no cancers in the controls.  In a communication by Lloyd et al. (2001), the 
authors concluded that longevity of irradiated mammals exposed to low-level exposures of bone-seeking 
radionuclides was independent of dose, except for radiation-induced malignancies or other radiation 
effects. 
3.3 GENOTOXICITY  
No reports were located regarding genotoxic effects in humans following acute- or intermediate-duration 
inhalation exposure to americium.  Chromosomal aberrations (symmetrical translocations and dicentrics 
and ring chromosomes) in lymphocyte preparations were elevated for an entire group of seven nuclear 
fuel production workers who were exposed for 11–22 years to external gamma radiation, with an 
additional internal exposure for six of these workers to alpha-emitting 241Am 5 years prior to the analysis 
(Bauchinger et al. 1997). The total effective dose equivalent for the workers from exposure to external 
gamma radiation and internal contamination with 241Am were: 393, 39, 207, 304, 202, 237, and 349 mSv 
(whole body) (39.3, 3.9, 20.7, 30.4, 20.2, 23.7, and 34.9 rem).  In five of the six cases that included 
internal contamination, the committed effective dose equivalent from 241Am represented 5–25% of the 
total dose, the main contribution coming from external exposure to gamma radiation.  In the other worker, 
internalized 241Am represented 66% of the total effective dose equivalent of 39 mSv (3.9 rem).  Another 
case involved a radiation worker and his wife, college-age daughter, and 10-year-old son who were 
exposed for several years in their house to elevated levels of 241Am that resulted in body burdens of 6.5– 
89 nCi (0.24–3.3 kBq) from a source used by the father for private experiments.  Chromosomal 
aberrations in isolated leukocytes were noted to be similar to those observed in other cases of accidental 
or therapeutic exposure to external radiation sources (Kelly and Dagle 1974).  The cytogenetic damage 
observed was low and only grossly comparable to historical control values available to the authors.  The 
limited human data do not indicate a significant genotoxic response to inhaled americium. 
No reports were located regarding genotoxic effects in animals following intermediate- or chronic-
duration inhalation exposure to americium.  A single report regarding genotoxic effects following acute 
inhalation exposure to americium indicated decreased numbers of pulmonary alveolar macrophages 

























3. HEALTH EFFECTS 
mice receiving a single 30-minute nose-only exposure to 241Am (as americium nitrate) producing a 
cumulative radiation dose of 2,000 rad (20 Gy) to lungs (Talbot et al. 1989).  The initial alveolar 
deposition was 32.4 nCi (1.2 kBq), but rapidly declined to about 8.1 nCi (300 Bq) by 21 days and to 
approximately 2.7 nCi (100 Bq) by the end of the study (day 98).  Following exposure to 241Am, 
essentially all PAMs contained 241Am; significant amounts of 241Am were still observed at each sacrifice 
time period between postexposure days 3 and 98. 
No reports were located regarding genotoxic effects in humans or animals following acute-, intermediate-, 
or chronic-duration oral or dermal exposure to americium. 
3.4 TOXICOKINETICS 
3.4.1 Absorption
3.4.1.1 Inhalation Exposure 
Evidence for absorption of inhaled americium to blood of humans is provided by several cases of workers 
who were accidentally exposed to airborne 241Am (Edvardsson and Lindgren 1976; Fry 1976; ICRP 1996; 
Kathren et al. 2003; Newton et al. 1983; Sanders 1974; Toohey and Essling 1980).  Although these cases 
do not provide a complete quantitative description of the absorption of inhaled americium in humans, they
clearly demonstrate that inhaled americium oxides (e.g., AmO2) can be absorbed, as indicated by the 
detection of 241Am radioactivity in regions of the body such as liver and bone, and excretion in urine. 
In one case, an adult worker inhaled aerosols of plutonium and americium dioxides (239PuO2 and 
241AmO2) (Newton et al. 1983).  Thoracic counts of radioactivity that were determined by an external 
radiation detector starting 7 days after the exposure showed that 241Am was removed from the chest area
with biological half-times of 11 (80%) and 920 (20%)days.  These estimates were assumed to reflect 
clearance from the lung to systemic compartments.  However, fecal excretion was estimated to be 
approximately 50% of the estimated initial deposit of 241Am in the lung, suggesting that extensive 
mechanical transport to the gastrointestinal tract, typical of inhaled large particles, may have occurred.  
External counting also detected 241Am in the skull on day 913 post accident, suggesting that 241Am was 



























3. HEALTH EFFECTS 
In a second case, an adult worker inhaled mixed oxides of curium and americium dioxides (244CmO2 and 
241AmO2) (244Cm:241Am airborne ratio, 3:1), which resulted in the deposition of approximately 450 nCi 
(16.6 kBq) of radioactivity in the lungs, or approximately 112 nCi (4.1 kBq) of 241Am (Sanders 1974).  
Chest counts of the subject indicated that total radioactivity was retained in the lungs with a half-time 
(i.e., decay-corrected) of 28 days; however, data on the elimination of each isotope from the lung were 
not reported.  Most of the elimination from the chest area was accounted for by recovery of radioactivity
in the feces, consistent with mechanical clearance of the deposited activity to the gastrointestinal tract.  
Evidence for systemic absorption in this case was the detection of 241Am in urine; approximately 1.1 nCi 
(41 Bq, 1% of the deposited activity) of 241Am was excreted in urine in 365 days, with a half-time of 
35 days. 
In a third case, two adults accidentally inhaled 241AmO2 (particle size not specified), which resulted in the 
deposition of approximately 15 nCi (555 Bq) of activity in the lungs (Fry 1976).  Chest activity measured 
over a period of 200–1,500 days after the accident indicated that the retention half-time for 241Am in the 
lungs was between 900 and 1,400 days.  Activity measured over the chest, liver, and extremities (knees 
and ankles, reflecting primarily bone activity) indicated that by 324 days after the accident, approximately
41% of the whole-body activity was in the lung, 47% was in the liver, and 12% was in bone.  After 
1,392 days, lung activity had decreased to 18%, liver activity was unchanged (47%), and bone activity
had increased to 35%. 
In a more recent case, an adult male accidentally inhaled 241Am (believed to be in oxide form), which 
resulted in an intake of approximately 6.3 kBq (170 nCi) of activity (Kathren et al. 2003).  Results of 
radioactivity measurements in the chest area between days 48 and 2,135 following the accident indicated 
that 241Am was cleared from the lungs with half-times of 110 and 10,000 days.
Additional evidence for absorption of inhaled americium, and more quantitative estimates of the extent of 
and rates of absorption, are provided by animal experiments.  The lung deposition and absorption of 
inhaled aerosols of americium nitrates and oxides have been studied in experimental animals; the results 
of representative studies are provided in Table 3-1.  In general, exposures were nose-only (although this 
was not always specified in the reports) to relatively well-characterized aerosols of 241Am compounds.  In 
most studies, the actual exposure concentration of americium was not reported.  Estimates of lung 
retention half-times reflect the rate of loss of radioactivity from the lung following any initial (3–8 days) 
loss of americium that may have been transferred to the gastrointestinal tract and excreted without 












   
 
 
   




   
 
 





















   
 
 

















3. HEALTH EFFECTS 
Table 3-1. Retention and Absorption Estimates in Animals  






















Aerosol No data 1.5±1.6 67 nCi 
21 ng
47 days (89%) 
550 days (11%) 
(retention)






No data 1.4 75 µCi/kg 
23 µg/kg
0.1 days (32%) 
160 days (68%) 
(retention)
Mewhinney et al. 1982 
Dog, 
adult
241AmO2 Aerosol,  
nose-only,  
20 minutes
No data 0.75±1.2 41% 
60–250 nCi/kg 
18–77 ng/kg
9 days (89%) 
283 days (11%) 
(retention)
No data 1.5±1.07 39% 
39–240 nCi/kg 
12–74 ng/kg
13 days (76%) 
171 days (24%) 
(retention)
No data 3.0±1.06 30% 
30–190 nCi/kg 
12–59 ng/kg
13 days (69%) 
167 days (31%) 
(retention)





Aerosol No data 2.2±1.8 190 nCi 
59 ng






































   
 
 
   

















   
 
    
 
 




   
 
 































3. HEALTH EFFECTS 
Table 3-1. Retention and Absorption Estimates in Animals  
Exposed to Americium Compounds by Inhalation 
Aerosol Lung deposition Lung retention or 
Animal Am Exposure AMAD (percent of absorption half-
model species Exposure concentrationa (µm±GSD) intake) lifeb 
Craig et al. 1979 
Dog, 241AmO2 Aerosol, 0.66 mCi/m3 0.63±2.64 13% 20–30 days 
adult nose-only 0.20 mg/m3 1,2 nCi 120 days 
0.38 ng 400 days 
(retention)
42 mCi/m3 1.25±1.77 30% 
13 mg/m3 120 nCi 
37 ng
340 mCi/m3 1.35±1.74 35% 
105 mg/m3 1,150 nCi 
355 ng
Stather et al. 1979 
Hamster, 241AmO2 Aerosol No data 1.9±2.0 45 nCi/kg 11 days 
adult 14 ng/kg 200 days 
(retention)
Stanley et al. 1982 
Rat, 241AmO2 Aerosol No data 2.3±1.7 7.8 nCi 	 95 days (89%) 
adult (dust)c 2.4 ng/kg	 2,800 days 
(11%) 
(retention)
Stradling et al. 1992, 1994 
Rat, 241AmO2 Aerosol, No data 2.1±1.78 0.14 nCi/kg 2,000 days 
adult (dust)d nose-only, 0.042 ng/kg >10,000 days 
1-hour (absorption)
Stradling and Stather 1989
Rat, 241Am Aerosol, No data 0.3±2.5 75 nCi/kg 49 days 
adult nitrate nose-only 23 ng/kg 315 days 
1–2 hour (absorption)
241AmO2 No data 1.4±2.0 26 nCi/kg 7,000 days 
(dust)e 8.1 ng/kg 7,000 days 
(absorption)
241Am No data 3.8±1.6 0.51 nCi/kg 170 days 
nitrate 0.16 ng/kg 1,200 days 
(dust)f (absorption)
241Am No data 1.8±2.4 0.11 nCi/kg 47 days 












   
 
 
   



























3. HEALTH EFFECTS 
Table 3-1. Retention and Absorption Estimates in Animals  













Lung retention or 
absorption half­
lifeb 







No data 1.26±1.29 11 nCi/kg 
3.6 ng/kg
0.21±1.61 89 nCi/kg 
27.6 ng/kg



















aWhere only activity was reported, mass concentration of Am was calculated assuming a specific activity of 3.24 Ci/g. 
bRetention reflects total elimination from lung; absorption reflects transfer to blood  
cPowder collected from plutonium oxide milling operation 
dDust from a weapons test site 
eDust from ambient oxidation of Pu metal 
fDust from corrosion of industrial process line equipment, mainly aged Pu/Am nitrate intimately mixed with corrosion 
products 
gDust from green salt formed in the electrorefining of Pu metal 
hDust derived from ignition of Pu (900–1,000 EC)
iDust derived from air oxidation of molten Pu
Note: Footnotes d-i apply to americium in a Pu-bearing matrix where Am absorption kinetics may have been determined 
by Pu dissolution. 























3. HEALTH EFFECTS 
estimates were based on curve-fitting of the data on lung radioactivity-time profiles and other 
assumptions.  Thus, some of the differences in estimates undoubtedly reflect differences in particle size 
(known to significantly affect deposition pattern within and mucociliary clearance from the respiratory
tract), solubility in biological fluids, curve-fitting method, duration of observations, and intra-study
variability; nevertheless, general trends are evident.  Retention and systemic absorption can be described 
with two or three rate functions that represent fast and slower processes for transfer of americium from
the lung (albeit with considerable differences in the rates reported in various studies, probably reflecting 
differences in particle size distribution, animal species, and exposure scenarios).  For example, in 
monkeys exposed to aerosols of 241AmO2 (AMAD, 1.4 µm), retention half-times of 241Am were 0.1 days
(32% of the initial deposited) and 160 days (68%) (Mewhinney and Muggenburg 1985).  Stanley et al. 
(1982) also observed both fast and slower phases of lung retention in monkeys exposed to 241AmO2. 
Mewhinney et al. (1982) found that in dogs exposed to aerosols of americium dioxide (AMAD 0.8– 
3.5 µm), approximately 30–50% of the inhaled activity was deposited in the lung; for an AMAD of 
0.8 µm, the estimated retention half-times were 9 and 290 days for 89% and 11% of the lung burden, 
respectively. Within 8 days of exposure, 32% of the initial lung burden was detected in extra-respiratory
tissues, mainly the liver (21%) and skeleton (11%).  The observations of rapid and slow phases of 
retention of americium initially deposited in the respiratory tract are consistent with the results of other 
studies of dogs exposed to 241AmO2 aerosols (Craig et al. 1975; Thomas et al. 1972).  Studies in rodents 
indicate that inhaled americium nitrates and chlorides are absorbed more rapidly than americium oxides 
(Stather et al. 1979b; Stradling and Stather 1989; Stradling et al. 1994).  Americium oxides in dusts from
weapon sites and industrial facilities were absorbed particularly slowly, with absorption half-times of 5– 
25 years, although this may also vary depending on the process that leads to the production of the dust.  
For example, americium oxides in dust formed during the ignition of plutonium were absorbed from the  
lung with a half-time of 0.5–1 year, whereas americium oxides produced from the air oxidation of molten 
Pu had absorption half-times exceeding 12 years (Moody et al. 1991).  This may reflect differences in the 
compounds produced (e.g., Pu-Am particles that are surface but not volume oxidized) or oxide species 
formed under different conditions (e.g., temperature, etc.). 
Information on the absorption of americium from the lung also can be derived from studies in which 
americium compounds were instilled directly into the trachea.  Although intratracheal instillation does not 
precisely mimic inhalation exposure, rates of absorption of the deposited americium have been shown to 
be comparable for both routes of exposure.  For example, Stradling et al. (1992) estimated nearly identical 
half-times for absorption of 241Am in rats that received either intratracheal instillations of 241Am oxide-
























3. HEALTH EFFECTS 
slower phase >10,000 days).  Estimates of absorption half-times in rats that received intratracheal 
instillations of 241AmO2 in various types of dusts from weapons or fuel facilities indicate a slow and fast 
component to absorption, with the fast component ranging from 1 to 5 years, and rates of absorption
following intratracheal instillation of americium nitrate, citrate, or hydroxide are higher than after 
instillation of americium oxides (Crawley et al. 1976; Müller et al. 1989; Stradling et al. 1989, 1992, 
1994). 
3.4.1.2 Oral Exposure 
Human studies indicate that <0.1% of the ingested activity is absorbed into blood, which is consistent 
with numerous observations that have been made in experimental animals.  Infant uptake may be closer to 
0.5% (ICRP, 1996). Absorption of americium contained in shellfish (molluscs) has been studied in 
humans.  Eight adult subjects (six males and two females) ingested molluscs (winkles), collected from
marine waters near the British Nuclear Fuels facility at Sellafield, Cumbria, that contained 241Am (Hunt et 
al. 1986a, 1986b).  The range in the ingested activity of 241Am was 18–76 Bq (0.49–2.1 nCi, 0.15– 
0.63 ng). Serial 24-hour urine samples were collected from each subject for up to 10 days after they
ingested the molluscs.  The fraction of the activity absorbed was estimated as the ratio of the observed 
cumulative urinary excretion of 241Am to that of the excretion predicted to occur if absorption had been 
complete.  The latter was predicted using a kinetic model of excretion of absorbed americium described 
by Takada et al. (1984).  The reported geometric mean absorption for the eight subjects was 
0.6x10-4 (geometric standard deviation [GSD], 0.1; range, 0.4x10-4–2.1x10-4), or 0.006% of the ingested 
activity.  Seven of the initial eight subjects and one new subject participated in a subsequent study (six 
males and two females) in which the same protocol was implemented and the 241Am activity range was 
10–25 Bq (0.27–0.68 nCi, 0.083–0.21 ng) (Hunt et al. 1990).  The arithmetic mean absorption fraction 
was 0.8x10-4 (range, 0.4x10-4–1.5x10-4) or 0.008% of the ingested activity.  When the results of the two 
studies were combined, the arithmetic mean absorption fraction was 0.9x10-4 (range, 0.3x10-4–2.5x10-4) 
or 0.009% of the ingested activity; absorption fractions for males and females were similar.  Three of the 
initial eight subjects and three new subjects participated in a third study (five males and one female) in 
which the same protocol was implemented; however, the subjects ingested cockles collected from
Ravenglass, Cumbria for a range of ingested activity of 15–17 Bq (0.41–0.46 nCi, 0.13–0.14 ng) (Hunt 





























3. HEALTH EFFECTS 
Information on the absorption of ingested AmO2 is provided from accidental oral exposures.  In one case, 
a worker ingested a ceramic particle containing approximately 2.85 µCi (105 kBq, 0.88 µg Am) of 
241AmO2. During the first 8 days after the particle was ingested, approximately 4 pCi (0.15 Bq) or 
0.00014% of the estimated activity was excreted in the urine (Smith et al. 1983).  In a second case, a 
worker swallowed two 2-mm (diameter) silver disks used in the manufacture of smoke detectors, which 
contained approximately 4.22 µCi (156 kBq, 1.3 µg) of 241Am.  The subject excreted the disks in feces on 
days 16 and 24 post ingestion.  Urinary 241Am excretion during this time was approximately 3 pCi 
(0.11 Bq, 0.7 ng Am) or 0.0007% of the ingested activity (Rundo et al. 1977).  The time lapse between 
ingestion and fecal excretion of the disks was related to suspected delay in esophageal transit and 
infrequent bowel movements by the subject. 
Studies in nonhuman primates provide additional evidence that <0.1% of an ingested amount of 
americium is absorbed.  Ham et al. (1994) estimated the gastrointestinal absorption of americium in 
marmosets by comparing the retention of 241Am in the liver and carcass after intraperitoneal injection of a 
citrate solution containing 241Am (1.6 Bq, 43 pCi, 0.012 ng Am) or after gastric intubation with 241Am
mixed with potato powder (250 Bq, 6.7 nCi, 2.0 ng Am).  The absorption fraction of 241Am mixed with 
potato powder was estimated to be approximately 6x10-4 or 0.06% of the administered activity.   
Gastrointestinal absorption of americium has also been estimated in pigs, guinea pigs, mice, and rats.  The 
results of representative studies are provided in Table 3-2.  Whilst these studies differ in the methodology
used to estimate absorption, they reveal certain important trends.  In general, the animal studies reveal a 
relatively low absorption of ingested americium across species (<1% in adult animals).  In the pig, guinea 
pig, hamster, and rat, absorption is higher by a factor of 30–200 in neonatal animals compared with adults 
and/or progressively decreases in magnitude with age after birth (to a factor of 4 at 30 days for the guinea 
pig) (Bomford and Harrison 1986; David and Harrison 1984; Sullivan et al. 1985).  Americium appears to 
be absorbed to a similar extent when it is ingested as an aqueous solution of water soluble nitrates or 
citrates or when it is incorporated into foods, such as molluscs, potato, or liver tissue (Bulman et al. 1993;
Ham et al. 1994; Harrison et al. 1988; Hisamatsu and Takizawa 1987; Stather et al. 1979a).  Absorption
of relatively water insoluble oxides of americium is lower by a factor of 4–10 compared with the 
absorption of americium citrate, whose absorption factor is a factor of 3–6 lower than that of americium
nitrate (Stather et al. 1979a; Sullivan 1980a, 1980b). Similarly, in rats, the absorption of americium from  
surface dust from a weapons site was lower by a factor of 10–50 compared to americium oxide or nitrate 
(Harrison et al. 1994; Sullivan 1980b). A species difference was noted; guinea pigs absorbed 5 times
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Dose and mediaa 
241Am in potato 





Basis for estimate of 
absorption
Absorption estimate based 
on comparisons with liver 
and carcass 241Am after an 
Reference







241Am citrate aqueous 
solution, single gavage 
dose, 190 µg/kg
241Am citrate aqueous 




Absorption estimate based 
on maximum whole-body 
241Am (8 days), without 
adjustment for excretion




241Am nitrate aqueous 
solution, single gavage 
dose
~3 Absorption estimate based 
on carcass 241Am (5 days),







241Am citrate aqueous 
solution, single dose 


















Absorption estimate based 
on comparisons with liver 
and carcass 241Am after an 
intraperitoneal dose 
(neonates) or intravenous 






Guinea pig and 
rat, adult
241Am in three surface 
dust samples, single 
dose applied to tongue 
(GP, 5–15 ng/kg) or









Absorption estimate based 
on comparisons with liver 
and carcass 241Am after an 






241Am nitrate, aqueous 
solution, single gavage 
dose, 2–4.4 µg
0.017–0.031 Absorption estimate based 







241Am nitrate, aqueous 
solution, single dose 














Absorption estimate based 
on comparisons with liver 
and carcass 241Am after an 





























































3. HEALTH EFFECTS 
Table 3-2. Absorption Estimates in Animals Exposed to Americium Compounds 
by Ingestion 
Animal model Dose and mediaa 
Absorption 
(percent of dose)
Basis for estimate of 
absorption Reference
Hamster, adult 241Am nitrate, aqueous 
solution, single gavage 
dose, 2.8 ng/kg
241Am citrate aqueous 




Absorption estimate based 
on comparisons with liver 
and carcass 241Am after an 
intravenous dose, with 
adjustment for excretion
Stather et al. 
1979
241Am dioxide, aged 
aqueous suspension, 
single gavage dose, 
19 ng/kg
0.0058
241Am in liver from 0.0034
exposed hamsters, 
single dose, 2.9 ng/kg
Mouse, adult 241Am nitrate, aqueous 
solution, single gavage 
dose, 32 µg/kg
241Am citrate, aqueous 




Absorption estimate based 
on sum of 241Am in 
carcass (excluding the 






241Am in liver from 0.0024–0.0026
exposed mice, single 
gavage dose
Rat, adult 241Am in wild molluscs 
or 241Am nitrate 
injected into mollusc 






Absorption estimate based 
on comparisons with liver 
and carcass 241Am after an 
intravenous dose, with 
adjustment for excretion, 
twice weekly for 8 weeks
Harrison et 
al. 1988
Rat, adult 241Am in potatoes 
exposed to 241Am, or 
injected into potatoes, 
single dose or daily for 
23 days
0.12–0.16 Absorption estimate based 
on comparisons with liver 
and carcass 241Am after an 
intravenous or




Rat, adult 241Am nitrate, aqueous 
solution, single gavage 
dose, 5 µg/kg
0.063 Absorption estimate based 




Rat, adult 241Am oxide, aqueous 
suspension, single 





























































3. HEALTH EFFECTS 
Table 3-2. Absorption Estimates in Animals Exposed to Americium Compounds 
by Ingestion 
Animal model Dose and mediaa 
Absorption 
(percent of dose)
Basis for estimate of 
absorption Reference
Rat, adult 241Am nitrate, aqueous 
solution, single gavage 
dose, 12 µg/kg; fed or 





Absorption estimate based 
on sum of 241Am in 
carcass (excluding the 
gastrointestinal tract) and 




Rat, neonate 241Am nitrate, aqueous 
solution, single gavage 
dose, 0.44 µg
4.6 Absorption estimate based 





241Am oxide, aqueous 
solution, single gavage 
dose, 0.59 µg
0.32 Absorption estimate based 





241Am nitrate, gavage 
single dose, 285 µg/kg 








Absorption estimate based 





241Am citrate, aqueous 
solution, single gavage 
dose, 285 µg/kg 








Rat, weanling 241Am nitrate, aqueous 
solution, single gavage 
dose, Fe deficient or 
replete, 7–9 µg/kg
4.8 (Fe deficient) 
1.8 (Fe replete)
Absorption estimate based 
on sum of 241Am in 
carcass, excluding the 





aWhere the chemical form and/or dose are not presented, these were not provided in the referenced report.  Where 
only activity was reported, mass concentration of americium was calculated assuming a specific activity of 3.24 Ci/g. 

























3. HEALTH EFFECTS 
compared to the fed state and iron deficiency compared with the iron-replete state (Sullivan and 
Ruemmler 1988; Sullivan et al. 1986).  Concurrent oral exposure to Fe3+ and americium also appears to 
increase the absorption of ingested americium; the latter effect may result from redox reactions in the 
gastrointestinal tract catalyzed by Fe3+ (Sullivan et al. 1986).  While the exact site and chemical species of 
americium that is absorbed from the gastrointestinal tract is not known, chemical speciation models 
applied to saliva and gastric fluid predict that the major species in saliva will be citrate and phosphate 
complexes, whereas in gastric fluid, the major species will be Am3+ (Webb et al. 1998).  Speciation 
models for americium in the small intestine have not been reported; however, complexes with citrate, 
lactate, and phosphate would be expected based on equilibrium constants for these weak acid complexes 
and their abundance in intestinal fluid (Webb et al. 1998). 
3.4.1.3 Dermal Exposure  
Information on the dermal absorption of americium in humans or animals is extremely limited.  Some
qualitative information is available from accidental exposures that included other routes of exposure.  One 
of the most well studied was an accident in which a worker received facial wounds from projectile glass 
(and other debris) and nitric acid during an explosion of a vessel containing 241Am (Filipy et al. 1995; 
McMurray 1983; Toohey and Kathren 1995).  The subject also inhaled 241Am released to the air as dust 
and nitric acid aerosols, which was evident from external chest measurements of radioactivity (Palmer et 
al. 1983).  Accurate estimates of dermal absorption of americium cannot be made from this case because 
of the complex exposure scenario and because of the occurrence of acid and projectile wounds to the skin 
that might have greatly affected the penetration of any americium that was deposited on the surface of the 
skin. Nevertheless, it is possible to conclude from measurements of the dermal 241Am activity soon after 
the accident and measurements of long-term excretion of 241Am that a substantial fraction of the initial 
radioactivity deposited in the area of the wounds was absorbed.  Quantitative measurements of internally
deposited 241Am in target organs were recorded from the third day following exposure to monitor rates of 
radionuclide excretion and accretion by these organs that continued up to time of death 11 years later.  
Based on measurements at day 3 postexposure, the organs that received the highest doses included the 
skin, liver, lung, and bone with estimated organ burdens of 26,000, 1,400, 960, and 480 kBq, respectively
(Breitenstein and Palmer 1989; Robinson et al. 1983).  The organ burdens of 241Am decreased under 
DTPA chelation therapy until conclusion after 5 years where monitoring data show that the activity
decreased in the skin, entered systemic circulation, and deposited into the bone and liver.  Dosimetric 




























3. HEALTH EFFECTS 
increased activities in the bone by about 67 kBq (1.8 µCi) and in the liver by about 7.4 kBq (0.2 µCi), and 
30 kBq (0.8 µCi) excreted via urine and feces.  Over the first 60 days after the accident, dermal 241Am
activity decreased from >5 mCi (185 MBq, 1.5 mg) to approximately 0.15 mCi, (5.5 MBq, 0.046 mg), 
largely as a result of skin decontamination procedures, although normal epidermal sloughing would be an 
expected contributor as well (Robinson et al. 1983).  Cumulative urinary and fecal excretion of 241Am
over an observation period of 5 years was estimated to be 1 mCi (37 MBq, 20% of the initial deposited 
activity), and peak body burden, excluding the skin, was estimated to have been approximately 0.08 mCi 
(3 MBq, 1.6% of the estimated initial deposited activity).  Thus, the combination of transdermal injection 
and dermal absorption, under these extreme conditions of mechanical and chemical skin wounds, may
have been as high as 20%. 
3.4.1.4 Other Routes of Exposure 
Several cases of accidental exposure to americium as a result of wound penetrations have been reported 
(Thompson 1983).  These exposures have resulted in 241Am burdens in the liver and skeleton, indicating 
absorption and distribution from the wound site (McInroy et al. 1989). 
3.4.2 Distribution  
3.4.2.1 Inhalation Exposure 
The liver is the primary soft tissue site of initial accumulation of absorbed americium in humans.  
Americium deposited in bone and skeletal muscle has longer retention half-times than americium in the 
liver. Therefore, at long times after exposure (years), bone and skeletal muscle will contain a larger 
fraction of the systemic americium burden than the liver (Filipy and Kathren 1996; Kathren 1994;
McInroy et al. 1995; Toohey and Kathren 1995).  Information on the distribution of americium within the 
human liver is not available; however, studies in dogs and rats have shown that within a few days after an 
intravenous injection, hepatic 241Am is associated with lysosomes (Gruner et al. 1981; Lindenbaum and 
Rosenthal 1972; Seidel et al. 1986; Sütterlin et al. 1984).  Americium in the hepatic cytosol is bound to
ferritin and other unidentified proteins (DOE 1984; Stover et al. 1970).  It is not known whether 
americium reacts with metallothionein; however, since americium forms stable complexes with






























3. HEALTH EFFECTS 
groups in proteins such as metallothionein would not be expected.  However, binding of 241Am to an 
unidentified low molecular weight protein fraction in a rat liver has been reported (DOE 1984).
The United States Transuranium and Uranium Registries (USTUR) collect data on the americium content 
of human tissues obtained from autopsies.  Recent data summaries reported from the USTUR show that 
after occupational inhalation exposures, 241Am activity resides primarily in the respiratory tract, skeleton, 
liver, and muscle (see Table 3-3).  In three cases in which occupational exposures were believed to have 
been primarily, if not exclusively by inhalation, the following average tissue distribution was observed at 
autopsy 30 or more years after exposure:  skeleton, 48%; respiratory tract, 35%; muscle, 10%; liver, 3%; 
and other issues, 4% (McInroy et al. 1989).  Analyses of larger sets of USTUR cases have shown that, 
excluding the respiratory tract and other site of entry tissues (e.g., wound, gastrointestinal tract), 
approximately 80–90% of the americium in the body is associated with the skeleton, liver, and muscle, 
the skeletal:soft tissue burden ratio is approximately 3, and the highest soft-tissue concentrations are 
observed in the liver (Filipy and Kathren 1996; Filipy et al. 1994; Kathren et al. 1988).  Whole-body
counting of workers who were chronically exposed to plutonium and americium aerosols yielded a similar 
distribution of 241Am between the skeleton and soft tissue.  In a separate study of 20 former workers, the 
geometric mean skeletal:liver burden ratio was 4.4 (GSD, 2.4; range, 1.2–17) (Badjin and Molokanov 
1998).  Further evidence that the skeleton and liver are the primary sites of accumulation of absorbed 
americium is provided by inhalation studies conducted in monkeys (Stanley et al. 1982), dogs (Craig et al. 
1975, 1979; Mewhinney et al. 1982; Thomas et al. 1972), and rats (Stradling et al. 1992, 1994).  
Americium is also taken up by teeth.  In rats, americium accumulates in the dental pulp of developing
teeth and eventually is incorporated into the mineralized dentin (Hammerström and Nilsson 1970b).
Information on the distribution of americium in blood after exposures to americium is available from an 
accident victim who was exposed by inhalation, dermal deposition, and wound penetration as a result of 
an explosion of a vessel containing 241Am, followed by aggressive chelation therapy (McMurray 1983).  
The internal 241Am activity was sufficiently high in this case to provide reliable estimates of blood and 
serum 241Am concentrations.  Essentially all of the 241Am in blood was in the serum (Robinson et al. 
1983).  Studies in animals provide further evidence that americium is confined largely to the plasma
portion of blood.  In baboons, dogs, and rats, >95% of americium in blood is associated with plasma.  A 
variety of human and animal studies (in vivo and in vitro) have shown that americium in plasma binds 
extensively to proteins (80–90%), including albumin and transferrin (Boocock and Popplewell 1966;
Bruenger et al. 1969; Cohen and Wrenn 1973; Cooper and Gowing 1981; Durbin 1973; Popplewell and 


















   
   
   
   
  
   
   
   
   
   
   
   






3. HEALTH EFFECTS 
Table 3-3. Tissue Americium Levels from Human Autopsies 
Mean percent of  Mean percent of systemic burden
Tissue body burden (excluding respiratory tract)
Based on three inhalation casesa 





Tissue Soft tissue:liver concentration ratioc (number of mixed exposures)








aMcInroy et al. 1989 
bEstimates of the contribution of the respiratory region to the total body burden in the three individuals from whom 
the mean value was calculated were 60.7, 23.7, and 14.7%.  See McInroy et al. (1989) for additional statistical 
information. 
cFilipy et al. 1994 
























3. HEALTH EFFECTS 
<1% of the americium was ultrafilterable; however, essentially all of the americium could be rendered 
ultrafilterable by the inclusion of 50 mM citrate in the serum incubate, suggesting reversible binding of 
americium to serum proteins (Chipperfield and Taylor 1972).  As noted above, bone is a primary site of 
long-term accumulation of americium in the skeleton.  One human case of inhaled americium oxide 
resulted in an estimated deposition of 78 kBq (2,100 nCi) and a reported body burden of 34 kBq 
(900 nCi) after 12 years; 79% was located in the bone (Fasiska et al. 1971).  In another human case, 
approximately 55% of an estimated lung deposition of 6.3 kBq (170 nCi) of 241Am was deposited in bone 
(Kathren et al. 2003).  In human autopsy samples of bone, 241Am is found primarily at the cortical and 
trabecular bone surfaces (Priest et al. 1995; Schlenker et al. 1989). 
Americium that is observed in the deeper regions of human bones is thought to result from burial of 
historic surface deposits by newly accreted bone. Supporting evidence for accretion being a mode of 
redistribution of americium in bone comes from studies of monkeys, rats, and dogs that received single 
injections of 241Am (Durbin 1973; Herring et al. 1962; Lloyd et al. 1972; Nenot et al. 1972; Polig 1976; 
Priest et al. 1983). In these studies, the initial deposition of 241Am occurred at bone surfaces, including 
the periosteal and endosteal surfaces of trabecular bone and along the vascular channels of cortical bone, 
with more pronounced deposition at surfaces that were undergoing resorption, and with subsequent 
overlay of new bone (Priest et al. 1983).  Because most americium in bone is associated primarily with 
the bone surface, the americium concentration in bone (per g bone ash) tends to vary with the bone ash 
content, as reflected by the variability in bone surface-to-volume ratio in a human who was 
occupationally exposed to americium (Kathren et al. 1987, 1990; Stevens et al. 1977).   
When residence times (time between exposure and autopsy) for the americium measured in autopsy cases 
are taken into consideration, the measured skeletal burdens are consistent with elimination half-times of 
approximately 50 years (McInroy et al. 1989, 1995).  This value represents an average; however, in an 
individual, exchanges between bone and soft tissue stores of americium may be more rapid during periods 
of active bone metabolism such as infancy and childhood, pregnancy, and menopause (Lloyd et al. 1999).
Studies in animals provide evidence for this concept (Durbin 1973).  After an intravenous injection of 
americium citrate, skeletal tissue accumulated approximately 76% of the injected activity in neonatal dogs 
and 29% in adult dogs (Stevens et al. 1977).  Higher skeletal uptakes of injected americium have also 
been observed in neonatal rats and mice, relative to adult animals (Hollins et al. 1973; Schoeters et al. 
1990) and in young rats (3 months of age) compared to old rats (13 months of age) (Sontag 1983).  On the 
other hand, americium uptake into maternal bone of lactating rats was similar to that of non-lactating rats, 

























3. HEALTH EFFECTS 
Thus, active mobilization of bone mineral, per se, may not always promote release of americium from
bone. 
Information on the placental transfer of inhaled americium in humans is not available.  Studies in animals 
that received parenteral injections of americium show that absorbed americium is transferred to the fetus.  
To some extent, therefore, this distribution pathway would be expected after inhalation exposure (Sikov 
1987; Sikov and Kelman 1989; Stather et al. 1992).  In baboons that received a single intravenous 
injection of americium citrate during the 5th month of pregnancy, approximately 0.4% of the activity was 
transferred to the fetus within 7 days post administration (Paquet et al. 1998).  The fetal:maternal whole-
body 241Am concentration ratio was approximately 0.1 and the tissue distribution in the fetus was similar 
to that observed in adult animals, with the skeleton and liver accounting for most of the 241Am activity in 
the body. Transfer of injected americium to the fetus has also been quantified in mice and rats that 
received intravenous injections of americium citrate during pregnancy (Sikov 1987).  In both rats and 
mice, the fetal skeleton and liver were the major sites of accumulation of americium (DOE 1986; 
Hisamatsu and Takizawa 1983; Sasser et al. 1986; Schoeters et al. 1990; Van Den Heuvel et al. 1992; 
Weiss et al. 1980).  In rats that received an injection of 241Am citrate on days 18 or 19 of pregnancy, fetal 
transfer was approximately 0.01% of the amount of americium administered to the dams.  The 
fetal:maternal 241Am concentration ratio in rats was approximately 0.02 (Hisamatsu and Takizawa 1983).  
In mice that received an injection of 243Am citrate (0.01 µCi/mouse) on day 16 of pregnancy, fetal transfer 
was approximately 0.04% of the administered maternal amount per gram of fetus; the ratio of 243Am
activity (µCi/g) in fetal tissue:maternal tissue exclusive of fetuses at the time of dissection was 
0.029 (Weiss et al. 1980) 
Information on the distribution of absorbed americium to mammary milk in humans is not available.  
Numerous studies in animals have shown that transfer to milk occurs and that neonates can be exposed to 
americium during lactation.  These studies include experiments in which the animals were exposed by 
intravenous injection or oral administration of americium; however, the implications are relevant to any 
route of exposure, including inhalation. In rats that received an intravenous injection of americium citrate 
during lactation, approximately 0.1% of the injected activity was transferred to the nursing pups (Sasser et 
al. 1986).  Oral and intravenous exposure to americium has resulted in the transfer of americium to 
mammary milk of cows, goats, and sheep (McClellan et al. 1962; Sutton et al. 1979).  In a study of sheep 
that received americium chloride intravenously, the concentration of americium in mammary milk was 2– 

























3. HEALTH EFFECTS 
3.4.2.2 Oral Exposure  
Although it has been demonstrated that americium can be absorbed through the gastrointestinal tract (see 
Section 3.4.1.2), the systemic distribution by the oral exposure route has been moderately characterized 
(ICRP, 1986, 1994a).  However, it is reasonable to suggest that the distribution of americium absorbed 
into the systemic circulation from the gastrointestinal tract would be similar to that absorbed after 
inhalation (see Section 3.4.2.1). Studies in experimental animals support this; the major sites of 
americium accumulation after ingestion of americium are the skeleton and liver.  In pigs ingesting 
americium citrate once, the distribution of the americium body burden 8 hours post ingestion, when the 
highest total body burdens were observed, was as follows: bone, 56%; liver, 29%, and muscle, 5% (Eisele 
et al. 1987). The skeleton and liver accounted for 40% (range, 8–67%) and 29% (range, 7–30%) of the 
body burden of 241Am, respectively, 7 days following a single gavage administration of americium citrate 
or nitrate to rats (Sullivan et al. 1985, 1986).  Although it is possible that americium absorbed from the 
gastrointestinal tract might be taken up preferentially by the liver because of the hepatic portal blood 
flow, there is no evidence that a first pass effect substantially alters the overall tissue distribution of 
absorbed americium.  For example, in marmosets that received an intravenous injection of americium
citrate, the liver accounted for 27% of the total body burden of americium (excluding the gastrointestinal 
tract); whereas after a single gavage administration of americium in potato powder, the liver accounted 
for 31% of the body burden (oral:intravenous ratio of 1.14) (Ham et al. 1994).  A similar comparison 
made in hamsters resulted in an oral:intravenous ratio for the fractional liver burden of 0.9 (Stather et al. 
1979a), and comparisons made in guinea pigs and rats resulted in ratios <1 (Bomford and Harrison 1986; 
David and Harrison 1984; Harrison et al. 1994). 
3.4.2.3 Dermal Exposure  
The tissue distribution of americium that is absorbed across the skin would be expected to be similar to 
that from other routes.  Evidence for this is provided from an accident in which a worker received facial 
wounds from projectile debris and nitric acid during an explosion of a vessel containing 241Am 
(McMurray 1983; Toohey and Kathren 1995).  The subject also inhaled 241Am released to the air as dust 
and nitric acid aerosols, which was evident from external chest measurements of radioactivity (Palmer et 
al. 1983).  However, since the peak tissue burdens (lung, liver, and bone) of 241Am, measured 3 days after 
the accident, were collectively only 0.08 mCi, whereas the 5-year cumulative excretion of 241Am was




























3. HEALTH EFFECTS 
and/or skin wounds. The bone:liver ratio of 241Am 3 days after the exposure was approximately 3, and 
was 17–23 at autopsy 11 years after the accident.  This suggests that bone and liver would be the major 
sites of accumulation of americium absorbed from the skin, as is the case for americium that is absorbed 
by other routes.  The bone:liver ratio at 3 days was probably strongly affected by the aggressive DTPA 
therapy being employed at that time, since americium can be more easily removed from soft tissue 
deposition sites than from bone.  Autopsy results (Toohey and Kathren 1995) were used to refine the 
estimates of organ burdens and doses and to facilitate a comparison with various models.  Terminal 
burdens and tissue doses were estimated for the skeleton (490±40 kBq [13±1 µCi as average of six 
separate methods], 18 Gy [1,800 rad]), bone surface (490±40 kBq [13±1 µCi], 510 Gy [51,000 rad]), liver 
(28 kBq [0.8 µCi], 8.1 Gy [810 rad]), lung (1.9 kBq [0.05 µCi], 1.6 Gy [160 rad]), and muscle (13.5 kBq 
[0.36 µCi], 28 Gy [2,800 rad]).  These USTUR measurements indicate that the long-term 241Am skeletal 
burden was 95% of the total in skeleton plus liver.  This compared favorably with estimates using newer 
models (ICRP 1993; Leggett 1992), but less so when based on earlier models (ICRP 1979; ICRP 1986).  
Another finding was that muscle was a major repository, based on the total radiation dose it received 
being larger than that of the liver, whose terminal burden was actually twice as large. 
3.4.2.4 Other Routes of Exposure 
Various cases have been reported of internal exposure to americium resulting from skin punctures with 
materials also containing plutonium.  Information on the distribution of americium in these cases has been 
derived from the analysis of autopsy tissues.  In most cases, the largest fraction of the 241Am activity
measured in the body was associated with tissues near the puncture wound.  In one case, 18 years after a 
puncture wound to the left hand resulting in the deposition of a splinter of plutonium metal, 80% of the 
measured 241Am activity (a product of 241Pu decay) was associated with the left arm axillary lymph nodes 
and left hand, 12% was measured in the skeleton, and 1% was measured in the liver (Popplewell and Ham
1989). The large amount of activity associated with the left arm lymph nodes and left hand reflects the 
local accumulation of americium near the wound site.  However, if such local accumulations are 
subtracted from the total body activity, then most of the systemic americium measured after puncture 
wound exposures has been associated with the skeleton (80–90%) while liver, muscle, and spleen account 
for the remainder (5–10%), with skeletal:liver ratios of approximately 9:1 (Lagerquist et al. 1972b; 
McInroy et al. 1989; Popplewell and Ham 1989).  These observations are consistent with those made 
























3. HEALTH EFFECTS 
A large degree of variation is apparent in retention rates for americium in the liver among various animal 
species (Durbin 1973), as indicated by measured or estimated liver clearance half-times of approximately
5–16 days in rats, 152 days in baboons, 1–10 years in dogs, and 10 years in Chinese hamsters.  A liver 
clearance half-time of 2 years has been estimated for humans (Griffith et al. 1983).  Refer to Section 3.5.1 
for information regarding toxicokinetic mechanisms that may play a role in interspecies differences in 
liver retention of americium.
3.4.3 Metabolism 
The metabolism of americium involves binding interactions with proteins and probably complex 
formation with various inorganic anions, such as carbonate and phosphate, and carboxylic acids, such as 
citrate and lactate (Durbin 1973; Taylor 1973; Webb et al. 1998).  These types of interactions would be 
expected for all routes of exposure. 
3.4.4 Elimination and Excretion 
3.4.4.1 Inhalation Exposure 
Americium deposited in the nasopharyngeal or tracheal-bronchial regions of the respiratory tract will 
undergo extensive mucociliary transport to the esophagus with subsequent ingestion and fecal excretion.  
Evidence for this in humans is provided by cases of accidental inhalation exposure of americium oxides in 
which a substantial fraction (>50%) of the estimated initially deposited activity was found to be excreted 
in feces during the first days to weeks after the exposure (Edvardsson and Lindgren 1976; Newton et al. 
1983; Sanders 1974).  Once absorbed from the lung, americium is excreted in feces and urine.  The 
relative contribution of each in humans is difficult to assess from existing data because most data are 
derived from accidental exposures, after which the victims were subjected to chelation therapy, which 
would have increased the urinary excretion of americium.  Following an accidental inhalation exposure in 
which approximately 1.22 µCi (45.1 kBq) of 244Cm and 241Am (in the form of mixed oxides) were 
deposited in the respiratory tract, the cumulative 1-year excretion of radioactivity was approximately
1,174 nCi (43.4 kBq, 96% of the deposited activity) in feces and 5.4 nCi (200 Bq, 0.4% of the deposited 
activity) in urine (Sanders 1974).  The equivalent fractions of 241Am, based on measurements of the 





















3. HEALTH EFFECTS 
14 treatments with the chelating agent, DTPA, which may have effectively increased rates of excretion of 
americium.
Studies of excretion in animals after inhalation exposures also indicate a relatively large contribution of 
fecal excretion to the total elimination of americium that deposits in the respiratory tract.  In dogs that 
inhaled an aerosol of AmO2, fecal and urinary excretion of americium during the first 10 days after 
exposure were 30 and 0.7% of the initial body burden, respectively, and were 50 and 6% of the initial 
burden, respectively, by 810 days postexposure (Craig et al. 1979).  Mechanical clearance from the upper 
respiratory tract to the gastrointestinal tract would be expected to make a substantial contribution to fecal 
excretion during the first few weeks after exposure and may continue for longer periods.  The observation 
that fecal excretion continued to be the main route of excretion months after the exposure suggests two 
possibilities: (1) mechanical clearance from the lower respiratory tract (e.g., lung) continues to contribute 
to fecal excretion for longer periods of time (ICRP 1994b), and (2) absorbed americium is excreted in 
feces, suggesting a role for biliary excretion (Durbin 1973). 
Lung deposition patterns and the relative contributions of the fecal and urinary pathways vary with the 
aerosol particle size.  Evidence for this is provided by a study in which dogs inhaled AmO2 aerosols 
having different size distributions.  As the particle size AMAD increased from 0.8 µm (±1.2 GSD) to 
3.5 µm (±1.06 GSD), the urine:fecal ratios of cumulative excretion (from days 8 to 730 after the 
exposure) decreased from 4 to 0.3 (Mewhinney et al. 1982).  These observations are consistent with an 
effect of particle size on deposition patterns in the respiratory tract.  Larger particles will be deposited in 
the tracheo-bronchial airways and will be subjected to mucociliary transport to the esophagus where they
can enter the gastrointestinal tract. Therefore, the fraction of the deposited activity transferred to the 
gastrointestinal tract and excreted in the feces would be expected to increase with increasing mean 
particle size of the inhaled aerosol.  The general trend of increased fecal excretion with increasing particle 
size would be expected to occur in humans, although the exact relationship between particle size and 
deposition patterns will vary across species because of species differences in airway geometry, breathing 
patterns, and air flow rates in the respiratory tract (see Section 3.4.5).  
Once absorbed into the general circulation, regardless of the route of exposure, americium is excreted in 
both feces and urine. Evidence for this derives from a human accident case study and from experiments 


























3. HEALTH EFFECTS 
3.4.4.2 Oral Exposure  
Urinary excretion of ingested americium has been measured in humans who ingested shellfish (molluscs)
that had assimilated americium from their aquatic environment.  In eight adult subjects (six males and 
two females) who ingested molluscs (winkles) containing 241Am (activity range 10–25 Bq, 0.27–0.68 nCi, 
0.083–0.21 ng), the mean cumulative urinary excretion during the 7 days after ingestion was 
approximately 0.0005% and the estimated fraction of the absorbed activity excreted in the urine was 
0.07% (Hunt et al. 1990). In a similar study of six subjects (five males and one female) who ingested 
cockles collected from Ravenglass, Cumbria (activity range of 15–17 Bq, 0.41–0.46 nCi, 0.13–0.14 ng), 
the mean cumulative urinary excretion during the 7 days post ingestion was approximately 0.0009% of 
the ingested americium and the estimated portion of the absorbed activity excreted in the urine was 0.08% 
(Hunt 1998).  Three of these subjects had participated in the earlier study with winkles (Hunt et al. 1990); 
urinary excretion during 3 days prior to ingestion of the cockles was used to correct for internalized 
americium from prior exposures.  Measured 241Am activity in the cockles was indistinguishable from the 
cumulative activity measured in fecal samples collected from the subjects during the 7 days post 
ingestion. 
Additional information on the excretion of ingested americium derives from an accident in which a 
worker ingested a ceramic particle containing 241AmO2 (Smith et al. 1983).  Five days after the accident, 
the particle, containing approximately 2.85 µCi (105 kBq) of 241Am (0.88 µg Am), was excreted in the 
feces. Previous fecal samples and one subsequent fecal sample collected the day after the particle was 
excreted had essentially no 241Am activity.  During the first 8 days after the particle was ingested, 
approximately 4 pCi (0.15 Bq, 0.00007% of the estimated activity) was excreted in the urine. 
Studies in rats and guinea pigs have shown that urinary excretion is the major route of excretion of 
americium absorbed from the gastrointestinal tract during the first week after exposure in these species.  
In rats that were administered americium nitrate or citrate by gavage, 30–80% of the estimated absorbed 
activity was excreted in urine during the first 7 days post administration (Sullivan 1980a; Sullivan et al. 
1985).  The wide range may reflect the uncertainty in the estimates of the relatively low fraction 
absorption of the americium.  The fraction of the absorbed activity that was excreted in urine was lower in 
iron-deficient rats (35%) than in iron-replete rats (78%) (Sullivan et al. 1985).  In guinea pigs, 35–50% of 
the absorbed activity was excreted in urine during the first 7 days after a single gavage dose of americium




























3. HEALTH EFFECTS 
Once absorbed into the general circulation, regardless of the route of exposure, americium is excreted in 
both feces and urine. Evidence for this derives from human accident case study and from experiments in 
animals that received an intravenous or intramuscular injection of americium (see Section 3.4.4.4). 
3.4.4.3 Dermal Exposure  
Information on the excretion of americium after dermal exposure in humans or animals is extremely
limited.  Some qualitative information is available from an accidental exposure in which a worker 
received facial wounds from projectile debris and nitric acid during an explosion of a vessel containing 
241Am (McMurray 1983).  The subject also inhaled 241Am released to the air as dust and nitric acid 
aerosols, which was evident from external chest measurements of internal radioactivity; thus, excretion 
estimates reflect combined inhalation, dermal, and wound penetration exposures (Palmer et al. 1983).  
Measurements of cumulative fecal and urinary excretion of 241Am during the first years after the accident, 
and periodic measurements made from day 10 to 11 years post accident, indicated a fecal:urine excretion 
ratio of approximately 0.2–0.3, although the ratio was approximately 1 on day 3 post accident 
(Breitenstein and Palmer 1989; Robinson et al. 1983).  The ratio was almost certainly affected, however, 
by initial chelation with Ca-DTPA, followed by daily intravenous therapy with the chelating agent, 
Zn-DTPA; these treatments would have increased the urinary excretion of americium (Breitenstein and 
Palmer 1989).  The above not withstanding, the observations made on this subject demonstrate that fecal 
excretion was an important pathway of excretion in this subject long after mechanical clearance of 
americium from the respiratory tract would have been complete.  This is consistent with observations 
made in nonhuman primates that show that americium is excreted into bile (see Section 3.4.4.4).  
However, the extent to which the biliary excretion pathway in humans might resemble that of nonhuman 
primates is not known. 
Once absorbed into the general circulation, regardless of the route of exposure, americium is excreted in 
both feces and urine. Evidence for this derives from experiments in animals that received an intravenous 
or intramuscular injection of americium (see Section 3.4.4.4). 
3.4.4.4 Other Routes of Exposure 
Measurements of fecal and urinary excretion of americium after an inhaled or ingested dose do not 


























3. HEALTH EFFECTS 
absorbed americium.  This is because inhaled americium is subject to mucociliary transport and ingestion, 
and only a small fraction of ingested americium is absorbed.  Studies in which animals were parenterally
administered americium have provided quantitative information on the routes of excretion of absorbed 
americium.  The relative contribution of the fecal and urinary pathways appears to vary with species and 
time post administration; however, in general, the fecal pathway predominates.  In monkeys, urinary
excretion of radioactivity following intravenously administered americium citrate was the major route of 
excretion only during the first few weeks post administration, at which time, cumulative urinary and fecal 
excretion accounted for 10 and 3% of the administered activity, respectively (Durbin 1973).  Long-term
cumulative excretion (months to years), however, was primarily in feces, with 37% of the administered 
activity excreted in feces and 20% excreted in urine. A similar pattern of urinary and fecal excretion over 
time was evident in baboons (Cohen and Wrenn 1973; Durbin 1973; Guilmette et al. 1980).  Similarly, in 
rats, dogs, and hamsters, urinary excretion of radioactivity following intramuscularly or intravenously
injected americium citrate or chloride was the major route of excretion only during the first few days to 
weeks, with a fecal:urine excretion ratio of approximately 0.11–0.15; however, over a 1–2-year period, 
the fecal:urine ratio was approximately 5–9 (Durbin 1973; Stather et al. 1979a). 
The large contribution of the fecal route to excretion of absorbed americium appears to be the result of 
excretion of americium into the bile.  In monkeys that received an intravenous injection of americium
citrate, 241Am was detected in gall bladder bile and its concentration increased as the relative rate of fecal 
excretion increased over time post injection (Durbin 1973).  Durbin (1973) estimated that at bile 
production rates similar to humans, biliary excretion could have accounted for most, if not all, of the fecal 
excretion of americium observed in the monkeys. 
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models  
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and 
disposition of chemical substances to quantitatively describe the relationships among critical biological 
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of 
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
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PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target 
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen et al. 
1987; Andersen and Krishnan 1994).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of 
PBPK models results in more meaningful extrapolations than those generated with the more conventional 
use of uncertainty factors. 
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model 
representation, (2) model parametrization, (3) model simulation, and (4) model validation (Krishnan and 
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of 
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters.  The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions. 
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  If the uptake and disposition of the chemical substance(s) is 
adequately described, however, this simplification is desirable because data are often unavailable for 
many biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty.  The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of 
PBPK models in risk assessment. 
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the 
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
Similar models have been developed for radionuclides.  These models provide a scientifically sound 
means to predict the target tissue dose of chemicals in humans who are exposed to environmental levels 
(for example, levels that might occur at hazardous waste sites) based on the results of studies where doses 
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Figure 3-1. Conceptual Representation of a Physiologically Based 























3. HEALTH EFFECTS 
of a PBPK model.  Figures 3-2 through 3-8 show models for radionuclides in general or specifically for 
americium.
For radionuclides, the PBPK model is replaced with a set of sophisticated physiologically based 
biokinetic (PBBK) models for inhalation, ingestion, and submersion.  These were developed to 
accomplish virtually the same end as the PBPK models above, while integrating additional parameters 
(for radioactive decay, particle and photon transport, and compound-specific factors).  Goals are to 
facilitate interpreting chest monitoring and bioassay data, assessing risk, and calculating radiation doses 
to a variety of tissues throughout the body.  The standard for these models has been set by the ICRP and 
their models receive international support and acceptance.  ICRP periodically considers newer science in 
a type of weight of evidence approach toward improving the state of knowledge and reducing
uncertainties associated with applying the model to any given radionuclide.  ICRP publications also allow 
for the use of situation- and individual-specific data to reduce the overall uncertainty in the results.  Even 
though there may be conflicting data for some parameters, such as absorption factors, one can use 
conservative values and still reach conclusions on whether the dose is below recommended limits.  One of 
the strengths of the ICRP model is that it permits the use of experimentally determined material-specific 
absorption parameter values rather than requiring the use of those provided for default types.  If the 
material of interest does not have absorption parameter values that correspond to those in the model (e.g., 
Type F, M, or S), the difference can have a profound effect on the assessment of intake and dose from
bioassay measurements.  This has been discussed in National Radiological Protection Board (NRPB) 
published reports on uranium (NRPB 2002).   
The ICRP (1994b, 1995) developed a Human Respiratory Tract Model for Radiological Protection, which 
contains respiratory tract deposition and clearance compartmental models for inhalation exposure that 
may be applied to particulate aerosols of americium compounds.  The ICRP (1986, 1989) has a biokinetic 
model for human oral exposure that applies to americium.  The National Council on Radiation Protection 
and Measurements (NCRP) has also developed a respiratory tract model for inhaled radionuclides (NCRP 
1997).  At this time, the NCRP recommends the use of the ICRP model for calculating exposures for 
radiation workers and the general public. Readers interested in this topic are referred to NCRP Report 
No. 125;  Deposition, Retention and Dosimetry of Inhaled Radioactive Substances (NCRP 1997).  In the 
appendix to the report, NCRP provides the animal testing clearance data and equations fitting the data that 
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Human Respiratory Tract Model for Radiological Protection (ICRP 1994b)     
Deposition. The ICRP (1994b) has developed a deposition model for behavior of aerosols and vapors in 
the respiratory tract. It was developed to estimate the fractions of substances in breathing air that are 
deposited in each anatomical region of the respiratory tract.  ICRP (1994b) provides inhalation dose 
coefficients that can be used to estimate radiation doses to organs and tissues throughout the body based 
on a unit intake of radioactive material.  The model applies to three levels of particle solubility, a wide 
range of particle sizes (approximately 0.0005–100 µm in diameter), and parameter values that can be 
adjusted for various segments of the population (e.g., sex, age, and level of physical exertion).  This 
model also allows one to evaluate the bounds of uncertainty in deposition estimates.  Uncertainties arise 
from natural biological variability among individuals and the need to interpret some experimental 
evidence that remains inconclusive.  It is applicable to particulate aerosols containing americium, but was 
developed for a wide variety of radionuclides and their chemical forms. 
The ICRP deposition model estimates the fraction of inhaled material initially retained in each 
compartment (see Figure 3-2).  The model was developed with five compartments:  (1) the anterior nasal 
passages (ET1); (2) all other extrathoracic airways (ET2) (posterior nasal passages, the naso- and 
oropharynx, and the larynx); (3) the bronchi (BB); (4) the bronchioles (bb); and (5) the alveolar 
interstitium (AI).  Particles deposited in each of the regions may be removed and redistributed either 
upward into the respiratory tract or to the lymphatic system and blood by different particle removal 
mechanisms.
For extrathoracic deposition of particles, the model uses measured airway diameters and experimental 
data, where deposition is related to particle size and airflow parameters, and scales deposition for women 
and children from adult male data.  Similar to the extrathoracic region, experimental data served as the 
basis for lung (bronchi, bronchioles, and alveoli) aerosol transport and deposition.  A theoretical model of 
gas transport and particle deposition was used to interpret data and to predict deposition for compartments 
and subpopulations other than adult males.  Table 3-4 provides reference respiratory values for the 
general Caucasian population during various intensities of physical exertion. 
Respiratory Tract Clearance.  This portion of the model identifies the principal clearance pathways
within the respiratory tract.  The model was developed to predict the retention of various radioactive 
materials.  The compartmental model represents particle deposition and time-dependent particle transport 
in the respiratory tract (see Figure 3-2) with reference values presented in Table 3-5.  This table provides 














































































































3. HEALTH EFFECTS 
Figure 3-2. Compartment Model to Represent Particle Deposition and 

Time-Dependent Particle Transport in the Respiratory Tract* 

*Compartment numbers shown in lower right corners are used to define clearance pathways. The clearance rates, 
half-lives, and fractions by compartment, as well as the compartment abbreviations are presented in Table 3-5. 














        
          
            
       
         
            
       
         
            
       






3. HEALTH EFFECTS 
Table 3-4. Reference Respiratory Values for a General Caucasian Population at 

Different Levels of Activitya
 
Breathing







Resting (sleeping); Maximal workload 8%
Breathing parameters: 
VT(L) 0.04 0.07 0.17 
B(m3h-1) 0.09 0.15 0.24 



















Sitting awake; Maximal workload 12% 
Breathing parameters: 
VT(L) N/A 0.1 0.21 
B(m3h-1) N/A 0.22 0.32 



















Light exercise; Maximal workload 32% 
Breathing parameters: 
VT(L) 0.07 0.13 0.24 
B(m3h-1) 0.19 0.35 0.57 



















Heavy exercise; Maximal workload 64% 
Breathing parameters: 
VT(L) N/A N/A N/A 
B(m3h-1) N/A N/A N/A 






















aSee Annex B (ICRP 1994b) for data from which these reference values were derived. 
B = ventilation rate; fR = respiration frequency; h = hour; L = liter; m = meter; min = minute; N/A = not applicable; 














      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
62 AMERICIUM
3. HEALTH EFFECTS 
Table 3-5. Reference Values of Parameters for the Compartment Model to 

Represent Time-dependent Particle Transport from the  

Human Respiratory Tract 

Part A
Clearance rates for insoluble particles
Pathway From To Rate (d-1) Half-timea 
m1,4 AI1 bb1 0.02 35 days
m2,4 AI2 bb1 0.001 700 days
m3,4 AI3 bb1 1x10-4 7,000 days
m3,10 AI3 LNTH 2x10-5 No data
m4,7 bb1 BB1 2 8 hours
m5,7 bb2 BB1 0.03 23 days
m6,10 bbseq LNTH 0.01 70 days
m7,11 BB1 ET2 10 100 minutes
m8,11 BB2 ET2 0.03 23 days
m9,10 BBseq LNTH 0.01 70 days
m11,15 ET2 GI tract 100 10 minutes
m12,13 ETseq LNET 0.001 700 days
m14,16 ET1 Environment 1 17 hours
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3. HEALTH EFFECTS 
Table 3-5. Reference Values of Parameters for the Compartment Model to 







Partition of deposit in each region between compartmentsb 
Fraction of deposit in region
Region or deposition site Compartment assigned to compartmentc 
ET2	 ET2 0.9995
ETseq 0.0005
BB	 BB1 0.993-fs 
BB2 fs 
BBseq 0.007






aThe half-times are approximate since the reference values are specified for the particle transport rates and are rounded in units 

of days-1. A half-time is not given for the transport rate from Al3 to LNTH, since this rate was chosen to direct the required amount 

of material to the lymph nodes.  The clearance half-time of compartment Al3 is determined by the sum of the clearance rates. 

bSee paragraph 181, Chapter 5  (ICRP 1994b) for default values used for relating fs to dae. 

cIt is assumed that fs is size-dependent. For modeling purposes, fs is taken to be: 

where 
fs = fraction subject to slow clearance
dae = aerodynamic particle diameter/(µm) 
ρ = particle density (g/cm3) 
χ = particle shape factor 
AI = alveolar-interstitial region; BB = bronchial region; bb = bronchiolar region; BBseq = compartment representing prolonged 
retention in airway walls of small fraction of particles deposited in the bronchial region; bbseq = compartment representing 
prolonged retention in airway walls of small fraction of particles deposited in the bronchiolar region; ET = extrathoracic region; 
ETseq = compartment representing prolonged retention in airway tissue of small fraction of particles deposited in the nasal 
passages; GI = gastrointestinal; LNET = lymphatics and lymph nodes that drain the extrathoracic region; LNTH = lymphatics and 























3. HEALTH EFFECTS 
fractions (Part B) for each compartment for insoluble particles.  ICRP (1994b) also developed modifying 
factors for some of the parameters, such as age, smoking, and disease status.  Parameters of the clearance 
model are based on human evidence for the most part, although particle retention in airway walls is based 
on experimental data from animal experiments. 
The clearance of particles from the respiratory tract is a dynamic process.  The rate of clearance generally
changes with time from each region and by each route.  Following deposition of large numbers of 
particles (acute exposure), the mass flow of material between compartments decreases as particles are 
cleared from the various regions.  Physical and chemical properties of deposited material determine the 
rate of dissolution, and as particles dissolve, absorption rates of material between the compartments tend 
to change. By creating a model with compartments of different clearance rates within each region (e.g., 
BB1, BB2, BBseq), the ICRP model overcomes problems associated with time-dependent functions.  
Each compartment clears to other compartments by constant rates for each pathway.
Particle transport from all regions is toward both the lymph nodes and the pharynx, and a majority of 
deposited particles, if sufficiently large, end up being swallowed.  In the front part of the nasal passages 
(ET1), nose blowing, sneezing, and wiping remove most of the deposited particles.  Particles remain here 
for about a day.  For particles with AMADs a few micrometers or greater, the ET1 compartment is 
probably the largest deposition site. A majority of particles deposited at the back of the nasal passages
and in the larynx (ET2) are removed quickly by the fluids that cover the airways.  In this region, particle 
clearance is completed within 15 minutes.  
Ciliary action removes deposited particles from both the bronchi and the bronchioles.  Though it is 
generally thought that mucociliary action rapidly transports most particles deposited here toward the 
pharynx, a fraction of these particles is cleared more slowly.  Evidence for this is found in human studies.  
For humans, retention of particles deposited in the lungs (BB and bb) is apparently biphasic.  The “slow” 
action of the cilia may remove as much as half of the bronchi- and bronchiole-deposited particles.  In 
human bronchi and bronchiole regions, mucus moves more slowly when it is closer to the alveoli.  For the 
faster compartment, it has been estimated that it takes about 2 days for particles to travel from the 
bronchioles to the bronchi and 10 days from the bronchi to the pharynx.  The second (slower) 
compartment is assumed to have approximately equal fractions deposited between BB2 and bb2, with 
both fractions having clearance half-times estimated at 20 days.  Particle size is a primary determinant of 
the fraction deposited in this slow thoracic compartment.  A small fraction of particles deposited in the 






























3. HEALTH EFFECTS 
If particles reach and become deposited in the alveoli, they tend to stay imbedded in the fluid on the 
alveolar surface or move into the lymph nodes.  The one mechanism by which particles are physically
resuspended and removed from the AI region is coughing.  For modeling purposes, the AI region is 
divided into three subcompartments to represent different clearance rates, all of which are slow. 
In the AI region, human lung clearance has been measured.  The ICRP model uses three half-times to 
represent clearance: about 30, 60, and 10% of the particles have half times that approximate 30, 700, and 
7,000 days, respectively.  Over time, AI particle transport falls, and some compounds have been found in 
lungs 10–50 years after exposure. 
Absorption into Blood.  The ICRP model assumes that absorption into blood occurs at equivalent rates in 
all parts of the respiratory tract, except in the anterior nasal passages (ET1), where no absorption occurs.  
It is essentially a 2-stage process, as shown in Figure 3-3.  First, there is a dissociation (dissolution) of 
particles, and then the dissolved molecules or ions diffuse across capillary walls and are taken up by the 
blood.  Immediately following dissolution, rapid absorption is observed.  For some elements, rapid 
absorption does not occur because of binding to respiratory-tract components.  In the absence of specific  
data for specific compounds, the model uses the following default absorption rate values for those specific 
compounds that are classified as Types F (fast), M (medium), S (slow), and V (instantaneous):  
•	 For Type F, there is rapid 100% absorption within 10 minutes of the material deposited in the BB, 
bb, and AI regions and 50% absorption of material deposited in ET2. Thus, for nose breathing, 
there is rapid absorption of approximately 25% of the deposit in ET; for mouth breathing, the 
value is 50%. 
•	 For Type M, about 70% of the deposit in AI eventually reaches the blood.  There is rapid 
absorption of about 10% of the deposit in BB and bb and 5% of material deposited in ET2. Thus, 
there is rapid absorption of approximately 2.5% of the deposit in ET for nose breathing and 5%
for mouth breathing. 
•	 For Type S, 0.1% is absorbed within 10 minutes and 99.9% is absorbed within 7,000 days, so
there is little absorption from ET, BB, or bb, and about 10% of the deposit in AI eventually
reaches the blood. 
•	 For Type V, complete absorption (100%) is considered to occur instantaneously (which is not 
relevant to americium compounds).  
ICRP (1995) considers the experimental data on americium nitrate, chloride, citrate, and hydroxide to 
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3. HEALTH EFFECTS 
Type M. ICRP (1995) recommends assigning all americium aerosols to Type M in the absence of 
specific information supporting an alternative classification.  Substance specific values should be used 
where feasible to reduce uncertainties in results. 
ICRP (1989) Americium Biokinetic Model 
Description of the model. 
ICRP (1989) developed a compartmental model of the kinetics of ingested americium in humans that is 
applicable to infants, children, adolescents, and adults.  The model is a modification and expansion of a 
similar model for plutonium, described by Leggett et al. (1984, 1985).  The fraction of ingested 
americium that is absorbed (uptake to blood) is assumed to vary with age and have values of 0.01 in 
infants up to 12 months of age and 0.001 from 12 months of age through adulthood (ICRP 1986).  
Absorbed americium enters the blood plasma where it distributes to the skeleton, liver, and other tissues 
(Figure 3-4).  Excretion pathways included in the model are plasma to urine and liver to feces.  Transfer 
rate coefficients between compartments are age-specific and, depending on the specific coefficient, values 
can change at ages 3 months, 1 year, 5 years, 10 years, 15 years, and adult (>15 years).  The model 
assumes that, in adults, 50% of the americium that enters the body and is not excreted is transferred to the 
liver and 30% is transferred to the skeleton.  In newborns, 70% is assumed to be transferred to the  
skeleton and 10% to the liver.  Skeletal deposition is assumed to distribute into two pools: 50% goes to 
the trabecular bone surface and 50% goes to the cortical bone surface.  A first-order rate coefficient for 
elimination of americium from liver to plasma is assumed to be 0.0019 day-1 (half-time, 365 days).   
Bone is divided into trabecular and cortical components, with each further divided into surface bone, bone 
volume, and bone cavity (marrow compartment).  Deposition of americium is assumed to occur from
plasma directly to bone surfaces, whereas elimination from bone occurs by transfer from the bone surface 
or volume to the marrow cavity, and then from the marrow cavity to plasma (Figure 3-4).  Transfers of 
americium within the cortical or trabecular bone compartments are modeled based on assumptions about 
rates of bone formation and resorption, which are assumed to be vary with age, but are equal within a 
given age group (Leggett et al. 1982).  Movement of americium to the marrow compartment is
determined by the bone resorption rate, whereas movement from the bone surface to the bone volume is 
assumed to occur by burial of surface deposits with new bone and is determined by the bone formation 
rate. During growth, bone formation and resorption are assumed to occur at different sites within bone; 
therefore, the rate of removal of americium from the bone surface is approximated by the sum of the bone 
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3. HEALTH EFFECTS 
the rate of bone formation, which results in burial of surface deposits (represented by movement of 
americium from the bone surface to bone volume).  In adults, the possibility of resorption and formation 
of bone occurring at the same site is assumed; therefore, only a portion of the bone formation rate results 
in burial of surface deposits and movement of americium from the bone surface to the bone volume.    
Validation of the model. 
The extent to which the ICRP model has been validated is not described in ICRP (1989). 
Risk assessment. 
The model has been used to establish the radiation dose (Sv) per unit of ingested 241Am activity (Bq) for 
ages 3 months to 70 years (ICRP 1989).
Target tissues. 
The model is designed to calculate the 241Am intake that would produce the maximum allowed
occupational radiation dose to all major organs, including the bone surfaces, bone marrow, and liver, but 
the conversion factors for other tissues and organs are published in the same tables. 
Species extrapolation.The model is based on both human and animal data.  It is intended, however, for 
applications to human dosimetry.  Applications to other species would require consideration of species-
specific adjustments in model parameters. 
Interroute extrapolation. 
The model is designed to simulate oral exposures to americium.  It can be applied to any other route of 
exposure for which the transfer rate to blood is available. 
Leggett (1992) Americium Biokinetic Model 
Description of the model. 
Leggett (1992) proposed a model for the retention and excretion of americium in humans.  The model is a 
modification of a similar model for plutonium (Leggett et al. 1984, 1985) with the following changes 
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3. HEALTH EFFECTS 
and other cell types; (2) the gonads are represented by a separate compartment; (3) a kidney compartment 
is included in place of the compartment for urinary tract tissue; (4) a compartment representing the 
urinary bladder contents is included; and  (5) other soft tissues are represented as having slow, 
intermediate, and fast turnover pools.  
The fraction of ingested americium that is absorbed (uptake from the small intestine to blood) is 
represented by age-specific functions that yield the following values: decreasing from 0.05 to 
0.0005 during the first 12 months, 0.0005 at 1–15 years of age, decreasing from 0.0005 to 0.0002 at 15– 
18 years of age, and 0.0002 from age 18 years through adulthood. The model assumes that, in adults, 
62% of the americium that enters the body and is not excreted is transferred to liver and 38% is 
transferred to the skeleton (skeleton:liver deposition ratio, 3:5).  In newborns, 88% is assumed to be 
transferred to the skeleton and 12% to the liver (skeleton:liver deposition ratio, 7:1).  The half-time for 
elimination of americium from the liver is assumed to be 365 days, although the half-time for elimination 
measured externally would be longer and would increase with increasing time after intake, due to 
recycling of americium from tissues to blood to tissues. 
Validation of the model. 
Predictions based on the model have been compared to observed urinary or fecal excretion of americium
in humans.  Model predictions agreed reasonably well with the empirical observations (Leggett 1992). 
Risk assessment. 
The Leggett (1992) model was developed to predict tissue doses and whole-body dose to people who may
be exposed to americium and for interpretation of bioassay data for americium.  The model is considered 
an updated version of the ICRP (1989) model for americium, which has been used to establish risk-based 
limits of intake of 241Am (ICRP 1989).  The Leggett (1992) and ICRP (1989) models predict similar long-
term average doses of americium to the liver and skeleton for an injection exposure and would be 
expected to predict similar radiation risks and risk-based intake limits (Leggett 1992).  Descriptions of 
applications of the Leggett (1992) model in risk assessment have not been reported. 
Target tissues. 
The model is designed to calculate americium excretion and time courses for americium levels in the 






























3. HEALTH EFFECTS 
Species extrapolation. 
The model is designed for applications to human dosimetry and cannot be applied to other species without
modification. 
Interroute extrapolation. 
The model is designed to simulate oral, inhalation, and parenteral (e.g., injection) exposures to americium
and cannot be applied to other routes of exposure without modification. 
ICRP (1993) Americium Biokinetic Model 
Description of the model. 
ICRP (1993) adopted the model of Leggett (1992) as its systemic biokinetic model for americium with 
the following modifications:  (1) the Leggett (1992) model addresses changes throughout life in the rate 
of bone turnover, whereas the ICRP (1993) model assumes bone turnover rates to remain constant in 
adults, and (2) assumptions regarding uptake and retention by gonadal tissues of children are more
cautious in the ICRP (1993) model compared to those used in the Leggett (1992) model. 
Validation of the model. 
The extent to which the ICRP model has been validated is not described in ICRP (1993). 
Risk assessment. 
The model has been used to establish the radiation dose (Sv) per unit of ingested 241Am activity (Bq) for 
ages 3 months to 70 years (ICRP 1993).
Target tissues. 
The model is designed to calculate the 241Am intake that would produce the maximum allowed
occupational radiation dose to all major organs, including the bone surfaces, bone marrow, and liver, but 

























3. HEALTH EFFECTS 
Species extrapolation. 
The model is based on both human and animal data.  It is intended, however, for applications to human 
dosimetry.  Applications to other species would require consideration of species-specific adjustments in 
model parameters. 
Interroute extrapolation. 
The model is designed to simulate oral exposures to americium.  It can be applied to any other route of 
exposure for which the transfer rate to blood is available. 
USTUR (1994) Americium Biokinetics Model 
Description of the model. 
The USTUR proposed modifications to the ICRP americium model, based on post-mortem americium
measurements in human exposure cases (Kathren 1994).  The major modifications are: (1) the initial 
deposition fraction is assumed to be skeleton 45%, liver 25%, muscle 20%, and other tissues 10%; and 
(2) the half-times for elimination of americium were assumed to be 2.5 years in liver, 10 years in muscle, 
50 years in skeleton, and 10 years in other tissues.  
Validation of the model. 
Predictions based on the model have been compared to observed post-mortem tissue americium levels in 
whole-body and tissue donations to the USTUR.  Model predictions agreed reasonably well with the 
empirical observations (Kathren 1995; USTUR 1997).  They, however, depend heavily on the accuracy of 
initial uptake and distribution data that, in certain cases, were difficult to reconstruct due to delays
between times of exposure and initial analysis. 
Risk assessment. 
The USTUR (Kathren 1994) model was developed to predict tissue doses and whole-body dose to people 
who may be exposed to americium.  The model has been used to verify annual limits on intake (ALIs) for 




























3. HEALTH EFFECTS 
Target tissues. 
The model is designed to calculate americium excretion and time courses for americium levels in the 
liver, skeleton, and gonads.  This output could be used to predict radiation doses to these tissues. 
Species extrapolation. 
The model is designed for application to human dosimetry and does not apply to other species. 
Interroute extrapolation. 
The model is designed to simulate oral, inhalation, and parenteral (e.g., injection, wounds) exposures to 
americium and cannot be applied to other routes of exposure without modification. 
Mewhinney and Griffith (1983) Americium Biokinetics Model
Description of the model. 
Mewhinney and Griffith (1983) proposed a model for the absorption and tissue distribution of inhaled 
americium dioxide in humans.  The model is a modification of a model of the beagle dog (Mewhinney
and Griffith (1982) and formed part of the basis for the Leggett (1992) model.  The model is similar to 
other actinide models (ICRP 1989; Leggett 1992), but has several additional features in the respiratory
tract portion of the model (Figure 3-6) including:  (1) dissolution of particles in the respiratory tract is 
simulated with rate functions, rather than zero or first-order rate constants, that include various parameters 
of particle size and surface area that affect dissolution rate (Mercer 1967); (2) the pulmonary region 
includes three pools; a pool of deposited particulate; a pool of dissolved americium which can be rapidly
absorbed into the blood; and a pool of locally bound americium (transformed) which can be absorbed into 
blood or mechanically cleared to the tracheobronchial region; and (3) absorption from the pulmonary
region of the respiratory tract includes a pathway for transfer to tracheobroncheal lymph nodes. 
Excretion is assumed to be in feces, from either the intestine or from the liver to the intestine, and from
the blood to the urine (i.e., the kidney is represented as a distribution compartment).  An absorption 
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Figure 3-6. Mewhinney and Griffith (1983) Model of Deposition and Retention of 





































































3. HEALTH EFFECTS 
Validation of the model. 
Predictions based on the model have been compared to observed time courses for lung, liver, and skeletal 
americium burden in dogs that inhaled americium oxide (Mewhinney and Griffith 1983).  Data on lung
retention for four humans who accidentally inhaled americium were also compared to model predictions.  
The empirical observations fell within predicted retention patterns for particle sizes (AMAD) 0.5 and 
1.8 µm (Mewhinney and Griffith 1983). 
Risk assessment. 
The Mewhinney and Griffith (1983) model was developed to predict lung retention and tissue 
distributions of americium in people who may be exposed to americium.  Descriptions of applications of 
the model in risk assessment have not been reported. 
Target tissues. 
The model calculates americium burdens in lung, liver, skeleton, kidney, and body.  This output could be 
used to predict radiation doses to these tissues. 
Species extrapolation. 
The model is designed for applications to human dosimetry; however, it predicts reasonably well the 
retention of americium in beagle dogs as well (Mewhinney and Griffith 1982).  The model cannot be 
applied to other species without modification. 
Interroute extrapolation. 
The model is designed to simulate inhalation exposures to americium; however, it could be applied to 
ingestion exposures since the model simulates the absorption of americium from the gastrointestinal tract.  
The model can be applied to other routes of exposure with modification. 
Durbin and Schmidt (1985) Americium Biokinetics Model 
Description of the model. 
Durbin and Schmidt (1985) proposed a model for tissue distribution and excretion of absorbed americium
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instantaneous; therefore, a central plasma (and blood) compartment is not included in the model (see 
Figure 3-7). Tissue compartments included in the model are slow and fast turnover bone compartments, 
representing cortical and trabecular bone, respectively; liver; and slow and fast turnover for other soft 
tissue compartments.  Excretion pathways include urine and feces.  Urinary excretion is represented as a 
sum of the contributions from bone, liver, and other soft tissues.  Fecal americium is assumed to be 
excreted from the liver. 
Validation of the model. 
Predicted skeletal americium concentrations were compared to values observed in a USTUR case and the 
predicted and observed values agreed reasonably well.  However, the same USTUR case was used to 
derive values for model parameters and, therefore, agreement with the observations would be expected.  
No other validation results are described. 
Risk assessment. 
The model was developed to predict skeletal and soft tissue burdens of americium in people who may be 
exposed to americium.  Comparisons of ALIs derived from the model and the ICRP (1979) model are 
presented. Descriptions of applications of the model in risk assessment have not been reported. 
Target tissues. 
The model calculates americium burdens in liver and skeleton.  This output could be used to predict 
radiation doses to these tissues. 
Species extrapolation. 
The model is designed for applications to human dosimetry.  The model cannot be applied to other 
species without modification. 
Interroute extrapolation. 
The model, as described in Durbin and Schmidt (1985), does not have an intake component, but it could 
be linked to an oral or inhalation intake model or a wound model to simulate the biokinetics of americium 
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Figure 3-7. Durbin and Schmidt (1985) Model of Distribution and Excretion of 
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Other Models 
Leggett (1992) also proposed a respiratory tract model.  Deposition of americium particles, depending on 
their size, are assumed to deposit in three compartments representing extrathoracic, fast-clearing thoracic, 
and slow-clearing thoracic regions of the respiratory tract (Figure 3-8). 
An early model to calculate doses to workers exposed to radionuclides by ingestion or inhalation was 
developed by ICRP (1979).  In 1996, ICRP recommended that a task group be set up to revise the model.   
This task group developed a new model for the human alimentary tract (Métivier 2003) that has yet to be 
endorsed by the ICRP.  
A biokinetic model for radionuclide-contaminated wounds is under development by a scientific 
committee established jointly by the U.S. National Council on Radiation Protection (USNCRP) and  
ICRP, a draft of which was recently published (Guilmette and Durbin 2003). 
3.5 MECHANISMS OF ACTION  
3.5.1 Pharmacokinetic Mechanisms 
Absorption.    Inhaled particulate aerosols of americium will be deposited in the respiratory tract.  
Amounts and patterns of deposition of particulates in the respiratory tract are affected by the size of the 
inhaled particles, age-related factors, breathing route (e.g., nose breathing versus mouth breathing), 
airway geometry, and airstream velocity within the respiratory tract (ICRP 1994b; James et al. 1994; Roy
et al. 1994). In general, large particles (>2.5 µm) preferentially deposit in the nasopharyngeal region 
where high airstream velocities and airway geometry facilitate inertial impaction (Chan and Lippman 
1980; James et al. 1994). In the tracheobronchial and alveolar regions, where airstream velocities are 
lower, processes such as sedimentation and interception become important for deposition of smaller 
particles (<2.4 µm).  Airflow velocity and airway geometry change with age, giving rise to age-related 
differences in particle deposition (James 1978; James et al. 1994; Phalen et al. 1985).  Anatomical 
features, as well as their use (nose versus mouth breathing), also affect the intake route (nose or mouth).  
Deposition in the various regions of the respiratory tract in children may be higher or lower than in adults 
depending on particle size; for submicron particles, fractional deposition in 2-year-old children has been 
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Figure 3-8. Leggett (1992) Model of Deposition and Retention of Americium in the 

Human Respiratory Tract 

AmO2 Other americium 
Pool To Half-time f Half-time f 
Extra-thoracic Blood – 0.0 0.4 days 0.05 
Gastrointestinal tract 0.4 days 1.0 0.4 days 0.95 
Fast thoracic Blood – 0.0 0.2 days 0.25 
Gastrointestinal tract 0.2 days 1.0 0.2 days 0.75 
Slow thoracic
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influenced by particle size and solubility as well as the pattern of regional deposition within the 
respiratory tract.  Larger particles (>2.5 µm) that are primarily deposited in the ciliated airways 
(nasopharyngeal and tracheobronchial regions) can be transferred by mucociliary transport into the 
esophagus and swallowed. Particles deposited in the alveolar region can be absorbed after extracellular 
dissolution or ingestion by phagocytic cells.  Americium-bearing pulmonary alveolar macrophages 
(PAMs) can either migrate to the airways where mucociliary transport to the esophagus can occur or to 
tracheobronchial lymph nodes (Taya and Mewhinney 1992; Taya et al. 1986, 1992).  The relative 
contributions of these two pathways to americium absorption have not been quantified.  Studies in dogs 
and monkeys have shown that americium is present in tracheobronchial lymph nodes within days after 
inhalation of americium dioxide (Mewhinney et al. 1982; Stanley et al. 1982; Thomas et al. 1972).  PAMs 
isolated from dogs, monkeys, and rats demonstrated the presence of phagocytosed and dissolved 
americium dioxide particles (Taya et al. 1992).
The site and mechanism of absorption of ingested americium are not known.  Based on studies of 
plutonium, it is likely that americium absorption occurs, at least to some extent, in the small intestine. 
Studies of the absorption of plutonium in preparations of in situ isolated segments of small intestine of 
immature miniature swine indicate that absorption of actinides can occur along the entire small intestine, 
with the highest rates of absorption occurring in the duodenum (Sullivan and Gorham 1982). 
Distribution.    Once americium is in systemic circulation, the route of exposure is not expected to 
affect its distribution.  The mechanisms by which americium is taken up and retained in bone are only
partially understood.  The distribution of americium in bone initially is confined to bone surfaces, 
including endosteal and periosteal surfaces, and adjacent to vascular canals in cortical bone (Polig 1976; 
Priest et al. 1983, 1995; Schlenker et al. 1989).  Deposition appears to be favored at sites of active bone 
resorption, and concentrations are highest in trabecular bone where there is a high surface to volume ratio 
(Kathren et al. 1987; Priest et al. 1983).  Surface deposits can eventually appear in somewhat deeper 
regions of bone as a result of accretion of new bone and burial of older surface deposits (Polig 1976; 
Priest et al. 1983). The observation that americium does not distribute more uniformly in bone has been 
taken as evidence that it does not exchange readily with calcium or other minerals in the bone mineral 
matrix and that the initial interactions with bone may be with organic components of bone (Bruenger et al. 
1973; Priest et al. 1983); however, experimental evidence for this is equivocal.  While americium has 
been shown to bind to the glycoprotein fraction of bovine cortical bone, even in the presence of an excess 
mass of bone mineral (Chipperfield and Taylor 1972), it also binds to bone mineral and bone calcium
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The highest concentrations of americium in soft tissues occur in the liver (Filipy and Kathren 1996).  The 
mechanisms of accumulation and retention of americium in liver have not been characterized.  In rats and 
hamsters, americium appears to initially and extensively associate with lysosomes (Gruner et al. 1981;
Seidel et al. 1986; Sütterlin et al. 1984).  Agents that disrupt microtubules and lysosome formation and 
processing, such as colchicine and vinblastine, have been shown to decrease liver uptake of americium in 
rats (Seidel 1984, 1985).  The effect is thought to involve disruption of hepatic microtubule formation, 
which is critical to the formation and intracellular processing of lysosomes, the initial site of accumulation
of americium in the liver.  The major bound form of americium in dog liver cytosol was shown to be a 
ferritin complex (Stover et al. 1970).  Substantial species differences in liver retention of americium have 
been observed. Most notable is the Chinese hamster for which liver retention half-times of 3,400 days
have been estimated, compared to 5–16 days in rat liver (Durbin 1973; McKay et al. 1972).  Elimination 
of americium from liver is relatively slow in dogs (1–10 years) compared with rats and mice (Durbin 
1973; Lindenbaum and Rosenthal 1972).  Mechanisms involved in the species differences in retention of 
americium in the liver have not been elucidated, although it has been proposed that animals with shorter 
retention times might be capable of excreting lysosomes in the bile (Sütterlin et al. 1984).  The relatively
slow elimination of americium from the hamster liver does not appear to be related to the initial tissue 
distribution, as the degree of association of americium with the lysosomal fraction of livers from rats and 
hamsters is similar (Sütterlin et al. 1984).   
The placental transfer of 241Am to the fetus has been studied in several animal models and in the in situ
perfused guinea pig placenta (Sikov 1987). After injections of 241Am in mice and rats, a small fraction 
(<0.1%) of the maternal dose is transferred to the fetus (Hisamatsu and Takizawa 1983; Sikov 1987;
Stather et al. 1992; Van Den Heuvel 1992; Weiss et al. 1980).  Placental concentrations generally exceed 
those of the fetus, and concentrations in the embryo/fetal membranes are higher than in the fetus (Sikov 
1987). Mechanisms of transport across the placenta have not been elucidated. 
Metabolism. As noted in Section 3.4.3, the metabolism of americium consists of binding interactions 
with proteins and probably complex formation with various inorganic anions, such as carbonate and 
phosphate, and carboxylic acids, such as citrate and lactate (Durbin 1973; Taylor 1973; Webb et al. 1998).
Experiments have not been conducted to determine whether americium binds to metallothionein, but such 


























3. HEALTH EFFECTS 
Excretion. Although fecal excretion appears to be a major route of excretion of absorbed americium,
the mechanisms by which americium is transferred to feces have not been characterized in humans.  
Injection studies in animals suggest a contribution of biliary excretion to the fecal excretion of absorbed 
americium (Durbin 1973).  Similarly, the mechanisms by which americium is excreted in urine have not 
been elucidated. Renal plasma clearance has been measured in rats, dogs, and monkeys; in all three 
species, the renal clearance was <10% of the glomerular filtration rate (Durbin 1973; Lloyd et al. 1970; 
Taylor et al. 1961; Turner and Taylor 1968).  However, simultaneous measurements of the renal plasma
clearance of ultrafilterable americium and glomerular filtration rate are not available; thus, the relative 
contributions of filtration, tubular secretion, and tubular reabsorption to urinary excretion of americium
cannot be ascertained with the available information.  Studies of human urine incubated with 241Am or 
urine collected from rats that were exposed to americium indicate that the major form of americium in 
urine appears to be a low molecular weight complex (1,000–10,000 daltons) with citrate (Stradling et al. 
1976).  This would be consistent with citrate complexes occurring in plasma from which they could enter 
the urine by glomerular filtration. 
3.5.2 Mechanisms of Toxicity
Americium toxicity results primarily from the damage done by the alpha particle emitted during 
radioactive decay.  This alpha particle has very limited penetration in tissue, and hence, the cellular 
damage (including damage to genomic material) occurs only in the immediate vicinity of the sequestered 
americium.  Alpha particles deposit all of their energy in a short distance of travel.  The large charge and 
mass of the alpha particle account for the strong interaction with surrounding cells.  The transferred 
energy ionizes localized cell matter in its path directly and via hydrolysis of water (approximately 70%) 
in human cells.  Radiation interaction with water produces ionized and excited water molecules referred 
to as radiolysis products.  These reactive water species have sufficiently long half-times that they can 
diffuse away from the interaction site and interact with biological molecules, which can increase the 
resulting cellular damage.  Thus, cellular damage can result both directly from radiation itself and 
indirectly from the chemical reactions involving reactive species of radiolysis products. 
3.5.3 Animal-to-Human Extrapolations 
Significant interspecies differences are apparent regarding liver retention rates of absorbed americium




















3. HEALTH EFFECTS 
Interspecies differences are also apparent in skeletal distribution of absorbed americium (Lynch et al. 
1989). However, no data were located to indicate significant interspecies differences in health effects 
associated with exposure to americium.
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS  
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine 
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors. However, appropriate 
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Colborn and Clement (1992), was also used in 1996 when Congress mandated the 
Environmental Protection Agency (EPA) to develop a screening program for “...certain substances 
[which] may have an effect produced by a naturally occurring estrogen, or other such endocrine
effect[s]...”.  To meet this mandate, EPA convened a panel called the Endocrine Disruptors Screening and 
Testing Advisory Committee (EDSTAC), which in 1998 completed its deliberations and made 
recommendations to EPA concerning endocrine disruptors. In 1999, the National Academy of Sciences 
released a report that referred to these same types of chemicals as hormonally active agents. The 
terminology endocrine modulators has also been used to convey the fact that effects caused by such 
chemicals may not necessarily be adverse.  Many scientists agree that chemicals with the ability to disrupt 
or modulate the endocrine system are a potential threat to the health of humans, aquatic animals, and 
wildlife. However, others think that endocrine-active chemicals do not pose a significant health risk, 
particularly in view of the fact that hormone mimics exist in the natural environment.  Examples of 
natural hormone mimics are the isoflavinoid phytoestrogens (Adlercreutz 1995; Livingston 1978; Mayr et 
al. 1992).  These chemicals are derived from plants and are similar in structure and action to endogenous 
estrogen. Although the public health significance and descriptive terminology of substances capable of 
affecting the endocrine system remains controversial, scientists agree that these chemicals may affect the 
synthesis, secretion, transport, binding, action, or elimination of natural hormones in the body responsible 
for maintaining homeostasis, reproduction, development, and/or behavior (EPA 1997a).  Stated 
differently, such compounds may cause toxicities that are mediated through the neuroendocrine axis.  As 
a result, these chemicals may play a role in altering, for example, metabolic, sexual, immune, and 
neurobehavioral function. Such chemicals are also thought to be involved in inducing breast, testicular, 
























3. HEALTH EFFECTS 
No studies were located regarding endocrine disruptive effects in humans or animals resulting from
exposure to americium.
3.7 CHILDREN’S SUSCEPTIBILITY  
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed.  Potential 
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed. 
Children are not small adults.  They differ from adults in their exposures and may differ in their 
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the 
extent of their exposure.  Exposures of children are discussed in Section 6.6 Exposures of Children. 
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less 
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are 
critical periods of structural and functional development during both prenatal and postnatal life and a 
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage 
may not be evident until a later stage of development.  There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to 
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants 
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi 
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975).  Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth 
and development, levels of particular enzymes may be higher or lower than those of adults, and 
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Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of 
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient 
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer. 
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per 
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their 
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar 
absorption (NRC 1993). 
No studies were located in which comparisons were made between the sensitivity of children and adults 
to the toxicity of americium.  Some studies indicate that radiation effects may be greater per unit dose in 
children than in adults.  However, study of bone cancer induction from injected 239Pu or 226Ra in dogs 
suggests that, on a per Gy basis, dogs exposed at 3 months of age were less sensitive than dogs exposed at 
1.5 years of age (Lloyd et al. 1999).  Both plutonium and radium are alpha-emitters that accumulate in 
bone, as does americium.  No direct evidence was located to indicate that the pharmacokinetics of 
americium in children may be different from that in adults.  Based on dosimetric considerations related to 
differences in the parameters of available models, as well as studies in animals, it seems likely that 
children may be more susceptible to americium toxicity than adults by virtue of age-related differences in 
pharmacokinetics or radiosensitivity.  Therefore, a potential for increased risk of effects to the bones of 
children is attributed to the uptake and long-term biological storage of 241Am in the bone during critical 
periods of growth, which may result in genetic damage and an increased risk for cancer.  Differences in 
airway geometry and airflow rates between children and adults would be expected to result in higher 
fractional deposition of inhaled submicron particles in children than in adults (Xu and Yu 1986) (see 
Section 3.5.1). Thus, children who are exposed to americium aerosols may receive a higher dose to the 
lung and greater absorption than would similarly exposed adults (ICRP 1995). 
Studies of experimental animals indicate that absorption of ingested americium may be as much as 
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Sullivan et al. 1985) (see Section 3.4.1.2 and Table 3-2).  Thus, infants exposed to levels of americium in 
food or water similar as adults, or who ingest similar amounts of americium subsequent to an inhalation 
exposure, may absorb more americium and acquire a higher internal burden of americium.  The ICRP 
(1989, 1994b, 1995) assumes age-related differences in intestinal absorption of americium swallowed 
following clearance from the lungs.  The fractional absorption value employed for a 3-month-old infant is 
a factor of 10 higher than for an adult. 
Absorption of americium is greater in iron-deficient animals than in iron-replete adult animals (Sullivan 
and Ruemmler 1988; Sullivan et al. 1986) (see Section 3.4.1.2).  Concurrent oral exposure to Fe3+ and 
americium also appears to increase the absorption of ingested americium; the latter effect may result from
redox reactions in the gastrointestinal tract catalyzed by Fe3+ (Sullivan et al. 1986). These differences are 
accounted for in the discussions and dosimetric/metabolic models of the ICRP (1989, 1993) and the NEA 
(1988). 
As inherent in these ICRP (1989, 1993) models, deposition of americium in bone occurs predominantly at 
bone surfaces that are actively undergoing resorption; therefore, exchanges between bone and soft tissue 
stores of americium would be expected to be more rapid during periods of active bone metabolism such 
as infancy and childhood, pregnancy, and menopause.  Higher skeletal accumulation of americium has 
been observed in neonatal animals that received americium intravenously than in similarly exposed adult 
animals (Hollins et al. 1973; Schoeters et al. 1990; Stevens et al. 1977) and in young rats (3 months of 
age) compared to old rats (13 months of age) (Sontag 1983).  This suggests the possibility that infants and 
children may accumulate higher concentrations of americium in bone than similarly exposed adults.  On 
the other hand, americium uptake into maternal bone of lactating rats was similar to that of nonlactating 
rats, while concurrent calcium uptake into bone was lower in lactating rats (Hollins and Durakovic 1972).  
Thus, active mobilization of bone mineral, per se, may not always promote release of americium from
bone (see Section 3.4.2.1).  Studies of other bone-seeking radionuclides indicate that vulnerability may be 
higher in adolescence and early adulthood than during earlier development or later adulthood (Carnes et 
al. 1997; Lloyd et al. 1999). 
Information on the transplacental transfer of americium in humans is not available directly, but the 
information from experiments with americium and other actinides has been used to derive biokinetic 
models and perform dosimetric models for the human (NCRP 1998; Sikov and Kelman 1989; USNRC 
1996). Studies in animals that received parenteral injections of americium have shown that absorbed 
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et al. 1986; Schoeters et al. 1990; Weiss et al. 1980) (see Section 3.4.2.1).  Limited reports indicate that 
relatively large doses of 241Am may induce fetal death and teratogenic effects in rodents (Moskalev et al. 
1969; Rommerein and Sikov 1986). 
Information on the distribution of absorbed americium to mammary milk in humans is not available; 
however, maternal (oral or intravenous) exposures of animals, including cows and goats, have shown that 
transfer to milk occurs and that neonates can be exposed to americium during lactation (McClellan et al. 
1962; Sasser et al. 1986; Sutton et al. 1979) (see Section 3.4.2.1).  Thus, it is possible that children who 
breast feed from mothers who have been exposed to americium, or who ingest milk from cows or other 
livestock that have been exposed to americium, may also be exposed to americium.
Bone serves as a long-term reservoir of americium in the body.  The kinetics of bone formation and 
remodeling appear to be important factors in the overall biokinetics of americium in experimental animals 
(ICRP 1989, 1993).  Quantitative evidence for their effects in humans has not been characterized, but 
exchanges between bone and soft tissue stores of americium would be expected to be more rapid during 
periods of active bone metabolism such as infancy and childhood, pregnancy, and menopause (see 
Section 3.4.2.1).  Thus, it is possible that, in humans, some of the maternal bone americium stores may be 
transferred to the fetus during gestation and may be incorporated into fetal bone during the development 
of the fetal skeleton. However, the finding of similar americium uptake in maternal bone of lactating and 
nonlactating rats (Hollins and Durakovic 1972) may be an indication that active bone metabolism is not 
necessarily a major source of americium release from bone at this maternal stage. 
3.8 BIOMARKERS OF EXPOSURE AND EFFECT 
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC 
1989). 
Due to a nascent understanding of the use and interpretation of biomarkers, implementation of biomarkers 
as tools of exposure in the general population is very limited.  A biomarker of exposure is a xenobiotic 
substance or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target 
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989).  The 




























3. HEALTH EFFECTS 
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures 
from more than one source.  The substance being measured may be a metabolite of another xenobiotic 
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic 
compounds).  Depending on the properties of the substance (e.g., biological half-life) and environmental 
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the 
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous 
substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as 
copper, zinc, and selenium).  Biomarkers of exposure to americium are discussed in Section 3.8.1. 
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989).  This definition encompasses biochemical or cellular signals of 
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial 
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung 
capacity.  Note that these markers are not often substance specific.  They also may not be directly 
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused 
by americium are discussed in Section 3.8.2. 
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or 
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response.  If biomarkers of susceptibility exist, they are 
discussed in Section 3.10 “Populations That Are Unusually Susceptible”. 
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Americium  
Biomarkers or tests to identify or quantify exposure to americium are available only at a limited number 
of government or nuclear facilities, or through contractors engaged in this type work.  Americium is a 
radioactive element.  Internalized americium can be quantified through the use of in vivo radiation 
counters that measure the gamma emissions specific to each isotope of americium (Graham and Kirkman 
1983; Palmer and Rhoads 1989; Palmer et al. 1983).  Americium within the body can be inferred from
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spectroscopy, mass spectrometry, and liquid scintillation techniques (Alvarez and Navarro 1996; Dacheux 
and Aupiais 1997; DOE 1997b; Guilmette 1986; McInroy et al. 1985).  Americium radioactivity can be 
measured in the teeth of rats, where it accumulates in the dental pulp of developing teeth and eventually is 
incorporated into the mineralized dentin (Hammerström and Nilsson 1970b), so it may be feasible to 
analyze human teeth for americium.
3.8.2 Biomarkers Used to Characterize Effects Caused by Americium  
Although a sufficiently high dose of americium may produce chromosomal aberrations in lymphocytes 
(Bauchinger et al. 1997; Kelly and Dagle 1974), these effects are not specific to americium or to ionizing 
radiation in general. 
3.9 INTERACTIONS WITH OTHER CHEMICALS  
Ethanol may enhance the fecal excretion of absorbed americium.  In baboons that received repeated oral 
doses of ethanol (1 mL ethanol/kg body weight), 3–6 months after receiving americium citrate 
intravenously, fecal excretion was approximately 2.5 times that of baboons that received water in place of 
the ethanol dose (Cohen et al. 1978). Long-term ethanol consumption accelerated the elimination of 
americium from the livers of beagle dogs that had been administered single intravenous injections of 
241Am (Taylor et al. 1992).  The risk of americium-induced liver tumors, however, was 2–3 times higher 
in the ethanol-treated dogs than in similarly 241Am-injected dogs not consuming ethanol. 
Colchicine (a drug used in treatment of gout) and vinblastine (a cancer chemotherapy agent) may
decrease liver uptake of americium.  In rats that received an intraperitoneal injection of either colchicine 
and vinblastine prior to an intravenous or intramuscular injection of americium citrate, liver uptake of 
americium was lower, relative to controls, and kidney and skeletal americium uptakes were higher (Seidel 
1984, 1985).  The effect is thought to involve disruption of hepatic microtubule formation, which is 
critical to the formation and intracellular processing of lysosomes, the initial site of accumulation of 

























3. HEALTH EFFECTS 
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE
A susceptible population will exhibit a different or enhanced response to americium than will most 
persons exposed to the same level of americium in the environment.  Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters result in reduced detoxification or excretion of 241Am, or compromised function of 
organs affected by 241Am.  Populations who are at greater risk due to their unusually high exposure to 
241Am are discussed in Section 6.7, Populations With Potentially High Exposures. 
As discussed in Section 3.7, theoretical pharmacokinetics consideration suggests that children may be at 
greater risk from the effects of exposure to americium.  Furthermore, some studies indicate that children 
may be more susceptible than adults to radiation-induced adverse effects.  A study of bone cancer 
induction from injected 239Pu or 226Ra in dogs suggests that, on a per Gy basis, dogs exposed as young 
adults (1.5 years of age) were more susceptible than either juveniles exposed at 3 months of age or older 
adults (5 years of age) (Lloyd et al. 1999).  Both plutonium and radium are alpha-emitters that accumulate
in bone, as does alpha-emitting americium. 
3.11 METHODS FOR REDUCING TOXIC EFFECTS  
This section will describe clinical practice and research concerning methods for reducing toxic effects of 
exposure to americium.  However, because some of the treatments discussed may be experimental and 
unproven, this section should not be used as a guide for treatment of exposures to americium.  When 
specific exposures have occurred, the Radiological Emergency Assessment Center/Training Site, poison 
control centers and medical toxicologists should be consulted for medical advice.  The following texts 
provide specific information about treatment following exposures to americium:
Ellenhorn MJ, Schonwald S, Ordog G, et al., eds.  1997.  Medical toxicology: Diagnosis and Treatment of 
Human Poisoning. 2nd Baltimore (Williams & Wilkins), 1682-1723. 
Haddad LM, Shannon MW, Winchester JF, eds.  1998.  Clinical Management of Poisoning and Drug 
Overdose. 3rd edition. Philadelphia (W.B. Saunders), 413-425. 
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3.11.1 Reducing Peak Absorption Following Exposure  
Topical applications of saline containing DTPA, tartaric acid, or citric acid (e.g., Schubert’s solution) 
have been used to remove americium from the skin and wounds after accidental dermal exposures 
(Breitenstein 1983).  These agents form stable, water-soluble complexes with americium.  Based on 
experiments with laboratory animals, it appears that aerosols of DTPA may reduce the absorption of 
soluble forms of inhaled americium compounds (Stradling et al. 2000).   Postexposure treatments that are 
effective in reducing toxic effects of radionuclides such as americium typically concentrate on 
decorporation (removal of americium from the body following absorption) and are discussed in 
Section 3.11.2.  
3.11.2 Reducing Body Burden  
Calcium or zinc complexes of polycarboxylate compounds such as DTPA or ethylenediaminetetratacetic 
acid (EDTA) have been used as chelating agents to accelerate the urinary excretion of americium in 
humans who were accidentally exposed to americium (Breitenstein 1983; Doerfel and Oliveira 1989;
Durbin 1973; Fasiska et al. 1971).  Extended chelation therapy was considered to have been a primary
factor in the long-term survival of a man who had been accidentally exposed to a massive amount of 
241Am (Breitenstein and Palmer 1989; Filipy et al. 1995; Toohey and Kathren 1995).  Immediate and 
continued DTPA treatment of rats that had been exposed to 241AmO2 by inhalation resulted in the near-
total blockage of 241Am translocation to liver and bone (Guilmette et al. 1988). Continuous subcutaneous 
infusion of DTPA was more effective in blocking the uptake than were periodic intravenous injections.  
Dogs receiving DTPA treatments following single intravenous injections of 241Am at activity levels of 
approximately 11 kBq/kg (297 nCi/kg) exhibited greater longevity and lower rates of bone cancer than 
241Am-treated dogs not given subsequent DTPA treatment (Lloyd et al. 1998). DTPA and EDTA form
relatively stable complexes with americium in the extracellular fluid that can be excreted in the urine 
(Durbin 1973; Taylor 1973).  The calcium and zinc complexes are used to decrease the risk of calcium
and zinc depletion.  Both DTPA and EDTA appear to affect primarily the americium in soft tissues, 
which exchanges more rapidly with americium in plasma than does americium in bone.  As a result, 
treatments with DTPA or EDTA may have only a marginal effect on bone americium levels (Durbin 
1973).  In a study in rats, DTPA treatment, administered beginning 1.5 hours following intravenously
administered 241Am citrate, decreased bone 241Am levels in trabecular bone at locations where bone 
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1976).  This effect may have resulted from accelerated excretion and, therefore, diminished redeposition 
of americium released during bone resorption. 
Hydroxypyridonate ligands such as octadentate 3,4,3-LI(1,2-HOPO) and hexadentate TREN-Me-
3,2-HOPO) have been shown to be highly effective chelating agents in laboratory animals  (Durbin et al. 
1994; Stradling et al. 2000).  Recent in vitro studies have indicated that octadentate 3,4,3-LI(1,2-HOPO) 
may be effective in decorporation of americium from bone tissues (Guilmette et al. 2003). 
3.11.3 Interfering with the Mechanism of Action for Toxic Effects  
No data were located regarding reduction of the toxic effects of radioactive americium through interfering 
with mechanisms of action. 
3.12 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of americium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of americium. 
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed. 
3.12.1 Existing Information on Health Effects of Americium 
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to 
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information concerning the health effects of americium.  Each dot in the figure indicates that one or more 
studies provide information associated with that particular effect.  The dot does not necessarily imply
anything about the quality of the study or studies, nor should missing information in this figure be 
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature. 
Information regarding health effects following exposure to americium is mainly limited to reports of acute 
exposure. Accidental occupational overexposure of a 64-year-old man resulted in signs of hematological 
and bone marrow damage.  Animal studies indicate that overexposure to americium can result in 
compromised hematological and immunological systems, as well as degenerative changes in the bone, 
liver, kidneys, and thyroid, and bone and liver cancer in long-term surviving animals.  Although most 
studies employed parenteral injection as the route of exposure, available inhalation data indicate similarity
in targets of toxicity.  Data regarding health effects related to oral or dermal exposure are lacking for both 
humans and animals.  Levels of radioactivity from americium employed in animal studies are much 
higher than those likely to be environmentally experienced by humans.  Therefore, americium does not 
likely pose an immediate health concern to humans. 
3.12.2 Identification of Data Needs 
Acute-Duration Exposure.    Human data regarding acute adverse health effects resulting from
exposure to americium are limited to the accidental occupational overexposure (inhalation, dermal, 
subcutaneous) of a 64-year-old man in whom possible hematological and bone marrow changes may have 
been elicited (Filipy et al. 1995; Priest et al. 1995).  Overexposure of animals to americium by the 
inhalation exposure route resulted in compromised respiratory function and radiation pneumonitis 
(Buldakov et al. 1972; DOE 1978; Thomas et al. 1972), persistent depressed blood values (Buldakov et 
al. 1972; Thomas et al. 1972), degenerative changes in bone, liver and kidney lesions, and gross atrophy 
and fibrosis of the thyroid gland (Thomas et al. 1972).  Following acute inhalation exposure to
americium, 4 of 15 dogs surviving more than 1,000 days developed osteosarcomas (Gillett et al. 1985).  
With the exception of the respiratory effects following inhalation exposure, the other targets of toxicity
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high levels of radioactivity (Carter et al. 1951; Dougherty 1970; Jee et al. 1985; Lloyd et al. 1970, 1994a, 
1994b; Schoeters et al. 1991; Taylor et al. 1983, 1991, 1993a; Van Den Heuvel et al. 1995).  Acute-
duration inhalation and oral MRLs were not derived for radioactive americium due to a lack of human or 
animal data.  To generate appropriate data for deriving acute-duration inhalation and oral MRLs for 
radioactive americium, at least one comprehensive acute inhalation study and one acute oral toxicity
study of at least one animal species exposed to several dose levels would be needed.  Such studies could 
be designed to also generate data regarding potential age-related differences in toxicity.  However, since 
americium is not found naturally, and is produced and used in small quantities, the risk of overexposure to 
americium in humans should be low.  Thus, additional studies may not be presently needed. 
Intermediate-Duration Exposure.    A single report indicated the potential for cytogenetic damage in 
a radiation worker and his family members following exposure to an americium source used by the father 
for private experiments at home for several years.  No additional human or animal data were located.  
Intermediate-duration inhalation and oral MRLs were not derived for americium due to the lack of human 
or animal data.  To generate appropriate data for deriving intermediate-duration inhalation and oral MRLs 
for americium, at least one comprehensive intermediate-duration inhalation and one intermediate-duration 
oral toxicity study of at least one animal species exposed to several dose levels would be needed.  Such 
studies could be designed to also generate data regarding potential age-related differences in toxicity.  
However, since americium is not found naturally, and is produced and used in small quantities, the risk of 
overexposure to americium in humans should be low. Thus, additional studies may not be presently 
needed. 
Chronic-Duration Exposure and Cancer.    No data were located regarding chronic-duration 
exposure of humans or animals to americium.  Chronic-duration inhalation and oral MRLs were not 
derived for americium due to the lack of human or animal data.  To generate appropriate data for deriving
chronic-duration inhalation and oral MRLs for americium, at least one comprehensive chronic-duration 
inhalation and one chronic-duration oral toxicity study of at least one animal species exposed to several 
dose levels would be needed.  Such studies could be designed to also generate data regarding potential 
age-related differences in toxicity.  However, since americium is not found naturally, and is produced and 
used in small quantities, the risk of overexposure to americium in humans should be low.  Thus, 
additional studies may not be presently needed. 
Genotoxicity.    Chromosomal aberrations have been reported in lymphocytes following exposure to 

























3. HEALTH EFFECTS 
numbers of micronucleated and multinucleated pulmonary alveolar macrophages in lung lavage of mice 
that had been exposed to 241Am by inhalation (Talbot et al. 1989).  External and internal exposure to 
radioactivity is a genotoxicity concern.  External exposure to gamma-emitting americium would be 
expected to result in genotoxic effects similar to those observed following external exposure to any other 
gamma-emitting radionuclide (see ATSDR 1999 for more information on ionizing radiation).  
Internalized americium could cause damage to nearby cellular components that might be encountered by
high energy alpha particles emitted from americium.  Additional genotoxicity studies could be designed 
to assess the potential for genotoxicity from internalized americium, with special emphasis on blood-
forming cells.
Reproductive Toxicity. No reports were located regarding reproductive effects in humans or 
animals following inhalation, oral, or dermal exposure to americium.  In a limited study, increased 
incidences of fetal death were observed following single intravenous injections of 241Am, administered to 
female rats prior to mating (Moskalev et al. 1969).  Concentrations of 241Am were much higher in 
placental tissues than in fetuses, and the investigators indicated that death may have been the result of 
placental changes. Animal studies could be designed to assess the potential for the reproductive toxicity
of americium. 
Developmental Toxicity.    Data concerning developmental effects related to exposure to americium
are restricted to a single report of decreased fetal weight, increased fetal death, and a tendency toward 
increased incidences of fetuses with anomalous ribs following exposure of pregnant rats with single 
intravenous injections of 241Am (Rommerein and Sikov 1986).  Animal studies could be designed to 
further assess the potential for the developmental toxicity of americium.
Immunotoxicity.    Information regarding the immunotoxicity of americium is limited to a report of 
lymphopenia in a man following accidental overexposure when a glass column containing 241Am blew up 
in his face (Filipy et al. 1995) and reports of depressed white blood cell counts in dogs exposed to 241Am
by inhalation (Buldakov et al. 1972; Thomas et al. 1972) or intravenous injection (Dougherty 1970).  
Additional animal studies could be designed to assess dose-response relationships. 
Neurotoxicity.    No data were located regarding neurotoxicity in humans or animals following 
exposure to americium.  Neurotoxic effects, noted in humans suffering from acute radiation syndrome due 
to ionizing radiation exposure, are well-characterized (see ATSDR 1999 for detailed information on the 

























3. HEALTH EFFECTS 
neurotoxic effects. However, it is extremely unlikely that an americium source capable of producing such 
an overexposure would be encountered.  Studies concerning the potential of americium to induce 
neurotoxicity do not appear to be needed at present. 
Epidemiological and Human Dosimetry Studies.    Epidemiological studies of radiation dose 
typically involve estimates of exposure that are based on whole-body measurements of internally-
deposited americium.  A need remains for epidemiological data that can provide quantitative human dose-
response information while supplying additional information on the health effects of exposure to ionizing 
radiation and americium; in particular, for cases of known internal exposure. 
Biomarkers of Exposure and Effect.     
Exposure. Americium may be detected during in vivo counting as well as in samples of urine, blood, 
feces, or body tissues. Due to the relatively long biological half-time of americium in skeleton, short-
term exposures cannot be readily distinguished from longer-term ones.  An increased understanding of the 
biokinetics and health effects of internalized americium can be achieved through continued monitoring of 
individuals following known overexposure to americium. 
Effect. Chromosomal aberrations have been reported in lymphocytes following exposure to 241Am
(Bauchinger et al. 1997; Kelly and Dagle 1974).  Additionally, high radiation doses from internally 
deposited americium can cause bone marrow changes and altered blood values (Filipy et al. 1995; Priest 
et al. 1995). However, none of these effects are specific to americium.
Absorption, Distribution, Metabolism, and Excretion.    Inhaled americium can be absorbed and 
transferred to the blood (Edvardsson and Lindgren 1976; Fry 1976; Newton et al. 1983; Sanders 1974; 
Toohey and Essling 1980).  Limited information indicates that americium is rather poorly absorbed via 
the gastrointestinal tract (Hunt 1998; Hunt et al. 1986a, 1986b).  Once americium reaches the blood, it is 
distributed throughout the body, accumulating mainly in the skeleton, liver, and muscle (Filipy and 
Kathren 1996; Filipy et al. 1994; Kathren et al. 1988; McInroy et al. 1989).  Animal studies indicate that 
americium can pass through the placental barrier of a pregnant mother to a developing fetus (DOE 1986; 
Hisamatsu and Takizawa 1983; Paquet et al. 1998; Sasser et al. 1986; Schoeters et al. 1990; Sikov 1987; 
Van Den Heuvel et al. 1992; Weiss et al. 1980), and also can be distributed to the breast milk of lactating 
mothers (McClellan et al. 1962; Sasser et al. 1986; Sutton et al. 1979).  The metabolism of americium
consists of binding interactions with proteins and probably complex formation with various inorganic 





















3. HEALTH EFFECTS 
Taylor 1973; Webb et al. 1998).  Americium is slowly eliminated from soft tissues and bone, but may
remain in the skeleton for much longer periods.  Once absorbed into the general circulation, americium is 
excreted in both feces and urine (Cohen and Wrenn 1973; Durbin 1973; Guilmette et al. 1980; Stather et 
al. 1979a). Additional quantitative toxicokinetic studies could be designed to further assess absorption 
following inhalation, oral, and dermal exposure, as well as age-related differences in the toxicokinetics of 
americium.  However, the predominant data need for americium, and other sources of internal radiation 
exposure, is the validation (through biokinetic studies) and refinement of the models that describe internal 
distribution from which the radiation dose derives. 
Comparative Toxicokinetics.    Toxicokinetic properties of americium are generally similar in 
humans and animals.  Inhaled americium, in relatively soluble forms, is readily absorbed in the 
respiratory system of humans and animals.  Ingested americium is not absorbed to any great extent in 
humans or animals.  Distribution patterns are generally similar; americium is found in highest 
concentrations in the skeleton, liver, and muscle of humans and animals.  Although studies were not 
located regarding transfer of americium from mother to developing fetus, studies in animals suggest that 
americium could be incorporated by a fetus following inhalation exposure of the pregnant mother. 
Methods for Reducing Toxic Effects.    Topical applications of saline containing DTPA, tartaric 
acid, or citric acid (e.g., Schubert’s solution) have been used to remove americium from the skin and 
wounds after accidental dermal exposures.  These agents form stable, water soluble complexes with 
americium.  Calcium or zinc complexes of DTPA have been used as chelating agents to accelerate the 
urinary excretion of americium.  Hydroxypyridonate ligands such as octadentate 3,4,3-LI(1,2-HOPO) and 
hexadentate TREN-Me-3,2-HOPO) have been shown to be highly effective chelating agents in laboratory
animals  (Durbin et al. 1994; Stradling et al. 2000).  Recent in vitro studies have indicated that octadentate 
3,4,3-LI(1,2-HOPO) may be effective in decorporation of americium from bone tissues (Guilmette et al. 
2000). 
Children’s Susceptibility.    Some studies suggest that children, especially neonates, may be more
susceptible than adults to radiation-induced adverse effects..  However, animal studies indicate that 
juvenile dogs are less susceptible than adults to americium-induced bone cancer (Lloyd et al. 1999).  No 
direct evidence was located to indicate that the pharmacokinetics of americium in children may be 
different from that in adults.  Based on dosimetric considerations related to differences in the parameters 
of available models, as well as studies in animals, it seems likely that children may be more susceptible to 





















3. HEALTH EFFECTS 
pharmacokinetics. Absorption of ingested americium may be as much as 200 times greater in neonatal 
animals than in adults (Bomford and Harrison 1986; David and Harrison 1984; Sullivan et al. 1985). 
As inherent in ICRP (1989, 1993) models, deposition of americium in bone occurs predominantly at bone 
surfaces that are actively undergoing resorption; therefore, exchanges between bone and soft tissue stores 
of americium would be expected to be more rapid during periods of active bone metabolism such as 
infancy and childhood, pregnancy, and menopause.  Higher skeletal accumulation of americium has been 
observed in neonatal animals that received americium intravenously than in similarly exposed adult 
animals (Hollins et al. 1973; Schoeters et al. 1990; Stevens et al. 1977) and in young rats (3 months of 
age) compared to old rats (13 months of age) (Sontag 1983).  This suggests the possibility that infants and 
children may accumulate higher concentrations of americium in bone than similarly exposed adults.  
Studies of other bone-seeking radionuclides provide further support for increased vulnerability during 
periods of rapid bone growth such as adolescence (Carnes et al. 1997; Lloyd et al. 1999). 
Information on the transplacental transfer of americium in humans is not available.  Studies in animals 
that received parenteral injections of americium have shown that absorbed americium is transferred to the 
fetus (Hisamatsu and Takizawa 1983; Paquet et al. 1998; Sasser et al. 1986; Schoeters et al. 1990; Weiss 
et al. 1980). 
Information on the distribution of absorbed americium to mammary milk in humans is not available; 
however, maternal (oral or intravenous) exposures of animals, including cows and goats, have shown that 
transfer to milk occurs and that neonates can be exposed to americium during lactation (McClellan et al. 
1962; Sasser et al. 1986; Sutton et al. 1979). 
Exchanges between bone and soft tissue stores of americium would be expected to be more rapid during 
periods of active bone metabolism such as infancy and childhood, pregnancy, and menopause.  Thus, it is 
possible that, in humans, some of the maternal bone americium stores may be transferred to the fetus 
during gestation and may be incorporated into fetal bone during the development of the fetal skeleton. 
Child health data needs relating to exposure are discussed in 6.8.1 Identification of Data Needs: 















3. HEALTH EFFECTS 
3.12.3 Ongoing Studies 
No ongoing studies examining adverse health effects in mammalian species exposed to americium were 
identified in the Federal Research in Progress database (FEDRIP 2004) or are currently listed by the 

























   
 
AMERICIUM 103 
4. CHEMICAL, PHYSICAL, and RADIOLOGICAL INFORMATION 
4.1 CHEMICAL IDENTITY  
Americium is a human-made actinide element (atomic number 95) and has no stable isotopes.  It was 
discovered by Glen Seaborg, Leon Morgan, Ralph James, and Albert Ghiorso in 1944 and isolated by
B.B. Cunningham as the isotope 241Am in Am(OH)3 in the fall of 1945.  It was named after the Americas 
(Seaborg 1991; Seaborg and Loveland 1990).  Actinides are the 15 elements starting with actinium,
atomic number 89, and extending to lawrencium, atomic number 103.  All of the isotopes of these 
elements are radioactive.  Of the 15 americium isotopes and isomers currently identified, the longest-lived 
is 243Am.   
4.2 PHYSICAL, CHEMICAL, AND RADIOLOGICAL PROPERTIES  
Americium is a silvery, ductile, very maleable, non-magnetic metal.  Americium melts at 1,176 ºC, boils 
at 2,011 ºC, and has an electron configuration of 5f77s2. The Chemical Abstract Service (CAS) registry
numbers, decay modes, half-lives, and specific activities of the four principal americium isotopes and 
isomers, 241Am,242mAm, 242Am, and 243Am, are presented in Table 4-1.  241Am and 243Am decay by alpha 
emission forming neptunium (atomic number 93), 237Np (t½=2.14x106 years) and 239Np (t½=2.355 days) as 
the respective products. 239Np subsequently decays to 239Pu (t½=2.411x104 years), and then to 235U, which 
is also a naturally-occurring isotope of uranium.  The decay of 241Am to 237Np is accompanied by a 
predominant gamma ray photon of 59.54 keV.  242mAm is an isomer (long-lived excited state of the 
nucleus) of 242Am and has a half-life of 141 years; 95.5% of 242mAm undergoes an isomeric transition to 
242Am (t½=16.02 hours) with the emission of a 48.6 keV gamma ray, and 0.5% decays by alpha emission 
to 238Np. 242Am primarily (87%) undergoes beta decay to curium 242 (atomic number 96) 
(t½=162.8 days), which decays to 238Pu (t½=87.74 years) and then to 234U (t½=2.45x105 years) (another 
naturally-occurring uranium isotope); 17% undergoes electron capture to 242Pu (t½=3.76x105 years).   
241Am has a high specific activity of 3.428 Ci/g (0.1268 TBq/g), emitting ~7x109 alpha particles/mg/ 
minute. 243Am has a specific alpha activity about 17 times lower than 241Am and is therefore more





















    
 
 









4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION 

































432.2 3.43 26.34 
33.192 
59.536 
242mAm 13981-54-9 I.T./95.5 
(242Am) 
0.048 141 10.5 48.63 







242Am 13981-54-9 $ -/83 (24 9 2 6Cm) 0.665 0.63 46 16.02 
hours 
808,000 42.2 
EC/17 (24 9 2 4Pu) 0.750 0.67 37 44.53 













aAn m after the atomic mass indicates one of multiple isomers of a given atomic mass. 

bLANL 1999 (1 Ci=0.037 TBq) 

cCAS Registry Number for 241Am3+ ion 
















4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION 
The known oxidation states of americium are +2, +3, +4, +5, and +6.  However, the stable oxidation 
states are +3 and +4; the common oxidation state is +3, in which state, the behavior of americium and 
other actinides is similar to the lanthanides.  The trivalent state is the only state of importance in 
biological systems.  The +2 oxidation state is very unstable and has only been produced in solid 
compounds.  The stability of the americium oxidation states higher than +3 is less than that of uranium, 
neptunium, and plutonium (Cotton and Wilkinson 1980; Nenot and Stather 1979; Seaborg 1991).  Am+3 
hydrolyzes and forms weak complexes with serum proteins and other ligands.  The physical and chemical 
properties of americium and selected americium compounds are shown in Table 4-2.  Properties of some 
americium ions are shown in Table 4-3.  The decay schemes for 241Am and 243Am are shown in 


















   
     
     
     
 
    
     
   
  
     
      
     










     
     
     
     
AMERICIUM 106 
4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION 
Table 4-2. Physical and Chemical Properties of Americium and  


























Color Silvery Black Tan Pink




Odor No data No data No data No data
Melting point, EC 1,176 >1,000 (decomposes) No data 500
Boiling point, EC 2,011 Not relevant No data No data












Density, g/cm3 12 11.68 11.77 5.87
Partition coefficients No data No data No data No data
Vapor pressure No data No data No data No data












   
     
     
     
     
 
    
     
     
     
      
     









     
     
     








4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION 
Table 4-2. Physical and Chemical Properties of Americium and  

Selected Americium Compounds 

Value
Property Americium(III) fluoride Americium nitrate Americium citrate
Atomic/molecular weighta 300 429 432
Chemical formula AmF3 Am(NO3)3 AmC6H5O7 
Synonyms No data Americium trinitrate No data
Chemical Abstracts Service 13708-80-0 25933-53-3 11078-88-9
Registry No.
Color Pink No data No data
Physical form Hexagonal crystals No data No data
Odor No data No data No data
Melting point, EC 1,393 No data No data
Boiling point, EC No data No data No data
Autoignition temperature Not relevant Not relevant Not relevant
Solubility: 
 Water No data No data No data 
 Other solvents No data No data No data
Density, g/cm3 9.53 No data No data
Partition coefficients No data No data No data
Vapor pressure No data No data No data
Refractive index No data No data No data
aCalculated for 243Am 

bThis is also a generic CAS Registry Number for americium (unspecified form).  






















4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION 
Table 4-3. Properties of Some Americium Ions 
Ion Color Stability 
Am3+ Pink or yellow Stable; difficult to oxidize 
Am4+ Color unknown Occurs in solution only as complex 
fluoride and carbonate ions
AmO2 + Yellow Disproportionates in strong acid; 
reduces fairly rapidly under action of 
own alpha emissions (241Am) at low 
acidification 
AmO2 2+ Rum colored Easily reduced; reduces fairly rapidly 















   

























   
  
  
    
    
 
 
    
  
   





    
    
    
 
 
    
    





4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION 
Table 4-4. 241Am Decay Schemea 
Nuclide Half-life 
Energies and intensities of emitted radiation 
Alpha (α) Beta (β) max Gamma (γ) 
keV % MeV % keV % 
241Am 
↓



























































































































217At ↓ 0.323 seconds 7,066 99.9 258.5 0.056 
213Bi 
97.84% ↓ 2.16% 





























209Pb ↓ 3.253 hours 0.644 100 
209Bi stable 






















    
  
     










    
 






    
    
 
 






















4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION 
Table 4-5. 243Am Decay Schemea 
Nuclide Half-life 
Energies and intensities of emitted radiation 
Alpha (α) Beta (β) max Gamma (γ) 
keV % MeV % keV % 
243Am 
↓


























































































































































































        
  
   
    








    
   






4. CHEMICAL, PHYSICAL, AND RADIOLOGICAL INFORMATION 
Table 4-5. 243Am Decay Schemea 
Nuclide Half-life 
Energies and intensities of emitted radiation 
Alpha (α) Beta (β) max Gamma (γ) 
keV % MeV % keV % 
219Rn 
↓










215Po ↓ 1.781 milli- 7,386 100.0 
seconds 
211Pb 36.1 minutes 1379 91.3 404.9 3.8 
↓ 547 6.3 832.0 3.5 
211Bi 
↓





207Tl ↓ 4.77 minutes 1427 99.7 897.8 0.26 
207Pb stable 
























5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
5.1 PRODUCTION  
Americium does not occur in nature.  Although the amount of 241Am produced is believed to be several 
kilograms a year, the only isotope produced for commercial use is 241Am.  No production figures were 
available in the published literature.  The amount of 243Am available ranges from 10 to 100 g (Seaborg 
and Loveland 1990). 
241Am and 243Am can be made from 239U or 239Pu by neutron activation involving an operating nuclear 
reactor or nuclear bomb detonation.  In this process, neutron activation of 238U can produce uranium
isotopes up to at least 241U, and each of these beta decays to a neptunium isotope of the same mass. 
Neutron activation of neptunium can produce isotopes starting with 239Np up through at least 244Np, and 
each of these isotopes beta decays to a plutonium isotope of the same mass.  Neutron activation of 
plutonium isotopes starting with 239Pu can produce isotopes through at least 246Pu, and of these, 241Pu, 
243Pu, 245Pu, and 246Pu beta decay to americium isotopes of the same mass.  241Am can be produced more 
directly through alpha bombardment of 238U to 241Pu (238U [α,n] 241Pu), and its subsequent beta decay.  
Each of these americium isotopes can also be neutron activated to isotopes up through at least 246Am.  The 
amount of any product is a function of the starting mass of either 238U or 239Pu and the neutron fluence 
over the activation period balanced by the natural radioactive decay of the isotopes being formed.  For 
example, an atom of 239Pu will naturally decay to 235U, unless it is first neutron activated to 240Pu. 240Pu 
will alpha decay to 236U, unless first activated to 241Pu. 241Pu will beta decay to 241Am, unless first neutron 
activated to 242Pu.  These processes can be managed through focused radiochemical separation or by the 
addition of special processing (proton bombardment) to help direct the effort toward a particular isotopic 
product (Parrington et al. 1996).  In general, lower mass isotopes are preferentially produced in the 
relatively low fluxes available inside nuclear reactors, while higher masses are more feasibly produced in 
extreme flux conditions present inside a nuclear detonation.  These processes are summarized in 
Figure 5-1. 
The relative activities of americium isotopes for a typical pressurized-water reactor (PWR) fuel assembly

























5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 





241Am 242Am 243Am 244Am 245Am 246Am 
239Pu 240Pu 241Pu 242Pu 243Pu 244Pu 245Pu 246Pu 
237Np 238Np 239Np 240Np 241Np 242Np 243Np 244Np 
235U 236U 237U 238U 239U 240U 242U 
238Pu237Pu 
Legend: Neutron activation (n,ƒÁ) reaction more significant to Am-241,243 formation 
Neutron activation (n,ƒÁ) reaction less significant to Am-241,243 formation 
Neutron activation (n, 2n reaction)
 









































5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
2002a). The respective activity ratios for a typical boiling water reactor (BWR) are 370, 2.1, and 4.8 Ci 
(14, 0.078, and 0.18 TBq).  There are 78 PWRs and 40 BWRs in the United States, several of which have  
ceased operation. Total projected inventories of these three radionuclides for all reactors are 2.2x108, 
1.6x106, and 1.9x106 Ci (8.1x106, 5.9x104, and 7.0x104 TBq), respectively.  The post-irradiation 
americium content of typical PWR and BWR fuel assemblies are 600 g (0.09%) and 220 g (0.07%), 
respectively.
The ratio of plutonium isotopes to 241Am is often reported in monitoring studies as it is an important tool
in dose assessment by enabling a determination of plutonium concentrations.  243Am is produced directly
by the capture of two neutrons by 241Am. The parent of 241Am is 241Pu, which constitutes about 12% of 
the 1% content of a typical spent fuel rod from a nuclear reactor, and has a half-life of 14.4 years.  
Separation of 241Am from its parent, 241Pu, and the other isotopes present can be effected by precipitation, 
ion exchange, or solvent extraction. 
Americium metal has been obtained by heating americium oxide, Am2O3, with lanthanum at 1,200 EC; 
americium, which is more volatile than other actinides, volatilizes and can readily be separated from other 
actinides. AmO2 can be obtained by igniting most trivalent americium compounds (Budavari 1996; 
Cotton and Wilkinson 1980; UIC 1997). 
5.2 IMPORT/EXPORT 
No U.S. import or export information is available for americium.
5.3 USE 
241Am has a long half-life and a predominant gamma ray energy of 59.5 keV, which makes it useful for a 
wide range of industrial gauging applications and for diagnosing certain thyroid disorders (Seaborg 1991). 
The most common application of americium is in ionization smoke detectors, and most of the several 
kilograms of americium produced each year are used for this purpose.  Smoke detectors today typically
contain approximately 1 µCi (37 kBq) of 241Am (EPA 2004b).  One gram of americium dioxide, AmO2, 
provides enough active material for more than 5,000 smoke detectors.  In the 1980s, annual sales of 
smoke detectors approached 12 million units.  A mixture of 241Am and beryllium known as 241Am-Be is























5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
in the glass industry (UIC 1997).  241Am is used worldwide to measure the rate of production by oil wells 
(Seaborg 1991).  No commercial uses for other americium isotopes were found.  However, 243Am can be 
used as a target material for the production of transcurium elements in high neutron flux reactors 
(Budavari 1996).  243Am is also the preferred isotope for investigating the chemical properties of 
americium, because its lower specific activity and gamma emissions relative to 241Am, which produce a 
lower radiation field for researchers and a lower radiation dose to experimental animals. 
5.4 DISPOSAL 
Radioactive wastes are categorized according to their origin, the type of waste present, and their level of 
activity.  The first distinction is between defense waste and commercial waste.  The former was generated 
during and after World War II, principally at DOE’s facilities at Hanford, Washington; Savannah River, 
South Carolina; and Idaho Falls, Idaho where plutonium and other isotopes were separated from
production reactor or nuclear-powered naval vessel spent fuel.  Commercial waste is produced by nuclear 
power plants, except for the long defunct commercial reprocessing facility at West Valley, New York.  
Nuclear waste is classified as transuranic waste (TRU), high-level waste (HLW), spent nuclear fuel 
(SNF), uranium and thorium mill tailings (UMT), and low-level waste (LLW).  LLW is further 
differentiated into four classes, A, B, C, and greater than class C, according to increasing level of activity
(listed in Tables 1 and 2 of 10 CFR 61.55 for long and short half-life radionuclides, respectively), with 
specific disposal requirements (USNRC 2004a).  SNF, HLW, TRU, and greater than class C (GTCC) 
waste are not generally suitable for near-surface disposal (EPA 2004d).  Class C waste would include 
much of the operating and decommissioning waste from nuclear power plants, typical radioactive material
licensee facilities, and sealed radioisotope sources.  LLW (less GTCC) is currently accepted at three sites 
(Barnwell, South Carolina; Envirocare, Utah; and Richland, Washington).  Defense TRU is currently
being buried at the Waste Isolation Pilot Plant (WIPP) 2,150 feet below ground in a geologically inactive 
salt deposit near Carlsbad, New Mexico (EPA 2004e).  GTCC, HLW, and SNF are destined for disposal 
at a HLW site, which is likely to be at Yucca Mountain, Nevada (USNRC 2004b).  Yucca’s 25-foot 
diameter main access tunnel and test disposal drifts have been bored, and research is underway to test and 
reduce uncertainties associated with various modeling parameters used to provide assurance that isolation 
of the waste from the biosphere for 10,000 years will be feasible (DOE 2004).  If LLW also contains 
hazardous material (i.e., toxic, corrosive, inflammable, or oxidizing), it is termed low level mixed waste 
(LLMW). EPA is considering the feasibility of disposing of some LLMW in RCRA-C landfills, and the























5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
liquid waste at the Hanford Reservation are slated for disposal at the future HLW repository; however, 
Hanford is considering managing the waste in a way that destroys the volatile organics and PCBs, 
separating the resulting waste into low and high level component streams, vitrifying each, disposing of 
the low activity waste on site in a virtual LLW facility, and holding the vitrified HLW until Yucca or the 
selected facility opens. UMT waste does not concern americium (DOE 1999a; Murray 1994). 
TRU contains radionuclides, like 241Am and 243Am, which follow uranium in the periodic table and have 
half-lives >20 years.  If its level of activity is less than 100 nanocuries (nCi) (3.7 kBq) of alpha-emitters
per gram of waste material (up from 10 nCi/g in 1982), the waste can be disposed of by shallow burial.  
Wastes with TRU concentrations >100 nCi/g go to WIPP.  TRU generally has low levels of radioactivity,
generates very little heat, contains volatile organics, and is grouped as contact handled (CH) with surface 
radiation levels not exceeding 200 mrem per hour, or remote handled (RH) waste with surface levels 
above 200 but not exceeding 1,000 mrem per hour (EPA 2004d).  
HLW includes spent fuel that is contained in fuel rods that have been used in a nuclear reactor and fuel 
reprocessing liquids, concentrates, and solids.  These fuel rods will contain some level of transuranic 
elements.  After removal, these rods are placed in pools adjacent to the commercial nuclear power plants 
and DOE facilities where they were produced.  It was originally intended that the fuel rods remain in 
these pools for only about 6 months to allow for a reduction in radioactivity and temperature, and then be 
transferred to a reprocessing or storage facility. There is no commercial reprocessing facility or 
permanent disposal facility for HLW operating in the United States.  The USNRC has issued standards 
for the disposal of HLW (10 CFR 61), and the DOE is pursuing the establishment of an HLW facility.  
Efforts to establish an HLW facility, which began over 2 decades ago, have experienced many delays.  
However, in July 2002, the U.S. Congress and the President selected Yucca Mountain, Nevada as the 
nation’s first long-term repository for HLW.  The underground tunnel system and several of its 
operational facilities have been completed through 2004.  The facility is projected to begin operation 
(accept HLW) in 2010, and efforts are underway to consider establishing a nearby interim storage facility
should that date need to be extended beyond the capacity of utilities to provide onsite storage of their SNF 
(DOE 2002b, 2004). 
LLW is officially defined as radioactive waste other than those previously defined.  These wastes come 
from reactors and institutions such as hospitals, universities, and research centers.  Most LLW contains 
very little or low concentrations of primarily short-lived radioactivity and essentially no transuranic 




















5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
However, some LLW contains sufficient quantities of radioactivity as to require special treatment.  
USNRC regulations for LLW disposal (10 CFR 61) permit shallow land burial, and the three states with 
licensed LLW disposal facilities (South Carolin, Utah, and Washington), as USNRC agreement states, 
have enacted more stringent regulations (Eisenbud 1987; Murray 1994; USNRC 2004c).  The EPA is 
developing cleanup regulations as well as general environmental standards for LLW disposal that would 
apply to DOE facilities (EPA 2001d).  The standards will facilitate planning and reduce costs for cleanup 
and disposal.  There are currently 23 DOE and commercial LLW disposal sites in the United States (EPA 
2001d). While some LLW facilities are closed, they are continuously monitored to detect releases of 
radioactivity into the environment.  The Manifest Information Management System (MIMS), maintained 
by the Idaho National Environmental and Engineering Laboratory (INEEL), contains information on low-
level radioactive waste shipments received at commercial low-level radioactive waste disposal facilities at 
Barnwell, South Carolina (January 1, 1986–present); Beaty, Nevada (April 1, 1986–December 31, 1992);
Richland, Washington (January 1, 1986–present); and Envirocare, Utah (January 1, 1998–December 31, 
1999).  In 1999, 3.67 Ci (136 GBq) of 241Am and <0.01 Ci (<0.4 GBq) of 243Am LLW was received at 
these facilities from academic, industrial, government, and utility generators throughout the United States 
(INEEL 2000). 
The USNRC and EPA each have responsibilities for regulating the cleanup of radioactivity and 
decommissioning of USNRC licensed sites.  USNRC and EPA reached an agreement in 2002, in response 
to Congressional mandate, to preclude double regulation of these efforts.  The agreement provides that 
EPA will defer exercise of authority under Comprehensive Environmental Response, Compensation, and 
Liability Act (CERCLA) for the majority of facilities decommissioned under USNRC authority.  It also 
contains provisions for joint consultation when certain EPA parameters are exceeded, including 
groundwater exceeding EPA-permitted levels, USNRC contemplation of restricted release or alternate 
release criteria, and residual soil radioactivity concentrations exceeding those in the agreement (USNRC 
2002). 
At present, DOE stores most of its spent fuel and HLW at three primary locations: the Hanford site in 
Washington, the INEEL in Idaho, and the Savannah River Site in South Carolina, representing 86% of the 
volume and 98% of the metal mass.  Some HLW/SNF is also stored at Oak Ridge National Laboratory in 
Tennessee, the West Valley site in New York, and the dry storage facility at Fort St. Vrain in Colorado 
(DOE 2002c). Much smaller amounts of spent nuclear fuel stored at other sites were to be shipped to the 
three prime sites for storage and preparation for ultimate disposal (DOE 1999a). The DOE National 
















5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL 
tons of heavy metal (MTHM) of 16 DOE categories of spent nuclear fuel stored in each of the three 
locations. The categories having the highest 241Am activities per spent nuclear fuel canister (decayed to 
2030) are ‘uranium metal’, ‘mixed oxides’, and ‘plutonium/uranium carbide, nongraphite’.  The 241Am
solid waste stored on the Hanford site in 1998 included 2.3 Ci (85 GBq) as LLW and 11 Ci (410 GBq) as 
TRU (Hanford 1999).  Between 1945 and 1970, the Farallon Islands Nuclear Waste Dump Site 
(FINWDS), approximately 30 miles west of San Francisco, received at least 500 TBq (14,000 Ci) of 
reportedly low-level nuclear waste, concrete-encapsulated in at least 47,500 55-gallon, 16-gauge steel 
drums (life-expectancy ~30 years in sea water) (Suchanek et al. 1996).  These were deposited at three 
sites 100, 900, and 1,800 m deep. 
According to EPA (2004a), smoke detectors (with the batteries removed) can be disposed of in the trash.  
However, EPA also notes that state and local practices for the safe disposal of smoke detectors vary.  
Some state radiation control programs conduct annual collection programs for smoke detectors, while 
other state and local governments recommend that the smoke detector be returned to the supplier (EPA 
























6. POTENTIAL FOR HUMAN EXPOSURE 
6.1 OVERVIEW
Americium has been identified in at least 8 of the 1,636 hazardous waste sites that have been proposed for 
inclusion on the EPA National Priorities List (NPL) (HazDat 2004).  However, the number of sites 
evaluated for americium is not known.  The frequency of these sites can be seen in Figure 6-1.  Of these 
sites, all are located within the United States.  
Americium is a human-made element.  In the environment, 241Am is present as a result of basically three 
sources: fallout from nuclear explosions, releases from nuclear reactors and reprocessing plants, and 
production and disposal of smoke detectors by producers and consumers.  The majority of the americium
present in the environment was the result of atmospheric nuclear weapons testing during the 1950s and 
1960s (EPA 2004c).  Additionally, there are accidental releases such as the Chernobyl accident, the burn-
up of a satellite powered by the aerospace reactor SNAP 9A, and the crash of a B-52 aircraft carrying 
nuclear weapons in Thule, Greenland.  Today, 241Am along with 90Sr, 137Cs, 238Pu, 239Pu, and 240Pu, are the 
isotopes that produce the majority of radiation associated with nuclear fallout (DOE 1997a). Low levels 
of 241Am may be found in environmental media worldwide from atmospheric nuclear weapons tests; these 
levels are referred to as fallout background levels.  In nuclear reactors, 241Am has been detected in 
primary coolant water, stack aerosols, and waste water (Rosner et al. 1978).  Because 241Am is produced 
from the decay of 241Pu (half-life=14.4 years), releases of 241Pu will result in an ingrowth of 241Am; 
clearly, releases of 241Pu and 241Am must be considered collectively.  The maximum quantity of 241Am
following an accidental release of 241Pu occurs in 70–80 years following the production of the 241Pu (EPA 
1976).  Consequently, the impact of 241Am from atmospheric nuclear weapons testing will reach its peak 
in about the year 2035 and then, based on this model, levels will decline according to its combined rate of 
formation and decay.  It should be noted that when the 241Am level reaches its peak, there will still be 
241Pu remaining. 241Am is used commercially as an ionization source in smoke detectors and it may be 
released into the environment from its production, use, and disposal.  241Am is the only americium isotope 
that is used commercially. 
Americium released to the atmosphere will be associated with particulate matter and will be deposited on 
land or surface water by dry or wet deposition (Essien et al. 1985).  Dry deposition results from  
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6. POTENTIAL FOR HUMAN EXPOSURE 
gravitational settling and impaction on surfaces.  Wet deposition returns americium to earth in
precipitation.  Radionuclides resulting from atmospheric weapons tests are often injected into the lower 
stratosphere, while other atmospheric releases are into the troposphere.  The residence time of particles in 
the atmosphere will depend on their aerodynamic size, as well as the altitude, latitude, season, and 
hemisphere because of atmospheric circulatory patterns.  For example, residence half-times of particles in 
the lower stratosphere range from 3 to 12 months in polar regions and from 8 to 24 months in equatorial 
regions, with removal being highest in the spring and lowest in the fall.  Half-times for particles in the 
troposphere are about 1 month.  Larger particles will remain in the atmosphere for shorter periods of time 
and are deposited closer to their emission source, while smaller particles remain in the air for longer 
periods of time and are deposited farther from their source.  In the absence of actual measurements, the 
deposition of 241Am in a region can be estimated by using the relationship between air concentration and 
deposition quantities for other isotopes that are attached to particulate matter in air.  Using this
methodology, the annual deposition of 241Am in New York was estimated to have reached a maximum of 
0.010 mCi/km2 (0.37 MBq/km2) in 1964 (Bennett 1979).  The cumulative 241Am deposition in the 
year 2000 is estimated to be 0.058 mCi/km2 (2.1 MBq/km2). If the ingrowth from 241Pu decay is included, 
the cumulative 241Am deposited by the year 2000 would be 0.80 mCi/km2 (30 MBq/km2). Americium
may also be injected into the atmosphere from water surfaces by the action of bubbles scavenging the 
water column and wave action (McKay et al. 1994; Walker et al. 1986).  Similarly, 241Am-contaminated 
soil may be released into air by wind action.   
Americium released to water in effluent, runoff, or atmospheric deposition adsorbs to particulate matter 
and is rapidly depleted from the water column and deposited in surface sediment (Murray and Avogadro 
1979). Adsorption is very high with distribution coefficients between the particulate-associated phase and 
the dissolved phase in sediment and water of the order of 105–106 (Davis et al. 1997; NRC 1981; 
Pattenden and McKay 1994).  Aquatic organisms can bioaccumulate americium via intake from the water 
or ingestion of sediment or organisms lower on the food scale.  In crustacean zooplankton, crustaceans, 
and molluscs, americium is accumulated from water by passive absorption onto exoskeletons (Fisher et al. 
1983). Ingested in suspended diatoms or other food, americium largely passes through the gut and is 
eliminated.  Biogenic debris from these animals, such as fecal pellets and discarded molts, facilitates 
vertical transport of 241Am into the depths and sediment.  
If land deposition occurs, americium will sorb to the soil, leach into the subsurface soil, and redistribute 
by the action of wind, water, or biotic transport.  Small mammals inhabiting areas containing radioactive 

























6. POTENTIAL FOR HUMAN EXPOSURE 
contaminated soil or plants and disturb 241Am-contaminated soil through their burrowing and excavating 
activities. In addition, small mammals may be consumed by animals higher in the food chain such as 
hawks and coyotes, which would add to the dispersal of americium from disposal areas.  Since fallout 
241Am is accompanied by its precursor, 241Pu, which also leaches into the ground, the amount of 241Am at 
a depth is a function of the leaching of both the americium and plutonium as well as the decay of these 
isotopes. Fallout 241Am is predominantly retained to the upper few centimeters of soil where it is 
associated with organic matter and bound to manganese and iron oxides (Bennett 1976; Bunzl et al. 1995;
Vyas and Mistry 1980).  However, transuranic radionuclides, including americium, have been found to 
migrate in groundwater, and have traveled underground from 80 to over 3,000 meters at several national 
laboratories. Colloidal materials can be mobile in groundwater systems for great distances and are 
capable of binding and transporting radionuclide contaminants, including americium, in subsurface 
systems (McCarthy et al. 1998a, 1998b; Penrose et al. 1990).  
Americium may be taken up from the soil by plants and translocated to other parts of the plants.  241Am­
contaminated dust may also be deposited on the above-ground parts of the plant.  Uptake of 241Am from
soil is low (Bennett 1979; EPA 1979; Nisbet and Shaw 1994; Romney et al. 1981; Schultz et al. 1976;
Zach 1985). Uptake from soil is a function of the chemical species, soil chemistry, plant species, and 
environmental conditions.  Concentration ratios of 241Am in plants to that in soil range over about 2 orders 
of magnitude depending on crop and soil type.  Uptake is higher under acidic conditions and lower in soil 
with high fractions of organic matter that play an important role in complexing americium, making it less 
available for uptake. Translocation of transuranic elements taken up through the roots into seeds and fruit 
is generally very low (Bennett 1979; Schreckhise and Cline 1980). Concentration ratios in seed, grain, 
and fruit range from 10-6 to 10-4, about a factor of 10 lower than in foliage.  Animals can accumulate 
americium by eating contaminated plants as well as by ingesting soil or other animals and by breathing 
air. Biological uptake in aquatic organisms may depend on factors such as temperature, time after intake, 
season of the year, and water quality.  The bioconcentration of 241Am in fish is low, especially to the 
edible parts of the fish (DOE 1996).  In a study performed in a nuclear waste pond where the levels of 
241Am were about 3 orders of magnitude above background levels, concentrations in fish filet were rarely
>10 times that of controls (Emery et al. 1981). In marine organisms consumed by humans, uptake is 
generally highest in mussels where the target organs are mainly the digestive gland, gill, and exoskeleton 
(Chassard-Bouchaud 1996; Fisher et al. 1996; Hamilton and Clifton 1980).  Transfer coefficients have 
been reported for many of these processes.  Available evidence suggests that americium is not 
biomagnified up the food chain to humans (Bulman 1978; Jaakkola et al. 1977).  More recent reports on 























6. POTENTIAL FOR HUMAN EXPOSURE 
Exposures of the general population to 241Am via air, water, soil, and food are generally very low; these 
‘background’ levels are a result of fallout from past atmospheric nuclear weapons tests.  Since 1973, 
241Am air concentrations have been <10-18 Ci/m3 (0.037 µBq/m3) and are continuing to decline (Bennett 
1979).  The United Nations Scientific Committee on the Effects of Atomic Radiation (UNSCEAR) (2000) 
reported that deposition and air concentrations of radionuclides from fallout dropped rapidly once 
atmospheric testing ceased in 1980.  Inhalation exposures for even long-lived transuranic radionuclides 
became insignificant after 1985.  Levels around nuclear power plants are indistinguishable from fallout 
background (EPRI 1981). 241Am levels in surface seawater of the North Sea and North Atlantic Ocean 
stayed around 10 Bq/m3 (270 pCi/m3) between 1976 and 1988 (Pattenden and McKay 1994), but may be 
considerably higher near discharges from nuclear facilities.  241Am in soil resulting from cumulative 
deposition and ingrowth in the New York region should reach a maximum of 0.88 mCi/km2 
(33 MBq/km2) in the year 2035.  In the FDA Total Diet Studies in 1983–1986 and 1987–1992, the 
concentrations of radionuclides were sufficiently low as to require no specific action or simple 
monitoring.  
The general population may be exposed to elevated levels of 241Am from nuclear accidents or from
residing in areas in the proximity of hazardous waste sites where this radionuclide is present.  Exposure is 
generally through the inhalation and ingestion of dust from these sites.  Workers involved in producing
ionization smoke detectors or other devices containing 241Am, workers at nuclear reactors or Department 
of Energy (DOE) facilities, and workers who use americium-containing devices (neutron backscatter 
sources for checking roof leaks and road undermining, and well logging equipment) may also be exposed 
to higher levels of 241Am.  In the environment and most occupational situations, americium is usually 
encountered in combination with plutonium and curium; exposure to americium alone is unlikely.
Elevated levels of 241Am have been identified in at least 8 of the 1,636 current or former EPA NPL 
hazardous waste sites (HazDat 2004).  However, the number of sites evaluated for americium is not 
known. The distribution of these sites within the United States is shown in Figure 6-1. 
6.2 RELEASES TO THE ENVIRONMENT 
Throughout this chapter, the units used to express concentration or intake of 241Am are the same units 
reported by the authors, which may be followed by converted units in parenthesis.  Concentrations of 




























6. POTENTIAL FOR HUMAN EXPOSURE 
unit, the becquerel (Bq), where 1 Ci=3.7x1010 Bq=0.037 TBq or 1 Bq=2.7x10-11 Ci=27 pCi. Activities 
may be converted into mass units using the specific activity, 3.43 Ci/g.  It should be remembered that 
since 241Pu (half-life=14.4 years) decays into 241Am, over time, inventories of 241Am will be augmented by
releases of 241Pu. The ratio of americium to plutonium isotopes is often used to characterize the nature of 
a radionuclide source. 
6.2.1 Air 
241Am has been detected in air at 3 of the 1,636 current or former NPL hazardous waste sites where it was 
detected in some environmental media (HazDat 2004). 
241Am is released into the atmosphere primarily by nuclear reactor operations, nuclear accidents, and 
nuclear weapons testing, but previous releases from plutonium production reactors have ended since they 
are no longer operational.  The 241Am released is augmented by the decay of 241Pu released during these 
events. The amount of 241Am released is often estimated by the amount deposited on earth.  In 1982, 
UNSCEAR estimated that the integrated deposition density of 241Am in the north temperate zone of the 
earth was 25 Bq/m2 (0.68 nCi/m2) (Suchanek et al. 1996). Since then, the effective deposition of 241Am
has grown by 1 Bq/m2 (0.03 nCi/m2) per year because of the radioactive decay of 730 Bq/m2 (20 nCi/m2) 
of deposited 241Pu (to approximately 45 Bq/m2 [1.2 nCi/m2]).
In atmospheric nuclear weapons tests, radionuclides are often injected into the stratosphere.  The amount 
of 241Am present in the atmosphere from nuclear weapons testing depends on the amount of unfissioned 
241Am and 241Pu, as well as lower isotopes of plutonium neutron activated to 241Pu during detonation and 
injected into the atmosphere, and the transport and residence time of both 241Am and its precursor in the 
various atmospheric compartments (e.g., stratosphere and troposphere).  For a particular weapon’s test, 
this will depend on such factors as the amount of plutonium and americium in the weapon, detonation 
yield, altitude and latitude of the detonation, and season.  High-yield U.S. tests were characterized by very
high ratios of 241Pu/239,240Pu, and these would produce relatively large quantities of 241Am (Roos et al. 
1994).  At this time, the legacy of past atmosphere nuclear weapons tests is a fairly uniform low level 
radiation background.  The peak global activity of 241Am resulting from nuclear weapons testing between 
1951 and 1978 and receiving global distribution is estimated to be 130 kCi (4,800 TBq), taking into 
account the simultaneous production of 241Am from 241Pu and its decay (Bennett 1979).   At the same 























6. POTENTIAL FOR HUMAN EXPOSURE 
The reactor accident at Chernobyl in April 1986 released radionuclides into the atmosphere, mostly 
between April 26 and May 6.  Estimates of quantities released are based on observations of deposition 
within 30 km of the reactor.  Releases in this area were predominantly highly irradiated fuel particles.  It 
is estimated that the discharge of 241Pu through May 6, 1986 was 5,200 TBq (140 kCi), which amounted 
to 3% of the reactor content of this radionuclide (Askbrant et al. 1996; Pattenden and McKay 1994).  The 
material was released mainly in the lower troposphere.
Subsequent to the primary events releasing radionuclides into the atmosphere, radionuclides can enter the 
atmosphere from resuspension of soil particles and forest fires (Lujaniene et al. 1999).  Resuspension 
studies performed with 241Am indicate that the activity to mass ratio is greatest for particles <45 µm in 
diameter (Cooper et al. 1994).  Therefore, the fine, resuspended soil released into the air would have a 
higher concentration of 241Am than the remaining surface soil.  This enhancement factor for resuspended 
soil in the inhalable fraction (<7 µm) ranged from 5.4 to 32.5 at six sites at Taranaki, a weapons testing 
range at Maralinga, South Australia (Cooper et al. 1994).  Another potential source of release is from
windblown soil from LLW disposal sites.  While low-level radioactive waste is required to be buried in a 
manner protective of near-term release, biotic transport by plants and small mammals may transport 
americium to the soil surface where it is accessible to wind.  In order to predict the impact of biotic 
transport, a model was applied to six composite waste streams containing isotopic concentrations for the 
western United States prepared by the USNRC to which current and past LLW disposal conditions 
applied. The containers and wastes were assumed to decompose with a 35-year half-life and active biotic 
transport was assumed to occur for 100 years following site closure and before institutional control of the 
site was lost. After 100 years, the activity at the soil surface (assumed to be uniformly mixed in the upper 
0.5 m of the entire burial ground) was estimated to be 8.7x103 and 2.8x105 pCi/m2 (0.32 and 10 kBq/m2) 
for 243Am and 241Am, respectively (Kennedy et al. 1985). 
241Am is released to the atmosphere at DOE facilities.  Air sampling data were used to estimate effluent 
release from the Savannah River Site (SRS) from the plant’s start-up in 1954 through 1989 (DOE 1991a).  
From this monitoring, it was estimated that 5.49 mCi (200 MBq) of 241Am was released to the atmosphere 
between 1977 and 1989. The SRS was a major U.S. nuclear production facility and included five nuclear 
reactors, a fuel and target fabrication plant, a naval fuel materials facility, two chemical separation plants, 
a heavy water production plant, and a laboratory.  Between 1977 and 1996, the total reported release from
the SRS of 241Am to the atmosphere was 0.0061 Ci (230 MBq).  Prior to 1977, no specific anaylsis for 


























6. POTENTIAL FOR HUMAN EXPOSURE 
3.86x10-5 and 4.28x10-6 Ci (1.43 and 0.158 MBq) for 241Am and 243Am, respectively (DOE 1999b).
241Am has been identified in air at the Hanford Site, Washington; Idaho National Engineering and 
Environmental Laboratory (INEEL), Idaho; and Los Alamos National Laboratory, New Mexico.  A 
maximum concentration of 13 MBq/L (350 µCi/L) was measured in 1991 in air at a point source (stack) 
at Hanford (HazDat 2004).  In 1994, atmospheric discharges of 241Am from four areas at the Hanford Site 
ranged from 0.067 to 66 µCi (2.5–2,400 kBq) (PNL 2000). 
6.2.2 Water 
241Am has been detected in surface water samples at 2 and in groundwater at 1 of 1,636 NPL hazardous 
waste sites where americium has been identified in some environmental component (HazDat 2004).
Americium is released into surface water primarily from plutonium production reactors, nuclear fuel 
reprocessing facilities, or nuclear accidents. It may also be released from radioactive waste storage 
facilities. Since 241Pu decays into 241Am, 241Am is also released as a result of 241Pu releases.  Water 
sampling data were used to estimate effluent releases from the SRS from the plant’s startup in 
1954 through 1989 (DOE 1991a).  From this monitoring, it was estimated that 290 mCi (11 GBq) of 
241Am was released into seepage basins between 1977 and 1989; however, no 241Am was released directly
into streams.  In 1999, 1.34x10-5Ci (0.496 MBq) of 241Am was released from the SRS into surface waters 
(DOE 1999b). 
Radionuclides have been released since 1952 at Sellafield, United Kingdom on the Irish Sea by the 
British Nuclear Fuels Limited (BNFL) reprocessing plant and, before that, by two plutonium-producing 
nuclear reactors.  In 1988, the estimated environmental inventory of 241Am from all previous operations 
totaled 859 TBq (23.2 kCi), consisting of 537 TBq (14.5 kCi) actually released plus 322 TBq (8.7 kCi) 
produced from the decay of 241Pu that was also released.  Annual discharges of 241Am from Sellafield 
ranged from 4.5 to 120 TBq/year (120–3,200 Ci/year) between 1964 and 1989, while those for 241Pu 
ranged from 1 to 2,800 TBq/year (27–76,000 Ci/year) between 1952 and 1989; maximum annual 
discharges occurred in 1973 for 241Pu and 1974 for 241Am (Pattenden and McKay 1994).  The annual 
liquid effluent discharges from a typical U.K. Magnox Station contained 34.3–121 Bq/L (0.926– 
3.27 nCi/L) of 241Am for the years 1991–1995 (Ware et al. 1998).  These discharges are from the final 
monitoring and delay tank.  (Magnox, an alloy of magnesium oxide and aluminum, has been used as a 


























6. POTENTIAL FOR HUMAN EXPOSURE 
"Magnox" is widely used to refer to the early gas cooled because it provides a simple way to uniquely
identify the group.) 
241Am was identified in surface water at Oak Ridge, Tennessee and Paducah Gaseous Diffusion Plant, 
Kentucky, as well as in groundwater as an unspecified form at the Hanford, Washington and Rocky Flats, 
Colorado NPL sites (HazDat 2004).  The distribution of NPL sites is shown in Figure 6-1. 
6.2.3 Soil 
241Am was detected in soil and sediment at 5 and 2 of the 1,636 NPL hazardous waste sites, respectively,
where it was detected in some environmental media (HazDat 2004). 
As a manufactured element, americium is not naturally present in the environment.  Contamination of the 
soil can occur either from deposition of americium or precursor plutonium originally discharged into the 
atmosphere, or from waste products discharged directly into or on the ground.  Except for the reentry into 
the atmosphere of the SNAP 9A satellite and the French atmospheric tests in the Mururoa Atoll between 
1966 and 1974 that occurred in the southern hemisphere, the main events resulting in the deposition of 
artificial radionuclides occurred in the northern hemisphere.  As a consequence, there is a progressive 
decline in the levels of artificial radioactivity from northern to southern latitudes.  Recent studies of the 
multi-isotopic radioactive content in ice layers in Antarctica have determined that 0.21 Bq/m2 
(5.7 pCi/m2) of 241Am was deposited in fallout between 1969 and 1993 (Baeza et al. 1999).  Therefore, the 
mean annual fallout in Antarctica is about 8.3 mBq/m2 (0.22 pCi/m2). 
The USNRC has projected the activities and volumes of low level radioactive waste from all sources 
buried at commercial nuclear waste burial sites to the year 2000 using information from the INEEL waste 
retrieval project and assuming that the waste disposal practices then used would continue into the future.  
The estimated 20-year decayed 241Am and 243Am concentrations were 380 and 230 pCi/m3 (14 and 
8.5 Bq/m3), respectively (Kennedy et al. 1985).  
The largest releases of 241Am to soil in the United States occur at DOE facilities. The 241Am inventory in
surface soil at the Nevada Test Site (NTS) estimated as part of the DOE’s Radionuclide Inventory and 
Distribution Program between 1981 and 1986 was 150 Ci (5,600 GBq) (DOE 1991b).  The highest 























6. POTENTIAL FOR HUMAN EXPOSURE 
weapons at the NTS in January 1951.  Since then, the NTS has become the primary site for testing nuclear 
weapons and studying the effect of these weapons on structures and military equipment; >600 nuclear 
explosions have taken place at this site.  At Rocky Flats, 241Am contamination in soil was largely formed 
from 241Pu in the storage tanks or in the ground (Litaor et al. 1996).  Waste oil stored in the tanks was 
from processing weapons-grade plutonium, which contained 0.58% 241Pu and <10-4% 241Am.  Between 
1978 and 1981, 48 and 179 kCi (1,800 and 6,600 TBq) of 241Am and 241Pu, respectively, were disposed in 
the Subsurface Disposal Area of INEEL (Arthur and Janke 1986).  No estimates are available of the 
quantities of these isotopes disposed of between 1952 and 1971 at the Radioactive Waste Disposal 
Complex of INEEL.  241Am is present at plutonium facilities and at plutonium reclamation facilities 
where 241Am is routinely separated from plutonium.  The Hanford plant was the site of a 1976 column
explosion, which resulted in extensive contamination and worker exposure (PNL 2000). 
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning 
Atmospheric Transport. In the atmosphere, americium is associated with particulate matter and the 
transport of americium in air will therefore be governed by that of its host particles (Bennett 1979).  
Radionuclides resulting from atmospheric weapons tests are often injected into the lower stratosphere, 
while other atmospheric releases are into the troposphere.  The residence time of particles in the 
atmosphere will depend on the aerodynamic particle size, altitude, latitude, season, and hemisphere 
because of atmospheric circulatory patterns.  For example, residence half-lives of particles in the lower 
stratosphere range from 3 to 12 months in polar regions and from 8 to 24 months in equatorial regions, 
with removal being highest in the spring and lowest in the fall.  Half-lives for particles in the troposphere 
are about 1 month.  Larger particles will remain in the atmosphere for short periods of time and are 
deposited closer to their emission source, while small particles remain in the air for longer periods of time 
and are deposited further from their source.  There are three deposition mechanisms: rain-out caused by 
droplet formation on aerosols within clouds, wash-out by falling precipitation, and dry deposition of 
particles onto the ground. Rain-out is the most important deposition process for americium, wash-out 
occurs relatively slowly and is dependent on the solubility of the pollutant in rainwater, and dry 
deposition makes an important contribution in areas of low rainfall.  Therefore, deposition of 241Am­
containing particulate matter will depend on location, season, and meteorological conditions.  In the 
absence of actual measurements, the deposition of 241Am in a region can be estimated by using the 



























6. POTENTIAL FOR HUMAN EXPOSURE 
particulate matter in air.  In this way, using the average annual air concentration to annual deposition rate 
for strontium 90 (90Sr), the deposition rate of 241Am in the New York area was estimated to reach a 
maximum of 10 µCi/km2 (37 kBq/km2) in 1964 and decline thereafter to 0.06 µCi/km2 (2.2 kBq/km2) by
1981 (Bennett 1979).  This would be expected to result in cumulative 241Am deposit of 58 µCi/km2 
(2.1 MBq/km2) in the New York region in 2000, assuming no additional atmospheric nuclear testing after 
1976.  If the ingrowth from 241Pu decay is included, the cumulative 241Am deposit in the year 2000 would 
be 800 µCi/km2 (30 MBq/km2). 
Sea-air Transport. Sea-air transport may occur as a result of bubble scavenging in the water column
coupled with ejection into the air when bubbles burst on the water surface.  Laboratory and field studies 
of this process showed respective 241Am enrichments in aerosols of 92–580 and 20–40 over that in the 
bulk seawater (Belot et al. 1982; McKay et al. 1994; Walker et al. 1986).  In extensive field studies, 
Mackay et al. (1994) found clear evidence of localized temporal and spatial variability in the enrichment 
of americium in sea spray over that in adjacent surf-zone seawater.  While the enrichment is typically 
between 50 and 80, it ranges from 4 to 400.  The aerosols produced by the sea spray are deposited nearby.  
Coastal strips in Cumbria, England have elevated levels of 241Am from sea spray (Pattenden and McKay
1994; Walker et al. 1986).  The water in this region of the Irish Sea receives effluent from the BNFL 
Sellafeld reprocessing plant.  Studies of coastal soils in Northern Scotland are also believed to obtain their 
241Am contamination from the sea, albeit by a different mechanism.  The activity level decreases with 
distance from the sea and is indistinguishable from background levels more than a few hundred meters 
inland. The actinide levels in these soils are in excess of those due to past nuclear explosions.  The 
influence of sea spray was ruled out because of the much lower actinide concentrations in the Scottish 
water compared with that in the Irish Sea.  In Northern Scotland, a stable foam or spume is formed along 
the coast that collects in rocky inlets.  It is thought that this spume, which is rich in particulate matter and 
actinides, builds up in inlets, both overflowing onto the surrounding land and blowing inland on onshore 
wind (Pattenden and McKay 1994). 
Leaching in Soil.  After being deposited on soil, 241Am may then leach into the soil.  Since fallout of 
241Am is accompanied by its precursor, 241Pu, which also leaches into the ground, in addition to being 
mobilized by colloidal action, the amount of 241Am at a depth is a function of the leaching of both 
americium and plutonium, the colloidal movement of plutonium, and the decay of these isotopes.  A 
depth profile of fallout americium was performed on samples at a representative site in North Eastham,
Massachusetts in 1972 (see Table 6-1).  Sixty-two percent of the activity resided in the upper 2 cm of soil 























    
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 
     
 
 









6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-1. Concentrations of 241Am in Soil and Sediment 
Site/sample type Depth, Number of 
(year) cm samples Concentration Unitsa Type Reference






0–5 157 0.26 (0.30) Bq/g d.w. Median 
(mean)
5–10 151 0.19 (0.27) Bq/g d.w. Median 
(mean)
10–15 127 0.081 (0.18) Bq/g d.w. Median 
(mean)
15–25 80 0.026 (0.11) Bq/g d.w. Median 
(mean)
25–40 59 0.012 (0.051) Bq/g d.w. Median 
(mean)
40–60 23 0.017 (0.035) Bq/g d.w. Median 
(mean)
0–40 53 0.11 (0.14) Bq/g d.w. Median 
(mean)
Village area 0–5 63 0.11 (0.22) Bq/g d.w. Median 
(mean)
5–10 62 0.13 (0.20) Bq/g d.w. Median 
(mean)
10–15 63 0.12 (0.19) Bq/g d.w. Median 
(mean)
15–25 59 0.064 (0.15) Bq/g d.w. Median 
(mean)
25–40 52 0.059 (0.13) Bq/g d.w. Median 
(mean)
40–60 20 0.012 (0.11) Bq/g d.w. Median 
(mean)
0–40 51 0.13 (0.17) Bq/g d.w. Median 
(mean)
Northern Marshall Islands Radiological Survey (NMIRS)c, site of U.S. atmospheric Robison 
weapons testing from 1946 to 1958, including BRAVO explosion on 3/1/54 et al. 1997a
16 Atolls/islands 0–5 182 0.49–569 Bq/g d.w. 	 Range of 
means 
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Table 6-1. Concentrations of 241Am in Soil and Sediment 
Site/sample type Depth, Number of 
(year) cm samples Concentration Unitsa Type Reference
10–15 182 0.47–207 Bq/g d.w.	 Range of 
means
15–25 182 0.15–48 Bq/g d.w.	 Range of 
means
25–40 182 0.038–21 Bq/g d.w.	 Range of 
means
Nuclear Weapons Testing Range, Maralinga, South Australia, site of 12 hydronuclear
experiments at Taranaki in 1960, 1961, and 1963 (Vixen B Trials) in which 22.2 kg of 





0–1 1 0.227–4.40 Bq/g d.w. Range
1–2 1 0.026–0.799 Bq/g d.w. Range
2–3 1 0.005–0.099 Bq/g d.w. Range
3–4 1 0.009–0.022 Bq/g d.w. Range
4–5 1 0.004–0.019 Bq/g d.w. Range
Lake Michigan, site 7 km from Grandhaven, Michigan, water depth 67 m (cores and 
sediment trap at 60 m)
Alberts et 
al. 1989
Core 0–1 NS 651±118 µBq/g 
d.w.
Mean±SD
1–2 NS 1,147±111 µBq/g 
d.w.
Mean±SD
2–3 NS 1,427±181 µBq/g 
d.w.
Mean±SD
3–4 NS 1,110±148 µBq/g 
d.w.
Mean±SD





NS 555±107 µBq/g 
d.w.
Mean±SD
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samples Concentration Unitsa Type Reference
Savannah River Estuary sedimentd DOE 1980
Tidal 
freshwater
0–5 NS 426±150 µBq/g 
d.w.
Mean±SD
5–15 NS 140±70 µBq/g 
d.w.
Mean±SD
15–30 NS 200±70 µBq/g 
d.w.
Mean±SD
30–50 NS 74±30 µBq/g 
d.w.
Mean±SD





0–5 NS 411±63 µBq/g 
d.w.
Mean±SD
5–15 NS 110±85 µBq/g 
d.w.
Mean±SD
15–25 NS 67±20 µBq/g 
d.w.
Mean±SD
Soil in northeastern United States from 1970 to 1974, undisturbed soil unless otherwise Bennett 
indicatede 1979










0–30 2 18f mBq/km2 Mean






North Eastham, Massachusetts, background falloute Bennett 
1979
0–2 NS 8.1±2 mBq/km2 Mean±SD
2–4 NS 2.7±0.3 mBq/km2 Mean±SD
4–6 NS 1.1±0.2 mBq/km2 Mean±SD
6–8 NS 0.59±0.1 mBq/km2 Mean±SD
8–10 NS 0.1±0.07 mBq/km2 Mean±SD
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aconversion:  1 Bq=2.7x10-11 Ci=27 pCi 
bContinuous monitoring program 1975–1993; decay corrected to 1999 
cDecay corrected to 1996 
dConcentration units converted from fCi/g 
eConcentration units converted from mCi/km2 
fDecay corrected to sampling date 

























6. POTENTIAL FOR HUMAN EXPOSURE 
results indicates that americium is slightly less mobile than plutonium in this soil.  Leaching studies of 
surface-deposited 241Am in three Indian soils of widely differing characteristics, namely laterite, medium
black, and alluvial, were conducted in soil columns using simulated rain corresponding to the mean 
annual precipitation (Vyas and Mistry 1980).  It was found that 98% of the americium was retained in 
upper 2 cm of soil; amending the soil with organic matter only slightly reduced its mobility.  The greatest 
retention was obtained with the medium black and laterite soils, where >99% of the 241Am was found in 
the upper 1 cm.  In 1990, Bunzl et al. (1994) investigated the residence time, and consequently the 
migration rates, of fallout 241Am in a typical undisturbed grassland soil (Alfisol) in Germany.  Since 
241Am is present from its own deposition and also due to ingrowth from 241Pu, the residence time of 
plutonium also had to be determined and a compartment model had to be employed.  The residence half­
time in a particular zone and mean migration rates of americium at various soil depths were (depth, 
residence half-time, mean migration rate): 0–2 cm, 8 years, 0.3 cm/year; 2–5 cm, 8 years, 0.4 cm/year; 5– 
10 cm, 10 years, 0.50 cm/year; 10–15 cm, 10 years, 0.5 cm/year; 15–20 cm, 4 years, 1 cm/year; and 20– 
30 cm, 9 years, 1 cm/year.  The migration rates were similar to, but somewhat greater than, those of 
plutonium.  After a period of 30 years, the 241Am concentration on the surface layer was significantly 
diminished as a result of the migration.  Stability constants for Am(III) indicate strong complexation with 
soil organic matter, and this could explain its increased mobility with depth.  In another study, Bunzl et al. 
(1995) investigated the association of 241Am from global fallout with various soil components in six 
successive layers of undisturbed grassland in Germany from 0 to 30 cm using a sequential extraction 
procedure. In this way, the fractions that were readily exchangeable, bound to iron and manganese 
oxides, bound to organic matter, and bound to mineral (residual fraction) were identified.  The association 
of a chemical with soil components controls their availability for plant uptake and transport.  The 
americium was mainly deposited on the soil surface 30–40 years ago as a result of atmospheric nuclear 
weapon tests. The total deposition (i.e., sum over all layers) of 241Am was 18±2 Bq/m2 (490±50 pCi/m2). 
On a Bq/kg basis, the data show that the highest activity was contained in the 2–5 cm layer, slightly less 
was present in the 5–10 cm layer, and activity declined markedly below 10 cm.  On a Bq/m2-cm thickness 
basis, the maximum activity was in the 5–10 cm layer.  The attachment of americium to soil component 
varied considerably with soil layer.  The largest amount of 241Am was attached to organic matter, 18– 
74%, depending on the soil layer.  A substantial fraction, 12–64%, was bound to oxides.  In the 5–10 cm
layer, the 241Am in the readily exchangeable fraction was a minimum, 1.5%, while that attached to soil 
minerals was a maximum, 68%.  In contrast, very little 241Am (<0.5%) was bound to mineral in the 
surface (0–2 cm) layer and the deepest soil layers (15–20 and 20–30 cm).  Compared with plutonium, 
much more americium is contained in the exchangeable fraction, a result that has been ascribed to 






















6. POTENTIAL FOR HUMAN EXPOSURE 
high molecular weight organic factions of dissolved organic matter in the soil solution of two grassland 
soils, a soddy podzolic soil and a peat soil, in the vicinity of the nuclear reactor at Chernobyl.  The 
distribution coefficients for 241Am in these soils were (soil type [depth], Kd in mL/g): soddy podzolic— 
sod layer (0–2 cm), 1,220; soddy podzolic—mineral layer (2–5 cm), 810; peat (0–2 cm), 2,760; and peat 
(2–5 cm), 4,550 (Bunzl et al. 1998).  While it was similarly shown that the concentration of 241Am was 2– 
3 times higher in organic matter than in whole sediment from Lake Michigan, organic matter was a very
minor constituent of the sediment (<0.5%), so organic matter was associated with a smaller percentage of 
americium despite its higher concentration (Alberts et al. 1989).  The bulk of the 241Am in Lake Michigan 
was found in the hydrous oxides fraction of both the sediment core samples and the suspended particulate 
matter. 
While laboratory studies predicted very little movement of actinides in subsurface environments, these 
radionuclides have been found to migrate in groundwater, and have traveled underground from 80 to over 
3,000 meters at Los Alamos National Laboratory (LANL), New Mexico and Oak Ridge National 
Laboratories (ORNL), Tennessee.  Colloidal materials, which can be mobile in underground systems over 
large distances, can bind and transport radionuclide contaminants in subsurface systems (McCarthy et al. 
1998a, 1998b; Penrose et al. 1990).   
Sorption to Sediment and Particles in Water.  When discharged into water, americium rapidly sorbs onto 
particulate matter in the water column, settles, and adsorbs to bottom sediment (Murray and Avogadro 
1979).  The distribution coefficient, Kd, of americium between the particulate-associated phase and the 
dissolved phase is 2.0x106 (Pattenden and McKay 1994).  The sediment-water distribution coefficient, Kd, 
was also 2.0x106 for intertidal sediment from the Ravenglass estuary near Sellafield, United Kingdom, in 
agreement with other investigators (Davis et al. 1997).  Equilibrium was established in 30 minutes.  
Adsorption is greatest for fine-grained particles.  A large fraction of the heavier sediment particles will 
settle out quickly and remain close to the source.  Finer particles (and soluble species) will remain 
suspended for longer periods and be dispersed by currents and tides.  The distribution in sediment will be 
site specific, being largely determined by hydrology and the nature of the underlying sediment.  Being a 
particle-reactive nuclide, like plutonium, americium’s distribution in sediment after release will mirror 
that of plutonium, although its loss from the water column appears to be more rapid.  The distribution of 
americium released from the BNFL reprocessing plant at Sellafield, United Kingdom near the Irish Sea 
changed very little between 1978 and 1988 (McCartney et al. 1994).  Americium in the effluent was 
entirely as Am(III).  In their study of actinide activity in waters entering the northern North Sea, Murray
























6. POTENTIAL FOR HUMAN EXPOSURE 
Scotland was very low, 0.06.  Assuming that the contamination was derived from discharges into the Irish 
Sea 2–2.5 years earlier and 300–500 km to the south where Am-to-Pu alpha activity ratios varied from
0.9 to 2.56, there was a decrease of about 1.7 in the ratio from the point of discharge in spite of the 
increase in 241Am due to the decay of 241Pu. Similar results have been observed during the transport of 
actinides discharged from the nuclear fuel reprocessing plant at La Hague, France and in the case of 
fallout into Mediterranean waters (Murray et al. 1979).  These observations have been ascribed to 
americium’s greater adsorption to suspended particulate matter, which then settle out; americium
consequently disappears more rapidly from surface water than plutonium.  Support for this conclusion 
was found in another study where the percentage activities associated with suspended materials were 
36±8 and 80±7 for plutonium and americium, respectively, <10 km from the point of discharge.  
Therefore, twice as much americium was associated with suspended matter than plutonium.  At a distance
of 100 km from the point of discharge, this fraction was still >50%.  Core profiles of sediment in the 
northeast Irish field reveal major subsurface peaks of Sellafield-derived 241Am in both the solid phase and 
interstitial water (Malcolm et al. 1990b).  These peaks were not related to the distribution of organic 
carbon or iron or magnesium oxides in the sediment or composition of the interstitial water, but rather 
resembled the discharge of 241Am and plutonium.  Studies of radionuclide concentrations in sediment 
cores from the Ravenglass salt marsh in West Cumbria, United Kingdom, suggest that the concentration 
profile of 241Am in sediment bear a qualitative resemblance to the Sellafield discharge patterns and to 
other cores from the eastern Irish Sea coastline.  A maximum concentration of 29,300 Bq/kg 
(0.792 µCi/kg) dry weight was found in the sediment core at 8.9 cm.  This maximum concentration for 
241Am is in the correct section of the sediment core to correlate with discharges in 1974 based on a 
sedimentation rate of 4 mm/year (Morris et al. 2000). 
Davis et al. (1997) investigated how various environmental factors influenced Kd. The presence of CO2 
gas had a marked effect, increasing the amount of americium leached from sediment by a factor of 40.  
The increase is attributable to the presence of stable americium-carbonate complexes in seawater and, to a 
lesser extent, the accompanying decrease in pH to 5.5 as a result of purging with CO2. Experiments on 
the effect of pH on Kd suggested that desorption of americium from sediment at low salinity is due to low 
pH rather than to a drop in ionic strength.  Therefore, the effect of low salinity and low pH in an estuary at 
low tide and when fresh water is backed up by the incoming tide is the remobilization of 241Am.
Resorption to sediment entering the estuary from rivers will result in the redistribution of activity. 
The disposal of large quantities of radionuclides in Arctic seas has raised concern about the behavior of 






















6. POTENTIAL FOR HUMAN EXPOSURE 
Sea sediment was 1x106 (1x105–3x106) mL/g, which is in accord with that for temperate coastal sediment, 
2x106 (1x105–2x107) mL/g.  The mean Kd values for americium in two areas in the Kara Sea, an Arctic 
bay where radionuclides have been dumped, were 4.3x104 and 35x104 for ambient water column samples 
and 57x104 and 16x104 for bottom sediment samples (Carroll and Harms 1999; Carroll et al. 1999).  The 
mean sediment water distribution function recommended by the International Atomic Energy Agency
(IAEA) is 2x106 (range 2x105–2x107). Therefore, use of the IAEA value in risk assessment modeling 
would underestimate the americium concentration in seawater.  Carroll et al. (1999) stressed that for 
particle-reactive elements like americium, it is important to use site-specific information for Kd. 
Extensive adsorption determinations of 241Am were obtained in freshwater, estuarine, and marine 
sediment-water systems (NRC 1981).  The Kd values for sorption range from 104 to 106 mL/g, accounting 
for upward of 95% removal of americium to the solid phase.  There were no apparent trends in Kd with 
salinity.  There was an increase in Kd with increasing pH that is typical of hydrolyzable metal ions.  The 
Kd declined with increasing sediment concentration. The mean sediment-water distribution coefficients 
obtained were (sample type, Kd with standard deviation [SD]x10-4): Lake Michigan—three sites, 
54.8 (37.3); Clinch River, Tennessee, 73.3 (36.4); Hudson River estuary—three sites, 6.76 (2.43)– 
29.6 (8.8); Lake Washington, Washington, 18.0 (4.3); Lake Nitinat, Washington—anoxic marine, 
25.4 (3.1); Washington Continental Shelf, 10.3 (1.8); Sinclair Inlet, Puget Sound, Washington,
45.4 (12.0); Saanich Inlet, British Columbia—anoxic fjord, 37.1 (8.4); and Skagit Bay, Puget Sound, 
Washington—estuary—two sites, 26.8 (7.4) and 38.0 (10.6).  Sediment-water distribution coefficients for 
241Am in various environments obtained from the literature include (site, Kd in mL/g): Lake Michigan, 
>50x104; Hanford, U-Pond, 1.9x104 and 8.7x104; and Rocky Flats, Pond A, 0.65x104 (NRC 1981). 
Laboratory measurements yielded Kd values of 5,000 and 400 in Dutch subsoil and river sand,
respectively (NRC 1981).  
Despite its high absorptivity, americium has migrated into groundwater and traveled underground at 
several national laboratories; the mobile forms were colloids and anionic complexes (McCarthy et al. 
1998a, 1998b; Penrose et al. 1990; Toran 1994).  Artinger et al. (1998) found that increasing 
concentrations of humic substances reduced americium adsorption on sandy aquifer material, confirming 
the involvement of colloid-sorbed americium in its subsurface transport.  The leachability of 
radionuclides in waste was assessed in soil column experiments in Carjo loam soil (B horizon) collected 
in the vicinity of the low level radioactive burial site at Los Alamos.  In the case of 241Am, 90% was 
retained in the silica sand layer placed on top of the soil column, 5% was in the upper 5 cm of the column, 

























6. POTENTIAL FOR HUMAN EXPOSURE 
in waste, 0.3% of the total 241Am present, sorbed to Puyo sandy loam and Carjo loam, respectively 
(Fowler et al. 1981). While americium should strongly adsorb to silicates and mineral oxides of the 
highly weathered shale saprolite in the unlined disposal trenches used for transuranic waste (TRU) at Oak 
Ridge National Laboratory, rapid migration in groundwater with little retardation over distances of 
80 meters has been observed (McCarthy et al. 1998a, 1998b).  This occurred when seasonal fluctuations 
in the water table permitted groundwater to contact TRU in the trenches.  As a result of laboratory studies, 
the mobilization and transport of americium has been demonstrated to result from complexation of the 
actinide by natural organic matter.  Storm events aid the mobilization by providing the physical 
connection between the TRU and groundwater and increasing the amount of organic matter in the soil 
solution and groundwater.   
In the absence of natural organic matter, the adsorption coefficient on the site-specific saprolite was 
8,900. A similar situation was documented in Los Alamos where nuclear wastes infiltrated a small 
aquifer. While the movement of 241Am was predicted to be limited to a few meters, the actinide was 
detectable in monitoring wells as far as 3,390 m downgradient from the discharge (Penrose et al. 1990).  
Further investigation indicated that the mobile americium was tightly bound to colloidal material between 
25 and 450 nm in dimension.  The distributions of 241Am activity with colloid particle size (<450 nm) in 
the well water were (particle size, percent): 25–450 nm, 28%; 5–25 nm, 0.75%; 2–5 nm, 26%; and <2 nm
(filtrate), 43%. The unbound americium fraction appeared to be a stable anionic complex of unknown 
composition.  At other sites at Los Alamos, contaminated plumes traveled 30 m in <30 years and 40 m in 
<20 years (Nyhan et al. 1985; Toran 1994).  Migration appeared to be related to the water content of the 
tuff (a rock composed of the finer kinds of volcanic detritus usually fused together by heat) bed 
underlying the disposal site, and not simply to fractures in the rock (Nyhan et al. 1985).  Investigation of
the possible mobility of 241Am in soils around Rocky Flats contaminated by leaking drums under 
simulated conditions of extreme rain events found that 90% of 241Am activity resided in the upper 12 cm
of soil, below which it rapidly decreased; 241Am activity in interstitial water never exceeded 0.4 Bq/L 
(11 pCi/L) at the deepest sampling layers even in a 100-year rain event (Litaor et al. 1996).  However, 
evidence was found, in line with other investigators, that actinides may move to greater depths in 
macropores possibly formed by decaying root channels or other biological processes. 
The behavior of colloidal americium was studied in an oligotrophic soft water lake used as the source of 
cooling water for a nuclear power plant in Wales (Orlandini et al. 1990).  241Am concentrations in the 
dissolved fraction (≤450 nm) were 5.8–18.2 fCi/L (210–673 µBq/L).  Most of the americium was 
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medium-sized colloids (5–100 nm) that contained ~54% of the activity; only a small fraction (~7%) of 
americium was ‘dissolved’ or in true solution, size <1.5 nm (3,000 molecular weight [MW]), where the 
americium would occur as free ions.  The Kd of americium to filterable particles (≥450 nm), the minimum
particle size that would settle by gravity, was found to be 470,000; the Kd of americium to colloidal 
particles was estimated to be about a factor of 20 higher.  Lower Kd values obtained for 241Am in dialysis 
experiments, which restrict the size of particles, compared to those obtained in shaking sorption 
experiments is a further indication that chemical species affects sorption (NRC 1981). 
Distribution of 241Am in a dialysis system containing sediment, phytoplankton, and detrital matter 
established that a substantial amount of americium accumulated in all three phases both in fresh and 
marine waters (NRC 1981).  The adsorption process was not reversible, and the longer the americium was 
adsorbed, the more difficult the chemical was to desorb.  Appreciable amounts of americium have been 
shown to adsorb to bacterial cells such as those found in the Waste Isolation Pilot Plant in New Mexico 
(Francis et al. 1998).  There is a potential that americium attached to biocolloids may facilitate its 
transport from the waste site. 
Biotic Transport. Biotic transport can be defined as the actions of plants and animals that result in the 
transport of a radioactive material or other substance from a waste site to locations where it can enter 
pathways that may result in exposure to humans.  Small mammals inhabiting areas containing radioactive 
contamination or radioactive waste sites may become contaminated with americium by consuming 
contaminated soil or plants and may disturb americium-contaminated soil through their burrowing and 
excavating activities.  These animals may therefore affect the distribution of americium within the waste 
site or transport americium to previously uncontaminated areas.  In addition, small mammals may be 
consumed by animals higher in the food chain, such as hawks and coyotes, which would add to the 
dispersal of americium from disposal areas.  However, results of studies of numerous species of wildlife 
that inhabit the waste disposal area at INEEL indicate that wildlife do not contribute significantly to the 
spread of radionuclides to the surrounding environment (Arthur and Janke 1986).  What may be more 
significant is the contribution of biotic intrusion on the soil covering the waste areas and the effect on 
moisture infiltration rates.  A study was conducted of the dispersal of radioactive isotopes by deer mice at 
the Subsurface Disposal Area (SDA) at INEEL in southwest Idaho (Arthur et al. 1987).  These animals, 
which make up 69% of the small mammal biomass at the SDA, contained significantly higher levels of 
241Am than in control areas; the isotope accumulated primarily in the pelt and lung tissue, but also the 
gastrointestinal tract. Of the 22.8 µCi (0.844 MBq) radionuclide inventory estimated to be contained in 





















6. POTENTIAL FOR HUMAN EXPOSURE 
been transported off site, of which about 1% was the transuranic radionuclides 238Pu, 239+240Pu, and 241Am.  
These transuranic radionuclides also make up about 1% of the 28.8 µCi (1.07 MBq) inventory present in 
deer mice feces.  It was estimated that during 1978–1979, deer mice excavated 12,450 kg of contaminated 
soil to the surface, which could be further dispersed by wind.  Evidence of burrowing activity by
earthworms and ants were also found at Rocky Flats, Colorado and other sites (Litaor et al. 1994).  
Models have been developed to estimate the amount of radioactivity transported to the surface as a result 
of burrowing activity by animals and plant uptake at a generic LLW disposal site in an arid region 
(Kennedy et al. 1985).  It was found that for 243Am, plants were about 200 times more effective at 
transporting waste to the surface than burrowing animals.  These results indicate that long-term biotic 
transport may affect the integrity of land burial, redistributing radionuclides such that they become a 
source of human exposure. Biotic transport will be affected by the oxygenation of soil, as waterlogged 
and anaerobic soils are less likely to be disturbed by earthworms and other burrowing animals (Livens 
and Hursthouse 1993). 
Uptake by Plants.  The uptake of chemicals by plants and their ingestion and bioaccumulation by animals 
is one mechanism by which a chemical present in soil, air, and water enters into the food chain of 
humans.  Plants may become contaminated with americium as a result of uptake via the root and 
deposition on the upper part of the plant.  Direct deposition occurs during the deposition period, but 
surface contamination may also occur from resuspension of or direct contact with contaminated soil.  
Surface deposits may be reduced by weathering or by washing or processing, thereby reducing the 
amount of americium consumed by humans.  Some studies indicate that foliar uptake and subsequent 
translocation, which is affected by rainfall and size of the deposited particles, may rival the soil-root 
pathway in magnitude (Cataldo et al. 1980).  Translocation of transuranic elements taken up through the 
roots into seeds and fruit is generally very low (Bennett 1979).  Uptake in seeds is significantly lower 
than for other above ground plant parts, and legumes accumulate about 10 times more than grasses 
(Schreckhise and Cline 1980). 
Plant uptake from soil depends on factors such as the form and availability of the chemical, soil 
chemistry, plant species, and environmental conditions.  Various studies indicate that 241Am uptake by
plants is on the order of 10-2 to 10-6, about an order of magnitude greater than 239Pu under the same 
conditions (Bennett 1979; EPA 1979; Romney et al. 1981; Schultz et al. 1976; Zach 1985). Uptake is 
somewhat greater under acidic conditions and greater to the leaves than to the grain or fruit.  Plant uptake 
experiments with potatoes, peas, and corn were performed using ‘fallout background’ soil in North 























6. POTENTIAL FOR HUMAN EXPOSURE 
30 cm of dried soil, 0.0033 Bq/g (89 fCi/g).  The concentration ratios (CRs) (activity per unit wet weight 
of plant/activity per unit dry weight of soil), also referred to as the transfer coefficient, were 1.7x10-3 for 
husked corn plus cob, 1.0x10-3 for peeled potatoes, and <1.6x10-3 for shelled peas (Bennett 1979). Flours 
that were milled from crops of wheat, rye, barley, and oats grown on German soil where radionuclides 
resulted exclusively from global fallout contained #5.2, 11, 31, and 70 µBq/kg (1.9 fCi/kg) of 241Am, 
respectively (Bunzl and Kracke 1987).  The respective soil to plant transfer factors were #0.86x10-4, 
1.5x104, 4.7x10-4, and 37x10-4. The concentration of 241Am in the bran was a factor of 10–38 higher than
in the flour for wheat, rye, and oats.  Romney et al. (1981) studied 241Am uptake in crops of peas, 
soybeans, tomatoes, and wheat grown in seven soils representative of major food production areas of the 
United States. The CRs in the foliage ranged from 10-5 to 10-2 and the CRs in the seed, grain, and fruit 
parts ranged from 10-6 to 10-4, about a factor of 10 lower than in the foliage.  Uptake varied among the 
difference soils by a factor of about 100.  However, Schulz et al. (1976) obtained less of a variation in 
uptake of 241Am by wheat in three California soils.  The CRs were 6.3x10-6, 16.4x10-6, and 6.1x10-6 in 
Aiken (a slightly acidic forest soil), Yolo (an agricultural soil), and Panoche (a calcareous soil) soil, 
respectively. The CRs for 239, 240Pu were approximately the same.  Nisbet and Shaw (1994) obtained CRs 
ranging from 0.04x10-4 to 4x10-4 for 241Am for carrots, cabbage, and barley grown in artificially-
contaminated peat, loam, and sand soils; the CRs were in the order carrot > cabbage > barley. The CRs 
therefore ranged over 2 orders of magnitude with crop and soil type.  Uptake was lowest in peat soil 
where the organic matter plays an important role in complexing the ions, making them less available for 
uptake. The CR remained unchanged for plants grown ≥3 years after contamination of the soil.  The soil-
plant transfer appears to be related to the concentration of 241Am in the soil solution, rather than the bulk 
soil. While Livens et al. (1994) obtained plant-soil CRs for 241Am in the range of 10-5–10-6, the plant-soil 
solution CR obtained was much higher, 210–640 L/kg (Bennett 1979).  The concentration ratio for 241Am
in composite vegatation samples (grasses and herbaceous species) collected in Lady Wood, a coniferous 
wood located 500 meters northeast of BNFL Sellafield, Cumbria, United Kingdom, ranged from 0.02 to 
0.32 (Copplestone et al. 1999).  Amendment of soil with lime and organic matter decreases uptake 
(Adriano 1979; Hoyt and Adriano 1979).  This is thought to reduce the solubility or increase americium
binding, thereby reducing its availability.  
The uptake of radionuclides into plants from soil at contaminated sites at DOE facilities and elsewhere 
has been the impetus for several studies.  Such concerns led to experiments conducted in May 1996 at the 
Los Alamos National Laboratory (LANL), New Mexico using stream channel sediment from Los Alamos 
Canyon (LAC).  This stream received various amounts of untreated radioactive waste in the 1940s 
























6. POTENTIAL FOR HUMAN EXPOSURE 
well as in soil from seven regional background locations (RBG) between 32 and 96 km around the LANL.  
The radionuclide content of this latter soil is reflective of global fallout.  The 241Am levels in LAC and 
RBG soils were 0.708 and 0.005 pCi/g dry weight (0.0262 and 0.0002 Bq/g), respectively.  The mean 
241Am concentrations (dry weight basis) in edible tissue of crops grown on LAC soil and RBG soil were 
(crop, LAC level [pCi/g (µBq/g)], RBG level [pCi/g (µBq/g)]): beans, 21.5x10-5 (7.96), 7.0x10-5 (2.6); 
corn, 27.8x10-5 (10.3), 4.1x10-5 (1.5); and zucchini, 182.5x10-5 (67.5), 27.1x10-5 (10.0). The CRs (activity 
of 241Am in dry plant tissue to that in dry soil) in the edible LAC crop tissues were (crop, concentration 
ratio): LAC beans, 3.04x10-4; LAC corn, 3.93x10-4; and LAC zucchini, 25.78x10-4. These ratios are much 
lower than those in composite nonedible crop tissue, which ranged from 48x10-4 to 740x10-4. The mean 
concentration (dry weight) of 241Am found for pinon pine nuts collected around LANL was 9.8x10-5 pCi/g 
(3.6 µBq/g) with a mean concentration ratio to soil of 0.0193 (dry basis) (Fresquez et al. 2000).  A garden 
plot was established on a portion of a drained contaminated pond at the Savannah River Site (SRS) 
having a mean 241Am concentration of 1.60±0.59 Bq/kg (43.2±15.9 pCi/kg) in soil (0–15 cm).  Geometric 
mean concentration ratios of 241Am (Bq/kg dry plant/Bq/kg dry soil) in the various crops were: corn 
kernel, 0.0011; corn husk, 0.0016; bush beans, 0.0072; turnip green, 0.0528; and turnip tuber, 0.0053 
(Whicker et al. 1999). Uptake for americium was similar to that of curium, but was much higher than for 
plutonium, thorium, and uranium.  Based on the conditions of the study, it was thought that root uptake 
was the primary mechanism of plant contamination.  The concentration ratios for americium are about an 
order of magnitude higher than a similar study in Tennessee.  Since it has been demonstrated that liming 
decreased uptake, the high uptakes in the SRS study have been ascribed to the acidity of the soil (pH 
3.8-4.5 vs. 7–7.5). SRS served as a primary source of reactor-produced nuclear materials, primarily
plutonium and tritium, for nearly 4 decades.  The CR for 241Am in barley grown on contaminated soil at 
the Nevada Test Site was of the order of 10-4 for vegetative growth and 25–100 times lower for the grain 
(Schulz et al. 1976).  Similar CRs (3x10-4–7x10-4) were obtained for green and root vegetables on land 
reclaimed from the sea that was contaminated with Sellafield discharges (Green and Wilkins 1995); an 
earlier study with potatoes, obtained CRs about an order of magnitude less (Popplewell et al. 1984).  
Bioconcentration in Aquatic Organisms.  Transuranic elements are generally associated with the gut or 
external surfaces of aquatic organisms.  Bioconcentration factors (BCFs) for 241Am measured at a pond at 
Savannah River, Georgia for fish and other plants and animals are presented in Table 6-2.  In a study
performed at a nuclear waste pond at Hanford, the maximum concentration of actinides, including 241Am, 
that would accumulate in the whole fish and fish fillet were measured.  In this waste pond, the sediment 
concentration of 241Am was about 150 pCi/g (5.5 Bq/g), approximately 3 orders of magnitude above 












   
     
     
    
     
     
     
     
     
     
     
     
    
     
     








6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-2. Bioconcentration Factors for 241Am 
Bioconcentration factora 







Fish muscle 25 USNRCc 
Bullhead catfish, bone 4,200 1 SRS



















Pine tree leaves 0.0052–0.021 0.013 2 SRS
0.0001–0.1 Literature valueb 
aThe bioconcentration factor is the concentration in organism dry weight/concentration in medium (i.e., water, soil as 
appropriate). 
bValues obtained from various literature sources cited in DOE 1996 
cUSNRC values cited in DOE 1996 


























6. POTENTIAL FOR HUMAN EXPOSURE 
concentration of 241Am in the water was about 0.2 fCi/mL (7 µBq/mL).  The results from the Hanford 
study indicate that both short- and long-term uptake of americium were low; that uptake was similar for 
short-term (5 days) and long-term (430 days), experiments; and that direct sediment-to-fish transfer was 
the primary route for americium uptake.  In both species of fish, there were only a few cases where fillet 
concentrations were >10 times those in controls.  The maximum concentration of 241Am obtained in bass 
and bluegill were 0.030 and 0.028 pCi/g (1.1 and 1.0 mBq/mL) dry weight in fillet and 0.067 and 
2.0 pCi/g dry weight (2.5 and 74 mBq/mL) in whole fish (Emery et al. 1981).  
In marine organisms, the target organs and tissues of americium bioaccumulation are mainly the digestive 
gland, gill, and exoskeleton (Chassard-Bouchaud 1996).  Uptake in mussels appears to be primarily from
seawater rather than ingested sediment (Hamilton and Clifton 1980).  Americium taken up by mussels 
from water was primarily associated with the shell, while that obtained from food was bound to soft tissue 
(Fisher et al. 1996). Absorption efficiencies from ingested food in mussels were also critical in
determining bioaccumulation.  Clifton et al. (1983) studied the depuration profiles in mussel populations 
chronically exposed to radioactive waste discharges from the BNFL reprocessing plant at Sellafield, 
Cumbria, into the northeast Irish Sea.  Apart from clearance from the digestive tract (half-life of 
0.9 hours), the half-time of 241Am is 303 days.  Essentially all of the 241Am taken up by a euphausiid, a 
shrimp-like zooplankton, was by passive adsorption onto exoskeletons, so that negligible americium was 
retained by the animal after molting (Fisher et al. 1983).  Wet weight concentration factors were of the 
order of 100 after a week of exposure, with the BCFs varying linearly with the surface area-to-weight 
ratio of the organism.  Americium was also taken up by feeding on suspensions of diatoms, but there was 
negligible assimilation and most americium passed through the gut and was defecated. 
Uptake and retention of americium by benthic organisms is quite variable (Fowler and Carvalho 1985).
In general, filter feeders such as tunicates can clear particles containing 241Am from seawater by filtration 
through the granchial basket and accumulate small amounts in internal tissue.  Mucous feeding guilds of 
suspension-feeders like crinoids do not efficiently trap americium; uptake appears to occur by
complexation or adsorption of dissolved americium to the body wall.  Echinoderms and some large 
crustaceans assimilated americium with their ingested prey, although large differences in half-times and 
assimilation efficiencies in different groups suggest different feeding-digestion physiologies.  Uptake in 
benthic marine isopods, is to a great extent, by surface adsorption to the exoskeleton and to a lesser extent 
through the gut, digestive gland, muscle, and haemolymph (Carvalho and Fowler 1985).  The half-time in 
the long-lived compartment was 261 days.  Elimination from the internal tissue was more rapid than from



























6. POTENTIAL FOR HUMAN EXPOSURE 
marine sediments contaminated by nuclear tests to benthic polychaetes was <1% (dry weight) (Hamilton 
et al. 1991). 
The biological uptake in aquatic organisms may depend on factors such as temperature, time after intake, 
season of the year, and water quality.  In the brittle star (Ophiothrix fragilis), a species that dominates 
Arctic benthic communities, the initial uptake was 3 times greater at 12 EC than at 2 EC, but depuration 
was not temperature dependent (Hutchins et al. 1996a).  After 14 days, the BCF was 48 at 2 EC and 53 at 
12 EC. In the sea star (Asteruas forbesi), another Arctic organism, temperature greatly enhanced the 
retention of americium ingested in food (Hutchins et al. 1996b).  The biological half-time of americium
ingested in food was 31 days at 12 EC and essentially infinite at 2 EC. Experiments performed on the 
freshwater snail (Lymnaea stagnalis) found higher 241Am uptakes from mesotrophic pond water at acid 
pH 5.0 than at pH 8.0 (Thiels et al. 1984).  In summer, the BCF in the freshwater snail was more than 
twice as high in acidic media as in alkaline media.  In addition, uptake was a function of season, being 
greater in August than in December.  This has been ascribed to changes in metabolic rate with changing 
photoperiods.  Uptake of 241Am by two freshwater benthic invertebrates, Hyallella and Tubifex, from
water was two orders of magnitude higher than from detritus or sand, suggesting that soluble 241Am is the 
principal route of uptake and that desorption from particulate matter must occur before the substance is 
available for uptake (Sibley and Stohr 1990).  No uptake was observed from labeled National Bureau of 
Standards (NBS) standard sediment.  
Mahon (1982) measured BCFs of 1,576 and 459 in algae and plankton, respectively.  Horikoshi et al. 
(1981) determined BCFs in several species of bacteria that ranged from 2,794 to 354,000; however, 
bioconcentration by the bacteria represented adsorption onto the cell surfaces of the bacteria rather than 
true biological uptake.   
Biomagnification in the Food Chain. The available evidence suggests that the transport of americium
up the food chain to man is slight (Bulman 1978).  Americium in the food chain, lichen-reindeer-man, 
was studied by determining the concentrations 241Am in lichen and reindeer liver in Finnish Lapland 
(Jaakkola et al. 1977).  During 1963–1974, 241Am in lichen ranged from 1 to 40 pCi/kg 
(0.037-1.48 Bq/kg) dry weight.  Levels in six reindeer livers in 1974–1976 contained 0.3–5.4 pCi/kg 



























6. POTENTIAL FOR HUMAN EXPOSURE 
6.3.2 Transformation and Degradation  
Americium isotopes are transformed by radioactive decay.  However, the half-lives of the principal 
americium isotopes, 241Am and 243Am, are very long, 432.2 and 7,370 years, respectively (Baum et al. 
2002), and there is only a small amount of transformation over a human lifetime.  241Am is formed by the 
decay of 241Pu (half-life of 14.4 years) (Baum et al. 2002) and this can lead to a significant transformation 
of that isotope to 241Am in humans, especially for 241Pu that is fixed in the bone. 
6.3.2.1 Air 
There is limited information available regarding the abiotic transformation of americium in the 
atmosphere.  Oxidation is the most common reaction that occurs in the atmosphere.  This would not be 
expected for americium compounds, which are generally present in the +3 oxidation state under 
environmental conditions. 
6.3.2.2 Water 
The principal abiotic processes affecting americium in water are precipitation and complex formation.  In 
natural waters, americium solubility is limited by the formation of hydroxyl-carbonate (AmOHCO3) 
precipitates. Solubility is unaffected by redox condition.  Increased solubility at higher temperatures may
be relevant in the environment of radionuclide repositories.  In environmental waters, americium occurs 
in the +3 oxidation state; oxidation-reduction reactions are not significant (Toran 1994). 
6.3.2.3 Sediment and Soil 
Americium will occur in soil in the trivalent state.  The transformations that may occur would involve 
complexation with inorganic and organic ligands (see Section 6.3.1) and precipitation reactions with 
anions and other substances present in the soil solution.  The 241Am occurring as an ingrowth progeny of




























6. POTENTIAL FOR HUMAN EXPOSURE 
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT  
In 1973, the EPA established The Environmental Radiation Monitoring System (ERAMS), a nationwide 
network for obtaining data in environmental samples.  ERAMS consists of a network of sampling stations 
that provide air, surface and drinking water, and milk samples that the EPA uses to obtain environmental 
concentrations of radioactive material. The objective of this system is to identify trends in the 
accumulation of long-lived radionuclides in the environment (EPA 2000b).  Sampling locations for 
ERAMS are located near primary population centers to provide optimal population coverage. ERAMS 
does not analyze samples for americium, but does measure concentrations of 238,239/240Pu in air, from
which it may be possible to infer levels of 241 Pu and 241 Am.  The most recent ERAMS report containing 
plutonium data is that covering January–December 1998 composites (EPA 2000b). 
6.4.1 Air 
The annual average 241Am concentration in surface air in the mid-latitudes resulting from nuclear testing 
between 1951 and 1978 was estimated using the atmospheric transport model and the amount of 241Am
that would have been produced as a result of the testing.  The results show a rapid increase in 241Am
surface air concentrations, which reached a maximum of 23 aCi/m3 (1 aCi=10-18 Ci) (0.85 µBq/m3) in 
1963–1964. Since 1973, levels have been <1 aCi/m3 (0.037 µBq/m3) and are continuing to decline, 
assuming no additional atmospheric nuclear testing (Bennett 1979).  Measurement of these low 1973 
levels would have required large sample volumes and exceedingly long sampling periods at common 
sampling rates.  Integral concentration over the entire fallout period is estimated to be 0.12 fCi-year/m3 
(4.4 µBq-year/m3). Confirmation for these concentration estimates comes from two sources: comparison 
with plutonium fallout and cumulative deposits of 241Am activity in soil, which is a reflection of integral 
air concentrations. UNSCEAR (2000) reported that deposition and air concentrations of radionuclides 
from fallout dropped rapidly once atmospheric testing ceased in 1980.  Inhalation exposures for even 
long-lived transuranic radionuclides became insignificant after 1985.   
The Electric Power Research Institute (EPRI 1981) conducted a survey of transuranic radionuclides in the 
terrestrial environs of nuclear power plants in the United States in 1978–1979.  The plants included two 
pressurized water reactors (PWRs) and two boiling water reactors (BWRs) that were of modern design 
and had been in operation at least 3 years.  The 241Am air concentrations around all of the power plants 



























6. POTENTIAL FOR HUMAN EXPOSURE 
Selected radionuclide levels in air were measured at Bragin, 55 km north of Chernobyl for 18 days from
April 28, 1986, 2 days after the start of releases from the Chernobyl accident, until May 15. The mean 
activity concentration of 241Am during this period was 40 µBq/m3 (1.1 fCi/m3) and the mean total 
radionuclide activity was 20 Bq/m3 (0.54 nCi/m3) (Knatko et al. 1993).  Debris from the Chernobyl
accident arrived in Denmark 1.5 days after the explosion.  Air samples collected at Roskilde, Denmark on 
April 27–28, contained a mean air concentration of 241Am of 5.2 µBq/m3 (0.14 fCi/m3). In May 1986, the 
mean concentration was 11 µBq/m3 (0.30 fCi/m3) (Aarkrog 1988).  Whereas debris from nuclear weapons 
testing is injected into the stratosphere, debris from Chernobyl was injected into the troposphere.  As the 
mean residence time in the troposphere is 20–40 days, it would appear that the fallout would have 
decreased to very low levels by the end of 1986.  However, from the levels of other radioactive elements, 
this was not the case. Sequential extraction studies were performed on aerosols collected in Lithuania 
after dust storms in September 1992 carried radioactive aerosols to the region from contaminated areas of 
the Ukraine and Belarus. The fraction distribution of 241Am in the aerosol samples was approximately
(fraction, percent): organically-bound, 18%; oxide-bound, 10%; acid-soluble, 36%; and residual, 32%
(Lujaniene et al. 1999).  Little americium was found in the more readily extractable ‘exchangeable and 
water soluble’ and ‘specifically adsorbed’ fractions. 
The accident at the Three Mile Island nuclear reactor in March 1979 resulted in contamination of the 
containment and auxiliary buildings.  An aerosol sample from the auxiliary building obtained by filtering 
about 1.4x109 cm3 of air through a fiberglass filter for 8 days contained an estimated total transuranic 
actinide radioactivity of 13 Bq (350 pCi), for an average concentration of 0.0093 Bq/m3 (0.25 pCi/m3) 
(assuming no oversampling in the confined space) of which 241Am was the major contributor (Kanapilly
et al. 1983). 
Air monitoring of 241Am was started at Hanford in 1993 to estimate regional background concentrations 
of the radionuclide before large-scale remediation work commenced (PNL 2000). Maximum and mean 
onsite levels of 241Am were 0.50 and 0.46 aCi/m3 (0.019 and 0.017 µBq/m3) in 1994 compared with 
0.90 and 0.41 aCi/m3 (0.033 and 0.015 µBq/m3) in 1993.  Concentrations were not measurable at 
perimeter sites or at distant community-operated surveillance stations in 1994 (PNL 1995). 
Annual average 241Am air concentrations of 2.9x10-5, 1.4x10-5, and 0.55x10-5 pCi/m3 (1.1, 0.52, and 
0.20 µBq/m3) at the 100-K Area, and 2.5x10-5, 1.6x10-5, and 0.32x10-5 pCi/m3 (0.93, 0.59, and 



























6. POTENTIAL FOR HUMAN EXPOSURE 
respectively. No data were reported for 241Am levels measured at distant community sites.  Average gross 
alpha concentrations in air on the Hanford Site in 1999, 2000, and 2001 were comparable to levels 
measured at distance stations.  These data indicate that the onsite levels were likely to be due to natural 
sources and worldwide radioactive fallout (PNNL 2000, 2001, 2002).  241Am was detected in 15 quarterly
air samples measured at distant sites, boundary sites, and the INEEL site in 2002.  Concentrations ranged 
from 1.6x10-12 to 8.4x10-12 pCi/mL of air (5.9x10-8–31x10-8 µBq/mL). 241Am was not detected in the 
other 16 samples. Concentrations were within historical measurements and were below regulatory
standards (DOE 2003b).  
In an attempt to obtain background 241Am concentrations around the Waste Isolation Pilot Plant (WIPP) 
in southeastern New Mexico, a plant developed for demonstrating the safe disposal of transuranic waste, 
high volume samples were obtained continuously over a 14-day period between February 23 and 
May 6, 1996 1 km from the facility.  Samplers concurrently obtained total suspended solids (TSP) and 
particles >10 µm (PM10) at a 5-m level elevation and PM10 at a 2-m level.  The activities of 241Am were 
8±2, 6±2, and 11±1 nBq/m3 (0.2±0.05, 0.16±0.054, and 0.31±0.03 aCi/m3) in the PM10-2 m, PM10-5 m,
and TSP-5 m samples, respectively (Lee et al. 1998). Approximately 50% of the 241Am activity 
concentration was in the PM10 fraction. Using values for the 239,240Pu concentrations measured at the site 
and those obtained in the early 1980s and estimated mean residence times for Pu in the troposphere and 
stratosphere, it is likely that the observed 241Am levels reflect resuspension of dust contamination at the 
WIPP site and not background 241Am levels.  Present background levels result from past atmospheric 
nuclear testing and would be fairly uniform throughout the northern hemisphere. 
6.4.2 Water 
241Am may enter surface water from nuclear power plants sited on the shores.  A region of possible 
concentration is the Great Lakes where 35 nuclear facilities are located in the lakes basin.  A sample of 
water from Lake Ontario collected in 1985 and filtered through a 0.45-µm Millipore filter contained 
0.3 mBq 241Am/L (8 fCi/L) (Platford and Joshi 1986).  A few water samples from the Savannah River, 
which received runoff and discharges from the DOE Savannah River Plant, contained 0.05 fCi 241Am/L 
(2 µBq/L), about the same levels as other American rivers (DOE 1980). 
In some surface waters that have been contaminated by waste discharge, the concentrations of americium


























6. POTENTIAL FOR HUMAN EXPOSURE 
detected in the creek where waste water is discharged from Argonne National Laboratory’s treatment 
plant. However, this creek is not used for drinking water and no 241Am has been detected in the Des 
Plains River into which it empties (ANL 1999).  While 241Am is associated with waste from the Hanford 
site operations, concentrations in groundwater were considered low (no value was given) and were not 
discussed in the PNNL (2002) report.  The 1995–1996 levels of 241Am in rivers and lakes in the exclusion 
zone of the Chernobyl Nuclear Power Plant ranged from 20 to 200 µBq/L (0.5–5 fCi/L) with 70% of the 
radioactivity being contained in the particulate phase (Matsunaga et al. 1998).  The particles appear to 
have originated from the erosion of surface soil in the area.  
The concentration of 241Am in filtered seawater is very variable.  Some 241Am levels (filtered through a 
0.22 µm filter) are (site, date, and concentration): Arctic Ocean, 7/81, 1.77 µBq/L (0.048 fCi/L); English 
Chanel, 4/85, 4.96 µBq/L (0.13 fCi/L); and Eastern Irish Sea, 4/84, 4,840 µBq/L (131 fCi/L) (Lovett et al. 
1990). 241Am concentrations in filtered seawater in the North Channel of the Irish Sea were about 
200 and 120 mBq/m3 (5.4 and 3.2 pCi/m3) in 1979 and 1986, respectively (Pattenden and McKay 1994).  
Because of the higher sediment load, near shore water generally has a larger fraction of americium bound 
to particles, and therefore, seawater from the northern coast of Scotland (which is impacted by the United 
Kingdom Atomic Energy Agency [UKAEA] Technology Dounreay Establishment, a nuclear research and 
development facility at Dounreay, Scotland) shows a large variation in near-shore concentrations (see 
Table 6-3). Levels were much higher in the immediate vicinity of Dounreay than elsewhere along the 
coast. The 1984 level was unusually high because the monthly discharge from the plant before the 
sampling was 40 times the mean monthly level.  Time series measurements on seaweeds and winkles 
show that the americium levels peaked in the early 1980s and then declined by 1989, when levels were 
the lowest they had been in 12 years.  In comparison, offshore 241Am levels in surface seawater of the 
North Sea and North Atlantic Ocean has remained relatively constant, at around 10 Bq/m3 (270 pCi/m3), 
between 1976 and 1988 (Pattenden and McKay 1994).  Nearshore levels of 241Am were much greater than 
offshore concentrations, and the activity in the dissolved and particle-associated fractions were broadly
similar.   
Mururoa and Fangataufa Atolls were used from 1975 to 1996 for underground testing of nuclear weapons.  
Of the nine sites at Mururoa sampled for underground water, two, Aristee and Ceto, had measurable 
241Am concentrations, 0.064 and 0.104 mBq/L (1.7 and 2.8 fCi/L), respectively.  The remaining seven 
sites at Mururoa and the two sites at Fangautaufa had 241Am had concentrations below the detection limit 
(<0.002–<0.008 mBq/L [<0.05–<0.2 fCi/L]).  At Aristee and Ceto, the 241Am concentrations in the 












    
      
 
 
     
      
      
      
 
     
      
 
 




     
 







6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-3. Concentrations of 241Am in Water 
Concentration
Number of 
Site/sample type Year samples (mBq/m3) (pCi/m3) Type
Dounreay, Scotland (north coast) near U.K. AEA Technology Dounreay Establishment R&D (nuclear 
reactor, reprocessing)
Filtered seawater 1984 13 6,058±9,912 164±268 Mean±SD
(0.45 µm)
1985 16 36±18 0.97±0.49 Mean±SD
1986 14 47±62 1.3±1.7 Mean±SD
1987 30 15±17 0.41±0.46 Mean±SD
Unfiltered 1986 14 110±147 3.0±4.0 Mean±SD
seawater
1987 30 35±65 0.95±1.8 Mean±SD
Scotland mainland and some island coasts (near shore)
Filtered seawater 
(13 sites)
1982 NR 1.9–140 0.051–3.78 Range








NR 220–650 5.9–17.6 Range
NR = not reported; R&D = Research and Development; SD = standard deviation; U.K. AEA = United Kingdom 
Atomic Energy Agency 
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water, respectively, and at the remaining seven sites at Mururoa, the 241Am concentrations were below the 
detection limit (<0.003–<0.001 mBq/L [0.08–0.03 fCi/L].  At the two Fangatufa Atoll sites, 241Am
concentrations were 0.016 and 0.006 mBq/L (0.43 and 0.16 fCi/L) of filtered water (Mulsow et al. 1999). 
The concentration of 241Am in New York City tap water in 1974 was estimated to be 0.03 fCi/L (1 µBq/L) 
based on the average 241Am/239,240Pu ratio of 0.10 obtained in 1975–1976 and the 1974 239,240Pu
concentration (Bennett 1979).   
6.4.3 Sediment and Soil 
Soil may become contaminated with 241Am from the deposition of the element released to the atmosphere 
from nuclear weapons’ testing and nuclear reactors, or secondarily, from the resuspension of 
contaminated soil.  241Am levels may then increase due to ingrowth from the decay of 241Pu (half-life 
14.4 years).  Soil surveillance provides baseline information with which unplanned releases can be 
compared, and long-term contamination trends can be determined.  It also provides information about 
direct exposure to humans (inhalation of dust, ingestion of dirt) as well as potential sources of exposure 
(contamination of groundwater, uptake into plants and animals).  The concentrations of 241Am in soil 
samples from the northeastern United States from 1970 to 1974 are shown in Table 6-1.  The areal 
activity at the sampling date ranged from 0.37 to 0.49 mCi/km2 (14–18 MBq/km2), which compares well 
with that calculated from estimated values obtained from releases from nuclear weapons testing combined 
with an atmospheric transport model (Bennett 1979).  241Am in soil resulting from cumulative deposition 
in the New York region was estimated as being fairly constant since about 1969 at about 0.060 mCi/km2 
(2 MBq/km2), whereas 241Pu peaked at about 20.1 mCi/km2 (744 MBq/km2) in 1965.  The decay of 241Pu 
adds to the cumulative deposits of 241Am in soil, bringing the total 241Am to about 0.8 mCi/km2 
(30 MBq/km2). The 241Am inventory should reach a maximum of 0.88 mCi/km2 (33 MBq/km2) in 2035. 
The radioactive decay of 241Am will then exceed its ingrowth, and the cumulative deposits of 241Am will 
then slowly be depleted. 
Nuclear Power Plants.  EPRI (1981) conducted a survey of transuranic radionuclides in the terrestrial 
environs of nuclear power plants in 1978–1979.  The plants included two PWRs and two BWRs that were 
of modern design and had been in operation at least 3 years.  The 241Am levels in soil samples collected 
























6. POTENTIAL FOR HUMAN EXPOSURE 
A survey of Big Trees Park was conducted in 1998 after soil samples taken in the park in 1993 and 1995 
revealed higher-than-expected concentrations of plutonium (LLNL 1999).  Big Trees Park is a public park 
in the city of Livermore, California located about one-half mile from Lawrence Livermore National 
Laboratory (LLNL).  The pattern of 241Am distribution was the same as that for plutonium with levels 
significantly higher inside ornamental tree wells than outside the wells or at depths.  Activity levels were 
well below EPA’s residential preliminary remediation goal of 2.5 pCi/g (93 mBq/g), which may have 
necessitated cleanup.  The source of the contamination was most likely sewage sludge from LLNL that 
was applied to the ornamental trees in the park. 
Great Britain.  In 1993, the Ministry of Agriculture, Fisheries, and Food (MAFF) in the United Kingdom
systematically surveyed the concentrations of 241Am in soil and grass samples near 18 nuclear sites in 
England and Wales (Sanchez et al. 1996).  241Am was detected in most soil samples; the range was 0.03– 
0.40 Bq/kg (0.8–11 pCi/kg) soil; three samples were below the detection limit.  Sanchez et al. (1998) 
measured the 241Am activity in root mat samples from tide washed pastures in 17 estuaries spanning the 
eastern seaboard of the Irish Sea from Solway in northwest England to David’s Head in southern Wales.  
Fourteen of the pastures had detectable levels of 241Am with median levels of 64–5,570 Bq/kg (1.7– 
150 nCi/kg) dry weight and individual samples of 14–10,230 Bq/kg (0.38–276 nCi/kg) dry weight.  241Am
accumulations in soils (to 10–15 cm depth) near Greeny Geo, Scotland ranged from 2,000 to 
11,400 Bq/m2  (54–308 nCi/m2) (Pattenden and McKay 1994).  This coastal area is contaminated by foam
or spume that forms in seawater in rocky inlets and blows over the land.  The seawater in the area 
receives discharges from the BNFL Sellafield facility.  Sediment from two Harbors on the Isle of Mann, 
which is impacted by the reprocessing plant at Sellafield in the United Kingdom, contained 241Am ranging 
from <2.0 to 8.1 Bq/kg (<50–220 pCi/kg) dry weight during 1990–1993 (McKenna and Longworth 
1995). Nearshore sediment core samples taken at several sites off the northern coast of Scotland (see 
Table 6-1) had fairly constant 241Am levels with depth showing that mixing had occurred to a depth of
74 cm (Pattenden and McKay 1994).  241Am concentrations found in a sand dune ecosystem near the 
British Nuclear Fuels reprocessing plant at Sellafield, Cumbria United Kingdom, were 183–250 Bq/kg 
(4.95–6.76 nCi/kg) (Copplestone et al. 2001). 
Los Alamos National Laboratory. Soil surveillance is conducted at national laboratories to monitor the 
levels of radionuclides and ascertain their possible migration.  Data from such a program at the LANL in 
1974–1996 was evaluated to ascertain whether there were changes in radionuclide concentrations during 
that period and whether changes could be ascribed to air emissions and fugitive dust (Fresquez et al. 



























6. POTENTIAL FOR HUMAN EXPOSURE 
Americium levels at LANL sites were significantly higher than at background sites.  The mean 1974– 
1996 concentrations of 241Am in soil at LANL and background sites were 0.011±0.006 and
0.006±0.002 pCi/g (0.41±0.22 and 0.22±0.07 mBq/g) dry weight, respectively.  Sediment 2.1 km
downstream of a National Pollutant Discharge Elimination System (NPDES) outfall in Mortandad 
Canyon, Los Alamos County, New Mexico in 1994 contained high levels, 8.93 pCi/g (330 Bq/g) dry
weight, of 241Am.  However, the 241Am concentrations in sediment upstream of the outfall and 4.0 km
downstream below a sediment trap were below upper limits of regional background levels, 0.023 pCi/g 
(0.85 Bq/g) dry weight. (Bennett et al. 1996). 
Brookhaven National Laboratory.  Sediment samples were analyzed from the Peconic River system on 
Long Island, NY, downstream of Brookhaven National Laboratory (BNL).  Near the sewage treatment 
plant closest to BNL, respective mean concentrations (dry weight) of 241Am from three locations at four 
depth intervals (0.00-0.06, 0.06-0.15, 0.15-0.24, and 0.24-0.37 m) were 31, 24, 5.6, and 1.7 Bq/kg (0.83, 
0.64, 0.15, and 0.045 nCi/kg).  At one location at the BNL property boundary mean concentrations of 
241Am were 18, 2.8, 0.29, and 0.28 Bq/kg (0.49, 0.076, 0.0078, and 0.0076 pCi/kg), respectively, for the 
same depth intervals.  Sediment samples from a control river, Connetquot River, were 1.4 and 0.74 Bq/kg 
(0.038 and 0.020 nCi/kg) (0.00-0.06 m) and 0.30 and 0.081 Bq/kg (0.0081 and 0.00022 nCi/kg)
(0.06-0.15 m) in two locations (Rapiejko et al. 2001). 
Rocky Flats. Rocky Flats (RF), near Golden, Colorado, was contaminated with 241Am as a result of past 
waste storage practices, which resulted in drums leaking contaminated oil (Litaor et al. 1994).  Sampling 
was performed in four regions of expected actinide activity (26 pits) east of RF.  Activity decreased with 
increasing distance east of the former storage site and was predominantly confined to the upper 12 inches 
of soil. The mean 241Am activities in the upper 3 inches of soil in the four regions were 1,653, 47.4, 2.9, 
and 3.7 Bq/kg (44.6, 1.28, 0.078, and 0.100 nCi/kg). In the region with the highest activity, the mean 
concentrations were 1,653, 1,063, 758, 595, 122, and 2.6 Bq/kg (44.6, 28.7, 20.5, 16.1, 3.3, and 
0.070 nCi/kg) at depths of 0–3, 3–6, 6–9, 9–12, 12–18, and 36–48 inches, respectively, indicating 
significant retention near the surface (Litaor et al. 1994).  Soil sampled at 118 plots around RF contained 
241Am ranging from 0.18 to 9,990 Bq/kg (0.0049–270 nCi/kg) with a mean and SD of 321 and 
1,143 Bq/kg (8.67 and 30.9 nCi/kg), respectively (Litaor 1995).  The distribution pattern reflects wind 
dispersion consistent with the prevailing winds at RF. 
Idaho National Engineering and Environmental Laboratory.  241Am contamination occurred outside the 


























6. POTENTIAL FOR HUMAN EXPOSURE 
of 241Am, 2,048 nCi/m2 (75.8 kBq/m2) in the 0–4 cm surface layer, near the perimeter of the SDA, were
thought to be due to flooding and to localized drainage of water, while low concentrations away from the 
SDA perimeter area resulted from wind transport (Markham et al. 1978).  With the exception of samples 
collected from the Waste Experimental Reduction Facility, soil samples collected in 2002 from within the 
INEEL ranged from not detected to 0.889 pCi/ g (dry weight) and were within the background range for 
the INEEL and surrounding areas. These levels were attributable to past fallout.  Soil samples collected 
from the perimeter and off-site around INEEL ranged from approximately 0.001 to 0.015 pCi/g (dry
weight). There were no significant differences in 241Am concentrations between boundary and distant 
samples, indicating that INEEL inputs did not contribute significantly to these concentrations (DOE 
2003b).   
Superfund National Priorities List (NPL) Sites.  241Am has been detected in soil at 5 of the 1,636 NPL 
hazardous waste sites where americium has been identified in some environmental compartment (HazDat 
2004); it was found in sediment at two of these sites.  The distribution of Superfund NPL sites is shown in 
Figure 6-1. 
Chernobyl. 241Am, in five samples of surface soil collected 1.5–15 km from the Chernobyl accident in 
July 1987, was predominantly in the 0.005–0.25 mm size fraction of soil, which comprised 65% of the 
mass (Berezhnoi et al. 1991). 
Bikini Atoll. Bikini Atoll was the site of 23 nuclear detonations between 1946 and 1958.  Surface soil 
collected at 20 sites on Bikini Atoll in 1972 contained 1.2–45 pCi/g (0.044–1.7 Bq/g) of 241Am (Nevissi et 
al. 1976).  This level will increase for several decades as a result of ingrowth from 241Pu before it begins 
to decrease, unless weathering causes the americium and plutonium to spread away from the surface and 
cause the concentration to decrease.   
More recent mean surface soil (0–5 cm) 241Am concentrations were 0.30 and 0.22 Bq/g (8 and 5.9 pCi/g) 
for the interior of the island and the village area, respectively (Robison et al. 1997b).  This indicates either 
that soil samples were collected at too great a depth (adding uncontaminated soil from deeper layers) or 
that weathering of surface media carried contamination into deeper layers (results in decreased 
concentrations for the samples).  Concentrations of 241Am in sediment from the surface of the lagoon floor 
ranged from 0.010 to >12 Bq/g from (0.27 to >320 pCi/g) with 1.1 and 0.60 Bg/g (30 and 16 pCi/g) being 
the average concentrations associated with fine and coarse sediments, respectively.  The highest 241Am
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was adjacent to the locations of the largest explosions.  The 241Am concentrations were reported to 
decrease from north to south and from east to west (Robison and Noshkin 1999). 
Alaska. The National Oceanic and Atmospheric Administration (NOAA) conducted a study in the 
Beaufort Sea in northwestern Alaska during the summer of 1993 to ascertain the levels of radionuclide 
activity in the U.S. Arctic (DOE 1997).  241Am was present in sediment at detectable levels at 8 of the 
13 sites sampled, ranging from 0.06 to 0.12 Bq/kg (1.6–3.2 pCi/kg).  From the average ratio of 
241Am:239+240Pu, it was concluded that the americium originated from global fallout.   
The Great Lakes.  In 1976, sediment at several sites was sampled in Lakes Erie and Ontario.  241Am was 
detected at only one site in Lake Erie, a site influenced by the Nuclear Fuels Reprocessing plant at West 
Valley, New York (U.S. Energy Research and Development Administration 1977).  Levels of 241Am
increased with depth at concentrations of 3.4, 7.9, 11.1, and 11.8 Bq/kg (92, 210, 300, and 319 pCi/kg) 
dry weight at 0–2, 2–4, 4-6, and 6–8 cm, respectively. 
Arctic. 241Am concentrations were measured in the surface marine sediments collected in the 
Spitsbergen-Bear Island region, located between the Arctic Ocean, Barents, Greenland, and Norwegian 
Seas, an area important to Norwegian fisheries.  Highest concentrations (dry weight) were found in the 
Spitsbergen area, ranging from 0.37 to 0.85 Bq/kg (10–23 pCi/kg). Lower levels were found in the 
deeper parts of the Norwegian Sea, ranging from 0.30 to 0.007 Bq/kg (8.1–0.2 pCi/kg) (Heldal et al. 
2002).
6.4.4 Other Environmental Media 
Concentrations of 241Am have been determined in various foods (Table 6-4) and biota (Table 6-5), some
of which may be eaten by humans.  Levels in food items and animals include those from diet studies as 
well as from areas contaminated by nuclear weapons testing and fuel reprocessing.  The highest levels 
were in clams, crabs, and lobsters (up to 0.46 Bq/kg [12 pCi/kg]).  In studies at DOE facilities and in the 
vicinity of the BNFL reprocessing plant at Sellafield and the Ravenglass Estuary, where pastures are 
subject to tidal inundations with seawater receiving discharges from the plant, results clearly show the 
effect on animals from feeding on contaminated pasture land (Arthur and Janke 1986; Bradford and 
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Table 6-4. Average Concentrations of 241Am in Food 
Concentrationa 
Local Food mBq/kg fCi/kg Reference
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Table 6-4. Average Concentrations of 241Am in Food 
Concentrationa 
Local Food mBq/kg fCi/kg Reference
Northern Marshall Islands Radiological Survey (NMIRS)c, fallout from U.S. Robison et al. 
atmospheric weapons testing from 1946 to 1958, including BRAVO explosion on 1997a
3/1/54
Reef fish, muscle; <0.23–1.4 <6.2–38
11 atolls/islands
 








Pork; 6 atolls/islands <0.11–2.8 <3.0–76
 
Chicken; 4 atolls/islands 1.2–4.1 32–110
 




Drinking coconut meat; <1.3 <35
5 atolls/islands
 








Breadfruit; 7 atolls/islands 0.26–8.2 7.0–220
 
Total Diet Study—New York, 1974d Bennett 1979
Shellfish 0.48±0.15 13±4
Whole grain products 0.074±0.044 2.0±1.2
Bakery products 0.063±0.02 1.7±0.6
Fresh vegetables 0.048±0.015 1.3±0.4
Fresh fruit 0.041±0.015 1.1±0.4
Root vegetables 0.030±0.007 0.80±0.19
Dry beans 0.022±0.012 0.60±0.34
Poultry 0.019±0.011 0.52±0.31
Potatoes (peeled) 0.013±0.002 0.36±0.06
Flour 0.013±0.007 0.36±0.18











   
    
    
    
    
    
    
    
    
  
    
    
    






6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-4. Average Concentrations of 241Am in Food 
Concentrationa 




Fresh fish 0.0089±0.0030 0.24±0.08
Eggs 0.0059±0.002 0.16±0.06
Macaroni 0.0059±0.009 0.16±0.25
Canned fruit 0.0026±0.0033 0.07±0.09









bTerrestrial food is from a continuous monitoring program in 1975–1993; marine food is from a 1988 report. 

cDecay correction to 1996. 
























   














6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-5. Concentrations of 241Am in Fauna 
Species Sample Location Concentration Unitsa Type Reference 
Fish
Farallon Islands Nuclear Waste Disposal Site (FINWDS) and Point Arena (reference site), Suchanek
1986–1987 et al. 1996 
Dover sole Flesh FINWDS 1,630±2,360 mBq/kg Mean±SD 
(n=3) w.w. 
Point Arena 126±88 
(n=6) 





Thornyheads Flesh FINWDS 186±35 mBq/kg Mean±SD 
(n=2) w.w. 
Point Arena 299±157 
(n=3) 
Vicinity of Los Alamos National Laboratory, 1997, Bottom-feeding fish (n=10/site) Fresquez 
et al. 1999 
Fish (2 sites) 	 Muscle+bone Reservoirs 1.7 (19.8) 10-5 pCi/g Mean (SD) 
d.w. 
Fish (4 sites) 	 Muscle+bone Rio Grande 84.1 (54.6) 10-5 pCi/g Mean (SD) 
d.w. 
Fish (5 sites) 	 Viscera Rio Grande 31.2–198.0 10-5 pCi/g Range of 
d.w. means 
Fish from Irish ports possibly impacted by Sellafield, 1988–1997	 Ryan et al. 
1999 
Plaice Edible 0.4–144 mBq/kg Range of 
portion w.w. means 
Whiting 	Edible 0.42–2.8 mBq/kg Range of 
portion w.w. means 
Cod 	Edible 0.62–26 mBq/kg Range of 
portion w.w. means 
Crustacea
Fish ports possibly impacted by Sellafield, 1988–1997 Ryan et al. 
1999 
Prawns 	Edible  12–138 mBq/kg Range of 
portion w.w. means 
North Eastern Irish Sea, Sellafield coastal area, U.K., commercially caught crabs and Swift and 
European lobsters, 1997 Nicholson 
2001 
crab (n=34) 	 Edible  1.7(0.8) Bq/kg Mean(SD) 
portion w.w. 
lobster Edible  8.3(11.3) Bq/kg Mean(SD) 




































6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-5. Concentrations of 241Am in Fauna 
Species Sample Location Concentration Unitsa Type 
Bivalves




et al. 1996 





Mussels Flesh Point Arena 126±88 Bq/kg d.w. Mean±SD 
(n=2) 
U.S. Mussels Watch, 1976–1978 (East Coast: Maine-Virginia; East/Gulf Coast: Virginia-




Flesh East coast 0.43–0.65 
(0.03–1.7) 









Bq/kg d.w. Range of 
means 
(range) 
Mussels and Flesh West coast 0.49 Bq/kg d.w. Range of 
oysters (0.14–18.5) means 
(range) 









Oysters Edible  14–27 mBq/kg Range of 
portion w.w. means 
Irish Sea, site impacted by Windscale Reprocessing Plant and reference sites, 1977 EPA 1984 
Mussels Flesh Isle of Man 550 (55) Bq/kg d.w. Mean (SD) 




Bq/kg d.w. Mean (SD) 
Mussels Flesh Ebro 0.52–0.88 Bq/kg d.w. Range of 










Milk <0.2–<0.3 Bq/L Range 
Grey seals 
(n=2) 
Liver <0.3 Bq/kg f.w. Range 
Grey seals 
(n=3) 
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Table 6-5. Concentrations of 241Am in Fauna 
Species Sample Location Concentration Unitsa
Mammals






Reindeer Meat 0.014 (0.003) Bq/kg d.w. Mean (SD) 
Reindeer Liver 0.013 (0.004) Bq/kg d.w. Mean (SD) 
Reindeer Kidney 0.0043 
(0.0010) 
Bq/kg d.w. Mean (SD) 
Material Disposal Area G, Los Alamos National Laboratory, New Mexico, mule deer and 
Rocky Mountain elk, 1991–1998
Ferenbaugh 
et al 2002 
Deer (n=11) Muscle 0.28 (0.22) mBq/kg 
w.w. 
Mean (SD) 
Elk (n=21) Muscle 0.47 (0.34) mBq/kg 
w.w. 
Mean (SD) 















Fox (adult) Muscle Area 13 25.0 pCi/kg 
w.w. 
Fox (adult) Muscle Area 13 17.0 pCi/kg 
w.w. 
Coyote Muscle Area 13 4.7 pCi/kg 
w.w. 
Vicinity of Sellafield and the Ravenglass Estuary, England, 1977–1982 Bradford 
and Curtis 
1984 
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Table 6-5. Concentrations of 241Am in Fauna 
Species Sample Location Concentration Unitsa Type Reference 
























Idaho National Engineering Laboratory–Subsurface Disposal Area (SDA) and control 
area, 1978–1979 
Coyote Feces 	 SDA (n=24) 0.4±0.9 pCi/kg Mean±SD 
Control 0.003±0.002 w.w. 
(n=12)
Cottontail Carcass SDA (n=10) 0.010±0.009 pCi/kg Mean±SD 
rabbit Control 0.001±0.001 w.w. 
(n=5) 
Cottontail Hide SDA (n=10) 0.029±0.046 pCi/kg Mean±SD 
rabbit Control 0.002±0.001 w.w. 
(n=5) 
Deer mice Carcass	 SDA (n=21) 0.010±0.02 pCi/kg Mean±SD 
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Table 6-5. Concentrations of 241Am in Fauna 
Species Sample Location Concentration Unitsa Type Reference 
Deer mice Hide 	 SDA (n=21) 0.27±0.83 pCi/kg Mean±SD 
Control 0.039±0.050 w.w. 
(n=5) 
Invertebrates
Idaho National Engineering Laboratory, Subsurface Disposal Area (SDA) and control Arthur and 
area, 1978–1979 Janke 1986 
Invertebrates Composite SDA (n=3) 0.022±0.020 pCi/kg Mean±SD 
Control <0.004 w.w. 
(n=1) 
aconversion:  1 Ci=3.7x1010 Bq=0.037 TBq or 1 Bq=2.7x10-11 Ci=27 pCi 
d.w. = dry weight; FINWDS = Farallon Islands Nuclear Waste Dump Site; f.w. = fat weight basis; n = number of 






















6. POTENTIAL FOR HUMAN EXPOSURE 
As part of the U.S. Mussel Watch program, monthly samples of mussels were collected from Bodega 
Head, California and Narragansett Bay, Rhode Island in 1977 and 1978 (Goldberg 1986).  The mean 
concentration of 241Am in samples ranged from 4.2 to 11.6 Bq/kg (0.11–0.31 nCi/kg) dry weight at 
Bodega Head and from 0.2 to 0.7 Bq/kg (0.005–0.02 nCi/kg) dry weight at Narragansett Bay.  No 
seasonal pattern was evident.  The ratio of 241Am to 239+240Pu ranged from 1.3 to 5.3 on the west coast site 
and from 0.2 to 1.0 on the east coast.  A surveillance program of U.S. coastal waters involving somewhat 
over 100 sites was another component of the Mussel Watch program.  The flesh of both oysters and 
mussels, collected from the three major coastlines of the United States in 1976, 1977, and 1978, was 
analyzed (EPA 1984).  The results are included in Table 6-5.  The levels of 241Am were higher on the 
west coast, which was ascribed to seasonal upwelling of the 241Pu- and 241Am-rich mid-depth north 
Pacific Ocean waters (affected by nuclear weapons test fallout), rather than from releases from the low-
level nuclear waste site off the Farallon Islands.  Another factor is the association of 241Am with fine 
particles and the greater exposure of west coast bivalves to open ocean fine particles than east coast 
bivalves. Paradoxically, americium does not show the same seasonal fluctuations associated with 
upwelling as plutonium; this may be due to americium’s greater adsorptivity and associated removal from
the water column, or its slower uptake in bivalves.  The NOAA conducted a study in the Beaufort Sea in 
northwestern Alaska during the summer of 1993 to ascertain the levels of radionuclide activity in the U.S. 
Arctic (DOE 1997a).  As part of this study, 241Am was determined in ashed samples of a variety of biota, 
including fish, invertebrates, crustaceans, whales, seal, and ducks, collected mostly in the coastal waters
off Barrows, Alaska and analyzed by high-resolution gamma spectroscopy.  241Am was not detectable in 
any of the samples (detection limits ≤0.6–≤80 mBq/kg [<20–<2,000 fCi/kg]).  
Fish and mussels were sampled near the Farallon Islands Nuclear Waste Dump Site (FINWDS), 
approximately 30 miles west of San Francisco and a reference site (see Table 6-5) (Suchanek et al. 1996).  
While many of the drums have been breached or are nearing their expected lifetime, no statistical 
difference was found between the levels of 241Am in the FINWDS fish and those from the reference site.  
A simple explanation is the fact that the fish species tested are quite mobile.  However, 241Am levels 
found in fish samples, 1.0 and 1.5 Bq/kg (27 and 41 pCi/kg), were higher than comparable fish muscle 
reported from relatively contaminated sites such as the Pacific Testing Grounds in Micronesia and in the 
Irish Sea near the Windscale Nuclear Plant at Sellafield, none of which exceeded 0.74 Bq/kg (20 pCi/kg).  
241Am concentrations were determined in fish and shellfish collected in 1990 from fish markets in the 
vicinity of the Vandellós I nuclear power plant (NPP) on the Spanish Mediterranean coast.  The 
Vandellós I NPP was decommissioned after 1989.  Mean 241Am concentrations (dry weight) for large 

























6. POTENTIAL FOR HUMAN EXPOSURE 
6.0 mBq/kg (1.7, 0.68, 1.5, and 0.16 pCi/kg), respectively.  At other locations along the Catalan coast, 
mean 241Am concentrations were 5.2, 10, 3.0, and 5.2 mBq/kg (0.14, 0.27, 0.081, and 0.14 pCi/kg), 
respectively, for the same species (Sanchez-Cabeza and Molero 2000).  As part of the Environmental 
Surveillance Program (at LANL), bottom-feeding fish were collected from reservoirs upstream and 
downstream from LANL in September 1997, as well as from five sites on the Rio Grande River starting at 
one site about 1 mile upstream of any stream crossing LANL land and analyzed for 241Am and other 
radionuclides (Fresquez et al. 1999).  The concentration of 241Am in muscle + bone in fish collected in the 
reservoirs was significantly lower than that collected in the river (see Table 6-5).  Mussel samples 
collected from two sites in the Irish Sea where the Windscale nuclear reprocessing plant is located show 
the influence of low levels of radionuclides from the nuclear fuel cycle (Table 6-5).  The 241Am found in 
the mussels were orders of magnitude higher than those on the U.S. coast.  The Isle of Mann site is in the 
middle of the Irish Sea about 50 km from Windscale and the Ravenglass estuary site is 16 km to the south 
of the plant. The 241Am input into the Irish Sea from fallout is dwarfed by the contribution by the 
Sellafield reprocessing facility in England.  Observations from surveys of 241Am in edible parts of fish 
and shellfish sampled from commercial landings at major Irish shipping ports between 1988 and 1997 
(Table 6-5) indicate that activity levels in fish landed at northeast Irish ports have remained low, generally
a fraction of a mBq/kg wet weight, while those in mussel, prawns, and oysters are much higher and have 
fluctuated in activity (up to 180 mBq/kg [4.9 pCi/kg] wet weight in prawns) over time (Ryan et al. 1999).  
Concentrations of 241Am in the edible portions of molluscs (Adamussium colbecki) and fish (Trematomus 
bernacchii) collected during the years 1987–1996 from Terra Nova Bay (Ross Sea) in Antarctic were 
reported to be 0.0087 and 0.0006 Bq/kg (0.24 and 0.02 pCi/kg), dry weight, respectively (Marzano et al. 
2000).
Enewetak and Bikini Atolls were used for nuclear weapons testing by the United States between 1946 and 
1958.  Log mean normal concentrations (wet weight) of 241Am found in fish muscle and invertebrate flesh 
collected since 1976 and decay corrected from collection date to October 1998 were determined.  At 
Enewetak Atoll, concentrations of 241Am in reef fish, pelagic fish, mollusks, and crustaceans were 0.0050, 
0.0024, 0.0010, and <0.1 Bq/kg (0.14, 0.064, 0.027, and <2.7 pCi/kg), respectively.  At Bikini Atoll, 
241Am concentrations in reef fish, pelagic fish, mollusks, and crustaceans were 0.0072, 0.0018, 0.32, and 
<0.1 Bq/kg (0.19, 0.049, 8.6, and <2.7 pCi/kg), respectively. 241Am concentrations were higher in the 
surface sediments at Bikini Atoll, ranging from 10 to >12,000 Bq/kg (0.27–>320 nCi/kg) as compared to 
Enewetak Atoll, ranging from <1 to 1,300 Bq/kg (0.027–35 nCi/kg).  The authors noted that it is difficult 
to conclude that there is a difference in the mean concentrations of radionuclides in the muscles of fish 
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Bikini and Enewetak Atolls, the transuranics in some fish may be unrelated to the environmental 
concentrations (Robison and Noshkin 1999). 
Fish samples were analyzed from the Peconic River system on Long Island, New York, downstream of 
BNL. Near the sewage treatment plant closest to BNL, mean concentrations of 241Am were 0.070 and 
0.019 Bq/kg (1.9 and 0.51 pCi/kg) in bullhead catfish and chain pickerel (whole fish), respectively.  A 
mean 241Am concentration in bullhead catfish from a control river, Connetquot River, was <0.02 Bq/kg 
(<0.54 pCi/kg).  In ponds farther downstream of BNL and the sewage treatment plant 241Am
concentrations were <0.03 Bq/kg (<0.8 pCi/kg) for all fish and <0.07 Bq/kg (<2 pCi/kg) for mussel flesh 
(Rapiejko et al. 2001). 
Fifteen cattle grazing for 1,064 days on a site at the Nellis Bombing and Gunnery Range, Nevada, where 
a nuclear device was explosively destroyed 16 years previously, had 241Am levels ranging from 0.74 to 
590 mBq/kg (0.02–16 pCi/kg) wet weight, 4.4 mBq/kg (0.10 pCi/kg) geometric mean in muscle (Gilbert 
et al. 1989). Levels in liver and kidney were much higher, 72 and 11 mBq/kg (1.9 and 0.30 pCi/kg), 
geometric mean, respectively. 
In 1993, the MAFF, United Kingdom systematically surveyed the concentrations of 241Am in grass 
samples near 18 nuclear sites in England and Wales (Sanchez et al. 1996). 241Am levels in vegetation 
samples were <0.10 Bq/kg (<2.7 pCi/kg).  Sanchez et al. (1998) measured the 241Am activity in vegetation 
from tide-washed pastures in 17 estuaries spanning the eastern seaboard of the Irish Sea from Solway in 
northwest England to David’s Head in southern Wales.  In 11 of the pastures, the median level of 241Am
in vegetation ranged from 14 to 575 Bq/kg (0.38–15.5 nCi/kg) dry weight; the others were <1 Bq/kg 
(<30 pCi/kg) dry weight.  241Am levels in individual samples in the 11 pastures were 13–1,260 Bq/kg 
(0.35–34 nCi/kg) dry weight. 
Brauning et al. (1986) reported radioactivity levels in municipal sludge.  Sludge from Stickney, Illinois 
that was used as an organic fertilizer contained 3.3 and 1.5 fCi/g (14 and 575 Bq/kg) dry weight of 241Am
in 1974 and 1975, respectively. Potential sources in this case were thought to be from background 
concentrations and fallout from nuclear weapons testing.  In Texas, 241Am was present in sludge samples 
in 1983 and 1986 from a facility that received sanitary waste from the Gulf Nuclear, Inc. facility.  
Potential sources of radionuclides in the sludge were industrial wastes.  Two incidents of contaminated 
sludge from companies producing foils for smoke detectors occurred in New York State.  One of the 




























6. POTENTIAL FOR HUMAN EXPOSURE 
incinerator ash between April 17, and May 7, 1984, after which it dropped to 13 pCi/g (0.48 Bq/g), 
corresponding to a sludge concentration of 5.2 pCi/g (0.19 Bq/g).  During the latter half of 1984 and 
1985, the 241Am concentrations in sludge were 3.5 and 2.5 pCi/g (130 and 93 mBq/g), respectively.  In the 
second incident, 241Am in sludge was as high as 120 pCi/g (4,400 mBq/g) in 1984, but dropped to an 
average of 24.8 pCi/g (920 mBq/g) in the latter half of 1985.  This facility placed its sludge in landfills 
(Brauning et al. 1986). 
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE  
Americium in the environment may be transferred to humans by inhalation and ingestion of food and, in
the case of children, ingestion of soil; in general, intake of americium should be small.  Much of the 
241Am so taken is found in the lungs, skeleton, and liver.  In addition to the 241Am taken up, additional 
241Am is produced by the decay of 241Pu that has been inhaled or ingested and absorbed.  No data on the 
body burden of 241Am in the general population were found.  However, the body burden from fallout was 
estimated from the concentration of 241Am in air and estimates of intake by ingestion.  The modeling 
study indicated that most of the 241Am body burden, 89% in 1978, was due to ingrowth from 241Pu. The 
model also estimated that the contribution of ingestion to the 241Am body burden was <1% of that due to 
inhalation. The total skeletal burden for 1970–1974 in New York was estimated from ashed skeletal 
samples to be 0.27 pCi (10 mBq) (Bennett 1979).  UNSCEAR (2000) reported that inhalation exposures 
for even long-lived transuranic radionuclides became insignificant after 1985.   
Ash from a 1974 90Sr total diet study in New York consisting of representational foods from 19 separate 
categories was analyzed for 241Am to ascertain the dietary intake of the radionuclide from fallout (Bennett 
1979).  It was estimated that over 95% of the 241Am transfer to food was from cumulative deposits in soil, 
rather than from direct deposition.  The highest concentrations of 241Am in food occurred in shellfish, 
followed by grain products and fresh fruits and vegetables.  The lowest concentrations were in meat, milk, 
eggs, fish, and processed foods. The same patterns of concentrations were obtained for 239,240Pu. The 
activity levels of 241Am in foods from New York from a total diet study, and in areas near nuclear 
weapons test sites and a fuel reprocessing facility are shown in Table 6-4.  Using dietary consumption 
estimates and the activity levels in the food items and tap water, the 241Am ingestion intake for a New 
Yorker was 0.40±0.05 pCi/year (15±2 mBq/year) in 1974.  The concentration of 241Am in tap water was 
estimated at 30±3 aCi/kg (1±0.1 µBq/kg) with 1,200 kg of water being consumed in a year.  The food 





















6. POTENTIAL FOR HUMAN EXPOSURE 
concentration of 241Am in food was largely a result of uptake from soil derived from cumulative deposits.  
Direct deposition from fallout was greatest in 1963–1964.  Additionally, direct deposition is a much less 
significant means of plants acquiring activity than root uptake.  The 241Am intake in diet from fallout will 
continue to increase due to ingrowth from 241Pu until the cumulative deposit reaches its projected 
maximum of 0.88 mCi/km2 (33 MBq/km2) in the year 2035, at which time, the dietary intake of 241Am
will have reached a maximum of 0.7 pCi/year (26 mBq/year) (Bennett 1979). 
As part of its Radionuclides in Food Program, the FDA determined concentrations of radionuclides in 
their Total Diet Study of food originating from the vicinity of nuclear reactors including raw vegetables, 
food crops (primarily fruits), fish, and milk.  While not specifically analyzed for, 241Am concentrations of 
radionuclides in both of these surveys in 1983–1986 and 1987–1992 were sufficiently low as to require 
no specific action or simple monitoring.  Imported foods were extensively monitored starting in May
1986 for contamination resulting from the Chernobyl accident.  While 241Am was identified in samples of 
imported food that probably originated from Chernobyl, the vast majority of samples were below FDA’s 
level of concern with only one oregano and three cheese shipments being detained (Cunningham et al. 
1989, 1994).  FDA has since published guidelines for radionuclide concentrations, including isotopes of 
americium and plutonium, in food (FDA 1998). 
A study in the Ravenglass estuary, where tidal action inundates pasture land with water that receives 
discharges from the BNF reprocessing plan in Sellafield, concluded that consumption of a diet consisting 
of locally produced food would result in dose levels far below recommended limits (Bradford and Curtis 
1984). Sanchez et al. (1998) measured the 241Am activity in vegetation from tide washed pastures in 
17 estuaries spanning the eastern seaboard of the Irish Sea from Solway in northwest England to David’s 
Head in southern Wales. From the mean and median 241Am activity in grass and appropriately reduced 
transfer factors, they predicted the activity in animal products, namely milk, beef, beef liver, lamb, and 
lamb liver.  From this, they estimated the committed effective dose for a 1-year-old child, a 10-year-old 
child, and an adult from eating these foods.  Assuming that the land above the high water mark was to be 
reclaimed for growing vegetables, the authors calculated estimates of dose derived from consumption of 
potatoes, which were determined to be the critical vegetable group in terms of radionuclide 
contamination.  The results are shown in Table 6-6, in which the relative doses for the various foods are 
beef liver>potatoes>lamb liver>beef>milk>lamb. 
Using transfer factors derived for uptake into plants and animals, Friberg and Vesanen (1999) have listed 















   
        
        
        
        
        
        







6. POTENTIAL FOR HUMAN EXPOSURE 
Table 6-6. Estimated Effective 241Am Dose from Food Raised on Land Impacted 
by Tidal Estuaries along the Irish Sea 
241Am Committed effective dose (µSv) from 
241AmbFood item Transfer factors concentrationa 
Mean Median Mean Median Adult 10-year old 1-year old
Milk 1.0x10-7 1.0x10-7 6.3x10-4 2.5x10-4 0.01 0.02 0.03
 
Beef 1.0x10-5 1.0x10-5 0.06 0.02 0.2 0.2 0.07
 
Beef liver 2.0x10-3 2.0x10-3 12.61 4.94 14.6 8.3 4.9
 
Lamb 4.0x10-5 4.0x10-5 0.03 0.01 0.05 0.03 0.01
 
Lamb liver 3.0x10-3 3.0x10-3 2.18 0.86 2.5 1.4 0.8
 
Potatoes 3.3 3.1 1.2
 
aFood concentrations were estimated from measured 241Am levels in grass (485 Bq/kg dry weight mean, 

190 Bq/kg dry weight median), by applying grass-to-food transfer factors.  Units are Bq/L for milk and Bq/kg fresh 

weight for other food items. 

bThe average consumption rates for the animal products were obtained from Byrom et al. (1995) and the dose 

coefficients were taken from SEPA (2000) (conversion:  1 Sv=100 rem). 

























6. POTENTIAL FOR HUMAN EXPOSURE 
on soil and pasture vegetation from a nuclear accident required to exceed the action level for foodstuffs 
recommended by the IAEA.  Critical activity levels for the α-emitting isotopes of Pu, Am, and Cm were 
determined to be 8 kBq/kg (0.2 µCi/kg) for soil top-layer and 3.5 kBq/kg (0.095 µCi/kg) for pasture 
vegetation. The lowest detection limit required for the α-emitting isotopes of Pu, Am, and Cm was 
determined to be 2 kBq/kg (0.05 µCi/kg).  Detection limits for the α-emitting isotopes of Pu, Am, and Cm
achieved with thorough radioanalytical procedures have been reported as low as 0.07 Bg/kg (2 pCi/kg) in
soil (Friberg and Vesanen 1999).   
The consumption of fish exposed to actinide contamination is a potential source of 241Am exposure.  This 
potential source of exposure has been evaluated by measuring the concentration of 241Am in bass and 
bluegill living in a nuclear waste pond on the Hanford site where the levels of 241Am in sediments are 
approximately 3 orders of magnitude above background levels.  Assuming that actinide behavior in the 
body is similar to that defined by the International Commission on Radiation Protection (ICRP) for 
Standard Man, the maximum levels occurring in fish fillets after 1 year in the waste pond (see Table 6-5) 
would not be sufficient to produce a significant radiation dose to a human eating 1 pound of fish fillets 
every day for 70 years (Emery et al. 1981).  Similarly, the consumption of fish from the Farallon Islands 
Nuclear Waste Dump Site off of San Francisco is expected to add ~1.5% to the typical annual dose to the 
whole body effective dose equivalent value to pooled radionuclide concentrations committed to age 70 
(Suchanek et al. 1996).  This increase is derived largely from the ingestion of 241Am. 
Lichens are very efficient collectors of deposited radionuclides.  Since caribou and reindeer depend on 
lichens for food during the winter season, the lichen-reindeer/caribou-human pathway can lead to elevated 
exposures to indigenous Inuit and Sami populations who eat large quantities of meat and organs from
caribou and reindeer.  Reindeer tissue samples were analyzed for transuranium elements in Finland 
following the Chernobyl accident in 1986.  Paatero and Jaakkola (1998) established that americium was 
transferred from lichen to reindeer via the gastrointestinal tract and not inhalation, and obtained a 
gastrointestinal-tract absorption coefficient of 0.00075 for 241Am.  This gastrointestinal-tract absorption 
coefficient is similar to that estimated for humans (0.0006–0.0008, see Section 3.3.1.2).  Concentrations 
of 241Am in reindeer resulting from Chernobyl fallout appear in Table 6-5.  Global fallout of plutonium, 
which correlates with that of americium, was considerably higher than Chernobyl fallout, ca. 70 Bq/m2 
(2 pCi/m2) compared to 1.5 Bq/m2 (0.04 pCi/m2) (Paatero and Jaakkola 1998).  Based on 241Am 
concentrations in reindeer in Finnish Lapland, estimated 241Am intake is 2 pCi/year (74 mBq/year) for 



























6. POTENTIAL FOR HUMAN EXPOSURE 
A modeling study for estimating exposure to man from dumping of radioactive waste in the Arctic Seas 
concluded that ingestion of molluscs was the dominant pathway for 241Am, and that 241Am along with 
239Pu would dominate the collective dose at longer time scales (Nielsen et al. 1997).  Another modeling 
study dealing with the effect of long-term release of 241Am into an estuarine coastal sea ecosystem found 
that the greatest intake by man is from eating marine food items such as seaweed, molluscs, crustaceans, 
and fish (Murray and Avogadro 1979).  Another important route of exposure is the inhalation of
contaminated airborne coastal sediment.  Ingestion of sediment by children and the contamination of 
crops by airborne sediment were estimated to be of minor importance.  Radiation from contaminated mud 
flats and direct exposure from water were considered to be of little consequence.  A survey of 241Am and 
plutonium in fish and shellfish in Ireland between 1988 and 1997 estimated that the mean doses from
241Am for the typical and heavy Irish consumer were 0.024 and 0.104 µSv/year (2.4 and 10.4 µrem/year), 
respectively (Ryan et al. 1999).  Americium contributes somewhat over a quarter of the combined 
plutonium-americium dose.  In 1988, this combined dose was roughly 10% of that which the typical Irish 
seafood consumer obtained from 137Cs; in 1997, this percentage had increased to 48%. 
Both the general population and workers may be exposed to 241Am from the production, distribution, and 
use of ionization chamber smoke detectors.  The USNRC investigated exposure relating to this device.  
Their 1979 report concluded that the sum of doses to the population resulting from production, 
distribution, use, and disposal of 14 million smoke detectors containing 3 µCi (100 kBq) of 241Am each 
(over 3 times that presently used) that were distributed in 1978 would result in a collective total body dose
of 1,100 person-rem (11 person-Sv)—much lower than that which could potentially result in one cancer 
death (USNRC 1979).  The risks reported in the 1979 report may be overestimates for current times, since 
radiation risk coefficients have changed and the amount of americium used per unit has been reduced.  
More recent information also indicates that exposure to 241Am in a home smoke detector is negligible 
(<0.01 mrem/year [<1x10-7 Sv/year]).  Smoke detectors today typically contain approximately 1 µCi 
(37 kBq) of 241Am (EPA 2004b).  Exposure to 241Am could result from improper disposal of smoke 
detectors; for example, if a detector was broken and then disposed of in a municipal landfill or 
incinerated. The 241Am from the broken detector could be consumed by a child, but uptake would be 
negligible based on human study results (Rundo et al. 1977).
Occupational exposure to 241Am may occur to workers manufacturing the 241Am-containing foil used in 
ionization-type smoke detectors or assembling the device.  Two manufacturers of the 241Am foils were 
surveyed in 1977 (USNRC 1979).  One reported an external population dose of 0.8 person-rem per curie 






















6. POTENTIAL FOR HUMAN EXPOSURE 
241Am they processed.  The maximum dose for an individual was approximately 0.8 rem (8 mSv).  The 
second manufacturer reported 0.2 person-rem per curie (0.05 person-pSv/Bq) of 241Am processed.  It 
should be noted that manufacturers of ionization chamber smoke detectors must be licensed by the 
USNRC or an agreement state, and that certain work practices are required to minimize exposure.  
Workers wear shoe covers, lab coats, and gloves, and wipe tests are performed weekly. During the 
manufacture of the smoke detector units, one manufacturer reported the yearly external doses among 
badged workers in 1978: 40% had no measurable dose, 40% had <100 mrem (<1 mSv), 15% had doses 
between 250 and 500 mrem (2.5 and 5.0 mSv), 4% had doses between 500 and 750 mrem (5.0 and 
7.5 mSv), and one individual had a dose between 750 and 1,000 mrem (7.5 and 10 mSv).  The total 
occupational dose in the ionization chamber smoke detector industry in 1978 was estimated to range from
15 to 48 person-rem.  The external doses to people involved in the distribution and retail sale of smoke 
detectors would be much less.  The hand dose to installers is estimated to be 0.6 µrem (6 nSv) per unit 
installed. An individual having one detector in the hallway and one in the bedroom would have an annual 
dose of 9.3 µrem (93 nSv).
Workers at plutonium reprocessing facilities, nuclear reactors, or transuranium and low level waste 
storage facilities, or those engaged in the production or processing of 243Am or 241Am may be 
occupationally exposed to americium.  In addition, workers at sites where nuclear testing was conducted 
may also be exposed to americium.  Workers in nuclear power stations may be exposed to airborne 
radionuclides. The USNRC publishes annual reports on occupational radiation exposure at USNRC-
licensed facilities.  Monthly cumulative 24-hour air filter samples were obtained from five different 
working areas of a BWR in India during normal operation and during refueling in order to measure the 
concentrations of transuranic radionuclides, including americium, in air.  The average air 241Am 
concentrations during normal operation were (work area, concentration in mBq/m3 [fCi/m3]): reactor 
building—103 feet elevation, 0.95 (26); reactor building—143 feet elevation, 0.22 (5.9); reactor 
building—200 feet elevation, 0.25 (6.8); turbine building—133 feet elevation, 0.07 (1.9); and radwaste 
building—2.50 (68) (Hedge and Bhat 1983).  During refueling, the respective concentrations were: 1.64, 
1.33, 0.78, 0.19, and 6.34 mBq/m3 (44.3, 35.9, 21, 5.1, and 171 fCi/m3). The derived air concentration 
recommended by the ICRP for occupational exposure is 80.0 mBq/m3 (2,200 fCi/m3) (Hedge and Bhat 
1983).  In 1997, the French radiation protection office conducted monitoring (24-hour urine 
analysis/whole body activity measurements) of workers in the non-nuclear energy field (i.e., nuclear 
medicine, research laboratories, and non-nuclear industries) to ascertain the occupational intake of 
radionuclides (De Vathaire et al. 1998).  241Am was not detected in samples from any of the 37 workers 



























6. POTENTIAL FOR HUMAN EXPOSURE 
The U.S. Transuranium and Uranium Registries (USTUR) include The National Human Radiobiology
Tissue Repository, which contains postmortem tissue from persons (primarily workers) with documented 
intakes of uranium or transuranic elements, such as americium.  The USTUR publishes annual reports 
detailing cases of accidental exposure and tissue levels of the different radioactive isotopes.  These reports 
and other information are available over the internet at http://www.tricity.wsu.edu/ustur/. Exposure is 
generally by inhalation, but entry into the body may also occur through wounds.  Americium is largely
retained in the lung, skeleton, and liver, but after long term exposure, significant amounts of 241Am are 
found in the muscle, respiratory tract, and other soft tissue (Filipy et al. 1994; McInroy et al. 1989).  In 
25 USTUR cases involving the registry of individuals who typically had ≥20 years of employment in 
facilities where 241Am was processed and who were likely to have had chronic, low-level inhalation 
exposure to the actinide, the 241Am organ content of the liver and skeleton ranged from 0.01 to 554 Bq 
(0.26 Bq, median) (0.3–15,000 pCi, 7.0 pCi, median) and from 0.04 to 6,623 Bq (0.99 Bq, median) (1– 
179,000 pCi, 27 pCi, median), respectively (Kathren et al. 1988). Seventy-five percent of the combined 
activity in the liver and skeleton resided in the skeleton (see Section 3.4).  Measurements of 241Am were
performed on the skulls of 66 residents of the Caithness area of Scotland near the Dounreay Nuclear 
Establishment between October 1990 and December 1991.  No 241Am was detected in any of these 
subjects (Ham et al. 2003). 
6.6 EXPOSURES OF CHILDREN  
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in 3.7 Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways. 
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a 
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age: from placental nourishment to breast milk 
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s 
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 

























6. POTENTIAL FOR HUMAN EXPOSURE 
Specific information on the exposure of children to americium is not available.  As for adults in the 
general population, small exposures to 241Am occur from normal ingestion of food and drinking water and 
inhaling air. While the potential for americium exposure is greater for children who consume foods 
grown in areas with elevated levels of americium in the soil, the uptake of americium into plants and 
animals is very low.  Children may be exposed to a substance brought into the home on parents’ work 
clothes, skin, hair, tools, or other objects from the workplace; however, with one exception, no instances 
of americium exposure in children by this route were found in the literature.  In this case, a man who did 
some experiments using an americium source brought home a secondary source and stored it in a dresser 
drawer (Kelly and Dagle 1974).  No information was located on americium levels in amniotic fluid, 
meconium, cord blood, neonatal blood, or breast milk, or other potential measurements relating to fetal or 
childhood body burdens.  
241Am may also find its way into municipal landfills because of improper disposal of smoke detectors or 
rubble of buildings containing smoke detectors.  Smoke detectors may be broken, exposing the 241Am
ionization source. Young children might get access to the 241Am and ingest it, although a human study
indicates that uptake from ingesting the americium source from a smoke detector is insignificant (Rundo 
et al. 1977). At hazardous waste sites, americium that is found in excess of fallout background levels is 
most likely to be in soil and presents a special hazard for young children.  Hand-to-mouth activity and 
inadvertent or intentional (pica) eating of contaminated dirt will result in oral exposure to americium.
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES  
Occupational exposures and general population exposures to potentially high levels of 241Am and other 
radionuclides might occur to people occupying land like the southern Solway and Dee marshes, areas 
tidally inundated by water contaminated by the BNFL nuclear fuel reprocessing plant at Sellafield, United 
Kingdom plant in England (Rose et al. 1996).  Modeling studies of human populations exposed to 241Am
in such coastal environments show that the highest levels of 241Am would occur in sediment and marine 
organisms, especially molluscs and seaweed (Murray and Avogadro 1979).  These human populations 
include farm workers and turf cutters and recreational users such as birdwatchers, hikers, fishermen, and 
bird shooters, as well as those who consume contaminated marsh produce, molluscs, and seaweed.  
Exposure routes would be ingestion and inhalation of dust.  Even so, the dose rates that would be received 



























6. POTENTIAL FOR HUMAN EXPOSURE 
Populations with potentially high exposure to 241Am from commercial devices such as ionization chamber 
smoke detectors might include production workers and firemen attending to fires in production facilities, 
or warehouses where a large number of sources or devices are housed.   
6.8 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of americium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of americium.  
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
6.8.1 Identification of Data Needs 
Physical, Chemical, and Radiological Properties.    Data on the physical and chemical properties 
of americium and americium compounds are available in the literature (Cotton and Wilkinson 1980; Lide 
1994, 1998; Nenot and Stather 1980; Seaborg 1991).  Data are also available on the radiological 
properties of americium isotopes (Baum et al. 2002; DOE 2003a; ICRP 1983; Lide 1998). 
Production, Import/Export, Use, Release, and Disposal.    Data regarding the past and present 
production and import/export volumes for 241Am and 243Am are not available.  The limited commercial 
use of 241Am provides a good estimate of probable production volumes.  The uses of americium are 
known (Budavari 1996; Seaborg 1991; UIC 1997; USNRC 1979).  However, information on the 
production, import/export volumes, and the amounts of 241Am used in various devices would be useful for 
estimating exposure. Estimates of the amounts of 241Am released as a result of nuclear tests and accidents
























6. POTENTIAL FOR HUMAN EXPOSURE 
USNRC regulations (10 CFR 61).  The Manifest Information Management System (MIMS), maintained 
by the INEEL, contains information on low-level radioactive waste shipments received at commercial 
low-level radioactive waste disposal facilities and the WIPP transuranic waste facility (INEEL 2000).  
The DOE stores most of its spent fuel at three primary locations: the Hanford site, Washington, the 
INEEL, Idaho, and the Savannah River Site, South Carolina.  The DOE National Spent Fuel Program
maintains a database of spent nuclear fuel stored in each of the three locations (DOE 1999a).  Information 
concerning the americium content of civilian nuclear power plants and naval nuclear propulsion plant 
spent fuel now in storage and awaiting disposition would be useful for estimating the amount of
americium stored in the country. 
Environmental Fate. The environmental fate of americium has been extensively studied in relation 
to its introduction into the Irish Sea from the BNFL nuclear fuel reprocessing plant at Sellafield, United 
Kingdom (Belot et al. 1982; Bennett 1976; Bunzl et al. 1994, 1995; Malcolm et al. 1990b; McCartney
et al. 1994; McKay et al. 1994; Murray et al. 1978, 1979; Pattenden and McKay 1994; Walker et al. 
1986).
Other studies have investigated transport in soil and at DOE waste disposal sites (Fowler et al. 1981;
McCarthy et al. 1998a, 1998b; Penrose et al. 1990).  As a result of these studies, the environmental fate of 
americium is reasonably well understood.  However, DOE has begun using the RESRAD Biota computer 
program, and it would be useful to validate uncertainties in associated input parameter values used in the 
model. 
Bioavailability from Environmental Media.    The absorption and distribution of americium as a 
result of inhalation and ingestion exposures have been discussed in Sections 3.3.1 and 3.3.2.  EPA lists 
identical uptake factors for inhaled and ingested americium (as well as all of the other transuranics other 
than plutonium) regardless of compound solubility, indicating that the knowledge base for americium is 
not sufficiently developed to quantify the differences that are recognized for most other elements, and 
additional studies would be helpful. 
Food Chain Bioaccumulation. Information about the levels of americium in aquatic and terrestrial 
organisms and its bioaccumulation in these organisms is available (DOE 1996; Fresquez et al. 1999;
Suchanek et al. 1996).  Data are also available on the uptake of americium in plants (Bennett 1979;



















   
  







6. POTENTIAL FOR HUMAN EXPOSURE 
1985) and levels in food (Bennett 1979; Cunningham et al. 1989, 1994; Robison et al. 1997a, 1997b).  
These data indicate that americium does not biomagnify in the food chain (Bennett 1979; Bulman 1978). 
Exposure Levels in Environmental Media. Monitoring data for the levels of americium in 
contaminated media at hazardous waste sites would be useful.  These data can then be used to estimate 
the intake and body burden of americium and assess the potential risk of adverse health effects in 
populations living in the vicinity of these sites. 
Information is available on the levels of 241Am in soil and sediment in areas affected only by global 
fallout, at DOE installations and other nuclear facilities, and at sites of nuclear explosions and accidents 
(Alberts et al. 1989; Bennett 1979; Cooper et al. 1994; DOE 1980; Pattenden and McKay 1994; Robison
et al. 1997a, 1997b; Sanchez et al. 1996).  241Am levels in soil around nuclear power plants in the United 
States were indistinguishable from fallout background (EPRI 1981). 
For the Radionuclides in Food Program, the FDA determined concentrations of radionuclide activity in
their Total Diet Study. Levels of 241Am in both the 1983–1986 and 1987–1992 studies were sufficiently
low as to require no specific action or simple monitoring (Cunningham et al. 1989, 1994).
The FDA (1998) has published derived intervention levels for 241Am in food at which action should be 
considered. Dietary values are 2.0 Bq/kg for 3-month-old children, increasing to 17 Bq/kg for 1-year-old 
children, and then decreasing to 8.8 Bq/kg for adults.  Since 1973, background fallout levels of 241Am in 
air have been <1 aCi/m3 (1 aCi=10-18 Ci) (0.037 µBq/m3) and are continuing to decline (Bennett 1979).
Levels in tap water are sufficiently low that levels must be estimated (Bennett 1979). 
UNSCEAR (2000) reported that deposition and air concentrations of radionuclides from fallout dropped 
rapidly once atmospheric testing ceased in 1980.  Inhalation exposures for even long-lived transuranic 
radionuclides became insignificant after 1985.   
Exposure Levels in Humans. Although some data on the levels of americium in human tissues 
exposed to natural background levels (food, water, and air) are available, few measurements have been 
made on the americium content in human tissues.  The principal source of information about 
occupationally exposed individuals is the USTUR database, established to document levels and 
distribution of uranium and transuranium isotopes in human tissues for occupationally exposed workers 
(USTUR 1999). Several major database files are available.  The Radiochemical file contains information 






















6. POTENTIAL FOR HUMAN EXPOSURE 
Physics file contains bioassay and other health physics data.  These two databases are regularly updated.  
The Medical file contains abstracted personal, medical, and clinical data; the Pathology file contains 
autopsy and pathology information; and the Skeletal Estimate file contains estimated actinide 
concentrations for unanalyzed half skeletons from donors (USTUR 1999).  The DOE has developed the 
Comprehensive Epidemiologic Data Resource (CEDR) Program to provide public access to health and 
exposure data concerning DOE installations.  In addition, studies relating to populations residing near 
DOE installations, and other studies of radiation exposures and health effects, such as atomic bomb 
survivors, are included in CEDR (CEDR 2000).  Additional research is needed to reassess the magnitude 
of any health risks associated with exposure to americium from smoke detector damage under realistic 
scenarios. 
Exposures of Children. Children will be exposed to americium in the same manner as adults in the 
general population (i.e., ingestion of food and water and inhalation of air).  Americium is potentially
found at hazardous waste sites at elevated levels.  Since children may have oral exposure to soil through 
hand-to-mouth activity, bioavailability studies of americium in soil via the oral route may be useful to 
assess the risk of this type of exposure. 
Child health data needs relating to susceptibility are discussed in 3.13.2 Identification of Data Needs: 
Children’s Susceptibility. 
Exposure Registries. Americium is not currently one of the chemicals for which a subregistry has 
been established in the National Exposure Registry.  Americium will be considered in the future when 
chemical selection is made for subregistries to be established.  The information that is amassed in the 
National Exposure Registry facilitates the epidemiological research needed to assess adverse health 
outcomes that may be related to the exposure to americium.
Other exposure registries are available for americium.  The USTUR established a database to document 
levels and distribution of uranium and transuranium isotopes in human tissues for occupationally exposed 
workers who donate their bodies to science (USTUR 1999).  The DOE has developed the CEDR Program
to provide public access to health and exposure data concerning DOE installations.  In addition, studies 
relating to populations residing near DOE installations, as well as other studies of radiation exposures and 

















6. POTENTIAL FOR HUMAN EXPOSURE 
6.8.2 Ongoing Studies 
The Federal Research in Progress database lists ongoing studies about environmental effects of 
americium (FEDRIP 2004).  The one current study listed in the FEDRIP database was R.D. Lloyd of the 
University of Utah at Salt Lake City, studying the consequences of exposure to a bone-seeking 
radionuclide, 239Pu. These studies will provide new knowledge on the biological behavior of plutonium
and other bone-seeking radionuclides, including americium, and improve the capability to predict the 
risks of exposure.  This research is supported by the National Cancer Institute.  The International Science 
and Technology Center (ISTC), headquartered in Moscow, which began operations on March 3, 1994, 

























7. ANALYTICAL METHODS 
The purpose of this chapter is to describe the analytical methods that are available for detecting,  
measuring, and/or monitoring americium, its metabolites, and other biomarkers of exposure and effect to 
americium.  The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is 
to identify well-established methods that are used as the standard methods of analysis.  Many of the 
analytical methods used for environmental samples are the methods approved by federal agencies and 
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other 
methods presented in this chapter are those that are approved by groups such as the Association of 
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).  
Additionally, analytical methods are included that modify previously used methods to obtain lower 
detection limits and/or to improve accuracy and precision. 
7.1 BIOLOGICAL MATERIALS  
Entry of americium into the human body can occur through ingestion, inhalation, or penetration through 
skin or via wounds.  The quantities of americium within the body can be assessed from the use of 
bioassays, which include in vivo measurements and/or in vitro measurements.  In vivo measurements can 
be obtained through techniques that directly quantify internally deposited americium (using, for example, 
a whole body counter).  Conversely, in vitro measurements provide an estimate of internally deposited 
americium, utilizing techniques that measure americium in body fluids, feces, urine, or tissue obtain 
through an autopsy.  Examples of these analytical techniques are given in NCRP Report No. 87 (1987) 
and are also listed in Table 7-1. The ultimate aim of making such measurements is to estimate intake and 
radiation dose.  In-vitro measurements provide an assessment of intake and dose only when the data are 
interpolated using appropriate biokinetic models, taking account of pattern of exposure, chemical form, 
and other parameters. 
7.1.1 Whole or Partial Body Measurements 
In vivo measurement techniques are the most direct and widely used approach for assessing the content of 
many radioisotopes, including americium, within the body.  The in vivo measurement of americium
































7. ANALYTICAL METHODS 
Table 7-1. Analytical Methods for Determining Americium  
in Biological Samples 
Sample 
matrix Sample preparation 
Analytical 









Urine Co-precipitation with 
oxalate 
α-spectroscopy 0.08 pCi/ 
80 cm3 








Urine Sample wet ashed, 











Sample wet ashed, Liquid 14 pCi/100 cm3
1,000 nCi 
 96% at 
1981 
Ham et al. 
purified by solvent scintillation 20,000 dpm 1977 
Urine 
extraction 
Sample with 241Am α-liquid 0.02 pCi/L 
spike  
96% at Hafez and 
spike co-precipitated scintillation 20 dpm spike Hafez 1992 





Urine Sample cleaned-up Biphasic liquid 1 pCi/200 cm3 84% Bomben et 
by co-precipitation, scintillation al. 1994 
treated with HNO3 
and H2O2, wet ashed 
Urine Spiked sample 
clean-up by co­












Sample wet ashed, 
spiked with 243Am, 
α-spectroscopy No data 98% McInroy et al. 
1985 




Soft Spiked sample wet α-spectroscopy No data 53% Qu et al. 
tissue ashed, treated with 1998 
HNO3/H2O2, purified 







Sample wet ashed, 







Ham et al. 
1977 





























7. ANALYTICAL METHODS 
Table 7-1. Analytical Methods for Determining Americium  
in Biological Samples 
Sample 
matrix Sample preparation 
Analytical 





Sample wet ashed, 
purified by solvent 
extraction 
Sample wet ashed, 
purified by solvent 
extraction 
Sample wet ashed, 
spiked with 243Am, 
































Sample wet ashed, 
purified by solvent 
extraction 
Sample wet ashed, 
purified by solvent 
extraction 
None
Sample dissolved in 




























Kramer et al. 
1989 







backbone down, in 
lucite box, and 
Gamma-ray 
spectroscopy
No data No data Lloyd et al. 
1970 
tissues positioned 33 cm 
from NaI(Tl) crystal;  




a1 Ci=3.7x1010 Bq=0.037 TBq or 1 Bq=2.7x10-11 Ci=27 pCi; 1 Ci=2.2x1012 dpm 























7. ANALYTICAL METHODS 
collectively known as whole body counters.  These radiation detectors commonly utilize hyperpure 
germanium to detect the 59.5 keV gamma-ray that 241Am promptly emits in 35.9% of its alpha decays to 
237Np (DOE 1979b, 2003a; Palmer et al. 1983).
Because the attenuation half thicknesses for the 59.5 keV gamma-ray are 3.5 cm for soft tissues and 
1.3 cm for bone, 241Am that has been deposited into specific organs or tissues, such as the lungs, liver, 
bones (e.g., skull or knee cap), or lymph nodes, can be detected and quantified using whole body or 
partial body counting techniques that appropriately account for attenuation by internal organs (Graham
and Kirkman 1983; Palmer and Rhoads 1989; Palmer et al. 1983).  Many configurations of the whole 
body counter have been utilized, ranging from the more common single-detector chest detectors to 
multiple-detector arrays (e.g., four HPGE detectors, two each of front and back over the lungs or 
abdomen) or linear whole body scanners that can be utilized to assess the regional distributions of 241Am
over the entire length of the body (Palmer et al. 1983; Toohey and Essling 1980).  Where appropriate, 
shielding of the room that houses the whole body counter and/or the detector is often used to increase the 
detection sensitivity of the equipment by minimizing background radiation.  Also, in vitro measurements 
of americium (see Section 7.1.2) are often used in conjunction with whole body counting when 
monitoring individuals working with americium. 
Calibration of whole body counters is performed so that the operator can obtain a more accurate and 
unbiased estimate of internalized americium activity.  The equipment calibration is achieved through the 
use of tissue-equivalent phantoms that are constructed to mimic the shape and density of the anatomical 
structure (e.g., the human torso), using tissue equivalent materials such as polystyrene or epoxides.  In 
some phantoms, a human rib cage is added to account for the attenuation of gamma-rays by bone in the 
whole body counts (DOE 1979b).  Americium standards are inserted or molded into the phantom at 
locations where this radionuclide is expected to accumulate, such as in the lung, liver, or bone. 
Comparisons of the activity obtained from the phantom to the known activity of the americium standards 
are used to determine the efficiency of the counting technique and, thus, provide the basis for calibrating 
the technique.  Calibration of whole body counters can be further refined by obtaining actual anatomical 
measurements of the individual to be measured.  For example, chest wall thickness measurements using 
ultrasound techniques are used to account for the variability in attenuation that result from individual 
differences in the chest wall thickness and improving the calibration of chest counts of americium (DOE 
1979b).  Another approach to refining the calibration of whole body counters is the comparison of 
external measurements to the actual americium content in organs and bone of cadavers (Palmer et al. 





























7. ANALYTICAL METHODS 
of the total body or organ burden of americium.  The calibration may include an assessment of the 
detection limit for the system or for the specific analytical protocol being used.   
In assessing initial exposure, whole body counting techniques measure the amounts of americium that 
have been retained within organs or tissues.  In cases of accidental ingestion, some of the americium may
have been excreted in the urine or feces before exposure is assessed.  In particular, soluble forms of 
americium are thought to be readily excreted through the urine.  Long-term assessment of americium
burden within an individual can be complicated by the mobilization of americium from the original site of 
deposition (e.g., the lung) to other sites within the body, such as the liver or bone (Fry 1976).  This can
lead to either overestimates or underestimates of the overall total body burden of americium, depending
on the regions in which the americium counts are obtained relative to the shift in radionuclide 
distribution, and if local concentrations have been augmented by mobilization of americium from other 
tissues. Overestimates can also occur in cases where external contamination in the vicinity of a detector 
contributes to the collected spectrum.  Showering immediately before monitoring to remove potential 
contamination should help reduce variability in temporal results and minimize the potential for obtaining 
false positive results. Additionally, the retention (biological half-life) of americium within the body can 
vary greatly between individuals (Fry 1976).  Direct comparisons of americium body burdens and 
clearance rates between laboratories can be complicated by the differing whole body measurement 
techniques, calibration methods, and methods used to account for normal background radiation counts 
that are utilized within the different laboratories (DOE 1979b).  These variations are largely resolved by
performing periodic internal monitoring and adjusting the model parameters to account for the 
individual’s actual distributed retention.  
7.1.2 Assay of Excreta 
In vitro analyses of americium are routinely performed in situations where in vivo analyses cannot be 
obtained, where in vivo measurements will not provide the information needed, or in support of an in vivo
monitoring program.  Urine is the preferred sample for in vitro analyses of americium, although other 
sample types, such as feces, tissue, bone, or blood, can also be used on a more limited basis.  Urine 
provides for an analysis of soluble or transportable americium, fecal analysis can be used to measure 
gastrointestinal clearance of ingested material plus bile-related systemic clearance, and tissue is used to 
assess whole or regional body burdens of americium (Guilmette and Bay 1981; Ide 1986; Ide et al. 1985;




















7. ANALYTICAL METHODS 
There are a number of methods that have the selectivity, and/or sensitivity, to measure americium in 
biological matrices including spectrophotometry, fluorimetry, mass spectrometry (MS), and radioassays 
(Dacheux and Aupias 1998; Hafez and Hafez 1992; Poupard and Jouniaux 1990; Thouvenot et al. 1993).  
Of these methods, radioassays (e.g., gross alpha analysis, alpha spectroscopy, gamma-ray spectroscopy, 
liquid scintillation techniques) are preferred because of their ease of use, detection sensitivity, and 
rapidity of analysis (Alvarez and Navarro 1996; Dacheux and Aupiais 1997; Guilmette 1986). These 
methods typically involve a preliminary concentration step and wet/dry ashing of the sample that is often 
followed by an oxidation of the radionuclides in the sample residue.  To remove the possible interferences 
of other elements and alpha-emitters, ion exchange, co-precipitation, and adsorption techniques are 
applied to the purified sample before alpha or liquid scintillation techniques are applied (see Table 7-1).  
Radioassays can also be applied to the measurement of americium in fecal samples, as well as tissue and 
bone samples obtained from autopsy, using methods that are similar to those described for urinalysis, 
except for some additional purification and extraction steps that are required to remove interfering 
materials such as iron (Guilmette and Bay 1981; Hafez and Hafez 1992; Ham et al. 1977; Qu et al. 1998). 
Of the radioassays that are commonly used to quantify americium, α-spectroscopy is used when isotopic 
analyses of americium must be conducted (e.g., to obtain distinct results for 241Am and 243Am). 243Am is 
often added as a tracer to estimate the recovery (efficiency of the radiochemical sample preparation 
method for removing americium from a biological matrix).  The α-spectroscopy technique differentiates 
between the two americium isotopes based on the difference in the energies of the alpha particles that are 
emitted from 241Am and 243Am, and then quantifies the amounts present in the sample by considering the 
system’s response to each, its detection efficiency, and the frequency with which the individual alpha 
particles are emitted. If 243Am is to be analyzed in a sample, 241Am can be used as a tracer.  If a sample 
needs to be monitored for both 241Am and 243Am, the sample is split prior to adding the tracer and two 
analyses are performed (PNNL 2003).  Mass spectrometric techniques, especially those using double 
focusing magnet spectrometers, are also capable of isotopic quantification of americium (Dacheux and 
Aupiais 1998; Poupard and Jouniaux 1990).  These techniques are more rapid than the α-spectroscopy
detection method, but the costs have been much higher.  The cost of mass spectrometers, however, has 
decreased in recent years, making the cost of analyzing samples by mass spectrometry and α-spectroscopy 
more comparable.  The breakeven point will depend on the sample throughput rate.  Higher sensitivity































7. ANALYTICAL METHODS 
Accuracy and bias of in vivo and in vitro measurements of americium are determined through the use of 
standard, certified radioactive sources with known concentrations of americium.  The primary source of 
certified americium standards is the National Institute of Standards and Technology (NIST).  Secondary
and tertiary level laboratories can also prepare, certify, and sell such sources, and the Health Physics 
Society is developing an accreditation program for providers who wish their products to be recognized as 
NIST-traceable (HPS 2004).  Standard solutions are available for 241Am (SRM 4322, 40 Bq/g [1.1 nCi/g])
and 243Am (SRM 4332, 40 Bq/g [1.1 nCi/g]).  Standard Reference Materials for human lung (SRM 4351) 
and human liver (SRM 4352) are also available from NIST. 
7.2 ENVIRONMENTAL SAMPLES 
There are two common approaches for measuring americium in the environment.  Americium can either 
be measured directly in the field (in situ) using portable survey instruments or be quantified from samples 
that were procured from the field and returned to the laboratory. 
7.2.1 Field Measurements of Americium 
In situ measurement techniques are extremely useful for the rapid characterization of radionuclide 
contamination in the environment, such as surface soils, sediments, and vegetation, or when monitoring 
personnel for internal exposure from or external contamination with americium.  Information regarding 
field measurement methods, minimum detectable concentrations, and soil-to-plant concentration factors is 
available for various radionuclides, including americium (MARSSIM 2000; NRC 1992, 1998b).  The 
measurement of radionuclides in the environment is conducted with portable survey instruments that are 
equipped with α-scintillators or gamma-ray spectrometers.  The use of gamma-ray spectrometers is 
preferred for measuring americium in the field, especially in the presence of plutonium isotopes.  The 
reason is that the low-energy 241Am gamma-ray photons are more penetrating than lower energy x-rays
from 238,239Pu for which it is a surrogate radionucide.  This makes measurements less affected by surface 
type and texture and by the presence of vegetation and surrounding soil (Byrne and Komosa 1993).  This 
provides the advantage for assessing the level of americium both on and below the surface (e.g., up to 
3-cm depth in some soils).  These gamma-ray spectrometers are equipped with either a thin phoswich 
type detector or a high purity germanium detector that is able to distinguish the 59.5 keV gamma-ray
emitted from 241Am from most environmental gamma-rays emitted from other radionuclides (Fong and 























7. ANALYTICAL METHODS 
photons of 241Am from the much lower energy photons emitted from 239Pu and 240Pu, which are usually
associated with americium.  Minimum detectable activities (MDAs) of 0.4 Bq/g (10 pCi/g) for 241Am are 
routinely achieved, with MDAs as low as 0.04 Bq/g (1 pCi/g) obtained with longer counting times 
(-30 days). 
One of the limitations of the portable field survey instruments in the measurement of americium is that 
their quantitative accuracy depends on how well the lateral and vertical distribution of americium in the 
soil compares with the calibration parameters used.  These methods can provide a rapid assessment of 
americium levels on or below surfaces in a particular environment; however, laboratory-based analyses of 
samples procured from these environmental surfaces must be performed in order to ensure accurate 
quantification of americium (and other radionuclides).  This is due, in part, to the strong self absorption of 
the 59.5 keV gamma-ray by environmental media, such as soil.  Consequently, uncertainty in the depth 
distribution of americium and density of the environmental media may contribute to a >30% error in the 
field survey measurements.  Refinements in calibration strategies are currently being developed to 
improve both the precision and the accuracy (10%) of gamma-ray spectroscopy measurements of 
americium within contaminated soils (Fong and Alvarez 1997). 
7.2.2 Laboratory Analysis of Environmental Samples  
Analytical methods for quantifying americium in environmental samples are summarized in Table 7-2.  
The methods that are commonly used in the analysis of americium based on activity are gross α analysis, 
α-spectroscopy, and gamma-ray spectroscopy.  MS detection techniques are used to measure the mass of 
americium in environmental samples.  The mass-activity conversion factor for 241Am is 0.29 µCi/µg 
(11 kBq/µg) or 3.43 µg/µCi (0.091 µg/kBq) (Harvey et al. 1993). 
The analysis of americium in air is based on the quantification of americium within particulates that 
become trapped on cellulose or glass fiber filters after a calibrated amount of air is pulled through the 
filters. The analysis for americium on a glass fiber filter is straight forward using gamma spectroscopy, 
but can be a rather complex procedure involving many solvent extraction and column purification steps, 
followed by electrodeposition and α-spectroscopy.  The extensive purification is required to prevent 
impurities within the sample from absorbing or reducing the energy of emitted alpha particles, termed 
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matrix Sample preparation method Detection limita Accuracy Reference 
Air 	 Sample collection on 
cellulose filter, dry ashed, 
solvent extracted 
Air 	 Filter wet ashed in 
HNO3/HF, purified with 
cation and anion 
exchange columns and 
electrodeposition 
Air 	 Cellulose filter dry ashed, 
dissolved in HNO3/HF, 
H2O2/HClO4, purified with 
anion exchange, TRU-
spec columns followed by 
electrodeposition.  
Water 	 Sample fusion with 
pyrosulfate, precipitated 
with barium sulfate 
Water 	 Wet ashed, purified by 
solvent extraction 
Water 	Treated with HNO3/H2O2, 
HF/HCl, anion exchange, 
TRU-spec column, 
electrodeposition 
Water 	 Solvent extracted 
Sea water 	 Co-precipitation with iron 
hydroxide, purified by 
anion exchange, co­
precipitation with BiPO4, 
cation exchange, electro­
deposition 
Sediments	 Sample fusion with KF 
and pyrosulfate, co­
precipitate with BaSO4 
Sediments 	 Sample leached with 
HNO3/HF, filtered, purified 





Soil 	 Sample fusion with KF 
and pyrosulfate, co­
precipitate with BaSO4 
Biphasic liquid 1 pCi 
scintillation 
α-spectroscopy No data 
α-spectroscopy 0.023 pCi/sample 
Scintillation No data 
counter 
Biphasic liquid 1 pCi/sample
scintillation 
α-spectroscopy 0.026 pCi/L 
PERALS 0.007 pCi/L 
α-spectroscopy No data 
Scintillation No data 
counter 
α-spectroscopy No data 
Gamma-ray 0.02–0.06 pCi/g 
spectroscopy
Scintillation No data 
counter 
95% 	 Bomben 
et al. 1994 
No data 	 Knab 1979 
102% 	 Goldstein 
et al. 1997 
99.5% 	 Sill and 
Williams
1969 
95% 	 Bomben 
et al. 1994 
101% 	 Goldstein 
et al. 1997 
104% 	 Dacheux 
and Aupiais 
1998 
64–79% 	 Lovette 
et al. 1990 
No data 	 Sill and 
Williams
1969 
95–99%  	 Guogang 
et al. 1998 
108–118%  	 Joshi 1989 
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matrix Sample preparation method Detection limita Accuracy Reference 
Soil 	 Wet ash in HNO3/HF, 
purified with cation and 
anion exchange columns, 
electrodeposition 
Soil 	 Dry ash, digest in 
HNO3/HCl, anion 
exchange, Ca-oxalate and
Fe (OH)2 coprecipitation, 
anion exchange, electro­
deposition 
Soil 	 Sample leached with 
HNO3/HF, filtered, purified 





Vegetation 	 Ashed, HNO3/HF, 
(grasses) 	 precipitation with oxalate 
and La, anion exchange, 
solvent extraction 
Vegetation 	 Ashed, digested with 
HNO3-H2O2, oxalate and 




Vegetation 	 Ashed, digested with 
HNO3-HCl, anion 
exchange, Ca-oxalate and
Fe precipitations, anion 
exchange, electro­
deposition 
Lichen, 	 Ashed, leached with HCl, 





α-spectroscopy No data 
α-spectroscopy 27 pCi/g 
α-spectroscopy No data 
Gamma-ray 0.02–0.06 pCi/g 
spectroscopy
α-spectroscopy 0.011 pCi/g 
α-spectroscopy 0.3 fCi/g 
α-spectroscopy 27 pCi/g 
α-spectroscopy 0.9 fCi/g 
No data 	 Knab 1979 




95–99%  	 Guogang 
et al. 1998 
108–118% 	 Joshi 1989 




et al. 1993 
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Ashed, digested with 
HNO3-H2O2, oxalate, and 















et al. 1993 
a1 Bq=2.7x10-11 Ci=27 pCi; 27 fCi=1 mBq 
KL-HDEHP = 50% di(2-ethylhexyl) phosphoric acid, 60–100 mesh resin; PERALS = Photon/electron rejecting alpha 

























7. ANALYTICAL METHODS 
prevent these materials from interfering with the α-spectroscopy measurements of 241Am and 243Am
(ASTM 1997; Lovette et al. 1990). Initially, the filter media is dissolved with HNO3 and H2O2, the 
residue is wet ashed with HNO3 and then purified using anion exchange chromatography, the solvent is 
extracted with 50% bis-(2-ethylhexyl) phosphoric acid (HDEHP) in toluene, the sample is again passed 
through an anion exchange column, and then the sample is oxidized with HNO3 and H2O2. 243Am is
commonly used as a surrogate for quantifying the chemical recovery of 241Am during sample preparation, 
so quantification of 241Am in a sample involves α-spectrometric analysis of both isotopes.  Preparation of 
the purified filter sample for α-spectroscopy requires electrodeposition of the americium from a sulfate 
solution onto a stainless steel or platinum disc from which alpha counts are obtained during the α ­
spectroscopy analysis (DOE 1997b).  The accuracy of this method of analysis for americium can vary
between 85 and 102% and the MDA often ranges between 0.032 and 0.023 pCi/sample (1.2 and 
0.85 mBq/sample) (Goldstein et al. 1997). 
For the analysis of americium in water, there is a broad array of available sample preparation and 
detection methodologies (see Table 7-2).  Many of the common and standardized analytical 
methodologies typically include the minimization of sample volume, purification through co­
precipitation, anion exchange column chromatography, and solvent extraction techniques followed by
radiochemical detection of americium in the purified sample.  Gross alpha analysis or liquid scintillation 
are common detection techniques that are utilized to quantify americium in these methods.  However, if 
lower detection sensitivity or isotopic determination is required, then α-spectroscopy is the preferred 
method to quantify 241Am (Dacheux and Aupiais 1997; DOE 1997b; Goldstein et al. 1997; Harvey et al. 
1993; Sill and Williams 1969).  These detection methods can provide measurements of total americium
activity within a sample, especially when appropriate steps have been taken to purify the sample of 
interfering materials or minimize the influence of other radionuclides on radiochemical activity (Dazhu et 
al. 1991).  The presence of alpha emitting radionuclides in the sample can contribute to the alpha counts 
measured in radiochemical detection methods and, thus, affect the accuracy of the assay for determining 
the quantity of americium within a sample. 
There are methods available to quantify the total mass of americium in environmental samples. Mass 
spectrometric methods provide total mass measurements of americium isotopes (Dacheux and Aupiais 
1997, 1998; Halverson 1984; Harvey et al. 1993); however, these detection methods have not gained the 
same popularity as is found for the radiochemical detection methods.  This may relate to the higher 
purchase price of an MS system, the increased knowledge required to operate the equipment, and the 



























7. ANALYTICAL METHODS 
which are commonly used to determine the total mass of uranium and curium in environmental samples, 
have limited utility to quantify americium, due to the low quantum yield of fluorescence for americium
(Thouvenot et al. 1993).  
Several rapid analysis techniques involving gamma spectroscopy or spectrometry have been developed 
that require either no or minimal sample preparation that can, under optimized conditions, provide the 
required selectivity and sensitivity to quantify americium in environmental samples, such as soils and 
sediments (Byrne and Komosa 1993; Cutshall et al. 1983; Guilmette 1986; Joshi 1989).  These techniques 
utilize either an intrinsic germanium detector or a phoswich-based cesium-sodium iodide low energy
photon detector that detects the gamma-rays emitted from 241Am in a neat (undiluted) or ashed 
environmental or biological sample.  On average, these methods have a minimum significant measurable 
activity (MSMA) of approximately 1 pCi/sample (0.037 Bq/sample).  To achieve this low MSMA, the 
counting efficiency of the detector must be standardized against the sample size and composition in order 
to assure the desired accuracy of the assay (Cutshall et al. 1983; Joshi 1989).  Using a germanium detector 
with its vastly superior energy resolution facilitates the identification of multiple isotopes in the same 
sample without photopeak interference.  It is the detector of choice for analyzing samples (and performing 
internal monitoring on individuals) by gamma spectroscopy.  The disadvantages of using germanium are 
its greater purchase price and requirement to be cooled with liquid nitrogen or by electrocryogenic means 
whenever it is in use. One limitation of the phoswich assays is the need to know the isotopic composition 
of the sample since the x-rays that accompany the decay of other radionuclides may also be counted by
the phoswich detector, which is typically calibrated with a wide energy window that focuses on the 59.5 
keV photon, but also detects higher energy x-rays and Compton scattered photons.
Several methods have been described in the Multi-Agency Radiation Survey and Site Investigation 
Manual (MARSSIM 2000) for the survey and investigation of sites contaminated with radioactive 
materials. At the high end of the survey instruments, costing over $1,000,000 in 1995, is an inductively
coupled plasma-mass spectrometer (ICP-MS) with a laser added to the front end to vaporize small 
portions of a surface or a volumetric material to be analyzed (laser ablation), thereby avoiding physical 
sample collection.  Prices in 2002 were a factor of two or three lower for an inductively coupled plasma
double focusing magnet mass spectrometer capable of very accurate americium isotopic measurements. 
The quantity of americium in soil, sediments, vegetation, and biota is determined using methods similar 
to those described above. For example, in a standardized method developed by DOE (1997b), soil 





















7. ANALYTICAL METHODS 
precipitation using calcium oxalate followed by co-precipitation with an Fe carrier.  A final purification of 
the sample is achieved by passing the sample through a series of anion exchange columns (e.g., HNO3, 
HCl, and NH4SCN), followed by electrodeposition of the americium (chloride form) onto a platinum disc 
in preparation for α-spectroscopy analysis. 
In another standardized method developed for the analysis of americium in soil (ASTM 1997), a different 
approach is taken towards purifying the dissolved soil sample that relies on a series of co-precipitations 
and solvent extractions to prepare the soil sample for α-spectroscopy analysis.  After the soil has been 
dissolved, the sample is initially purified by co-precipitation with barium sulfate, followed by solvent 
extraction of the redissolved precipitate with 15% HDEHP in n-hexane.  The extracted trivalent actinides 
and lanthanides are stripped from the organic phase using nitric acid containing sodium bromate.  The 
subsequent solution containing the trivalent actinides and lanthanides is extracted again with 15% 
HDEHP in n-hexane to remove plutonium, thorium, and tetravalent curium.  The aqueous phase is further 
purified through co-precipitation with a lanthanum carrier to isolate the rare earth fluorides followed by a 
treatment using silver nitrate and ammonium persulfate/ammonium fluoride to precipitate all remaining 
rare earth fluorides, except for hexavalent americium fluoride.  The hexavalent americium is reduced back 
to the trivalent state using hydrogen peroxide and then reprecipitated with a neodymium carrier in 
preparation for α-spectroscopy analysis.  Both the DOE and the American Society for Testing and 
Materials (ASTM) methods of analysis provide good precision (<6% standard derivation) with no 
statistically significant bias (at the 5% level) observed.  Analysis of americium in sediments, vegetation, 
and biota can also be performed using variations of the abovementioned methods or other methods, as 
exemplified in Table 7-2. 
The detection limits, accuracy, and precision of any analytical methodology, as well as the composition of 
the sample medium, are important parameters in determining the appropriateness of a method to quantify 
a specific analyte at the desired level of sensitivity within a particular matrix.  The lower limit of 
detection (LLD) has been adopted to refer to the intrinsic detection capability of a measurement 
procedure (sampling through data reduction and reporting) to aid in determining which method is best 
suited for the required sample quantification (NRC 1984).  Several factors influence the LLD, including
background counting rates, size or concentration of sample, detector sensitivity, recovery of desired 
analyte during sample isolation and purification, level of interfering contaminants, and, particularly, 
counting time.  Because of these variables, the LLDs between laboratories and for samples in the same 

























7. ANALYTICAL METHODS 
The accuracy of a measurement technique in determining the quantity of a particular analyte in 
environmental samples is greatly dependent on the reliability of the calibrating technique.  Thus, the 
availability of standard, certified radiation sources with known concentrations of americium are required 
in order to ensure the reliability of the calibration methods and the accuracy of americium measurements 
in environmental samples.  The primary source of certified americium standards is the NIST.  Standard 
solutions of 241Am (SRM 4322, 40 Bq/g [1.1 nCi/g]) and 243Am (SRM 4332, 40 Bq/g [1.1 nCi/g]) are 
available. Standard reference materials are also available from NIST and the International Atomic
Energy Agency (IAEA) for a number of environmental matrices; for example, soils and sediments (Rocky 
Flats Soil [SRM 4353], river sediment [SRM 4350B], and Peruvian soil [SRM 4355] and sediments 
[IAEA 367, IAEA 135]). 
7.3 ADEQUACY OF THE DATABASE
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the 
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether 
adequate information on the health effects of americium is available.  Where adequate information is not 
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the 
initiation of a program of research designed to determine the health effects (and techniques for developing 
methods to determine such health effects) of americium.  
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA. They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.  
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.    Analytical methods with 
satisfactory sensitivity and precision are available to determine the levels of americium in human tissues 






















7. ANALYTICAL METHODS 
Methods for Determining Parent Compounds and Degradation Products in Environmental 
Media. Analytical methods with the required sensitivity and accuracy are available for quantification 
of americium, both total and isotopic, in environmental matrices (see Table 7-2). 
Whether in the environment or in the human body, americium will undergo radioactive decay to form a 
series of radioactive nuclides that end in a stable isotope of lead (for 243Am) or bismuth (for 241Am) (see 
Chapter 4). The decay series proceeds slowly due to the long half-lives of some of the intermediate decay
series isotopes.  Therefore, more sensitive analytical methods for accurately measuring very low levels of 
these radionuclides would be useful. Practically speaking, since 239Pu (for 243Am) and 237Np (for 241Am) 
have such extremely long half-lives, 2.41x104 and 2.14x106 years, respectively, few decay products need 
to be considered since they would only begin to achieve measurable levels in the distant future. 
7.3.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2004) database did not list any current studies involving 
























8. REGULATIONS AND ADVISORIES 

The international, national, and state regulations and guidelines regarding americium in air, water, and 
other media are summarized in Table 8-1.   
The USNRC maintains a database of information regarding licensees authorized to possess americium
isotopes (241Am through 244Am) within the 18 non-Agreement States (states not committed to self-
regulation). This database includes more than 2,000 records of licensees and site possession limits in the 
microcurie to curie range. The isotope, 241Am, accounts for most of the licenses. Such records for 
USNRC Agreement States are maintained by the individual state radioactive material regulatory
organizations. The USNRC and EPA each have responsibilities for regulating the cleanup of
radioactivity and decommissioning of USNRC licensed sites.  USNRC and EPA reached an agreement in 
2002, in response to Congressional mandate, to preclude double regulation of these efforts.  The 
agreement provides that EPA will defer exercise of authority under CERCLA for the majority of facilities 
decommissioned under USNRC authority.  It also contains provisions for joint consultation when certain 
EPA parameters are exceeded, including groundwater exceeding EPA-permitted levels, USNRC 
contemplation of restricted release or alternate release criteria, and residual soil radioactivity
concentrations exceeding those in the agreement (USNRC 2002). 
No inhalation or oral MRLs were derived for americium or americium compounds. 
The EPA IRIS database has withdrawn its cancer classification for radionuclides, but the EPA Office of 
Air and Radiation believes that all radionuclides, including the americium isotopes, should be considered 
to be known carcinogens, and has assigned them to Group A.  Carcinogenic toxicity values for 241Am are
listed in EPA’s Federal Radiation Guidance Report No. 13 (EPA 2000a).  Lifetime excess total cancer 
risk per unit intake are included for inhalation (Table 2.1), drinking water ingestion (Table 2.2), and 
submersion, ground plane exposure, and soil intake (Table 2.3).  Media-specific usage rates (Table 3.1) 
provide a means of adjusting the values to be compatible with specific population groups (e.g., tap water 
intakes range from a low of 0.188 L/day for a newborn female to a high of 1.643 L/day for a 50-year-old 
male, with a societal average of 1.11 L/day).  The EPA has not derived reference concentrations (RfCs) or 
reference doses (RfDs) for americium (IRIS 2002), but has derived a maximum contaminant level (MCL) 
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8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Americium  







ACGIH Effective dose 
 Any single year 
Averaged over 5 years 
Annual equivalent dose to 
Lens of the eye 
Skin 
Hands and feet 
Embryo-fetus exposures once the 
pregnancy is known
Monthly equivalent dose 
Dose to the surface of women’s 
abdomen (lower trunk) 
Intake of radionuclide 
NIOSH REL (10-hour TWA) 
NATIONAL
Regulations: 







OSHA PEL (8-hour TWA) 
















 Gross alpha activity, less U, Rn 
c. 	Food 
FDA Derived intervention levela (DIL; 
Bq/kg food) for 241Am in accidentally-
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Agency 
Table 8-1. Regulations and Guidelines Applicable to Americium  
Description Information Reference 
NATIONAL (cont.) 
c. 	Food 
Sources of radiation used for 
inspection of food; sealed units 
producing radiation—241Am 
DOT Activity values for radionuclides in 
transport
241Am, 242Am, and 243Am 
A1 
A2 














Radioactive waste—release limits for 
containment requirementsb 
241Am or 243Am




 Carcinogenicity—slope factorsc 
















External exposure—risk/year per 
pCi/g in soil 
241Am 
243Am 
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8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Americium  
Agency Description 	 Information Reference 
NATIONAL (cont.)
USNRC Activity values for radionuclides in 
transport







Byproduct material for in vitro clinical
or laboratory testing—241Am 
Calibration or reference sources; 
shall not possess at any one time, at 
any one location of storage or use of 
241Am 
Exemption for low-level materials; 
contains only Americium in special 
form 
Export of byproduct material
General applicability to domestic 
licensing of byproduct material; 
quantity of licensed material requiring 
labeling 
241Am 
Ionizing radiation measuring 
instruments containing, for purposes 
of internal calibration or 
standardization, one or more sources 
of byproduct material; exempt
quantities of 241Am 





USNRC 	 Quantity of radioactive material
requiring need for an emergency plan 
for responding to a release—241Am,
242Am, and 243Am 
 Release fraction
 Quantity 
Standards for protection against 
radiation—quantity of licensed
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Agency 
Table 8-1. Regulations and Guidelines Applicable to Americium  
Description Information Reference 
STATEd 
a. Air 
















New Jersey Maximum permissible average 
concentrations in air 















New Jersey Maximum permissible average 

















Colorado Standards applicable to surface 
waters—241Am 
15 pCi/L 
Groundwater levels of radioactive 





































CO Dept of Public 
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8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Americium  
Agency Description 	 Information Reference 
STATE (cont.)
New Jersey Maximum permissible average 
concentrations in water 






Maximum permissible average 



















Standards for protection against 
radiation—241Am 
California 	 Ionizing radiation measuring 
instruments containing, for purposes 
of internal calibration or 
standardization, one or more source 
of radioactive material; 241Am is 
considered an exempt quantity 
Colorado	 Determination of A1and A2 for 
transportation 
241Am, 242mAm, and 243Am 
A1 
A2 
S 1x10-4 µCi/mL 
I 8x10-4 µCi/mL 
S 1x10-4 µCi/mL 
I 3x10-3 µCi/mL 
S 4x10-3 µCi/mL 
I 4x10-3 µCi/mL 
S 1x10-4 µCi/mL 
I 8x10-4 µCi/mL 
S 1x10-1 µCi/mL 
I 1x10-1 µCi/mL 
S 4x10-6 µCi/mL 
I 2x10-5 µCi/mL 
S 4x10-6 µCi/mL 
I 9x10-5 µCi/mL 
S 1x10-4 µCi/mL 
I 1x10-4 µCi/mL 
S 4x10-6 µCi/mL 
I 3x10-5 µCi/mL 
S 5x10-3 µCi/mL 































     
   
 



























8. REGULATIONS AND ADVISORIES 
Table 8-1. Regulations and Guidelines Applicable to Americium  
Agency Description Information Reference 
STATE (cont.)
Florida Quantity of radioactive material BNA 2001 
requiring need for an emergency plan 
for responding to a release 
241Am, 242Am, and 243Am 
Release fraction 0.001% 
Quantity 2 Ci 
Georgia Packages transported between Not to exceed 20 Ci BNA 2001 
locations within the U.S. which
contain only Am or Pu in special form 
with an aggregate radioactivity
Mississippi Packages transported between Not to exceed 20 Ci BNA 2001 
locations within the U.S. which
contain only Am or Pu in special form 
with an aggregate radioactivity
aThe FDA-recommended Derived Intervention Level (DIL) for radionuclides of 241Am, is defined as the DIL for the most 
sensitive age group (3 months) that was calculated from the most limiting Protective Action Goal (PAG; 50 mSv 
committed dose equivalent to the bone). 
bRelease limit per 1,000 metric tons of heavy metal (MTHM) or other unit of waste. 
cRadionuclide slope factors are calculated by EPA’s Office of Radiation and Indoor Air (ORIA) to assist HEAST users with
risk-related evaluations and decision-making at various stages of the remediation process.  Ingestion and inhalation slope 
factors are central estimates in a linear model of the age-averaged, lifetime attributable radiation cancer incidence (fatal
and nonfatal cancer) risk per unit of activity inhaled or ingested, expressed as risk/picocurie (pCi).  External exposure
slope factors are central estimates of the lifetime attributable radiation cancer incidence risk for each year of exposure to 
external radiation from photon-emitting radionuclides distributed uniformly in a thick layer of soil, and are expressed as 
risk/year per pCi/gram of soil. 
dThe states included in this section are only those that were available from the BNA database. 
ACGIH = American Conference of Governmental Industrial Hygienists; ALI = annual limits on intake; BNA = Bureau of 
National Affairs; CFR = Code of Federal Regulations; DAC = derived air concentration; DIL = Derived Intervention Level;
DOE = Department of Energy; DOT = Department of Transportation; EPA = Environmental Protection Agency;
FDA = Food and Drug Administration; I = insoluble; IARC = International Agency for Research on Cancer; 
mSv = millisievert; NIOSH = National Institute for Occupational Safety and Health; OSHA = Occupational Safety and 
Health Administration; PAG = protective action goal; PEL = permissible exposure limit; S = soluble; REL = recommended
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10.  GLOSSARY 
Some terms in this glossary are generic and may not be used in this profile. 
Absorbed Dose, Chemical—The amount of a substance that is either absorbed into the body or placed in 
contact with the skin. For oral or inhalation routes, this is normally the product of the intake quantity and 
the uptake fraction divided by the body weight and, if appropriate, the time, expressed as mg/kg for a 
single intake or mg/kg/day for multiple intakes.  For dermal exposure, this is the amount of material 
applied to the skin, and is normally divided by the body mass and expressed as mg/kg.   
Absorbed Dose, Radiation—The mean energy imparted to the irradiated medium, per unit mass, by
ionizing radiation.  Units: rad (rad), gray (Gy). 
Absorbed Fraction—A term used in internal dosimetry.  It is that fraction of the photon energy (emitted 
within a specified volume of material) which is absorbed by the volume.  The absorbed fraction depends 
on the source distribution, the photon energy, and the size, shape and composition of the volume. 
Absorption—The process by which a chemical penetrates the exchange boundaries of an organism after 
contact, or the process by which radiation imparts some or all of its energy to any material through which 
it passes. 
Absorption Coefficient—Fractional absorption of the energy of an unscattered beam of x- or gamma-
radiation per unit thickness (linear absorption coefficient), per unit mass (mass absorption coefficient), or 
per atom (atomic absorption coefficient) of absorber, due to transfer of energy to the absorber.  The total 
absorption coefficient is the sum of individual energy absorption processes (see Compton Effect, 
Photoelectric Effect, and Pair Production). 
Absorption Coefficient, Linear—A factor expressing the fraction of a beam of x- or gamma radiation 
absorbed in a unit thickness of material.  In the expression I=Ioe-µx, Io is the initial intensity, I the intensity
of the beam after passage through a thickness of the material x, and µ is the linear absorption coefficient. 
Absorption Coefficient, Mass—The linear absorption coefficient per cm divided by the density of the 
absorber in grams per cubic centimeter.  It is frequently expressed as µ/ρ, where µ is the linear absorption 
coefficient and ρ the absorber density.
Absorption Ratio, Differential—Ratio of concentration of a nuclide in a given organ or tissue to the 
concentration that would be obtained if the same administered quantity of this nuclide were uniformly
distributed throughout the body. 
Activation—The process of making a material radioactive by bombardment with neutrons or protons. 
Activity—The number of radioactive nuclear transformations occurring in a material per unit time (see 
Curie, Becquerel). The term for activity per unit mass is specific activity. 
Activity Median Aerodynamic Diameter (AMAD)—The diameter of a unit-density sphere with the 
same terminal settling velocity in air as that of the aerosol particle whose activity is the median for the 






























Acute Exposure, Chemical—Exposure to a chemical for a duration of 14 days or less, as specified in the 
Toxicological Profiles. 
Acute Exposure, Radiation—The absorption of a relatively large amount of radiation (or intake of a 
radioactive material) over a short period of time. 
Acute Radiation Syndrome—The symptoms which taken together characterize a person suffering from 
the effects of intense radiation.  The effects occur within hours or days. 
Ad libitum—Available in excess and freely accessible.  
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit surface area or 
per unit weight of organic carbon of a specific particle size in the soil or sediment to the concentration of 
the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—See Distribution Coefficient 
Alpha Particle—A positively charged particle ejected spontaneously from the nuclei of some radioactive 
elements.  It is identical to a helium nucleus, i.e., 2 neutrons and two protons, with a mass number of 4 
and an electrostatic charge of +2. 
Alpha Track—The track of ionized atoms (pattern of ionization) left in a medium by an alpha particle 
that has traveled through the medium. 
Annihilation (Positron-Electron)—An interaction between a positive and a negative electron in which 
they both disappear; their rest mass, being converted into electromagnetic radiation (called annihilation 
radiation) with two 0.51 MeV gamma photons emitted at an angle of 180E to each other. 
Annual Limit on Intake (ALI)—The derived limit for the amount of radioactive material taken into the 
body of an adult worker by inhalation or ingestion in a year.  It is the smaller value of intake of a given 
radionuclide in a year by the reference man that would result in a committed effective dose equivalent of 
5 rem or a committed dose equivalent of 50 rem to any organ or tissue. 
Atom—The smallest particle of an element that cannot be divided or broken up by chemical means.  It 
consists of a central core called the nucleus, which contains protons and neutrons and an outer shell of 
electrons. 
Atomic Mass (u)—The mass of a neutral atom of a nuclide, usually expressed in terms of "atomic mass 
units." The "atomic mass unit" is one-twelfth the mass of one neutral atom of carbon-12; equivalent to 
1.6604x10-24 g. 
Atomic Mass Number—See Mass Number. 
Atomic Number—The number of protons in the nucleus of an atom.  The "effective atomic number" is 
calculated from the composition and atomic numbers of a compound or mixture.  An element of this 
atomic number would interact with photons in the same way as the compound or mixture.  (Symbol: Z). 
Atomic Weight—The weighted mean of the masses of the neutral isotopes of an element expressed in 



































Attenuation—A process by which a beam from a source of radiation is reduced in intensity by
absorption and scattering when passing through some material. 
Attenuation Coefficient—The fractional reduction in the intensity of a beam of radiation as it passes 
through an absorbing medium.  It may be expressed as reduction per unit distance, per unit mass 
thickness, or per atom, and is called the linear, mass, or atomic attenuation coefficient, respectively. 
Auger Effect—The emission of an electron from the extranuclear portion of an excited atom when the 
atom undergoes a transition to a less excited state. 
Background Radiation—The amount of radiation to which a member of the general population is 
exposed from natural sources, such as terrestrial radiation from naturally occurring radionuclides in the 
soil, cosmic radiation originating from outer space, and naturally occurring radionuclides deposited in the 
human body.
Becquerel (Bq)—International System of Units unit of activity and equals that quantity of radioactive 
material in which one transformation (disintegration) occurs per second (see Units). 
 Terabecquerel (TBq)—One trillion becquerel. 
 Gigabecquerel (GBq)—One billion becquerel. 
 Megabecquerel (MBq)—One million becquerel. 
 Kilobecquerel (kBq))—One thousand becquerel.
 Millibecquerel (mBq)—One-thousandth of a becquerel. 
 Microbecquerel (µBq)—One-millionth of a becquerel. 
Beta Particle—An electron that is emitted from the nucleus of an atom during one type of radioactive 
transformation.  A beta particle has a mass and charge equal in magnitude to that of the electron.  The 
charge may be either +1 or -1.  Beta particles with +1 charges are called positrons (symbolized β+), and 
beta particles with -1 charges are called negatrons (symbolized β-). 
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms 
at a specific time or during a discrete time period of exposure divided by the concentration in the 
surrounding water at the same time or during the same period. 
Biologic Effectiveness of Radiation—See Relative Biological Effectiveness. 
Biological Half-time—The time required for a biological system, such as that of a human, to eliminate by 
natural process half of the amount of a substance (such as a chemical substance, either stable or 
radioactive) that has entered it. 
Biomagnification—The progressive increase in the concentration of a bioaccumulated chemical in 
organisms as that chemical is passed from the bottom to the top of the food web. 
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility. 
Body Burden, Chemical—The total amount of a chemical found in an animal or human body. 
Body Burden, Radioactivity—The amount of radioactive material found in an animal or human body. 



































Branching—The occurrence of two or more modes by which a radionuclide can undergo radioactive 
decay.  For example, 214Bi can undergo alpha or beta minus decay, 64Cu can undergo beta minus, beta 
plus, or electron capture decay.  An individual atom of a nuclide exhibiting branching disintegrates by one 
mode only. The fraction disintegrating by a particular mode is the "branching fraction" for that mode.  
The "branching ratio" is the ratio of two specified branching fractions (also called multiple 
disintegration). 
Bremsstrahlung—X rays that are produced when a charged particle accelerates (speeds up, slows down, 
or changes direction) in the strong field of a nucleus. 
Buildup Factor—The ratio of the radiation intensity, including both primary and scattered radiation, to
the intensity of the primary (unscattered) radiation. 
Cancer Effect Level (CEL)—The lowest dose of chemical or radiation in a study, or group of studies, 
that produces significant increases in the incidence of cancer (or tumors) between the exposed population 
and its appropriate control.
Capture, Electron—A mode of radioactive decay involving the capture of an orbital electron by its 
nucleus. Capture from a particular electron shell, e.g., K or L shells, is designated as "K-electron capture" 
or "L-electron capture." 
Capture, K-Electron—Electron capture from the K shell by the nucleus of the atom.  Also loosely used 
to designate any orbital electron capture process. 
Carcinogen—A chemical or radiation that is capable of inducing cancer. 
Carcinoma—Malignant neoplasm composed of epithelial cells, regardless of their derivation. 
Case-Control Study—A type of epidemiological study which examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without outcome. 
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest 
some potential topics for scientific research but are not actual research studies. 
Cataract—A clouding of the crystalline lens of the eye which obstructs the passage of light. 
Ceiling Value—A concentration of a substance that should not be exceeded, even temporarily. 
Charged Particle—A nuclear particle, atom, or molecule carrying a positive or negative charge. 
Chronic Exposure—A long-term, continuous exposure to a chemical or radioactive material.  For 
example, exposure to a chemical for 365 days or more, as specified in the Toxicological Profiles. 
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a 
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are 





























Collective Dose—The sum of the individual doses received in a given period of time by a specified 
population from exposure to a specified source of radiation.  Collective dose is expressed in units such as 
man-rem and person-sievert. 
Committed Dose Equivalent (HT,50)—The dose equivalent to organs or tissues of reference (T) that will 
be received from an intake of radioactive material by an individual during the 50 years following the 
intake. 
Committed Effective Dose Equivalent (HE,50)—The sum of the products of the weighting factors 
applicable to each of the body organs or tissues that are irradiated and the committed dose equivalent to 
those organs or tissues. 
Compton Effect—An attenuation process observed for x- or gamma radiation in which an incident 
photon interacts with an orbital electron of an atom to produce a recoil electron and a scattered photon 
whose energy is less than the incident photon. 
Containment—The confinement of a chemical or radioactive substance in such a way that it is prevented 
from being dispersed from its container or into the environment, or is released only at a specified rate. 
Contamination—Deposition of a stable or radioactive substance in any place where it is not desired. 
Cosmic Rays—High-energy particulate and electromagnetic radiations that originate outside the earth's 
atmosphere and interact with the atmosphere to produce a shower of secondary cosmic rays. 
Count (Radiation Measurements)—The external indication of a radiation-measuring device designed to 
enumerate ionizing events.  It refers to a single detected event.  The term “count rate” refers to the total 
number registered in a given period of time.  The term is sometimes erroneously used to designate a 
disintegration, ionizing event, or voltage pulse. 
Counter, Gas-flow Proportional (GPC)—An instrument for detecting beta particle radiation.  Beta 
particles are detected by ionization of the counter gas which results in an electrical impulse at an anode 
wire. 
Counter, Geiger-Mueller (GM counter)—Highly sensitive, gas-filled radiation-measuring device that 
detects (counts) individual photons or particulate radiation. 
Counter, Scintillation—The combination of a crystal or phosphor, photomultiplier tube, and associated 
circuits for counting light emissions produced in the phosphors by ionizing radiation.  Scintillation 
counters generally are more sensitive than GM counters for gamma radiation. 
Counting, Cerenkov—Relatively energetic β-particles pass through a transparent medium of high 
refractive index and a highly-directional, bluish-white light ("Cerenkov" light) is emitted.  This light is 
detected using liquid scintillation counting equipment.  
Cross-sectional Study—A type of epidemiological study of a group or groups which examines the 

































Curie (Ci)—A unit of radioactivity.  One curie equals that quantity of radioactive material in which there 
are 3.7x1010 nuclear transformations per second. The activity of 1 gram of radium is approximately 1 Ci. 
Attocurie (aCi)—One-thousandth of a femtocurie (3.7x10-8 disintegrations per second). 
 Femtocurie (fCi)—One-billionth of a microcurie (3.7x10-5 disintegrations per second).
 Megacurie (MCi)—One million curies (3.7x1016 disintegrations per second). 
 Microcurie (µCi)—One-millionth of a curie (3.7x104 disintegrations per second). 
 Millicurie (mCi)—One-thousandth of a curie (3.7x107 disintegrations per second). 
 Nanocurie (nCi)—One-billionth of a curie (3.7x101 disintegrations per second). 
 Picocurie (pCi)—One-millionth of a microcurie (3.7x10-2 disintegrations per second). 
Daughter Products—See Progeny and Decay Product 
Decay Chain or Decay Series—A sequence of radioactive decays (transformations) beginning with one 
nucleus. The initial nucleus, the parent, decays into a daughter or progeny nucleus that differs from the 
first by whatever particles were emitted during the decay.  If further decays take place, the subsequent 
nuclei are also usually called daughters or progeny.  Sometimes, to distinguish the sequence, the daughter 
of the first daughter is called the granddaughter, etc. 
Decay Constant (λ)—The fraction of the number of atoms of a radioactive nuclide which decay in unit 
time (see Disintegration Constant). 
Decay Product, Daughter Product, Progeny—A new nuclide formed as a result of radioactive decay.  
A nuclide resulting from the radioactive transformation of a radionuclide, formed either directly or as the 
result of successive transformations in a radioactive series.  A decay product (daughter product or 
progeny) may be either radioactive or stable. 
Decay, Radioactive—Transformation of the nucleus of an unstable nuclide by spontaneous emission of 
radiation, such as charged particles and/or photons (see Disintegration). 
Delta Ray—An electron removed from an atom of a medium that is irradiated, or through which 
radiation passes, during the process of ionization (also called secondary electron).  Delta rays cause a 
track of ionizations along their path. 
Derived Air Concentration (DAC)—The concentration of radioactive material in air that, if breathed by
the reference man for a working year of 2000 hours under conditions of light work (at a rate of 1.2 liters 
of air per hour), would result in an intake of one ALI (see Annual Limit on Intake). 
Deterministic Effect—A health effect, the severity of which varies with the dose and for which a 
threshold is believed to exist (also called a non-stochastic effect). 
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result 
from exposure to a chemical or radiation prior to conception (either parent), during prenatal development, 
or postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any
point in the life span of the organism. 
Disintegration Constant—Synonymous with decay constant.  The fraction of the number of atoms of a 




























Disintegration, Nuclear—A spontaneous nuclear transformation (radioactivity) characterized by the 
emission of energy and mass from the nucleus.  When large numbers of nuclei are involved, the process is 
characterized by a definite half-life (see Transformation, Nuclear). 
Distribution Coefficient (Kd)—Describes the distribution of a chemical between the solid and aqueous 
phase at thermodynamic equilibrium, is given as follows: 
[C]sKd = [C]w , Units = (L solution)/(kg solid),  
where [C]s is the concentration of the chemical associated with the solid phase in units of (mg)/(kg solid), 
and [C]w is the concentration of the chemical in the aqueous phase in units of (mg)/(L solution).  As the 
magnitude of Kd decreases, the potential mobility of the chemical to groundwater systems increases and 
vice versa. 
Dose—A general term denoting the quantity of a substance, radiation, or energy absorbed.  For special 
purposes it must be appropriately qualified.  If unqualified, it refers to radiation absorbed dose. 
Absorbed Dose—The energy imparted to matter by ionizing radiation per unit mass of irradiated 
material at the place of interest.  The unit of absorbed dose is the rad.  One rad equals 100 ergs 
per gram.  In SI units, the absorbed dose is the gray which is 1 J/kg (see Rad). 
Cumulative Dose (Radiation)—The total dose resulting from repeated or continuous exposures 
to radiation. 
Dose Assessment—An estimate of the radiation dose to an individual or a population group usually by
means of predictive modeling techniques, sometimes supplemented by the results of measurement. 
Dose Equivalent (DE)—A quantity used in radiation safety practice to account for the relative biological 
effectiveness of the several types of radiation.  It expresses all radiations on a common scale for 
calculating the effective absorbed dose.  The NRC defines it as the product of the absorbed dose, the 
quality factor, and all other modifying factors at the location of interest.  ICRP has changed its definition 
to be the product of the absorbed dose and the radiation weighting factor.  (The unit of dose equivalent is 
the rem.  In SI units, the dose equivalent is the sievert, which equals 100 rem.) 
Dose, Fractionation—A method of administering therapeutic radiation in which relatively small doses 
are given daily or at longer intervals. 
Dose, Protraction—A method of administering therapeutic radiation by delivering it continuously over a 
relatively long period at a low dose rate. 
Dose, Radiation—The amount of energy imparted to matter by ionizing radiation per unit mass of the 
matter, usually expressed as the unit rad, or in SI units, the gray.  100 rad'1 gray (Gy) (see Absorbed 
Dose). 
Committed Dose Equivalent (HT,50)—The dose equivalent to organs or tissues of reference (T) 
that will be received from an intake of radioactive material by an individual during the 50 years 




































Committed Effective Dose Equivalent (HE,50)—The sum of the products of the weighting 
factors applicable to each of the body organs or tissues that are irradiated and the committed dose 
equivalent to those organs or tissues. 
Effective Dose —A dose value that attempts to normalize the detriment to the body (for cancer 
mortality and morbidity, hereditary effects, and years of life lost) from a non-uniform exposure to 
that of a uniform whole body exposure.  Effective dose is calculated as the sum of products of the 
equivalent dose and the tissue weighting factor (wT) for each tissue exposed.  (E = ∑DT,R wR wT)). 
Effective Dose Equivalent (HE)—This dose type is limited to internal exposures and is the sum
of the products of the dose equivalent to the organ or tissue (HT) and the weighting factors (wT) 
applicable to each of the body organs or tissues that are irradiated.  (HE = ∑wT HT). 
Equivalent Dose—A dose quantity that places the biological effect of all radiation types on a 
common scale for calculating tissue damage.  Alpha particles, for example, are considered to 
cause 20 times more damage than gamma rays.  Equivalent dose is calculated as the sum of 
products of the average absorbed dose (in gray) in an organ or tissue (DT,R) from each type of 
radiation and the radiation weighting factor (wR) for that radiation (∑DT,R wR). 
External Dose—That portion of the dose equivalent received from radiation sources outside the 
body. 
Internal Dose—That portion of the dose equivalent received from radioactive material taken into 
the body. 
Limit—A permissible upper bound on the radiation dose. 
Maximum Permissible Dose (MPD)—The greatest dose equivalent that a person or specified 
part thereof shall be allowed to receive in a given period of time. 
Median Lethal Dose (MLD)—Dose of radiation required to kill, within a specified period 
(usually 30 days), 50% of the individuals in a large group of animals or organisms.  Also called 
the LD50, or LD50/30 if for 30 days. 
Threshold Dose—The minimum absorbed dose that will produce a detectable degree of any
given effect. 
Tissue Dose—Absorbed dose received by tissue in the region of interest, expressed in rad (see 
Dose, Gray, and Rad). 
Dose Rate—The amount of radiation dose delivered per unit time.  Generically, the rate at which 
radiation dose is delivered to any material or tissue. 
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a 
toxicant and the incidence of the adverse effects. 
Dosimetry—Quantification of radiation doses to cells, tissues, organs, individuals or populations 
resulting from radiation exposures. 






































Electron—A stable elementary particle having an electric charge equal to ±1.60210x10-19 C (Coulombs) 
and a rest mass equal to 9.1091x10-31 kg. A positron is a positively charged "electron" (see Positron). 
Electron Volt—A unit of energy equivalent to the energy gained by an electron in passing through a 
potential difference of one volt.  Larger multiple units of the electron volt are frequently used:  keV for 
thousand or kilo electron volts; MeV for million or mega electron volts (eV).  1 eV=1.6x10-12 erg. 
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to 
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurred. The terms, as used here, include malformations and variations, altered growth, and in
utero death. 
Energy—Capacity for doing work.  Gravitationally, "potential energy" is the energy inherent in a mass 
because of its spatial relation to other masses.  Chemically or radiologically, “potential energy” is the 
energy released when a chemical reaction or radiological transformation goes to completion.  "Kinetic 
energy" is the energy possessed by a mass because of its motion (SI unit: joules): 
Binding Energy (Electron)—The amount of energy that must be expended to remove an 
electron from an atom. 
Binding Energy (Nuclear)—The energy represented by the difference in mass between the sum
of the component parts and the actual mass of the nucleus.  It represents the amount of energy
that must be expended to break a nucleus into its component neutrons and protons. 
Excitation Energy—The energy required to change a system from its ground state to an excited 
state. Each different excited state has a different excitation energy. 
Ionizing Energy—The energy required to knock an electron out of an atom.  The average energy
lost by electrons or beta particles in producing an ion pair in air or in soft tissue is about 34 eV. 
Radiant Energy—The energy of electromagnetic radiation, such as radio waves, visible light, x 
and gamma rays. 
Enrichment, Isotopic—An isotopic separation process by which the relative abundances of the isotopes 
of a given element are altered, thus producing a form of the element that has been enriched in one or more 
isotopes and depleted in others.  In uranium enrichment, the percentage of uranium-235 in natural 
uranium can be increased from 0.7% to >90% in a gaseous diffusion process based on the different 
thermal velocities of the constituents of natural uranium (234U, 235U, 238U) in the molecular form UF6. 
EPA Health Advisory—An estimate of acceptable drinking water levels for a chemical substance based 
on health effects information. A health advisory is not a legally enforceable federal standard, but serves 
as technical guidance to assist federal, state, and local officials. 
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of 
disease or other health-related conditions within a defined human population during a specified period.   
Equilibrium, Radioactive—In a radioactive series, the state which prevails when the ratios between the 
activities of two or more successive members of the series remains constant. 
Secular Equilibrium—If a parent element has a very much longer half-life than the daughters 
































attain equilibrium) then, after equilibrium is reached, equal numbers of atoms of all members of 
the series disintegrate in unit time.  This condition is never exactly attained, but is essentially
established in such a case as 226Ra and its transformation series to stable 206Pb. The half-life of 
226Ra is about 1,600 years; of 222Rn, approximately 3.82 days, and of each of the subsequent 
members, a few minutes.  After about a month, essentially the equilibrium amount of radon is 
present; then (and for a long time) all members of the series disintegrate the same number of 
atoms per unit time.  At this time, the activity of the daughter is equal to the activity of the parent. 
Transient Equilibrium—If the half-life of the parent is short enough so the quantity present 
decreases appreciably during the period under consideration, but is still longer than that of 
successive members of the series, a stage of equilibrium will be reached after which all members 
of the series decrease in activity exponentially with the period of the parent.  At this time, the 
ratio of the parent activity to the daughter activity is constant. 
Equilibrium, Electron—The condition in a radiation field where the energy of the electrons entering a 
volume equals the energy of the electrons leaving that volume. 
Excitation—The addition of energy to a system, thereby transferring it from its ground state to an excited 
state. Excitation of a nucleus, an atom, or a molecule can result from absorption of photons or from
inelastic collisions with other particles.  The excited state of an atom is an unstable or metastable state and
will return to ground state by radiation of the excess energy. 
Exposure (Chemical)—Contact of an organism with a chemical or physical agent.  Exposure is 
quantified as the amount of the agent available at the exchange boundaries of the organism (e.g., skin, 
lungs, gut) and available for absorption. 
Exposure (Radiation)—Subjection to ionizing radiation or to a radioactive material.  For example, 
exposure in air is a measure of the ionization produced in air by x or gamma radiation; the sum of the 
electric charges on all ions of one sign produced in air when all electrons liberated by photons in a 
volume of air are completely stopped in air (dQ), divided by the mass of the air in the volume (dm). The 
unit of exposure in air is the roentgen, or coulomb per kilogram (SI units). One roentgen is equal to 
2.58x10-4 coulomb per kilogram (C/kg). 
Fission, Nuclear—A nuclear transformation characterized by the splitting of a nucleus into at least two 
other nuclei with emission of several neutrons, accompanied by the release of a relatively large amount of 
energy. 
Gamma Ray, Penetrating—Short wavelength electromagnetic radiation of nuclear origin. 
Genetic Effect of Radiation—Inheritable change, chiefly mutations, produced by the absorption of 
ionizing radiation by germ cells.  Genetic effects have not been observed in any human population 
exposed at any dose level. 
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of 
affected cells, can be expressed as a mutagenic, clastogenic or carcinogenic event because of specific 
alteration of the molecular structure of the genome. 
Gray (Gy)—SI unit of absorbed dose, 1 J/kg.  One gray equals 100 rad (see Units). 



































Half-life, Radioactive—Time required for a radioactive substance to lose 50% of its activity by decay.  
Each radio-nuclide has a unique physical half-life.  Known also as physical half-time and symbolized as 
Tr or Trad. 
Half-time, Biological—Time required for an organ, tissue, or the whole body to eliminate one-half of any 
absorbed substance by regular processes of elimination.  This is the same for both stable and radioactive 
isotopes of a particular element, and is sometimes referred to as half-time, symbolized as tbiol or Tb. 
Half-time, Effective—Time required for a radioactive element in an organ, tissue, or the whole body to 
be diminished 50% as a result of the combined action of radioactive decay and biological elimination, 
symbolized as Te or Teff. 
Biological half-time × Radioactive half-lifeEffective half-time = Biological half-time + Radioactive half-life 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or 
irreversible health effects. 
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals. 
Immunological Effects—Functional changes in the immune response. 
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.  Literally, “in 
glass.” 
In Vivo—Occurring within the living organism.  Literally, “in life.” 
Intensity—Amount of energy per unit time passing through a unit area perpendicular to the line of 
propagation at the point in question.
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles. 
Internal Conversion—Process in which a gamma ray knocks an electron out of the same atom from
which the gamma ray was emitted.  The ratio of the number of internal conversion electrons to the 
number of gamma quanta emitted in the de-excitation of the nucleus is called the "conversion ratio." 
Ion—Atomic particle, atom or chemical radical bearing a net electrical charge, either negative or positive. 
Ion Pair—Two particles of opposite charge, usually referring to the electron and positive atomic or 
molecular residue resulting after the interaction of ionizing radiation with the orbital electrons of atoms. 
Ionization—The process by which a neutral atom or molecule acquires a positive or negative charge. 
Primary Ionization—(1) In collision theory:  the ionization produced by the primary particles as 
contrasted to the "total ionization" which includes the "secondary ionization" produced by delta 







































Specific Ionization—Number of ion pairs per unit length of path of ionizing radiation in a 
medium; e.g., per centimeter of air or per micrometer of tissue.
Total Ionization—The total electric charge of one sign on the ions produced by radiation in the 
process of losing its kinetic energy. For a given gas, the total ionization is closely proportional to 
the initial ionization and is nearly independent of the nature of the ionizing radiation.  It is 
frequently used as a measure of absorption of radiation energy. 
Ionization Density—Number of ion pairs per unit volume. 
Ionization Path (Track)—The trail of ion pairs produced by an ionizing particle in its passage through 
matter. 
Ionizing Radiation—Any radiation capable of knocking electrons out of atoms and producing ions.  
Examples: alpha, beta, gamma and x rays, and neutrons. 
Isobars—Nuclides having the same mass number but different atomic numbers.
Isomers—Nuclides having the same number of neutrons and protons but capable of existing, for a 
measurable time, in different quantum states with different energies and radioactive properties.  
Commonly the isomer of higher energy decays to one with lower energy by the process of isomeric 
transition. 
Isotopes—Nuclides having the same number of protons in their nuclei, and hence the same atomic
number, but differing in the number of neutrons, and therefore in the mass number.  Identical chemical 
properties exist in isotopes of a particular element.  The term should not be used as a synonym for nuclide 
because isotopes refer specifically to different nuclei of the same element. 
 Stable Isotope—A nonradioactive isotope of an element. 
Joule—The S.I. unit for work and energy.  It is equal to the work done by raising a mass of one newton 
through a distance of one meter (J = Nm), which corresponds to about 0.7 ft-pound. 
Kerma (k)—A measure of the kinetic energy transferred from gamma rays or neutrons to a unit mass of 
absorbing medium in the initial collision between the radiation and the absorber atoms.  The SI unit is 
J/kg. The special name of this unit is the rad (traditional system of units) or Gray (SI). 
Labeled Compound—A compound containing one or more radioactive atoms intentionally added to its 
structure. By observations of radioactivity or isotopic composition, this compound or its fragments may
be followed through physical, chemical, or biological processes.
Late Effects (of radiation exposure)—Effects which appear 60 days or more following an acute 
exposure.
LD50/30—The dose of a chemical or radiation expected to cause 50% mortality in those exposed within 
30 days. For radiation, this is about 350 rad (3.5 gray) received by humans over a short period of time. 
Lethal Concentration(Lo) (LCLo)—The lowest concentration of a chemical in air that has been reported 




































Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for 
a specific length of time is expected to cause death in 50% of a defined experimental animal population 
within a specified time, usually 30 days. 
Lethal Dose(Lo) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that is 
expected to have caused death in humans or animals within a specified time, usually 30 days. 
Lethal Dose(50) (LD50)—The dose of a chemical which has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical 
is expected to cause death in 50% of a defined experimental animal population. 
Linear Energy Transfer (LET)—A measure of the energy that a charged particle transfers to a material 
per unit path length.  
Average LET—The energy of a charged particle divided by the length of the path over which it 
deposits all its energy in a material.  This is averaged over a number of particles. 
High-LET—Energy transfer characteristic of heavy charged particles such as protons and alpha 
particles where the distance between ionizing events is small on the scale of a cellular nucleus. 
Low-LET—Energy transfer characteristic of light charged particles such as electrons produced 
by x and gamma rays where the distance between ionizing events is large on the scale of a 
cellular nucleus. 
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest dose of chemical in a study, or group 
of studies, that produces statistically or biologically significant increases in frequency or severity of 
adverse effects between the exposed population and its appropriate control. 
Lung Clearance Class (fast, F; medium, M; slow, S)—A classification scheme for inhaled material 
according to its rate of clearance from the pulmonary region of the lungs to the blood and the 
gastrointestinal tract. 
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or 
function. 
Mass Numbers (A)—The number of nucleons (protons and neutrons) in the nucleus of an atom.
Minimal Risk Level—An estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse noncancerous effects over a specified duration of exposure. 
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population. 
Mutagen—A substance that causes changes (mutations) in the genetic material in a cell.  Mutations can 




































Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of 
death or pathological conditions. 
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
substance. 
Neutrino (ν)—A neutral particle of infinitesimally small rest mass emitted during beta plus or beta minus 
decay.  This particle accounts for conservation of energy in beta plus and beta minus decays.  It plays no 
role in damage from radiation. 
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a substance at which there were no 
statistically or biologically significant increases in frequency or severity of adverse effects seen between 
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not 
considered to be adverse. 
Nuclear Reactor—A power plant that heats the medium (typically water) by using the energy released 
from the nuclear fission of uranium or plutonium isotopes instead of burning coal, oil, or natural gas.  All 
of these sources of energy simply heat water and use the steam which is produced to turn turbines that 
make electricity or propel a ship. 
Nucleon—Common name for a constituent particle of the nucleus.  Applied to a proton or neutron. 
Nuclide—A species of atom characterized by the constitution of its nucleus.  The nuclear constitution is 
specified by the number of protons (Z), number of neutrons (N), and energy content; or, alternatively, by
the atomic number (Z), mass number A(N+Z), and atomic mass.  To be regarded as a distinct nuclide, the 
atom must be capable of existing for a measurable time.  Thus, nuclear isomers are separate nuclides, 
whereas promptly decaying excited nuclear states and unstable intermediates in nuclear reactions are not 
so considered. 
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical 
in n-octanol and water, in dilute solution. 
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) which represents the best estimate of relative risk (risk as a ratio of the 
incidence among subjects exposed to a particular risk factor divided by the incidence among subjects who 
were not exposed to the risk factor).  An odds ratio of greater than 1 is considered to indicate greater risk 
of disease in the exposed group compared to the unexposed. 
Pair Production—An absorption process for x- and gamma radiation in which the incident photon is 
absorbed in the vicinity of the nucleus of the absorbing atom, with subsequent production of an electron 
and positron pair (see annihilation).  This reaction can only occur for incident photon energies exceeding 
1.02 MeV. 
Parent—Any radionuclide nuclide which, upon disintegration, yields a new nuclide (termed the progeny
or daughter), either directly or as a later member of a radioactive series. 
Permissible Exposure Limit (PEL)—A maximum allowable atmospheric level of a substance in 
workplace air averaged over an 8-hour shift. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent 






























and physiologically-based.  A data-based model divides the animal system into a series of compartments 
which, in general, do not represent real, identifiable anatomic regions of the body whereas the 
physiologically-based model compartments represent real anatomic regions of the body.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate 
(disposition) of an exogenous substance in an organism. Utilizing computational techniques, it provides 
the means of studying the absorption, distribution, metabolism and excretion of chemicals by the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically-based dose-
response model which quantitatively describes the relationship between target tissue dose and toxic end 
points. These models advance the importance of physiologically based models in that they clearly 
describe the biological effect (response) produced by the system following exposure to an exogenous 
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—A model comprising a series of 
compartments representing organs or tissue groups with realistic weights and blood flows.  These models 
require a variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output,
alveolar ventilation rates and, possibly membrane permeabilities.  The models also utilize biochemical 
information such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also 
called biologically based tissue dosimetry models. 
Photoelectric Effect—An attenuation process observed for x and gamma radiation in which an incident 
photon interacts with a tightly bound inner orbital electron of an atom delivering all of its energy to knock
the electron out of the atom.  The incident photon disappears in the process. 
Photon—A quantum of electromagnetic energy (E) whose value is the product of its frequency (ν) in 
hertz and Planck's constant (h).  The equation is:  E = hν. 
Population dose—See Collective dose.
Positron—A positively charged electron. 
Potential, Ionization—The energy expressed as electron volts (eV) necessary to separate one electron 
from an atom, resulting in the formation of an ion pair. 
Power, Stopping—A measure of the ability of a material to absorb energy from an ionizing particle 
































Prefix—A modifier that allows units of measure to be expressed as submultiples or multiples of the 
primary unit (e.g., 10-3 curie is 1 mCi and 103 becquerels is 1 kBq). 
Factor Prefix Symbol Factor Prefix Symbol 
10-18 atto a 103 kilo k 
10-15 femto f 106 mega M 
10-12 pico p 109 giga G 
10-9 nano n 1012 tera T 
10-6 micro µ 1015 peta P 
10-3 milli m 1018 exa E 
10-2 centi c 
Progeny—The decay product or daughter products resulting after a radioactive decay or a series of 
radioactive decays.  The progeny can also be radioactive, and the chain continues until a stable nuclide is 
formed. 
Proton—Elementary nuclear particle with a positive electric charge equal numerically to the charge of 
the electron and a rest mass of 1.007 mass units. 
Quality—A term describing the distribution of the energy deposited by a particle along its track; 
radiations that produce different densities of ionization per unit intensity are said to have different 
"qualities."
Quality Factor (Q)—The linear-energy-transfer-dependent factor by which absorbed doses are 
multiplied to obtain (for radiation protection purposes) a quantity that expresses - on a common scale for 
all ionizing radiation - the approximate biological effectiveness of the absorbed dose. 
Type of radiation Quality factor 
X, gamma, or beta 1 
Alpha particles 20
Neutrons of unknown energy 10 
High energy protons 10 
Rad—The traditional unit of absorbed dose equal to 100 ergs per gram, or 0.01 joule per kilogram (0.01 
Gy)  in any medium (see Absorbed Dose). 
Radiation—The emission and propagation of energy through space or through a material medium in the 
form of waves (e.g., the emission and propagation of electromagnetic waves, or of sound and elastic 
waves). The term radiation or radiant energy, when unqualified, usually refers to electromagnetic 
radiation. Such radiation commonly is classified according to frequency, as microwaves, infrared, visible 
(light), ultraviolet, and x and gamma rays (see Photon.) and, by extension, corpuscular emission, such as 
alpha and beta radiation, neutrons, or rays of mixed or unknown type, as cosmic radiation. 
Radiation, Annihilation—Photons produced when an electron and a positron unite and cease to 
exist. The annihilation of a positron-electron pair results in the production of two photons, each 
of 0.51 MeV energy. 



































Radiation, Characteristic (Discrete)—Radiation originating from an excited atom after removal 
of an electron from an atom.  The wavelength of the emitted radiation is specific, depending only
on the element and particular energy levels involved. 
Radiation, External—Radiation from a source outside the body. 
Radiation, Internal—Radiation from a source within the body (as a result of deposition of 
radionuclides in body tissues). 
Radiation, Ionizing—Any electromagnetic or particulate radiation capable of producing ions, 
directly or indirectly, in its passage through matter (see Radiation). 
Radiation, Monoenergetic—Radiation of a given type in which all particles or photons originate 
with and have the same energy. 
Radiation, Scattered—Radiation which during its passage through a substance, has been 
deviated in direction. It may also have been modified by a decrease in energy. 
Radiation, Secondary—A particle or ray that is produced when the primary radiation interacts 
with a material, and which has sufficient energy to produce its own ionization, such as 
bremsstrahlung or electrons knocked from atomic orbitals with enough energy to then produce 
ionization (see Delta Rays). 
Radiation Weighting Factor (also called Quality Factor)—In radiation protection, a factor (1 for x-
rays, gamma rays, beta particles; 20 for alpha particles) weighting the absorbed dose of radiation of a 
specific type and energy for its effect on tissue. 
Radioactive Material—Material containing radioactive atoms. 
Radioactivity—Spontaneous nuclear transformations that result in the formation of new elements.  These 
transformations are accomplished by emission of alpha or beta particles from the nucleus or by the 
capture of an orbital electron. Each of these reactions may or may not be accompanied by a gamma 
photon. 
Radioactivity, Artificial—Man-made radioactivity produced by particle bombardment or 
nuclear fission, as opposed to naturally occurring radioactivity.
Radioactivity, Induced—Radioactivity produced in a substance after bombardment with 
neutrons or other particles.  The resulting activity is "natural radioactivity" if formed by nuclear 
reactions occurring in nature and "artificial radioactivity" if the reactions are caused by man. 
Radioactivity, Natural—The property of radioactivity exhibited by more than 50 naturally
occurring radionuclides. 
Radioisotope—An unstable or radioactive isotope of an element that decays or disintegrates 
spontaneously, emitting radiation.   
Radionuclide—Any radioactive isotope of any element.  Approximately 5,000 natural and artificial 
































Radiosensitivity—Relative susceptibility of cells, tissues, organs, organisms, or any living substance to 
the injurious action of radiation.  Radiosensitivity and its antonym, radioresistance, are used 
comparatively, rather than absolutely. 
Reference Dose (RfD)—An estimate of the daily exposure of the human population to a potential hazard 
that is likely to be without risk of deleterious effects during a lifetime.  The RfD is operationally derived 
from the NOAEL (from animal and human studies) by a consistent application of uncertainty factors that 
reflect various types of data used to estimate RfDs and an additional modifying factor, which is based on 
a professional judgment of the entire database on the chemical.  The RfDs are not applicable to non-
threshold effects such as cancer. 
Relative Biological Effectiveness (RBE)—The RBE is a factor used to compare the biological 
effectiveness of absorbed radiation doses (i.e., rad) due to different types of ionizing radiation.  More 
specifically, it is the experimentally determined ratio of an absorbed dose of a radiation in question to the 
absorbed dose of a reference radiation (typically 60Co gamma rays or 200 kVp x rays) required to produce 
an identical biological effect in a particular experimental organism or tissue (see Quality Factor). 
Rem—The traditional unit of dose equivalent that is used in the regulatory, administrative, and 
engineering design aspects of radiation safety practice.  The dose equivalent in rem is numerically equal 
to the absorbed dose in rad multiplied by the quality factor (1 rem is equal to 0.01 sievert). 
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under 
CERCLA. Reportable quantities are (1) 1 pound or greater or (2) for selected substances, an amount 
established by regulation either under CERCLA or under Sect. 311 of the Clean Water Act.  Quantities 
are measured over a 24-hour period. 
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result 
from exposure to a chemical.  The toxicity may be directed to the reproductive organs and/or the related 
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of 
this system. 
Roentgen (R)—A unit of exposure (in air) to ionizing radiation.  It is the amount of x or gamma rays
required to produce ions carrying 1 electrostatic unit of electrical charge in 1 cubic centimeter of dry air 
under standard conditions.  Named after William Roentgen, a German scientist who discovered x rays in 
1895. 
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is 
undertaken. Retrospective studies are limited to causal factors that can be ascertained from existing 
records and/or examining survivors of the cohort. 
Self-Absorption—Absorption of radiation (emitted by radioactive atoms) by the material in which the 
atoms are located; in particular, the absorption of radiation within a sample being assayed. 
Short-Term Exposure Limit (STEL)—The maximum concentration to which workers can be exposed 
for up to 15 minutes continually.  No more than four excursions are allowed per day, and there must be at 
































SI Units—The International System of Units as defined by the General Conference of Weights and 
Measures in 1960. These units are generally based on the meter/kilogram/second units, with special 
quantities for radiation including the becquerel, gray, and sievert. 
Sickness, Acute Radiation (Syndrome)—The complex symptoms and signs characterizing the condition 
resulting from excessive exposure of the whole body (or large part) to ionizing radiation.  The earliest of 
these symptoms are nausea, fatigue, vomiting, and diarrhea, and may be followed by loss of hair 
(epilation), hemorrhage, inflammation of the mouth and throat, and general loss of energy.  In severe 
cases, where the radiation dose is relatively high (over several hundred rad or several gray), death may
occur within two to four weeks.  Those who survive six weeks after exposure of a single high dose of 
radiation may generally be expected to recover. 
Sievert (Sv)—The SI unit of any of the quantities expressed as dose equivalent. The dose equivalent in 
sieverts is equal to the absorbed dose, in gray, multiplied by the quality factor (1 sievert equals 100 rem).  
The sievert is also the SI unit for effective dose equivalent, which is the sum of the products of the dose 
equivalent to each organ or tissue and its corresponding tissue weighting factor. 
Specific-Activity—Radioactivity per unit mass of a radionuclide, expressed, for example, as Ci/gram or 
Bq/kilogram.
Specific Energy—The actual energy per unit mass deposited per unit volume in a small target, such as 
the cell or cell nucleus, as the result of one or more energy-depositing events.  This is a stochastic 
quantity as opposed to the average value over a large number of instance (i.e., the absorbed dose). 
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population. 
Stochastic Effect—A health effect that occurs randomly and for which the probability of the effect 
occurring, rather than its severity, is assumed to be a linear function of dose without a threshold (also 
called a nondeterministic effect). 
Stopping Power—The average rate of energy loss of a charged particle per unit thickness of a material or 
per unit mass of material traversed. 
Surface-seeking Radionuclide—A bone-seeking internal emitter that deposits and remains on the bone 
surface for a long period of time, although it may eventually diffuse into the bone mineral.  This contrasts 
with a volume seeker, which deposits more uniformly throughout the bone volume. 
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical. 
Target Theory (Hit Theory)—A theory explaining some biological effects of radiation on the basis that 
ionization, occurring in a discrete volume (the target) within the cell, directly causes a lesion which 
subsequently results in a physiological response to the damage at that location.  One, two, or more "hits" 
(ionizing events within the target) may be necessary to elicit the response. 

































Threshold Limit Value (TLV)—The maximum concentration of a substance to which most workers can 
be exposed without adverse effect.  TLV is a term used exclusively by the ACGIH.  Other terms used to 
express similar concepts are the MAC (Maximum Allowable Concentration) and PEL (Permissible 
Exposure Limits). 
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour 
workday or 40-hour workweek. 
Tissue Weighting Factor (Wt)—Organ- or tissue-specific factor by which the equivalent dose is 
multiplied to give the portion of the effective dose for that organ or tissue.  Recommended values of 
tissue weighting factors are: 
Tissue Weighting Factors for Calculating Effective Dose  

Equivalent and Effective Dose for Selected Tissues
 
Tissue weighting factor 
Tissue NCRP115/ICRP60 USNRC/ICRP26 
Bladder 0.05 – 
Bone marrow 0.12 0.12 
Bone surface 0.01 0.03 
Breast 0.05 0.15 
Colon 0.12 – 
Esophagus 0.05 – 
Gonads 0.20 0.25 
Liver 0.05 – 
Lung 0.12 0.12 
Skin 0.01 – 
Stomach 0.12 – 
Thyroid 0.05 0.03 
Remainder 0.05 0.30 
Total 1.00 1.00 
ICRP60 = International Commission on Radiological Protection, 1990 Recommendations of the ICRP  

NCRP115 = National Council on Radiation Protection and Measurements. 1993. Risk Estimates for Radiation Protection, 

Report 115.  Bethesda, Maryland
 
USNRC = Nuclear Regulatory Commission, Title 10, Code of Federal Regulations, Part 20 

Toxic Dose (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, which 
is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution and elimination of toxic compounds in the living organism. 
Toxicosis—A diseased condition resulting from poisoning.
Transformation, Nuclear—The process of radioactive decay by which a nuclide is transformed into a 
different nuclide by absorbing or emitting particulate or electromagnetic radiation. 
Transition, Isomeric—The process by which a nuclide decays to an isomeric nuclide (i.e., one of the 
same mass number and atomic number) of lower quantum energy.  Isomeric transitions (often abbreviated 








































Tritium—The hydrogen isotope with one proton and two neutrons in the nucleus (Symbol: 3H).  It is 
radioactive and has a physical half-life of 12.3 years. 
Unattached Fraction—That fraction of the radon daughters, usually 218Po and 214Po, which has not yet 
attached to a dust particle or to water vapor. As a free atom, it has a high probability of being exhaled and 
not retained within the lung.  It is the attached fraction which is primarily retained. 
Uncertainty Factor (UF)—A factor used in operationally deriving the RfD from experimental data.  UFs 
are intended to account for (1) the variation in sensitivity among the members of the human population,
(2) the uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating 
from data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using 
LOAEL data rather than NOAEL data.  Usually each of these factors is set equal to 10. 
Units, Prefixes—Many units of measure are expressed as submultiples or multiples of the primary unit 
(e.g., 10-3 curie is 1 mCi and 103 becquerel is 1 kBq). 
Factor Prefix Symbol Factor Prefix Symbol 
10-18 atto A 103 kilo k
10-15 femto F 106 mega M 
10-12 pico p 109 giga G 
10-9 nano N 1012 tera T 
10-6 micro Μ 1015 peta P 
10-3 milli M 1018 exa E 
10-2 centi C 
Units, Radiological—
Units Equivalents 
Becquerel* (Bq) 1 disintegration per second = 2.7x10-11 Ci
Curie (Ci) 3.7x1010 disintegrations per second = 3.7x1010 Bq 
Gray* (Gy) 1 J/kg = 100 rad 
Rad (rad) 100 erg/g = 0.01 Gy
Rem (rem) 0.01 sievert 
Sievert* (Sv) 100 rem
*International Units, designated (SI) 
Working Level (WL)—Any combination of short-lived radon daughters in 1 liter of air that will result in 
the ultimate emission of 1.3x105 MeV of potential alpha energy. 
Working Level Month (WLM)—A unit of exposure to radon daughters corresponding to the product of 
the radon daughter concentration in Working Level (WL) and the exposure time in nominal months 
(1 nominal month = 170 hours).  Inhalation of air with a concentration of 1 WL of radon daughters for 
170 working hours results in an exposure of 1 WLM.
X rays—Penetrating electromagnetic radiations whose wave lengths are very much shorter than those of 

















vacuum.  X rays (called characteristic x rays) are also produced when an orbital electron falls from a high 
energy level to a low energy level. 
Zero-Threshold Linear Hypothesis (or No-Threshold Linear Hypothesis)—The assumption that a 
dose-response curve derived from data in the high dose and high dose-rate ranges may be extrapolated 
through the low dose and low dose range to zero, implying that, theoretically, any amount of radiation 






















APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS 
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological 
information and epidemiologic evaluations of a hazardous substance.  During the development of 
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to 
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure. An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration 
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of 
cancer effects.  These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of 
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or 
action levels. 
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor 
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects.  MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method 
suitable for this route of exposure. MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level 

















MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that 
are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of 
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants, 
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR 
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention. Although human data are preferred, MRLs often must be based on animal studies 
because relevant human studies are lacking.  In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive.  Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals. 
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the 
Division of Toxicology, expert panel peer reviews, and agency-wide MRL Workgroup reviews, with 
participation from other federal agencies and comments from the public.  They are subject to change as 
new information becomes available concomitant with updating the toxicological profiles.  Thus, MRLs in 
the most recent toxicological profiles supersede previously published levels.  For additional information 
regarding MRLs, please contact the Division of Toxicology, Agency for Toxic Substances and Disease 





































APPENDIX B.  USER'S GUIDE 
Chapter 1 
Public Health Statement 
This chapter of the profile is a health effects summary written in non-technical language.  Its intended 
audience is the general public, especially people living in the vicinity of a hazardous waste site or 
chemical release.  If the Public Health Statement were removed from the rest of the document, it would 
still communicate to the lay public essential information about the chemical. 
The major headings in the Public Health Statement are useful to find specific topics of concern.  The 
topics are written in a question and answer format.  The answer to each question includes a sentence that 
will direct the reader to chapters in the profile that will provide more information on the given topic. 
Chapter 2 
Relevance to Public Health 
This chapter provides a health effects summary based on evaluations of existing toxicologic, 
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight­
of-evidence discussions for human health end points by addressing the following questions. 
1. What effects are known to occur in humans? 
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous 
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects 
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter. 
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using 
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer 
potency or perform cancer risk assessments.  Minimal Risk Levels (MRLs) for noncancer end points (if 
derived) and the end points from which they were derived are indicated and discussed. 
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section. 
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral 


























meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans. 
MRLs should help physicians and public health officials determine the safety of a community living near 
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational 
exposure. 
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.10, "Interactions with Other Substances,” and Section 3.11, "Populations that are 
Unusually Susceptible" provide important supplemental information. 
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a 
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA) 
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.   
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR 
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable 
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect 
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor 
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used 




Tables and Figures for Levels of Significant Exposure (LSE) 
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects.  These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end 
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in
10,000 to 1 in 10,000,000. Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in 
conjunction with the text.  All entries in these tables and figures represent studies that provide reliable, 
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs). 
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends 
































See Sample LSE Table 3-1 (page B-6)
(1) 	 Route of Exposure. One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure.  Typically
when sufficient data exists, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Table 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation 
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each 
route of exposure and will not, therefore, have all five of the tables and figures. 
(2) 	Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.  
In this example, an inhalation study of intermediate exposure duration is reported.  For quick 
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure. 
(3) 	Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.  
Systemic effects are further defined in the "System" column of the LSE table (see key number 
18). 
(4) 	 Key to Figure. Each key number in the LSE table links study information to one or more data 
points using the same key number in the corresponding LSE figure.  In this example, the study 
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL 
(also see the two "18r" data points in sample Figure 3-1). 
(5) 	Species. The test species, whether animal or human, are identified in this column.  Chapter 2, 
"Relevance to Public Health," covers the relevance of animal data to human toxicity and 
Section 3.5, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent 
human doses to derive an MRL. 
(6) 	Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure 
regimen are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies. In this case (key number 18), rats were exposed to “Chemical x” via inhalation 
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al. 
1981). 
(7) 	System. This column further defines the systemic effects.  These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular.  "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered 
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated. 
(8) NOAEL. A NOAEL is the highest exposure level at which no harmful effects were seen in the 


































which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").
(9) 	LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect. 
LOAELs have been classified into "Less Serious" and "Serious" effects.  These distinctions help 
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL.  The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs. 
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile. 
(11)	 CEL. A CEL is the lowest exposure level associated with the onset of carcinogenesis in 
experimental or epidemiologic studies.  CELs are always considered serious effects.  The LSE 
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing 
measurable cancer increases. 
(12)	 Footnotes. Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm. 
LEGEND 
See Sample Figure 3-1 (page B-7) 
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the 
reader quickly compare health effects according to exposure concentrations for particular exposure 
periods. 
(13) Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated. 
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 

exists. The same health effects appear in the LSE table. 

(15) Levels of Exposure. Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day. 
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the Table) to the MRL of 
0.005 ppm (see footnote "b" in the LSE table). 
(17)	 CEL. Key number 38r is one of three studies for which CELs were derived.  The diamond 




















(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the 
cancer dose response curve at low dose levels (q1*). 
(19) Key to LSE Figure. The Key explains the abbreviations and symbols used in the figure. 
 
 














































































→	 TABLE 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect) 
Exposure Less serious (ppm) Serious (ppm)frequency/ NOAEL 
















































Nitschke et al. 1981 
Wong et al. 1982 
NTP 1982 
NTP 1982 
(CEL, multiple organs) 
(CEL, lung tumors, nasal 
tumors) 
(CEL, lung tumors, 
hemangiosarcomas) 
12 →	 a The number corresponds to entries in Figure 3-1. 
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of  5x10-3 ppm; dose adjusted for intermittent exposure and divided 






















































APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 
Some terms are generic and may not be used in this profile. 
ACGIH American Conference of Governmental Industrial Hygienists 
ACOEM American College of Occupational and Environmental Medicine 
ADI acceptable daily intake 
ADME absorption, distribution, metabolism, and excretion 
AED atomic emission detection 
AFID alkali flame ionization detector 
AFOSH Air Force Office of Safety and Health 
ALI annual limit on intake 
ALT alanine aminotransferase
AML acute myeloid leukemia 
AOAC Association of Official Analytical Chemists 
AOEC Association of Occupational and Environmental Clinics 
AP alkaline phosphatase 
APHA American Public Health Association 
AST aspartate aminotransferase
atm atmosphere 
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria 
BAT best available technology 
BCF bioconcentration factor 
BEI Biological Exposure Index
BMD benchmark dose 
BMR benchmark response 
BSC Board of Scientific Counselors 
C centigrade 
CAA Clean Air Act 
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention 
CEL cancer effect level 
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act 
CFR Code of Federal Regulations 
Ci curie 
CI confidence interval 
CL ceiling limit value 
CLP Contract Laboratory Program
cm centimeter 
CML chronic myeloid leukemia 
CPSC Consumer Products Safety Commission 
CWA Clean Water Act 
DAC derived air concentration 
DHEW Department of Health, Education, and Welfare 






































DNA deoxyribonucleic acid 
DOD Department of Defense 
DOE Department of Energy
DOL Department of Labor 
DOT Department of Transportation 
DOT/UN/ Department of Transportation/United Nations/ 
NA/IMCO     North America/International Maritime Dangerous Goods Code 
DWEL drinking water exposure level 
ECD electron capture detection 
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level 
EPA Environmental Protection Agency
F Fahrenheit 
F1 first-filial generation 
FAO Food and Agricultural Organization of the United Nations 
FDA Food and Drug Administration 
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act 
FPD flame photometric detection 
fpm feet per minute 
FR Federal Register 




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank  
IARC International Agency for Research on Cancer 
IDLH immediately dangerous to life and health 
ILO International Labor Organization 
IRIS Integrated Risk Information System
Kd adsorption ratio 
kg kilogram
kkg metric ton 
Koc organic carbon partition coefficient 
Kow octanol-water partition coefficient 
L liter 
LC liquid chromatography
LC50 lethal concentration, 50% kill 
LCLo lethal concentration, low 
LD50 lethal dose, 50% kill 
LDLo lethal dose, low 
LDH lactic dehydrogenase 
LH luteinizing hormone 
LOAEL lowest-observed-adverse-effect level 
LSE Levels of Significant Exposure 































MA trans,trans-muconic acid 
MAL maximum allowable level 
mCi millicurie 
MCL maximum contaminant level 
MCLG maximum contaminant level goal 
MF modifying factor 




mmHg millimeters of mercury
mmol millimole 
mppcf millions of particles per cubic foot 
MRL Minimal Risk Level 
MS mass spectrometry
NAAQS National Ambient Air Quality Standard 
NAS National Academy of Science 
NATICH National Air Toxics Information Clearinghouse 
NATO North Atlantic Treaty Organization 
NCE normochromatic erythrocytes 
NCEH National Center for Environmental Health 
NCI National Cancer Institute 
ND not detected 
NFPA National Fire Protection Association 
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences 
NIOSH National Institute for Occupational Safety and Health 
NIOSHTIC NIOSH's Computerized Information Retrieval System 
NLM National Library of Medicine 
nm nanometer 
nmol nanomole 
NOAEL no-observed-adverse-effect level 
NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List 
NR not reported 
NRC National Research Council 
NS not specified 
NSPS New Source Performance Standards 
NTIS National Technical Information Service 
NTP National Toxicology Program
ODW Office of Drinking Water, EPA 
OERR Office of Emergency and Remedial Response, EPA 
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA 
OPPT Office of Pollution Prevention and Toxics, EPA 































OR odds ratio 
OSHA Occupational Safety and Health Administration 
OSW Office of Solid Waste, EPA 
OTS Office of Toxic Substances 
OW Office of Water 
OWRS Office of Water Regulations and Standards, EPA 
PAH polycyclic aromatic hydrocarbon 
PBPD physiologically based pharmacodynamic  
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit 
pg picogram
PHS Public Health Service 
PID photo ionization detector 
pmol picomole 
PMR proportionate mortality ratio 
ppb parts per billion 
ppm parts per million 
ppt parts per trillion 
PSNS pretreatment standards for new sources 
RBC red blood cell 
REL recommended exposure level/limit 
RfC reference concentration 
RfD reference dose 
RNA ribonucleic acid 
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances 
SARA Superfund Amendments and Reauthorization Act 
SCE sister chromatid exchange 
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase 
SIC standard industrial classification 
SIM selected ion monitoring 
SMCL secondary maximum contaminant level 
SMR standardized mortality ratio 
SNARL suggested no adverse response level 
SPEGL Short-Term Public Emergency Guidance Level 
STEL short term exposure limit 
STORET Storage and Retrieval 
TD50 toxic dose, 50% specific toxic effect 
TLV threshold limit value 
TOC total organic carbon 
TPQ threshold planning quantity
TRI Toxics Release Inventory
TSCA Toxic Substances Control Act 
TWA time-weighted average 
UF uncertainty factor 
U.S. United States
USDA United States Department of Agriculture 
USGS United States Geological Survey






































volatile organic compound 
white blood cell 
World Health Organization 
greater than 
greater than or equal to 
equal to 
less than 








cancer slope factor 
negative 
positive 
weakly positive result 









































APPENDIX D.  OVERVIEW OF BASIC RADIATION PHYSICS, CHEMISTRY, 
AND BIOLOGY 
Understanding the basic concepts in radiation physics, chemistry, and biology is important to the 
evaluation and interpretation of radiation-induced adverse health effects and to the derivation of radiation 
protection principles. This appendix presents a brief overview of the areas of radiation physics,
chemistry, and biology and is based to a large extent on the reviews of Mettler and Moseley (1985), 
Hobbs and McClellan (1986), Eichholz (1982), Hendee (1973), Cember (1996), and Early et al. (1979). 
D.1 RADIONUCLIDES AND RADIOACTIVITY 
The substances we call elements are composed of atoms.  Atoms in turn are made up of neutrons, protons 
and electrons: neutrons and protons in the nucleus and electrons in a cloud of orbits around the nucleus.  
Nuclide is the general term referring to any nucleus along with its orbital electrons.  The nuclide is 
characterized by the composition of its nucleus and hence by the number of protons and neutrons in the 
nucleus. All atoms of an element have the same number of protons (this is given by the atomic number) 
but may have different numbers of neutrons (this is reflected by the atomic mass numbers or atomic 
weight of the element).  Atoms with different atomic mass but the same atomic numbers are referred to as 
isotopes of an element. 
The numerical combination of protons and neutrons in most nuclides is such that the nucleus is quantum
mechanically stable and the atom is said to be stable, i.e., not radioactive; however, if there are too few or 
too many neutrons, the nucleus is unstable and the atom is said to be radioactive.  Unstable nuclides 
undergo radioactive transformation, a process in which a neutron or proton converts into the other and a 
beta particle is emitted, or else an alpha particle is emitted.  Each type of decay is typically accompanied 
by the emission of gamma rays.  These unstable atoms are called radionuclides; their emissions are called 
ionizing radiation; and the whole property is called radioactivity.  Transformation or decay results in the 
formation of new nuclides some of which may themselves be radionuclides, while others are stable 
nuclides. This series of transformations is called the decay chain of the radionuclide.  The first 
radionuclide in the chain is called the parent; the subsequent products of the transformation are called 
progeny, daughters, or decay products. 
In general there are two classifications of radioactivity and radionuclides:  natural and artificial (man­
made). Naturally-occurring radioactive materials (NORMs) exist in nature and no additional energy is 
necessary to place them in an unstable state.  Natural radioactivity is the property of some naturally
occurring, usually heavy elements, that are heavier than lead.  Radionuclides, such as radium and 
uranium, primarily emit alpha particles.  Some lighter elements such as carbon-14 and tritium (hydrogen­
3) primarily emit beta particles as they transform to a more stable atom.  Natural radioactive atoms 
heavier than lead cannot attain a stable nucleus heavier than lead.  Everyone is exposed to background 
radiation from naturally-occurring radionuclides throughout life.  This background radiation is the major 
source of radiation exposure to man and arises from several sources.  The natural background exposures 
are frequently used as a standard of comparison for exposures to various artificial sources of ionizing 
radiation. 
Artificial radioactive atoms are produced either as a by-product of fission of uranium or plutonium atoms 
in a nuclear reactor or by bombarding stable atoms with particles, such as neutrons or protons, directed at 
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emission of particles, such as positive or negative beta particles and one or more high energy photons 
(gamma rays).  Unstable (radioactive) atoms of any element can be produced. 
Both naturally occurring and artificial radioisotopes find application in medicine, industrial products, and 
consumer products. Some specific radioisotopes, called fall-out, are still found in the environment as a 
result of nuclear weapons use or testing.
D.2 RADIOACTIVE DECAY
D.2.1 Principles of Radioactive Decay
The stability of an atom is the result of the balance of the forces of the various components of the nucleus.  
An atom that is unstable (radionuclide) will release energy (decay) in various ways and transform to 
stable atoms or to other radioactive species called daughters, often with the release of ionizing radiation.  
If there are either too many or too few neutrons for a given number of protons, the resulting nucleus may
undergo transformation.  For some elements, a chain of daughter decay products may be produced until 
stable atoms are formed.  Radionuclides can be characterized by the type and energy of the radiation 
emitted, the rate of decay, and the mode of decay.  The mode of decay indicates how a parent compound 
undergoes transformation. Radiations considered here are primarily of nuclear origin, i.e., they arise from
nuclear excitation, usually caused by the capture of charged or uncharged nucleons by a nucleus, or by the 
radioactive decay or transformation of an unstable nuclide.  The type of radiation may be categorized as 
charged or uncharged particles, protons, and fission products) or electromagnetic radiation (gamma rays
and x rays).  Table D-1 summarizes the basic characteristics of the more common types of radiation 
encountered. 
D.2.2 Half-Life and Activity
For any given radionuclide, the rate of decay is a first-order process that is constant, regardless of the 
radioactive atoms present and is characteristic for each radionuclide.  The process of decay is a series of 
random events; temperature, pressure, or chemical combinations do not effect the rate of decay.  While it 
may not be possible to predict exactly which atom is going to undergo transformation at any given time, it 
is possible to predict, on average, the fraction of the radioactive atoms that will transform during any
interval of time. 
The activity is a measure of the quantity of radioactive material.  For these radioactive materials it is 
customary to describe the activity as the number of disintegrations (transformations) per unit time.  The 
unit of activity is the curie (Ci), which was originally related to the activity of one gram of radium, but is 
now defined as that quantity of radioactive material in which there are: 
1 curie (Ci) = 3.7x1010 disintegrations (transformations)/second (dps) or 2.22x1012 disintegrations 
(transformations)/minute (dpm). 
The SI unit of activity is the becquerel (Bq); 1 Bq = that quantity of radioactive material in which there is 
1 transformation/second. Since activity is proportional to the number of atoms of the radioactive 
material, the quantity of any radioactive material is usually expressed in curies, regardless of its purity or 
concentration. The transformation of radioactive nuclei is a random process, and the number of 
transformations is directly proportional to the number of radioactive atoms present.  For any pure 
radioactive substance, the rate of decay is usually described by its radiological half-life, TR, i.e., the time 
it takes for a specified source material to decay to half its initial activity.  The specific activity is the 







































     
  





unit mass of related materials, such as the element itself or a chemical compound labeled with the 
radionuclide.  The higher the specific activity of a radioisotope, the faster it is decaying.
The activity of a radionuclide at time t may be calculated by: 
-0.693t/Trad A = Aoe
where A is the activity in dps or curies or becquerels, Ao is the activity at time zero, t is the time at which 
measured, and Trad is the radiological half-life of the radionuclide (Trad and t must be in the same units of 
time). The time when the activity of a sample of radioactivity becomes one-half its original value is the 
radioactive half-life and is expressed in any suitable unit of time. 
Table D-1. Characteristics of Nuclear Radiations 
Typical Path lengthb 
Radiation Rest massa Charge energy range Air Solid Comments 
Alpha (α) 4.00 amu +2 4–10 MeV 5–10 cm 25–80 µm Identical to ionized 
He nucleus 
Negatron (β–) 5.48x10-4 amu; –1 0–4 MeV 0–10 m 0–1 cm Identical to electron 
0.51 MeV 
Positron (β+) 5.48x10-4 amu; +1 0-4 MeV 0–10 m 0–1 cm Identical to electron 
0.51 MeV except for sign of 
charge 
Neutron 1.0086 amu; 0 0–15 MeV b b Free half-life: 16 
939.55 MeV min 
X ray (e.m.  – 0 5 keV–100 keV b b Photon from
photon) transition of an
electron between 
atomic orbits 
Gamma (p) – 0 10 keV–3 MeV b b Photon from
nuclear(e.m.  photon) 
transformation 
a The rest mass (in amu) has an energy equivalent in MeV that is obtained using the equation E=mc2, where 1 amu = 932 MeV. 
b Path lengths are not applicable to x- and gamma rays since their intensities decrease exponentially; path lengths in solid tissue
are variable, depending on particle energy, electron density of material, and other factors. 
 amu = atomic mass unit; e.m. = electromagnetic; MeV = Megaelectron Volts 
The specific activity is a measure of activity, and is defined as the activity of a radionuclide per mass of 
that radionuclide. This activity is usually expressed in curies per gram and may be calculated by
curies/gram = 1.3x108 / (Trad) (atomic weight)  or 
[3.577 x 105 x mass(g)] / [Trad  x atomic weight]
where Trad is the radiological half-life in days. 
In the case of radioactive materials contained in living organisms, an additional consideration is made for 
the reduction in observed activity due to regular processes of elimination of the respective chemical or 


















   




    















(Tbiol) which is the time required for biological processes to eliminate one-half of the activity. This time 
is virtually the same for both stable and radioactive isotopes of any given element. 

Under such conditions the time required for a radioactive element to be halved as a result of the combined 

action of radioactive decay and biological elimination is the effective clearance half-time: 

Teff = (Tbiol x Trad) / (Tbiol + Trad). 
Table D-2 presents representative effective half-lives of particular interest. 
Table D-2. Half-Lives of Some Radionuclides in Adult Body Organs 
Half-lifea 












Iodine 131 Thyroid 8 d 80 d 7.3 d 
Strontium 90 Bone 28 y 50 y 18 y
Plutonium 239 Bone surface 24,400 y 50 y 50 y
Lung 24,400 y 500 d 474 d 
Cobalt 60 Whole body 5.3 y 99.5 d 95 d 
Iron 55 Spleen 2.7 y 600 d 388 d 
Iron 59 Spleen 45.1 d 600 d 42 d 
Manganese 54 Liver 303 d 25 d 23 d 
Cesium 137 Whole body 30 y 70 d 70 d 
ad = days, y = years
bMixed in body water as tritiated water 
D.2.3 Interaction of Radiation with Matter 
Both ionizing and nonionizing radiation will interact with materials; that is, radiation will lose kinetic 
energy to any solid, liquid or gas through which it passes by a variety of mechanisms.  The transfer of 
energy to a medium by either electromagnetic or particulate radiation may be sufficient to cause 
formation of ions. This process is called ionization.  Compared to other types of radiation that may be 
absorbed, such as ultraviolet radiation, ionizing radiation deposits a relatively large amount of energy into 
a small volume. 
The method by which incident radiation interacts with the medium to cause ionization may be direct or 
indirect. Electromagnetic radiations (x rays and gamma photons) are indirectly ionizing; that is, they give 
up their energy in various interactions with cellular molecules, and the energy is then utilized to produce a 
fast-moving charged particle such as an electron.  It is the electron that then may react with a target 
molecule.  This particle is called a “primary ionizing particle.  Charged particles, in contrast, strike the 
tissue or medium and directly react with target molecules, such as oxygen or water.  These particulate 
radiations are directly ionizing radiations.  Examples of directly ionizing particles include alpha and beta 

































Mass, charge, and velocity of a particle, as well as the electron density of the material with which it 
interacts, all affect the rate at which ionization occurs.  The higher the charge of the particle and the lower 
the velocity, the greater the propensity to cause ionization.  Heavy, highly charged particles, such as alpha 
particles, lose energy rapidly with distance and, therefore, do not penetrate deeply.  The result of these 
interaction processes is a gradual slowing down of any incident particle until it is brought to rest or 
"stopped" at the end of its range. 
D.2.4 Characteristics of Emitted Radiation 
D.2.4.1 Alpha Emission.    In alpha emission, an alpha particle consisting of two protons and two 
neutrons is emitted with a resulting decrease in the atomic mass number by four and reduction of the 
atomic number of two, thereby changing the parent to a different element.  The alpha particle is identical 
to a helium nucleus consisting of two neutrons and two protons.  It results from the radioactive decay of 
some heavy elements such as uranium, plutonium, radium, thorium, and radon.  The alpha particles 
emitted by a given radionuclide have the same energy and intensity combination.  Most of the alpha 
particles that are likely to be found have energies in the range of about 4 to 8 MeV, depending on the 
isotope from which they came. 
The alpha particle has an electrical charge of +2.  Because of this double positive charge and their size, 
alpha particles have great ionizing power and, thus, lose their kinetic energy quickly.  This results in very
little penetrating power. In fact, an alpha particle cannot penetrate a sheet of paper.  The range of an 
alpha particle (the distance the charged particle travels from the point of origin to its resting point) is 
about 4 cm in air, which decreases considerably to a few micrometers in tissue.  These properties cause 
alpha emitters to be hazardous only if there is internal contamination (i.e., if the radionuclide is inside the 
body). 
D.2.4.2 Beta Emission. A beta particle (&) is a high-velocity electron ejected from a disintegrating 
nucleus. The particle may be either a negatively charged electron, termed a negatron (&-) or a positively
charged electron, termed a positron (&+).  Although the precise definition of "beta emission" refers to 
both &- and &+, common usage of the term generally applies only to the negative particle, as distinguished
from the positron emission, which refers to the &+ particle. 
D.2.4.2.1 Beta Negative Emission.  Beta particle (&-) emission is another process by which a 
radionuclide, with a neutron excess achieves stability.  Beta particle emission decreases the number of 
neutrons by one and increases the number of protons by one, while the atomic mass number remains 
unchanged.1  This transformation results in the formation of a different element.  The energy spectrum of 
beta particle emission ranges from a certain maximum down to zero with the mean energy of the 
spectrum being about one-third of the maximum.  The range of betas is much less in tissue than in air.  
Beta negative emitting radionuclides can cause injury to the skin and superficial body tissues, but mostly
present an internal contamination hazard. 
D.2.4.2.2 Positron Emission.    In cases in which there are too many protons in the nucleus, positron 
emission may occur.  In this case a proton may be thought of as being converted into a neutron, and a 
positron (&+) is emitted.1  This increases the number of neutrons by one, decreases the number of protons 
by one, and again leaves the atomic mass number unchanged.  The gamma radiation resulting from the 
annihilation (see glossary) of the positron makes all positron emitting isotopes more of an external 
radiation hazard than pure & emitters of equal energy. 





































D.2.4.2.3 Gamma Emission.    Radioactive decay by alpha, beta, or positron emission, or electron 
capture often leaves some of the energy resulting from these changes in the nucleus.  As a result, the 
nucleus is raised to an excited level.  None of these excited nuclei can remain in this high-energy state.  
Nuclei release this energy returning to ground state or to the lowest possible stable energy level.  The 
energy released is in the form of gamma radiation (high energy photons) and has an energy equal to the 
change in the energy state of the nucleus.  Gamma and x rays behave similarly but differ in their origin; 
gamma emissions originate in the nucleus while x rays originate in the orbital electron structure or from
rapidly changing the velocity of an electron (e.g., as occurs when shielding high energy beta particles or 
stopping the electron beam in an x ray tube). 
D.3 ESTIMATION OF ENERGY DEPOSITION IN HUMAN TISSUES 
Two forms of potential radiation exposures can result: internal and external.  The term exposure denotes 
physical interaction of the radiation emitted from the radioactive material with cells and tissues of the 
human body.  An exposure can be "acute" or "chronic" depending on how long an individual or organ is 
exposed to the radiation.  Internal exposures occur when radionuclides, which have entered the body (e.g.,
through the inhalation, ingestion, or dermal pathways), undergo radioactive decay resulting in the 
deposition of energy to internal organs.  External exposures occur when radiation enters the body directly
from sources located outside the body, such as radiation emitters from radionuclides on ground surfaces, 
dissolved in water, or dispersed in the air.  In general, external exposures are from material emitting 
gamma radiation, which readily penetrate the skin and internal organs.  Beta and alpha radiation from
external sources are far less penetrating and deposit their energy primarily on the skin's outer layer.  
Consequently, their contribution to the absorbed dose of the total body dose, compared to that deposited
by gamma rays, may be negligible. 
Characterizing the radiation dose to persons as a result of exposure to radiation is a complex issue.  It is 
difficult to: (1) measure internally the amount of energy actually transferred to an organic material and to 
correlate any observed effects with this energy deposition; and (2) account for and predict secondary
processes, such as collision effects or biologically triggered effects, that are an indirect consequence of 
the primary interaction event. 
D.3.1 Dose/Exposure Units 
D.3.1.1 Roentgen.    The roentgen (R) is a unit of x or gamma-ray exposure and is a measured by the 
amount of ionization caused in air by gamma or x radiation.  One roentgen produces 2.58x10-4 coulomb 
per kilogram of air.  In the case of gamma radiation, over the commonly encountered range of photon 
energy, the energy deposition in tissue for a dose of 1 R is about 0.0096 joules (J) /kg of tissue. 
D.3.1.2 Absorbed Dose and Absorbed Dose Rate.    The absorbed dose is defined as the energy
imparted by radiation to a unit mass of the tissue or organ.  The unit of absorbed dose is the rad; 1 rad = 
100 erg/gram = 0.01 J/kg in any medium.  An exposure of 1 R results in a dose to soft tissue of 
approximately 0.01 J/kg. The SI unit is the gray which is equivalent to 100 rad or 1 J/kg.  Internal and 
external exposures from radiation sources are not usually instantaneous but are distributed over extended 
periods of time.  The resulting rate of change of the absorbed dose to a small volume of mass is referred 
to as the absorbed dose rate in units of rad/unit time. 
D.3.1.3 Working Levels and Working Level Months.    Working level (WL) is a measure of the 
atmospheric concentration of radon and its short-lived progeny.  One WL is defined as any combination 
of short-lived radon daughters (through polonium-214), per liter of air, that will result in the emission of 
1.3x105 MeV of alpha energy.  An activity concentration of 100 pCi radon-222/L of air, in equilibrium


































WL unit can also be used for thoron daughters.  In this case, 1.3x105 MeV of alpha energy (1 WL) is 
released by the thoron daughters in equilibrium with 7.5 pCi thoron/L.  The potential alpha energy
exposure of miners is commonly expressed in the unit Working Level Month (WLM).  One WLM 
corresponds to exposure to a concentration of 1 WL for the reference period of 170 hours, or more 
generally
WLM = concentration (WL) x exposure time (months)  (one “month” = 170 working hours). 
D.3.2 Dosimetry Models 
Dosimetry models are used to estimate the dose from internally deposited to radioactive substances.  The 
models for internal dosimetry consider the amount of radionuclides entering the body, the factors 
affecting their movement or transport through the body, distribution and retention of radionuclides in the 
body, and the energy deposited in organs and tissues from the radiation that is emitted during spontaneous 
decay processes.  The dose pattern for radioactive materials in the body may be strongly influenced by the 
route of entry of the material.  For industrial workers, inhalation of radioactive particles with pulmonary
deposition and puncture wounds with subcutaneous deposition have been the most frequent.  The general 
population has been exposed via ingestion and inhalation of low levels of naturally occurring 
radionuclides as well as radionuclides from nuclear weapons testing. 
The models for external dosimetry consider only the photon doses (and neutron doses, where applicable) 
to organs of individuals who are immersed in air or are exposed to a contaminated object.   
D.3.2.1 Ingestion.    Ingestion of radioactive materials is most likely to occur from contaminated 
foodstuffs or water or eventual ingestion of inhaled compounds initially deposited in the lung. Ingestion 
of radioactive material may result in toxic effects as a result of either absorption of the radionuclide or 
irradiation of the gastrointestinal tract during passage through the tract, or a combination of both.  The 
fraction of a radioactive material absorbed from the gastrointestinal tract is variable, depending on the 
specific element, the physical and chemical form of the material ingested, and the diet, as well as some 
other metabolic and physiological factors.  The absorption of some elements is influenced by age, usually 
with higher absorption in the very young. 
D.3.2.2 Inhalation.    The inhalation route of exposure has long been recognized as being a major 
portal of entry for both nonradioactive and radioactive materials.  The deposition of particles within  the 
lung is largely dependent upon the size of the particles being inhaled.  After the particle is deposited, the 
retention will depend upon the physical and chemical properties of the dust and the physiological status of 
the lung.  The retention of the particle in the lung depends on the location of deposition, in addition to the 
physical and chemical properties of the particles.  The converse of pulmonary retention is pulmonary
clearance. There are three distinct mechanisms of clearance which operate simultaneously.  Ciliary
clearance acts only in the upper respiratory tract.  The second and third mechanisms act mainly in the 
deep respiratory tract.  These are phagocytosis and absorption.  Phagocytosis is the engulfing of foreign 
bodies by alveolar macrophages and their subsequent removal either up the ciliary "escalator" or by
entrance into the lymphatic system.  Some inhaled soluble particles are absorbed into the blood and 
translocated to other organs and tissues. 
D.3.3 Internal Emitters 
An internal emitter is a radionuclide that is inside the body.  The absorbed dose from internally deposited 
radionuclide depends on the energy absorbed per unit mass by the irradiated tissue.  For a radionuclide 
distributed uniformly throughout an infinitely large medium, the concentration of absorbed energy must 

































approximated by a tissue mass whose dimensions exceed the range of the particle.  All alpha and most 
beta radiation will be absorbed in the organ (or tissue) of reference.  Gamma-emitting radionuclide 
emissions are penetrating radiation, and a substantial fraction of gamma energy may be absorbed in 
tissue. The dose to an organ or tissue is a function of the effective retention half-time, the energy released 
in the tissue, the amount of radioactivity initially introduced, and the mass of the organ or tissue. 
D.4 BIOLOGICAL EFFECTS OF RADIATION 
When biological material is exposed to ionizing radiation, a chain of cellular events occurs as the ionizing 
particle passes through the biological material.  A number of theories have been proposed to describe the 
interaction of radiation with biologically important molecules in cells and to explain the resulting damage 
to biological systems from those interactions.  Many factors may modify the response of a living 
organism to a given dose of radiation.  Factors related to the exposure include the dose rate, the energy of 
the radiation, and the temporal pattern of the exposure.  Biological considerations include factors such as 
species, age, sex, and the portion of the body exposed.  Several excellent reviews of the biological effects 
of radiation have been published, and the reader is referred to these for a more in-depth discussion 
(Brodsky 1996; Hobbs and McClellan 1986; ICRP 1984; Mettler and Moseley 1985; Rubin and Casarett 
1968). 
D.4.1 Radiation Effects at the Cellular Level 
According to Mettler and Moseley (1985), at acute doses up to 10 rad (100 mGy), single strand breaks in 
DNA may be produced.  These single strand breaks may be repaired rapidly.  With doses in the range of 
50–500 rad (0.5–5 Gy), irreparable double-stranded DNA breaks are likely, resulting in cellular 
reproductive death after one or more divisions of the irradiated parent cell.  At large doses of radiation, 
usually greater than 500 rad (5 Gy), direct cell death before division (interphase death) may occur from
the direct interaction of free-radicals with essential cellular macromolecules.  Morphological changes at 
the cellular level, the severity of which are dose-dependent, may also be observed.
The sensitivity of various cell types varies. According to the Bergonie-Tribondeau law, the sensitivity of 
cell lines is directly proportional to their mitotic rate and inversely proportional to the degree of 
differentiation (Mettler and Moseley 1985).  Rubin and Casarett (1968) devised a classification system
that categorized cells according to type, function, and mitotic activity.  The categories range from the 
most sensitive type, "vegetative intermitotic cells", found in the stem cells of the bone marrow and the 
gastrointestinal tract, to the least sensitive cell type, "fixed postmitotic cells," found in striated muscles or 
long-lived neural tissues. 
Cellular changes may result in cell death, which if extensive, may produce irreversible damage to an 
organ or tissue or may result in the death of the individual.  If the cell recovers, altered metabolism and 
function may still occur, which may be repaired or may result in the manifestation of clinical symptoms.  
These changes may also be expressed at a later time as tumors or cellular mutations, which may result in 
abnormal tissue. 
D.4.2 Radiation Effects at the Organ Level 
In most organs and tissues the injury and the underlying mechanism for that injury are complex and may
involve a combination of events.  The extent and severity of this tissue injury are dependent upon the 
radiosensitivity of the various cell types in that organ system.  Rubin and Casarett (1968) describe and 
schematically display the events following radiation in several organ system types.  These include:  a 
rapid renewal system, such as the gastrointestinal mucosa; a slow renewal system, such as the pulmonary




























injury results from the direct destruction of highly radiosensitive cells, such as the stem cells in the bone 
marrow. Injury may also result from constriction of the microcirculation and from edema and 
inflammation of the basement membrane, designated as the histohematic barrier, which may progress to 
fibrosis. In slow renewal and nonrenewal systems, the radiation may have little effect on the parenchymal 
cells, but ultimate parenchymal atrophy and death over several months result from fibrosis and occlusion 
of the microcirculation. 
D.4.3 Low Level Radiation Effects 
Cancer is the major latent harmful effect produced by ionizing radiation and the one that most people 
exposed to radiation are concerned about.  The ability of alpha, beta, and gamma radiation to produce 
cancer in virtually every tissue and organ in laboratory animals has been well-demonstrated.  The 
development of cancer is not an immediate effect.  Radiation-induced leukemia has the shortest latent 
period at about 2 years, while other radiation induced cancers, such as osteosarcoma, have latent periods 
greater than 20 years. The mechanism by which cancer is induced in living cells is complex and is a topic 
of intense study.  Exposure to ionizing radiation can produce cancer at any site within the body; however, 
some sites appear to be more common than others, such as the breast, lung, stomach, and thyroid.   
DNA is the major target molecule during exposure to ionizing radiation.  Other macromolecules, such as 
lipids and proteins, are also at risk of damage when exposed to ionizing radiation.  The genotoxicity of 
ionizing radiation is an area of intense study, as damage to the DNA is ultimately responsible for many of 
the adverse toxicological effects ascribed to ionizing radiation, including cancer.  Damage to genetic 
material is basic to developmental or teratogenic effects, as well.  However, for effects other than cancer, 
there is little evidence of human effects at low levels of exposure. 
D.5 UNITS IN RADIATION PROTECTION AND REGULATION 
D.5.1 Dose Equivalent (or Equivalent Dose) 
Dose equivalent (as measured in rem or sievert) is a special radiation protection quantity that is used for 
administrative and radiation safety purposes to express the absorbed dose in a manner which considers the 
difference in biological effectiveness of various kinds of ionizing radiation.  ICRP (1990) changed this 
term to equivalent dose, but it has not yet been adopted by the USNRC or DOE.   
The USNRC defines the dose equivalent, H, as the product of the absorbed dose, D, and the quality
factor, Q, at the point of interest in biological tissue using the formula H = D x Q.  The NCRP similarly
defines equivalent dose, H, as the product of the absorbed dose, D, and the radiation weighting factor, wr 
in the equation H = Dwr. The dose equivalent concept is applicable only to doses that are not great 
enough to produce biomedical effects.  
The quality factor or radiation weighting factor is a dimensionless quantity that depends in part on the 
stopping power for charged particles, and it accounts for the differences in biological effectiveness found 
among the types of radiation.  Originally relative biological effectiveness (RBE) was used rather than Q 
to define the quantity, rem, which was of use in risk assessment.  The generally accepted values for 
quality factors and radiation weighting factors for various radiation types are provided in Table D-3.  The 
dose equivalent rate is the time rate of change of the dose equivalent to organs and tissues and is 


















    






















Table D-3.  Quality Factors (Q) and Radiation Weighting Factors 
Type of radiation Quality factor (Q) Radiation Weighting Factor (wr) 
X, gamma, or beta radiation 1 1 
Alpha particles, multiple-charged 20 20 
particles, fission fragments and
heavy particles of unknown charge
Neutrons (100 keV to 2 MeV), 7.5–11 20 
protons, alpha particles, charged 
particles of unknown energy depending on energy
Neutrons of unknown energy 10 
Thermal neutrons 2 5 
High-energy protons 10 5 
Source: USNRC. 2004.   Standards for the protection against radiation, tables 1004(b).1 and 1004(b).2.  10 CFR 20.1004. 
U.S. Nuclear Regulatory Commission, Washington, D.C. NCRP 1993.
D.5.2 Relative Biological Effectiveness 
RBE is used to denote the experimentally determined ratio of the absorbed dose from one radiation type 
to the absorbed dose of a reference radiation required to produce an identical biologic effect under the 
same conditions. Gamma rays from cobalt-60 and 200–250 kVp x-rays have been used as reference 
standards. The term RBE has been widely used in experimental radiobiology, and the term quality factor 
(or radiation weighting factor) is used in calculations of dose equivalents for radiation safety purposes 
(ICRP 1977; NCRP 1971; UNSCEAR 1982).  Any RBE value applies only to a specific biological end 
point, in a specific exposure, under specific conditions to a specific species.  There are no generally
applicable values of RBE since RBEs are specific to a given exposure scenario. 
D.5.3 Effective Dose Equivalent (or Effective Dose) 
The absorbed dose is usually defined as the mean energy imparted per unit mass to an organ or tissue.  
This represents a simplification of the actual problem.  Normally when an individual ingests or inhales a 
radionuclide or is exposed to external radiation that enters the body (gamma), the dose is not uniform
throughout the whole body.  The simplifying assumption is that the detriment will be the same whether 
the body is uniformly or non-uniformly irradiated.  In an attempt to compare detriment from absorbed 
dose of a limited portion of the body with the detriment from total body dose, the ICRP (1977) has 
derived a concept of effective dose equivalent.  ICRP (1990) changed this term to effective dose, but it
has not yet been adopted by the USNRC or DOE. 
The effective dose equivalent, HE, is 
HE = ∑ Wt Ht 
where Ht is the dose equivalent (or equivalent dose) in the tissue t, Wt is the tissue weighting factor in that 
tissue, which represents the estimated proportion of the stochastic risk resulting from tissue, t, to the 
stochastic risk when the whole body is uniformly irradiated for occupational exposures under certain 




























Table D-4. Tissue Weighting Factors for Calculating Effective Dose  

Equivalent and Effective Dose for Selected Tissues
 
Tissue weighting factor 
Tissue NCRP115/ ICRP60 USNRC/ICRP26 
Bladder 0.05 – 
Bone marrow 0.12 0.12 
Bone surface 0.01 0.03 
Breast 0.05 0.15 
Colon 0.12 – 
Esophagus 0.05 – 
Gonads 0.20 0.25 
Liver 0.05 – 
Lung 0.12 0.12 
Skin 0.01 – 
Stomach 0.12 – 
Thyroid 0.05 0.03 
Remainder 0.05 0.30 
Total 1.00 1.00 
ICRP60 = International Commission on Radiological Protection, 1990 Recommendations of the ICRP  

NCRP115 = National Council on Radiation Protection and Measurements. 1993. Risk Estimates for Radiation Protection, 

Report 115.  Bethesda, Maryland
 
USNRC = Nuclear Regulatory Commission, Title 10, Code of Federal Regulations, Part 20 

D.5.4 SI Units 
The ICRU (1980), ICRP (1984), and NCRP (1985) now recommend that the rad, roentgen, curie, and rem
be replaced by the SI units: gray (Gy), Coulomb per kilogram (C/kg), Becquerel (Bq), and sievert (Sv), 
respectively. The relationship between the customary units and the international system of units (SI) for 














    
 
 
   
























Table D-5. Comparison of Common and SI Units for Radiation Quantities 
Customary
Quantity units Definition SI units Definition 
Activity (A) curie (Ci) 3.7x1010 trans- becquerel (Bq) s-1 
formations s-1 
Absorbed dose (D) rad 10-2 Jkg-1 gray (Gy) Jkg-1 
-1 -1Absorbed dose rate rad per second 10-2 Jkg-1s gray per second  Jkg-1 s
(Ď) (rad s-1) (Gy s-1) 
Dose equivalent (H) rem 10-2 Jkg-1 sievert (Sv) Jkg-1 
-1 -1Dose equivalent rate rem per second 10-2 Jkg-1s sievert per second Jkg-1 s
( ) (rem s-1) (Sv s-1) 
Effective dose rem 10-2 Jkg-1 Sievert (Sv) Jkg-1 
Equivalent dose (H) rem 10-2 Jkg-1 Sievert (Sv) Jkg-1 
Linear energy kiloelectron 1.602x10-10 Jm-1 kiloelectron volts 1.602x10-10 Jm-1 
transfer (LET) volts per per micrometer 
micrometer (keV µm-1) 
(keV µm-1) 
Jkg-1 = Joules per kilogram; Jkg-1s-1 = Joules per kilogram per second; Jm-1 = Joules per meter; s-1 = per second 
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